<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD000467.pub2" GROUP_ID="MUSKEL" ID="938899082413034682" MERGED_FROM="" MODIFIED="2017-11-29 14:53:30 +0000" MODIFIED_BY="Jordi Pardo Pardo" NOTES="&lt;p&gt;Exported from Review Manager 4.2.10&lt;br&gt;Exported from Review Manager 4.3 Beta&lt;br&gt;Short title (no longer in use): Calcium Channel Blockers for Raynaud's phenomenon in scleroderma&lt;/p&gt;&lt;p&gt;30/10/1995&lt;/p&gt;" NOTES_MODIFIED="2017-11-29 09:51:17 -0500" NOTES_MODIFIED_BY="[Empty name]" REVIEW_NO="C113-R" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="5.0"><COVER_SHEET MODIFIED="2017-11-29 09:51:17 -0500" MODIFIED_BY="[Empty name]"><TITLE MODIFIED="2017-11-11 06:34:43 -0500" MODIFIED_BY="[Empty name]">Calcium channel blockers for primary and secondary Raynaud's phenomenon</TITLE><CONTACT><PERSON ID="5415" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Janet</FIRST_NAME><MIDDLE_INITIALS/><LAST_NAME>Pope</LAST_NAME><SUFFIX/><POSITION>Professor of Medicine</POSITION><EMAIL_1>Janet.Pope@sjhc.london.on.ca</EMAIL_1><EMAIL_2/><URL/><MOBILE_PHONE/><ADDRESS><DEPARTMENT>Department of Medicine and Epidemiology and Biostatistics</DEPARTMENT><ORGANISATION>University of Western Ontario</ORGANISATION><ADDRESS_1>St. Joseph's Health Care</ADDRESS_1><ADDRESS_2>268 Grosvenor St</ADDRESS_2><CITY>London</CITY><ZIP>N6A 4V2</ZIP><REGION>ON</REGION><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>+ 1 519 646 6332</PHONE_1><PHONE_2/><FAX_1>+ 1 519 646 6334</FAX_1><FAX_2/></ADDRESS><FOOTNOTE/></PERSON></CONTACT><CREATORS MODIFIED="2017-11-29 09:48:02 -0500" MODIFIED_BY="Jordi Pardo Pardo"><PERSON ID="z1407030129210861412222600414951" ROLE="AUTHOR"><PREFIX/><FIRST_NAME>Fadumo</FIRST_NAME><MIDDLE_INITIALS/><LAST_NAME>Rirash</LAST_NAME><SUFFIX/><POSITION/><EMAIL_1>frirash@gmail.com</EMAIL_1><EMAIL_2/><URL/><MOBILE_PHONE/><ADDRESS><DEPARTMENT>Department of Medicine</DEPARTMENT><ORGANISATION>University of Western Ontario</ORGANISATION><ADDRESS_1>268 Grosvenor Street</ADDRESS_1><ADDRESS_2/><CITY>London</CITY><ZIP>N6A 4V2</ZIP><REGION>ON</REGION><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1/><PHONE_2/><FAX_1/><FAX_2/></ADDRESS><FOOTNOTE/></PERSON><PERSON ID="2F09218C82E26AA200E3043BC9FFD2BC" ROLE="AUTHOR"><PREFIX/><FIRST_NAME>Paul</FIRST_NAME><MIDDLE_INITIALS>C</MIDDLE_INITIALS><LAST_NAME>Tingey</LAST_NAME><SUFFIX/><POSITION/><EMAIL_1>Paul.c.tingey@gmail.com</EMAIL_1><EMAIL_2/><URL/><MOBILE_PHONE/><ADDRESS><DEPARTMENT>Department of Medicine</DEPARTMENT><ORGANISATION>University of Western Ontario</ORGANISATION><ADDRESS_1>1151 Richmond Street</ADDRESS_1><ADDRESS_2/><CITY>London</CITY><ZIP>N6A 3K7</ZIP><REGION>ON</REGION><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>519 661 2111</PHONE_1><PHONE_2/><FAX_1/><FAX_2/></ADDRESS><FOOTNOTE/></PERSON><PERSON ID="2F09225782E26AA200E3043B38DE59D0" ROLE="AUTHOR"><PREFIX/><FIRST_NAME>Sarah</FIRST_NAME><MIDDLE_INITIALS>E</MIDDLE_INITIALS><LAST_NAME>Harding</LAST_NAME><SUFFIX/><POSITION>Resident</POSITION><EMAIL_1>sarah.harding@erlanger.org</EMAIL_1><EMAIL_2/><URL/><MOBILE_PHONE/><ADDRESS><DEPARTMENT>Department of Pediatrics</DEPARTMENT><ORGANISATION>University of Tennessee at Chattanooga</ORGANISATION><ADDRESS_1>910 Blackford St</ADDRESS_1><ADDRESS_2/><CITY>Chattanooga</CITY><ZIP>37405</ZIP><REGION>Tennessee</REGION><COUNTRY CODE="US">USA</COUNTRY><PHONE_1/><PHONE_2/><FAX_1/><FAX_2/></ADDRESS><FOOTNOTE/></PERSON><PERSON ID="17387" ROLE="AUTHOR"><PREFIX>Ms</PREFIX><FIRST_NAME>Lara</FIRST_NAME><MIDDLE_INITIALS>J</MIDDLE_INITIALS><LAST_NAME>Maxwell</LAST_NAME><SUFFIX/><POSITION>Managing Editor, Cochrane Musculoskeletal Group</POSITION><EMAIL_1>lmaxwell@uottawa.ca</EMAIL_1><EMAIL_2/><URL/><MOBILE_PHONE/><ADDRESS><DEPARTMENT>Centre for Practice-Changing Research (CPCR)</DEPARTMENT><ORGANISATION>Ottawa Hospital Research Institute (OHRI), The Ottawa Hospital - General Campus</ORGANISATION><ADDRESS_1>501 Smyth Road, Box 711</ADDRESS_1><ADDRESS_2/><CITY>Ottawa</CITY><ZIP>K1H 8L6</ZIP><REGION>ON</REGION><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>1 613-737-8899 ext 75081</PHONE_1><PHONE_2/><FAX_1/><FAX_2/></ADDRESS><FOOTNOTE/></PERSON><PERSON ID="45BA46DE82E26AA200C069ECEBB1DB93" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Elizabeth</FIRST_NAME><MIDDLE_INITIALS/><LAST_NAME>Tanjong Ghogomu</LAST_NAME><SUFFIX/><POSITION/><EMAIL_1>cmsg@uottawa.ca</EMAIL_1><EMAIL_2>ETanjongGhogomu@bruyere.org</EMAIL_2><URL/><MOBILE_PHONE/><ADDRESS><DEPARTMENT>Bruyère Research Institute</DEPARTMENT><ORGANISATION>University of Ottawa</ORGANISATION><ADDRESS_1>43 Bruyère St</ADDRESS_1><ADDRESS_2>Annex E, room 213</ADDRESS_2><CITY>Ottawa</CITY><ZIP>K1N 5C8</ZIP><REGION>ON</REGION><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>1 613-562-6262 ext 2962</PHONE_1><PHONE_2/><FAX_1/><FAX_2/></ADDRESS><FOOTNOTE/></PERSON><PERSON ID="12662" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>George</FIRST_NAME><MIDDLE_INITIALS>A</MIDDLE_INITIALS><LAST_NAME>Wells</LAST_NAME><SUFFIX>MSc, PhD</SUFFIX><POSITION>Professor</POSITION><EMAIL_1>gawells@ottawaheart.ca</EMAIL_1><EMAIL_2/><URL/><MOBILE_PHONE/><ADDRESS><DEPARTMENT>Department of Epidemiology and Community Medicine</DEPARTMENT><ORGANISATION>University of Ottawa</ORGANISATION><ADDRESS_1>Room H1281</ADDRESS_1><ADDRESS_2>40 Ruskin Street</ADDRESS_2><CITY>Ottawa</CITY><ZIP>K1Y 4W7</ZIP><REGION>ON</REGION><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>+1 613 798 5555 x18640</PHONE_1><PHONE_2>+1 613 798 5555 x18642</PHONE_2><FAX_1/><FAX_2/></ADDRESS><FOOTNOTE/></PERSON><PERSON ID="5474" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Peter</FIRST_NAME><MIDDLE_INITIALS/><LAST_NAME>Tugwell</LAST_NAME><SUFFIX/><POSITION>Professor of Medicine, &amp; Epidemiology and Community Medicine, Canada</POSITION><EMAIL_1>tugwell.bb@uottawa.ca</EMAIL_1><EMAIL_2/><URL/><MOBILE_PHONE/><ADDRESS><DEPARTMENT>Department of Medicine</DEPARTMENT><ORGANISATION>Faculty of Medicine, University of Ottawa</ORGANISATION><ADDRESS_1/><ADDRESS_2/><CITY>Ottawa</CITY><ZIP>K1H 8M5</ZIP><REGION>ON</REGION><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>613-562-5800 ext: 1945</PHONE_1><PHONE_2/><FAX_1>613-562-5659</FAX_1><FAX_2/></ADDRESS><FOOTNOTE/></PERSON><PERSON ID="5415" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Janet</FIRST_NAME><MIDDLE_INITIALS/><LAST_NAME>Pope</LAST_NAME><SUFFIX/><POSITION>Professor of Medicine</POSITION><EMAIL_1>Janet.Pope@sjhc.london.on.ca</EMAIL_1><EMAIL_2/><URL/><MOBILE_PHONE/><ADDRESS><DEPARTMENT>Department of Medicine and Epidemiology and Biostatistics</DEPARTMENT><ORGANISATION>University of Western Ontario</ORGANISATION><ADDRESS_1>St. Joseph's Health Care</ADDRESS_1><ADDRESS_2>268 Grosvenor St</ADDRESS_2><CITY>London</CITY><ZIP>N6A 4V2</ZIP><REGION>ON</REGION><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>+ 1 519 646 6332</PHONE_1><PHONE_2/><FAX_1>+ 1 519 646 6334</FAX_1><FAX_2/></ADDRESS><FOOTNOTE/></PERSON></CREATORS><DATES MODIFIED="2017-11-29 08:58:44 -0500" MODIFIED_BY="[Empty name]"><UP_TO_DATE><DATE DAY="19" MONTH="5" YEAR="2017"/></UP_TO_DATE><LAST_SEARCH><DATE DAY="19" MONTH="5" YEAR="2017"/></LAST_SEARCH><NEXT_STAGE><DATE DAY="19" MONTH="5" YEAR="2019"/></NEXT_STAGE><PROTOCOL_PUBLISHED ISSUE="1" YEAR="1996"/><REVIEW_PUBLISHED ISSUE="11" YEAR="2017"/><LAST_CITATION_ISSUE ISSUE="11" YEAR="2017"/></DATES><WHATS_NEW MODIFIED="2015-05-14 07:43:46 -0400" MODIFIED_BY="[Empty name]"/><HISTORY MODIFIED="2017-11-29 09:51:17 -0500" MODIFIED_BY="[Empty name]"><WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2017-11-11 06:43:58 -0500" MODIFIED_BY="[Empty name]"><DATE DAY="5" MONTH="9" YEAR="2008"/><DESCRIPTION><P>Converted to new review format</P></DESCRIPTION></WHATS_NEW_ENTRY></HISTORY><SOURCES_OF_SUPPORT MODIFIED="2017-11-14 03:16:57 -0500" MODIFIED_BY="[Empty name]"><INTERNAL_SOURCES MODIFIED="2017-11-14 03:16:57 -0500" MODIFIED_BY="[Empty name]"><SOURCE MODIFIED="2017-11-14 03:16:57 -0500" MODIFIED_BY="[Empty name]"><NAME>St. Joseph's Hospital, London, Ontario</NAME><COUNTRY CODE="CA">Canada</COUNTRY><DESCRIPTION><P>Pope Research Corporation</P></DESCRIPTION></SOURCE></INTERNAL_SOURCES><EXTERNAL_SOURCES/></SOURCES_OF_SUPPORT><MESH_TERMS VERIFIED="NO"/><KEYWORDS/></COVER_SHEET><MAIN_TEXT MODIFIED="2017-11-29 09:50:00 -0500" MODIFIED_BY="[Empty name]"><SUMMARY MODIFIED="2017-11-14 07:10:36 -0500" MODIFIED_BY="[Empty name]"><TITLE MODIFIED="2017-11-11 07:01:24 -0500" MODIFIED_BY="[Empty name]">Calcium channel blockers for treatment of patients with Raynaud&#8217;s phenomenon</TITLE><SUMMARY_BODY MODIFIED="2017-11-14 07:10:36 -0500" MODIFIED_BY="[Empty name]"><P>Raynaud's phenomenon (RP) is a disorder that results in decreased blood flow to the fingers and toes as the result of vasospasm. Symptoms include discoloration (such as a fingertip turning white, then blue and/or red), pain, and, in severe cases, open sores of the digits. Cold, stress, and emotional discomfort are the most common triggers of a Raynaud's attack. No underlying disease is associated with primary RP. Secondary RP is associated with underlying conditions such as systemic sclerosis.</P><P>This review assessed the benefits and harms of calcium channel blockers (CCBs) compared with placebo (a substance that appears the same as the active drug but has no active ingredient) for treatment of patients with RP, based on studies published up to May 19, 2017. CCBs are drugs that increase blood flow to the digits and usually are used as first-line treatment for patients with RP. The objective of this review was to determine the benefits and harms of CCBs overall, by dose and type of drug and by type of RP (primary vs secondary).</P><P><B>Study characteristics</B></P><P>We identified and included 38 studies with 982 people 18 years old and over with disease of various duration and severity. Nine studies included patients with primary RP, five included patients with secondary RP, and the rest examined patients with both types of RP. Trial duration ranged from 2 to 20 weeks.</P><P><B>What did this review discover about the use of CCBs versus placebo for RP?</B></P><P>Reviewers found that:</P><P>&#8226; CCBs probably reduce slightly the frequency, severity, and overall patient assessment of Raynaud's attacks (moderate-quality evidence downgraded for concerns of imprecision or inconsistency);</P><P>&#8226; CCBs may improve slightly the duration and pain of Raynaud's attacks (low-quality evidence downgraded for imprecision and inconsistency);</P><P>&#8226; because of lack of data and high dropout rates, effects of CCBs on risk of dropout due to treatment side effects remain uncertain;</P><P>&#8226; the most common side effects were headache, dizziness, nausea, palpitations, and ankle edema; and</P><P>&#8226; serious adverse events (death or hospitalization) were not reported.</P><P><B>Best estimates of what happens to people with RP who take CCBs for 2 to 20 weeks</B></P><P>When investigators considered both primary and secondary RP, they reported that 528 people who took CCBs experienced six fewer attacks per week than those who took placebo. People who took a CCB had an average of 8 attacks per week, compared with 14 attacks per week among those taking placebo.</P><P>Duration of attacks (in minutes) was about the same for people taking CCBs or placebo. However, this finding was based on a small number of people.</P><P>Severity of attacks measured on a 10-cm scale (lower scores indicate less severe attacks) was 0.62 cm lower with CCBs; this was equal to a 6% reduction. People who took a CCB rated the severity of an attack as 6.1 cm, compared with 6.7 cm for those taking placebo.</P><P>Pain was reduced by 1.5 points on a 0 to 10 scale (15% absolute reduction, lower score means less pain) with CCBs compared with placebo. People who took a CCB reported a pain score of 1.6 points, compared with 3.1 points for those taking placebo.</P><P>Overall disability was reduced by 0.4 points on a 0 to 10 scale (4% absolute reduction, lower score means less disability) among people who took CCBs compared with placebo. People who took a CCB reported a disability score of 3.5 points, compared with 3.9 points for those taking placebo.</P><P>Six more people out of 100 who took a CCB withdrew from the study owing to adverse events (6% more withdrawals). Out of 100 people taking a CCB, 25 withdrew from the study, compared with 19 out of 100 taking placebo.</P><P>This review suggests that CCBs (particularly drugs in the dihydropyridine class such as nifedipine) in higher doses may be beneficial for the management of RP, particularly primary RP. Although slightly more participants taking CCBs withdrew as the result of treatment side effects, no reported side effects were serious.</P></SUMMARY_BODY></SUMMARY><ABSTRACT MODIFIED="2017-11-24 19:58:22 -0500" MODIFIED_BY="[Empty name]"><ABS_BACKGROUND MODIFIED="2017-11-11 06:45:24 -0500" MODIFIED_BY="[Empty name]"><P>Raynaud's phenomenon is a vasospastic disease characterized by digital pallor, cyanosis, and extremity pain. Primary Raynaud's phenomenon is not associated with underlying disease, but secondary Raynaud's phenomenon is associated with connective tissue disorders such as systemic sclerosis, systemic lupus erythematosus, and mixed connective tissue disease. Calcium channel blockers promote vasodilation and are commonly used when drug treatment for Raynaud's phenomenon is required.</P></ABS_BACKGROUND><ABS_OBJECTIVES MODIFIED="2017-11-11 06:46:23 -0500" MODIFIED_BY="[Empty name]"><P>To assess the benefits and harms of calcium channel blockers (CCBs) versus placebo for treatment of individuals with Raynaud's phenomenon with respect to Raynaud's type (primary vs secondary) and type and dose of CCBs.</P></ABS_OBJECTIVES><ABS_SEARCH_STRATEGY MODIFIED="2017-11-11 06:49:02 -0500" MODIFIED_BY="[Empty name]"><P>We searched the Cochrane Central Register of Controlled Trials (May 19, 2017), MEDLINE (1946 to May 19, 2017), Embase (1947 to May 19, 2017), clinicaltrials.gov, and the World Health Organization (WHO) International Clinical Trials Registry Portal. We applied no language restrictions. We also searched bibliographies of retrieved articles and contacted key experts for additional and unpublished data.</P></ABS_SEARCH_STRATEGY><ABS_SELECTION_CRITERIA MODIFIED="2017-11-11 06:49:11 -0500" MODIFIED_BY="[Empty name]"><P>All randomized controlled trials (RCTs) comparing calcium channel blockers versus placebo.</P></ABS_SELECTION_CRITERIA><ABS_DATA_COLLECTION MODIFIED="2017-11-11 06:49:29 -0500" MODIFIED_BY="[Empty name]"><P>Two review authors independently assessed search results and risk of bias and extracted trial data. We used the GRADE approach to assess the quality of evidence.</P></ABS_DATA_COLLECTION><ABS_RESULTS MODIFIED="2017-11-24 19:58:22 -0500" MODIFIED_BY="[Empty name]"><P>This review contains 38 RCTs (33 cross-over RCTs) with an average duration of 7.4 weeks and 982 participants; however, not all trials reported all outcomes of interest. Nine of the identified trials studied patients with primary Raynaud's phenomenon (N = 365), five studied patients with secondary Raynaud's phenomenon (N = 63), and the rest examined a mixture of patients with primary and secondary Raynaud's phenomenon (N = 554). The most frequently encountered risk of bias types were incomplete outcome data and poor reporting of randomization and allocation methods.</P><P>When researchers considered both primary and secondary Raynaud's phenomenon, evidence of moderate quality (downgraded for inconsistency) from 23 trials with 528 participants indicates that calcium channel blockers (CCBs) were superior to placebo in reducing the frequency of attacks. CCBs reduced the average number of attacks per week by six ( weighted mean difference (WMD) -6.13, 95% confidence interval (CI) -6.60 to - 5.67; I² = 98%) compared with 13.7 attacks per week with placebo. When review authors excluded Kahan 1985C, a trial showing a very large reduction in the frequency of attacks, data showed that CCBs reduced attack frequency by 2.93 per week (95% CI -3.44 to -2.43; I² = 77%).</P><P>Low-quality evidence (downgraded for imprecision and inconsistency) from six trials with 69 participants suggests that the average duration of attacks did not differ in a statistically significant or clinically meaningful way between CCBs and placebo (WMD -1.67 minutes, 95% CI -3.29 to 0); this is equivalent to a -9% difference (95% CI -18% to 0%).</P><P>Moderate-quality evidence (downgraded for inconsistency) based on 16 trials and 415 participants showed that CCBs reduced attack severity by 0.62 cm (95% CI -0.72 to - 0.51) on a 10-cm visual analogue scale (lower scores indicate less severity); this was equivalent to absolute and relative percent reductions of 6% (95% CI -11% to -8%) and 9% (95% CI -11% to -8%), respectively, which may not be clinically meaningful.</P><P>Improvement in Raynaud's pain (low-quality evidence; downgraded for imprecision and inconsistency) and in disability as measured by a patient global assessment (moderate-quality evidence; downgraded for imprecision) favored CCBs (pain: WMD -1.47 cm, 95% CI -2.21 to -0.74; patient global: WMD -0.37 cm, 95% CI -0.73 to 0, when assessed on a 0 to 10 cm visual analogue scale, with lower scores indicating less pain and less disability). However, these effect estimates were likely underpowered, as they were based on limited numbers of participants, respectively, 62 and 92. For pain assessment, absolute and relative percent improvements were 15% (95% -22% to -7%) and 47% (95% CI -71% to -24%), respectively. For patient global assessment, absolute and relative percent improvements were 4% (95% CI -7% to 0%) and 9% (95% CI -19% to 0%), respectively.</P><P>Subgroup analyses by Raynaud's type, CCB class, and CCB dose suggest that dihydropyridine CCBs in higher doses may be more effective for primary Raynaud's than for secondary Raynaud's, and CCBs likely have a greater effect in primary than in secondary Raynaud's. However, differences were small and were not found for all outcomes. Dihydropyridine CCBs were studied as they are the subgroup of CCBs that are not cardioselective and are traditionally used in RP treatment whereas other CCBs such as verapamil are not routinely used and diltiazem is not used as first line subtype of CCBs. Most trial data pertained to nifedipine.</P><P>Withdrawals from studies due to adverse effects were inconclusive owing to a wide CI (risk ratio [RR] 1.30, 95% CI 0.51 to 3.33) from two parallel studies with 63 participants (low-quality evidence downgraded owing to imprecision and a high attrition rate); absolute and relative percent differences in withdrawals were 6% (95% CI -14% to 26%) and 30% (95% CI -49% to 233%), respectively. In cross-over trials, although a meta-analysis was not performed, withdrawals were more common with CCBs than with placebo. The most common side effects were headache, dizziness, nausea, palpitations, and ankle edema. However, in all trials, no serious adverse events (death or hospitalization) were reported.</P></ABS_RESULTS><ABS_CONCLUSIONS MODIFIED="2017-11-23 17:57:53 -0500" MODIFIED_BY="[Empty name]"><P>Randomized controlled trials with evidence of low to moderate quality showed that CCBs (especially the dihydropyridine class) may be useful in reducing the frequency, duration, severity of attacks, pain and disability associated with Raynaud's phenomenon. Higher doses may be more effective than lower doses and these CCBs may be more effective in primary RP. Although there were more withdrawals due to adverse events in the treatment groups, no serious adverse events were reported.</P></ABS_CONCLUSIONS></ABSTRACT><BODY MODIFIED="2017-11-29 09:37:53 -0500" MODIFIED_BY="[Empty name]"><BACKGROUND MODIFIED="2017-11-28 10:39:57 -0500" MODIFIED_BY="[Empty name]"><CONDITION MODIFIED="2017-11-23 20:29:52 -0500" MODIFIED_BY="[Empty name]"><P>Raynaud's phenomenon (RP) is defined as vasospasms or "attacks" of the arteries or arterioles of the extremities (and rarely other areas) causing pallor and at least one other color change upon reperfusion, such as cyanosis or rubor (<LINK REF="REF-Herrick-2005" TYPE="REFERENCE">Herrick 2005</LINK>; <LINK REF="REF-Wigley-2002" TYPE="REFERENCE">Wigley 2002</LINK>). During an RP attack, blood flow to the extremities is restricted with subsequent pallor and/or pain. Each attack is characterized by its frequency, duration, and level of pain. Primary RP is idiopathic and occurs in the absence of other underlying causes such as connective tissue disease. Secondary RP occurs in people with underlying diseases affecting the blood vessels, especially systemic sclerosis (also called SSc, scleroderma) and systemic lupus erythematosus (<LINK REF="REF-Wigley-2002" TYPE="REFERENCE">Wigley 2002</LINK>). RP may also be accompanied by digital ulcers, which may occur secondary to severe ischemia (loss of blood to the digits) (<LINK REF="REF-Wigley-2002" TYPE="REFERENCE">Wigley 2002</LINK>). In most cases (&gt; 80%), exposure to cold temperatures triggers this physiologic response, but emotional stress has been documented as another trigger (<LINK REF="REF-Garc_x00ed_a_x002d_Carrasco-2008" TYPE="REFERENCE">García-Carrasco 2008</LINK>; <LINK REF="REF-Wigley-2002" TYPE="REFERENCE">Wigley 2002</LINK>). Primary RP has an earlier onset (median age at onset is around 14 years) and is characterized by milder symptoms. Secondary RP often has a later onset (usually after age 40) with more severe symptoms and may be associated with complications such as tissue loss, ulcers, and amputation (<LINK REF="REF-Wigley-2002" TYPE="REFERENCE">Wigley 2002</LINK>). Irreversible digital ischemia may develop in patients whose RP occurs secondary to a systemic sclerosis spectrum disorder (<LINK REF="REF-Herrick-2005" TYPE="REFERENCE">Herrick 2005</LINK>).</P><P>The prevalence of this condition is based on climate conditions so is geographically variable but has been estimated at around 3% to 5% in the general population, with most cases (80% to 90%) diagnosed as primary RP (<LINK REF="REF-Maundrell-2015" TYPE="REFERENCE">Maundrell 2015</LINK>; <LINK REF="REF-Silman-1990" TYPE="REFERENCE">Silman 1990</LINK>). Secondary RP accounts for about 10% to 20% of RP prevalence, but this depends on the underlying cause. More than 90% of patients with SSc have RP (<LINK REF="REF-Levien-2010" TYPE="REFERENCE">Levien 2010</LINK>; <LINK REF="REF-Maundrell-2015" TYPE="REFERENCE">Maundrell 2015</LINK>). SSc is an autoimmune connective tissue disease characterized by fibrosis of the skin and internal organs, including the gastrointestinal tract, lungs, kidney, and heart, along with significant vasculopathy and pulmonary arterial hypertension
 
(<LINK REF="REF-Ortonne-1989" TYPE="REFERENCE">Ortonne 1989</LINK>). In general, RP is much more common among women (prevalence of primary RP has been estimated at between 2% and 20% in women compared with 1% to 12% among men), and primary RP has a genetic component (about 50% of patients with primary RP have a first-degree relative with the disease) (<LINK REF="REF-Maundrell-2015" TYPE="REFERENCE">Maundrell 2015</LINK>). Diagnosis of primary RP is based on patient history (i.e., sensitivity to cold exposure with pallor, then rubor or cyanosis of the fingers and toes after cold exposure) and a thorough evaluation to rule out the presence of underlying causes. Diagnosis of secondary Raynaud's phenomenon may be associated with older age at onset (i.e., after age 40), often with more severe symptoms, as well as positive laboratory tests, suggesting an underlying connective tissue disease (i.e., positive antinuclear antibodies, positive rheumatoid factor, and the presence of specific autoantibodies), and magnification of the nail folds, indicating the presence of a microvascular disease (<LINK REF="REF-Wigley-2002" TYPE="REFERENCE">Wigley 2002</LINK>).</P><P>The pathogenesis of Raynaud's phenomenon is not clearly understood, but a general hypothesis is that the major underlying cause is an imbalance of vasoconstrictors and vasodilators (with imbalance more toward the prevalence of vasoconstrictors) (<LINK REF="REF-Herrick-2005" TYPE="REFERENCE">Herrick 2005</LINK>). Existing evidence suggests that causes of the underlying pathogenesis of Raynaud's phenomenon likely include abnormalities in the blood vessels (i.e., smooth muscle and endothelium), in neural control of vascular tone, and in intravascular mediators, including those produced by platelet activation and oxidative stress (<LINK REF="REF-Herrick-2005" TYPE="REFERENCE">Herrick 2005</LINK>). However, vascular abnormalities may be minimal in primary Raynaud's phenomenon and more severe in secondary Raynaud's phenomenon (<LINK REF="REF-Herrick-2005" TYPE="REFERENCE">Herrick 2005</LINK>; <LINK REF="REF-Wigley-2002" TYPE="REFERENCE">Wigley 2002</LINK>). This might explain why Raynaud's phenomenon secondary to systemic sclerosis spectrum disorders but not primary Raynaud's phenomenon often leads to irreversible digital ischemia and is much more severe (<LINK REF="REF-Herrick-2005" TYPE="REFERENCE">Herrick 2005</LINK>). In addition, secondary Raynaud's phenomenon is often associated with structural abnormalities in the microvascular system and arteries. Given that Raynaud's phenomenon is more common among women, some have hypothesized that hormonal factors may be involved (<LINK REF="REF-Herrick-2005" TYPE="REFERENCE">Herrick 2005</LINK>). It has been estimated that 14% to 37% of cases of primary Raynaud's phenomenon eventually progress to secondary Raynaud's phenomenon (<LINK REF="REF-Maundrell-2015" TYPE="REFERENCE">Maundrell 2015</LINK>).</P><P>For most people with Raynaud's phenomenon (the vast majority who have primary Raynaud's phenomenon), treatment is conservative (i.e., avoiding cold temperatures and emotional stress, keeping warm, stopping smoking); however, for RP requiring a pharmacological intervention (usually secondary RP), many different drugs may be beneficial (<LINK REF="REF-Garc_x00ed_a_x002d_Carrasco-2008" TYPE="REFERENCE">García-Carrasco 2008</LINK>; <LINK REF="REF-Goundry-2012" TYPE="REFERENCE">Goundry 2012</LINK>; <LINK REF="REF-Herrick-2005" TYPE="REFERENCE">Herrick 2005</LINK>; <LINK REF="STD-Wigley-1987" TYPE="STUDY">Wigley 1987</LINK>).</P></CONDITION><INTERVENTION MODIFIED="2017-11-23 20:30:05 -0500" MODIFIED_BY="[Empty name]"><P>Many randomized controlled trials have examined treatments for both primary and secondary RP. Secondary RP has been studied mostly in SSc and other connective tissue diseases. Conservative treatments and older treatments (i.e. ganglion blockers, alpha blockers) have been superseded by a variety of drugs considered to be more efficacious with lower side effect profiles (<LINK REF="REF-Hansteen-1976" TYPE="REFERENCE">Hansteen 1976</LINK>). These include calcium channel blockers (CCBs), prostacyclin analogues, angiotensin-converting enzyme inhibitors, and phosphodiesterase inhibitors, among others (<LINK REF="REF-Garc_x00ed_a_x002d_Carrasco-2008" TYPE="REFERENCE">García-Carrasco 2008</LINK>). CCBs have become the first line of pharmacological treatment for RP owing to their effectiveness and tolerability (<LINK REF="REF-Garc_x00ed_a_x002d_Carrasco-2008" TYPE="REFERENCE">García-Carrasco 2008</LINK>).</P></INTERVENTION><THEORY MODIFIED="2017-11-23 20:30:24 -0500" MODIFIED_BY="[Empty name]"><P>Calcium channel blockers (CCBs) are calcium channel antagonists that bind to voltage-gated calcium channels to prevent influx of calcium ions into smooth and cardiac muscle cells, thereby promoting vasodilation (<LINK REF="REF-Sturgill-1998" TYPE="REFERENCE">Sturgill 1998</LINK>). The most common class of CCBs is the dihydropyridines, which include nifedipine, nicardipine, amlodipine, and felodipine. Non-dihydropyridine classes of CCBs include benzothiazepine (i.e., diltiazem), phenylalkylamine (i.e., verapamil), and others. Dihydropyridines are more effective for RP, as they are highly selective for vascular smooth muscle in the walls of arteries. They are fast acting and thus are used more often (<LINK REF="REF-Sturgill-1998" TYPE="REFERENCE">Sturgill 1998</LINK>).</P></THEORY><IMPORTANCE MODIFIED="2017-11-28 10:39:57 -0500" MODIFIED_BY="[Empty name]"><P>Multiple studies have shown that CCBs have some efficacy in treating individuals with RP. Previous meta-analyses showed efficacy in the treatment of patients with primary RP and RP secondary to SSc (<LINK REF="STD-Ennis-2016" TYPE="STUDY">Ennis 2016</LINK>; <LINK REF="STD-Thompson-2001" TYPE="STUDY">Thompson 2001</LINK>; <LINK REF="STD-Thompson-2005" TYPE="STUDY">Thompson 2005</LINK>). However, the vascular dysfunction that underlies RP is not clearly understood, and variable patient responses to treatment are based on RP type and severity. As such<I>, </I>no specific guidelines outlining the most efficacious drug interventions have been developed (<LINK REF="STD-Dziadzio-1999" TYPE="STUDY">Dziadzio 1999</LINK>; <LINK REF="REF-Goundry-2012" TYPE="REFERENCE">Goundry 2012</LINK>). Moreover, the nuances of treatment have not been well studied<I>. </I>No previous meta-analyses have examined effects of dose or CCB type, or differences in response dependent on the subtype of RP. This review is different from previous reviews in that review authors analyzed effect of CCBs in both primary and secondary RP and by CCB type and dose.</P><P>This review is based on the generic protocol for drug interventions for Raynaud's phenomenon (<LINK REF="REF-Pope-2015" TYPE="REFERENCE">Pope 2015</LINK>).</P></IMPORTANCE></BACKGROUND><OBJECTIVES MODIFIED="2017-11-11 10:40:54 -0500" MODIFIED_BY="[Empty name]"><P>To assess the benefits and harms of calcium channel blockers (CCBs) versus placebo for treatment of individuals with Raynaud&#8217;s phenomenon (RP) with respect to Raynaud's type (primary vs secondary) and type and dose of CCBs. </P></OBJECTIVES><METHODS MODIFIED="2017-11-28 11:10:52 -0500" MODIFIED_BY="[Empty name]"><SELECTION_CRITERIA MODIFIED="2017-11-23 20:30:49 -0500" MODIFIED_BY="[Empty name]"><CRIT_STUDIES MODIFIED="2017-11-11 11:02:34 -0500" MODIFIED_BY="[Empty name]"><P>We included randomized controlled trials (RCTs) and cross-over RCTs that lasted one week or longer. We included studies reported as full text, those published as abstract only, and unpublished data. We applied no language restrictions.</P></CRIT_STUDIES><CRIT_PARTICIPANTS MODIFIED="2017-11-11 11:07:21 -0500" MODIFIED_BY="[Empty name]"><P>We used no standardized definition of RP. Studies included primary RP and/or RP secondary to systemic sclerosis or other connective tissue diseases (<LINK REF="REF-LeRoy-1992" TYPE="REFERENCE">LeRoy 1992</LINK>; <LINK REF="REF-Masi-1980" TYPE="REFERENCE">Masi 1980</LINK>) and enrolled participants with RP at any stage. </P><P>In the absence of an accepted definition for RP, we included all participants reported to have RP and noted the criteria that authors used to define RP. </P></CRIT_PARTICIPANTS><CRIT_INTERVENTIONS MODIFIED="2017-11-11 11:08:16 -0500" MODIFIED_BY="[Empty name]"><P>Interventions of interest were CCBs and placebo. We applied no restrictions on interventions and comparators, such as delivery, dose, duration, and intensity. We allowed all co-interventions.</P></CRIT_INTERVENTIONS><CRIT_OUTCOMES MODIFIED="2017-11-23 20:30:49 -0500" MODIFIED_BY="[Empty name]"><P>We considered outcomes for trials one week or longer in duration. Outcome measurements included the following.</P><SUBSECTION><HEADING LEVEL="4">Major outcomes</HEADING><UL><LI>Frequency of attacks (average attacks/week)</LI><LI>Duration of attacks (average duration per attack in minutes)</LI><LI>Severity of attacks</LI><LI>Pain (i.e. visual analogue scale [VAS], numerical rating scale [NRS])</LI><LI>Patient global assessment (measured on various scales, i.e. 0 to 10 VAS)</LI><LI>Withdrawals (due to treatment adverse effects)</LI><LI>Serious adverse events (treatment adverse effects leading to death or withdrawal from study and hospitalization)</LI></UL></SUBSECTION><SUBSECTION><HEADING LEVEL="4">Minor outcomes</HEADING><UL><LI>Function</LI><LI>Raynaud's condition score (RCS; <LINK REF="REF-Merkel-2002" TYPE="REFERENCE">Merkel 2002</LINK>)</LI><LI>Physician's global assessment</LI><LI>Change in digital ulceration</LI><LI>Treatment preference</LI><LI>General improvement</LI><LI>Side effects</LI></UL></SUBSECTION></CRIT_OUTCOMES></SELECTION_CRITERIA><SEARCH_METHODS MODIFIED="2017-11-14 05:29:43 -0500" MODIFIED_BY="[Empty name]"><ELECTRONIC_SEARCHES MODIFIED="2017-11-14 05:28:55 -0500" MODIFIED_BY="[Empty name]"><P>We designed a sensitive search strategy to retrieve RCTs from electronic bibliographic databases. We identified items from the following databases on May 19, 2017.</P><UL><LI>Cochrane Library via Wiley (May 19, 2017) including the Cochrane Central Register of Controlled Trials (CENTRAL), the Database of Reviews of Effects (DARE), Health Technology Assessment (HTA), and the Economic Evaluations Database (EED).</LI><LI>MEDLINE via OVID (1946 to May 19, 2017).</LI><LI>Embase via OVID (1947 to May 19, 2017).</LI><LI>Clinicaltrials.gov (all years).</LI><LI>World Health Organization (WHO) International Clinical Trials Portal (all years).</LI></UL><P>We applied no language restrictions. We used the randomized controlled trials filter from Chapter 6 of the <I>Cochrane Handbook for Systematic Reviews of Interventions</I>. We devised the search strategy for the Cochrane Library Web interface, then adapted it for use with other databases. We have presented the search strategy in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>.</P></ELECTRONIC_SEARCHES><OTHER_SEARCHES MODIFIED="2017-11-14 05:29:43 -0500" MODIFIED_BY="[Empty name]"><P>We searched all bibliographies of retrieved articles and contacted key experts for additional and unpublished data.</P><P>For safety assessments, we searched the websites of regulatory agencies including US Food and Drug Administration-MedWatch (http://www.fda.gov/Safety/MedWatch/default.htm), European Medicines Evaluation Agency (http://www.ema.europa.eu), Australian Adverse Drug Reactions Bulletin (http://www.tga.gov.au/safety/ews-monitoring.htm), and UK Medicines and Healthcare products Regulatory Agency (MHRA) pharmacovigilance and drug safety updates (http://www.mhra.gov.uk/Safetyinformation/index.htm), using the keywords "nifedipine," "nicardipine," "nisoldipine," "diltiazem," "verapamil," "amlodipine," "isradipine," and "BAY K 9320," on July 23, 2017.</P><P>On July 19, 2017, we searched PubMed for errata or retractions from included studies published in full text (www.ncbi.nlm.nih.gov/pubmed) and found none.</P></OTHER_SEARCHES></SEARCH_METHODS><DATA_COLLECTION MODIFIED="2017-11-28 11:10:52 -0500" MODIFIED_BY="[Empty name]"><STUDY_SELECTION MODIFIED="2017-11-28 11:10:52 -0500" MODIFIED_BY="[Empty name]"><P>We included only randomized trials that compared CCBs versus placebo. We included trials comparing CCBs versus other active treatments if they also included a placebo group. We excluded trials comparing CCBs versus other forms of treatment (i.e., natural herbal methods and surgical methods). Two review authors (PTi, SH, or FR) independently reviewed references retrieved through the search and identified studies that met the inclusion criteria. JP resolved differences regarding selection.<BR/></P></STUDY_SELECTION><DATA_EXTRACTION MODIFIED="2017-11-24 21:02:57 -0500" MODIFIED_BY="[Empty name]"><P>We recorded study characteristics and outcome data on a data collection form that had been piloted on at least one study in the review. One review author (FR) extracted study characteristics from included studies, and a second review author (LJM or ETG) spot-checked study characteristics for accuracy against the trial report. We extracted the following study characteristics.</P><UL><LI>Methods: study design, total duration of study, details of any "run-in" period, washout period, number of study centers and locations, study setting, withdrawals, and date of study.</LI><LI>Participants: N, mean age, age range, sex, disease duration, severity of condition, diagnostic criteria, inclusion criteria, and exclusion criteria.</LI><LI>Interventions: intervention, comparison, concomitant medications, and excluded medications.</LI><LI>Outcomes: primary and secondary outcomes specified and collected and time points reported.</LI><LI>Characteristics of trial design: as outlined below in the <LINK TAG="QUALITY_ASSESSMENT" TYPE="SECTION">Assessment of risk of bias in included studies</LINK> section.</LI><LI>Notes: funding for trial and notable declarations of interest of trial authors.</LI></UL><P>We extracted the number of events and the number of participants per treatment group for dichotomous outcomes, and means and standard deviations and number of participants per treatment group for continuous outcomes. We converted the standard deviation (SD) to a standard error (SE) for entry into the generic inverse variance method in RevMan version 5 (2014), using the formula SE = SD/(square root) (N).</P><P>We noted in the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table if outcome data were not reported in a usable way, and when data were transformed or estimated from a graph. We resolved disagreements by consensus or by consultation with a third person (JP or GAW). One review author (FR) transferred data into the Review Manager RevMan version 5 (2014). We double-checked that data were entered correctly by comparing data presented in the systematic review against data in the study reports.</P><P>For all outcomes, we extracted data from studies and reported as follows:</P><UL><LI>If both final values and change from baseline values were reported for the same outcome, we preferentially extracted changes from baseline.</LI><LI>If both unadjusted and adjusted values were reported for the same outcome, we extracted the adjusted values.</LI><LI>If data are analyzed based on intention-to-treat (ITT) and another sample (i.e. per-protocol, as-treated), we extracted both but noted these differences.</LI><LI>If data were available for multiple time points, we used the data that corresponded most closely with those of other RCTs.</LI></UL><P>For cross-over studies, we extracted changes in each arm (placebo and treatment) by comparing them with baseline values for each arm when available, or by noting differences between final treatment and placebo.</P></DATA_EXTRACTION><QUALITY_ASSESSMENT MODIFIED="2017-11-28 11:10:34 -0500" MODIFIED_BY="[Empty name]"><P>Two review authors (SH, PTi, or FR) independently assessed the risk of bias of each included study according to the domain-based evaluation outlined in the <I>Cochrane Handbook for Systematic Reviews of Interventions </I>(<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>)<I>.</I> We compared assessments, identified inconsistencies, and reached consensus.</P><P>For each included study, we rated the following domains as "low risk," "high risk," or "unclear risk" for "risk of bias" assessments.</P><UL><LI>Random sequence generation.</LI><LI>Allocation concealment.</LI><LI>Blinding of participants and personnel.</LI><LI>Blinding of outcome assessment.</LI><LI>Incomplete outcome data.</LI><LI>Selective outcome reporting.</LI><LI>Other bias: We considered cross-over effects and baseline characteristics.</LI></UL><P>We reported an assessment of bias for each included study in a "Risk of bias" table within the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> section.</P></QUALITY_ASSESSMENT><EFFECT_MEASURES MODIFIED="2017-11-24 21:03:20 -0500" MODIFIED_BY="[Empty name]"><P>We estimated treatment effects for continuous outcomes using weighted mean difference (WMD) or standardized mean difference (SMD). When investigators used different scales to measure the same conceptual outcome (i.e. pain), we calculated SMDs instead, along with corresponding 95% confidence intervals (CIs). We back-translated the SMD to a typical scale (i.e. 0 to 10 for pain) by multiplying the SMD by a typical among-person standard deviation (i.e. standard deviation at baseline of the control group from the most representative trial) (as per Chapter 12 of the <I>Cochrane Handbook for Systematic Reviews of Interventions</I>) (<LINK REF="REF-Sch_x00fc_nemann-2011" TYPE="REFERENCE">Schünemann 2011</LINK>).</P><P>We estimated dichotomous outcomes using risk ratios (RRs) by dividing the proportion of events in the treatment group by the proportion of events in the control group. We reported 95% CIs with each outcome estimate.</P><P>In the <LINK TAG="INTERVENTION_EFFECTS" TYPE="SECTION">Effects of interventions</LINK> section under Results and in the "Comments" column of <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>, we provided absolute percent difference, relative percent change from baseline, and number needed to treat for an additional beneficial outcome (NNTB) (we provided NNTB only when the outcome showed a statistically significant difference).</P><P>For dichotomous outcomes, we calculated the NNTB from the control group event rate and the risk ratio using the Visual Rx NNT calculator (<LINK REF="REF-Cates-2008" TYPE="REFERENCE">Cates 2008</LINK>). We calculated the NNTB using the Wells calculator (available at the Cochrane Musculoskeletal Group [CMSG] Editorial Office).</P><P>For dichotomous outcomes, we calculated absolute risk difference using the risk difference statistic in RevMan version 5 (2014) and expressed the result as a percentage. For continuous outcomes, we calculated absolute benefit as improvement in the intervention group minus improvement in the control group, in original units, expressed as a percentage.</P><P>We calculated relative percent change for dichotomous data as "Risk ratio - 1" and expressed this as a percentage. For continuous outcomes, we calculated relative difference in changes from baseline as absolute benefit divided by the baseline mean of the control group, expressed as a percentage.</P></EFFECT_MEASURES><UNIT_OF_ANALYSIS MODIFIED="2017-11-23 20:32:16 -0500" MODIFIED_BY="[Empty name]"><P>The participant was the unit of analysis for each outcome. For cross-over trials, calculation of standard errors and use of the generic inverse variance method accounted for the fact that observations were paired.</P><P>When a single trial reported multiple trial arms, we included only the relevant arms. If two comparisons were combined in the same meta-analysis (i.e. different doses, different drugs), we halved the control group to avoid double-counting.</P></UNIT_OF_ANALYSIS><MISSING_DATA MODIFIED="2017-11-11 17:22:16 -0500" MODIFIED_BY="[Empty name]"><P>We made all possible efforts to obtain any missing data. We had foreign language studies translated when possible, and we used the Cochrane network to try to obtain articles that were not available at the national libraries in Ottawa and Washington, if they also were not available at local universities. When feasible, we estimated missing standard deviations (using standard errors, P values, confidence intervals, error bars in graphs, range and sample size, etc., if available).</P></MISSING_DATA><HETEROGENEITY_ASSESSMENT MODIFIED="2017-11-14 05:38:32 -0500" MODIFIED_BY="[Empty name]"><P>We assessed heterogeneity by using Chi² and I² tests and by visually inspecting forest plots for outliers. </P><P>As recommended in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Deeks-2011" TYPE="REFERENCE">Deeks 2011</LINK>), an I² value of 0% to 40% might "not be important"; 30% to 60% may represent "moderate" heterogeneity; 50% to 90% may represent "substantial" heterogeneity; and 75% to 100% represents "considerable" heterogeneity. As noted in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I>, we will keep in mind that the importance of I² depends on the magnitude and direction of effects; and on the strength of evidence for heterogeneity.</P><P>For the Chi² test, a P value &#8804; 0.10 indicates evidence of statistical heterogeneity.</P><P>We reported the presence of substantial heterogeneity and investigated possible causes by following the recommendations provided in Section 9.6 of the <I>Cochrane Handbook for Systematic Reviews of Interventions</I>.</P></HETEROGENEITY_ASSESSMENT><BIAS_ASSESSMENT MODIFIED="2017-11-11 17:40:41 -0500" MODIFIED_BY="[Empty name]"><P>For outcomes when more than 10 studies were present, we examined funnel plots to assess publication bias (<LINK REF="REF-Egger-1997" TYPE="REFERENCE">Egger 1997</LINK>; <LINK REF="REF-Sterne-2011" TYPE="REFERENCE">Sterne 2011</LINK>). We used this approach to assess frequency of attacks and severity of attacks.</P></BIAS_ASSESSMENT><DATA_SYNTHESIS MODIFIED="2017-11-23 20:32:22 -0500" MODIFIED_BY="[Empty name]"><P>We undertook meta-analyses only when this was meaningful (i.e., when treatments, participants, and the underlying clinical question were similar enough for pooling to make sense). We used the generic inverse variance method for the meta-analysis by entering the estimate of treatment effect and the standard error for each study. For <LINK REF="STD-RTSI-2000" TYPE="STUDY">RTSI 2000</LINK>, we reported a geometric mean and found that the P value for attack frequency was not given with enough precision for calculation of a standard error for inclusion in the meta-analysis.</P><P>We used a fixed-effect model and performed a sensitivity analysis using the random-effects model.</P></DATA_SYNTHESIS><SUBGROUP_ANALYSIS MODIFIED="2017-11-28 10:39:57 -0500" MODIFIED_BY="[Empty name]"><P>In addition to examining all CCBs versus placebo for any subset of RP, we performed the following subgroup analyses when possible.</P><UL><LI>Dihydropyridine type CCBs versus placebo. Dihydropyridine CCBs were studied as they are the subgroup of CCBs that are not cardioselective and are traditionally used in RP treatment whereas other CCBs such as verapamil are not routinely used and diltiazem is not used as first line subtype of CCBs.</LI><LI>CCBs versus placebo by dose (i.e., low dose, medium, medium/high dose). Low, medium and high doses for CCBs were defined as specified in the guideline in <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>. Since only three studies used high doses of CCBs, we combined trials using high doses CCBs with the medium dose CCBs for outcomes where data for analysis was available. We had most data with respect to dose for nifedipine. Clinical impression is to start with lower doses and that if tolerated, higher doses may yield more benefit.</LI><LI>CCBs versus placebo by actual CCB drug (mainly nifedipine, nicardipine, and nisoldipine, as these CCBs were used most frequently in included trials).</LI><LI>CCBs versus placebo by Raynaud's type (primary or secondary).</LI><LI>Nifedipine versus placebo by disease type (primary or secondary RP).</LI></UL><P>For major outcomes with significant heterogeneity (I² &gt; 50%), we tested robustness of results derived from the fixed effect by repeating the analysis using a random-effects model. Because results from the two models were similar (i.e., in direction of effect), we reported fixed-effect results throughout.</P></SUBGROUP_ANALYSIS><SENSITIVITY_ANALYSIS MODIFIED="2017-11-14 05:41:41 -0500" MODIFIED_BY="[Empty name]"><P>To address the presence of significant heterogeneity (I² &gt; 50%; <LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>), we performed post hoc sensitivity analyses. We repeated analyses of major outcomes with significant heterogeneity by omitting the study or studies believed to be responsible for the heterogeneity. Reasons for omission included the following.</P><UL><LI>Study used a scale of measure different from that used in other studies.</LI><LI>Study used study duration different from that used in other studies.</LI></UL><SUBSECTION><HEADING LEVEL="4">Grading the evidence</HEADING><P>In addition to providing tools that can be used to assess risk of study bias, we used the GRADE approach in evaluating the overall quality of evidence for reported outcomes (<LINK REF="REF-Grade-2008" TYPE="REFERENCE">Grade 2008</LINK>). Through this approach, we assessed the quality of evidence as follows: (1) high quality from RCTs, (2) moderate quality downgraded by one level owing to a study limitation, (3) low quality double-downgraded for study limitations, and, last, (4) very low quality triple-downgraded owing to multiple study limitations. We downgraded evidence using the following GRADE approach.</P><UL><LI>Limitations in the design and implementation of available studies, suggesting high likelihood of bias.</LI><LI>Indirectness of evidence (indirect population, intervention, control, outcomes) (not applicable to this meta-analysis, as only RCTs were analyzed).</LI><LI>Unexplained heterogeneity or inconsistency of results (including problems with subgroup analyses).</LI><LI>Imprecision of results (wide confidence intervals).</LI><LI>High probability of publication bias.</LI></UL></SUBSECTION><SUBSECTION><HEADING LEVEL="4">"Summary of findings" table</HEADING><P>We have summarized the major outcomes of this review - frequency of attack, duration of attack, severity of attack, pain, patient global assessment, withdrawals due to adverse events, and serious adverse events - in <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>. This table contains intervention effect estimates, comparators, and details on quality of evidence.</P></SUBSECTION></SENSITIVITY_ANALYSIS></DATA_COLLECTION></METHODS><RESULTS MODIFIED="2017-11-29 09:37:53 -0500" MODIFIED_BY="[Empty name]"><STUDY_DESCRIPTION MODIFIED="2017-11-22 20:23:37 -0500" MODIFIED_BY="[Empty name]"><P>Refer to <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies,</LINK> <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies,</LINK> and <LINK TAG="CHARACTERISTICS_OF_AWAITING_STUDIES" TYPE="SECTION">Characteristics of studies awaiting classification</LINK> for descriptions of individual studies.</P><SEARCH_RESULTS MODIFIED="2017-11-14 05:42:25 -0500" MODIFIED_BY="[Empty name]"><P>The search performed on December 2, 2015, and updated on May 19, 2017, yielded 3389 hits (1061 from the Cochrane Library, 1027 from Medline, 1251 from Embase, and 50 from clinicaltrials.gov). After we screened out duplicates, 2337 articles remained. Further screening of these publications yielded 305 articles. When we examined the 305 articles further, we identified 77 articles, from which we excluded 30 with reasons and found that seven trials were awaiting classification, two trials were ongoing, and 38 trials met the inclusion criteria of this review. <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK> provides further details on our research results in a flow diagram format.</P></SEARCH_RESULTS><INCLUDED_STUDIES_DESCR MODIFIED="2017-11-11 18:27:16 -0500" MODIFIED_BY="[Empty name]"><P>We included 38 trials that investigated effects of CCBs versus placebo in 982 participants with RP (<LINK REF="STD-Aldoori-1986" TYPE="STUDY">Aldoori 1986</LINK>; <LINK REF="STD-Bravard-1983" TYPE="STUDY">Bravard 1983</LINK>; <LINK REF="STD-Challenor-1987" TYPE="STUDY">Challenor 1987</LINK>; <LINK REF="STD-Challenor-1989" TYPE="STUDY">Challenor 1989</LINK>; <LINK REF="STD-Constantini-1987" TYPE="STUDY">Constantini 1987</LINK>; <LINK REF="STD-Corbin-1986" TYPE="STUDY">Corbin 1986</LINK>; <LINK REF="STD-Ettinger-1984" TYPE="STUDY">Ettinger 1984</LINK>; <LINK REF="STD-Ferri-1992" TYPE="STUDY">Ferri 1992</LINK>; <LINK REF="STD-Finch-1988" TYPE="STUDY">Finch 1988</LINK>; <LINK REF="STD-French-Co_x002d_op-1991" TYPE="STUDY">French Co-op 1991</LINK>; <LINK REF="STD-Gjorup-1986a" TYPE="STUDY">Gjorup 1986a</LINK>; <LINK REF="STD-Gjorup-1986b" TYPE="STUDY">Gjorup 1986b</LINK>; <LINK REF="STD-Hawkins-1985" TYPE="STUDY">Hawkins 1985</LINK>; <LINK REF="STD-Kahan-1985a" TYPE="STUDY">Kahan 1985a</LINK>; <LINK REF="STD-Kahan-1985b" TYPE="STUDY">Kahan 1985b</LINK>; <LINK REF="STD-Kahan-1985c" TYPE="STUDY">Kahan 1985c</LINK>; <LINK REF="STD-Kahan-1987" TYPE="STUDY">Kahan 1987</LINK>; <LINK REF="STD-Kallenberg-1987" TYPE="STUDY">Kallenberg 1987</LINK>; <LINK REF="STD-Kinney-1982" TYPE="STUDY">Kinney 1982</LINK>; <LINK REF="STD-Kirch-1987" TYPE="STUDY">Kirch 1987</LINK>; <LINK REF="STD-La-Civita-1997" TYPE="STUDY">La Civita 1997</LINK>; <LINK REF="STD-Leppert-1989" TYPE="STUDY">Leppert 1989</LINK>; <LINK REF="STD-Malamet-1984" TYPE="STUDY">Malamet 1984</LINK>; <LINK REF="STD-Meyrick-Thomas-1987" TYPE="STUDY">Meyrick Thomas 1987</LINK>; <LINK REF="STD-Muller_x002d_Buhl-1983" TYPE="STUDY">Muller-Buhl 1983</LINK>; <LINK REF="STD-Nilsson-1987" TYPE="STUDY">Nilsson 1987</LINK>; <LINK REF="STD-Rhedda-1985" TYPE="STUDY">Rhedda 1985</LINK>; <LINK REF="STD-Rodeheffer-1983" TYPE="STUDY">Rodeheffer 1983</LINK>; <LINK REF="STD-RTSI-2000" TYPE="STUDY">RTSI 2000</LINK>; <LINK REF="STD-Rupp-1987" TYPE="STUDY">Rupp 1987</LINK>; <LINK REF="STD-Sarkozi--1986" TYPE="STUDY">Sarkozi 1986</LINK>; <LINK REF="STD-Sauza-1984" TYPE="STUDY">Sauza 1984</LINK>; <LINK REF="STD-Smith-1982" TYPE="STUDY">Smith 1982</LINK>; <LINK REF="STD-Teixeira-da-Costa" TYPE="STUDY">Teixeira da Costa</LINK>; <LINK REF="STD-Waller-1986" TYPE="STUDY">Waller 1986</LINK>; <LINK REF="STD-White-1986" TYPE="STUDY">White 1986</LINK>; <LINK REF="STD-Wigley-1987" TYPE="STUDY">Wigley 1987</LINK>; <LINK REF="STD-Wollersheim-1991" TYPE="STUDY">Wollersheim 1991</LINK>). See <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>.</P><P>Only nine of these studies exclusively studied patients with primary RP (N = 365 participants), five studied patients with secondary RP (N = 63 participants), and remaining studies (N = 554 participants) examined a mixture of patients with primary RP and secondary RP.</P><P>Of the 38 trials included in this systematic review, 36 were double-blind and two were single-blind; 33 were of cross-over design and five were of parallel design. All studies were randomized, or appeared to be randomized. The duration of studies ranged from 2 to 20 weeks, with an average of 7.4 weeks and a median of 3 weeks per arm, with publication years ranging from 1982 to 2000.</P><P>Of the 38 included studies, 21 used low-dose CCBs, 13 used medium-dose CCBs, and three used high-dose CCBs (see <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK> for dosage ranges). Twenty-two RCTs compared nifedipine versus placebo (<LINK REF="STD-Aldoori-1986" TYPE="STUDY">Aldoori 1986</LINK>; <LINK REF="STD-Bravard-1983" TYPE="STUDY">Bravard 1983</LINK>; <LINK REF="STD-Challenor-1989" TYPE="STUDY">Challenor 1989</LINK>; <LINK REF="STD-Constantini-1987" TYPE="STUDY">Constantini 1987</LINK>; <LINK REF="STD-Corbin-1986" TYPE="STUDY">Corbin 1986</LINK>; <LINK REF="STD-Finch-1988" TYPE="STUDY">Finch 1988</LINK>; <LINK REF="STD-Gjorup-1986b" TYPE="STUDY">Gjorup 1986b</LINK>; <LINK REF="STD-Hawkins-1985" TYPE="STUDY">Hawkins 1985</LINK>; <LINK REF="STD-Kahan-1985a" TYPE="STUDY">Kahan 1985a</LINK>; <LINK REF="STD-Kahan-1985c" TYPE="STUDY">Kahan 1985c</LINK>; <LINK REF="STD-Kallenberg-1987" TYPE="STUDY">Kallenberg 1987</LINK>; <LINK REF="STD-Kirch-1987" TYPE="STUDY">Kirch 1987</LINK>; <LINK REF="STD-Malamet-1984" TYPE="STUDY">Malamet 1984</LINK>; <LINK REF="STD-Meyrick-Thomas-1987" TYPE="STUDY">Meyrick Thomas 1987</LINK>; <LINK REF="STD-Nilsson-1987" TYPE="STUDY">Nilsson 1987</LINK>; <LINK REF="STD-Rodeheffer-1983" TYPE="STUDY">Rodeheffer 1983</LINK>; <LINK REF="STD-RTSI-2000" TYPE="STUDY">RTSI 2000</LINK>; <LINK REF="STD-Sarkozi--1986" TYPE="STUDY">Sarkozi 1986</LINK>; <LINK REF="STD-Sauza-1984" TYPE="STUDY">Sauza 1984</LINK>; <LINK REF="STD-Smith-1982" TYPE="STUDY">Smith 1982</LINK>; <LINK REF="STD-Waller-1986" TYPE="STUDY">Waller 1986</LINK>; <LINK REF="STD-White-1986" TYPE="STUDY">White 1986</LINK>). The daily dose of nifedipine ranged from 10 to 80 mg/d, the mean dose was 45 mg/d, and the median dose was 40 mg/d. Six trials compared nicardipine versus placebo (<LINK REF="STD-Ferri-1992" TYPE="STUDY">Ferri 1992</LINK>; <LINK REF="STD-French-Co_x002d_op-1991" TYPE="STUDY">French Co-op 1991</LINK>; <LINK REF="STD-Kahan-1987" TYPE="STUDY">Kahan 1987</LINK>; <LINK REF="STD-Rupp-1987" TYPE="STUDY">Rupp 1987</LINK>; <LINK REF="STD-Wigley-1987" TYPE="STUDY">Wigley 1987</LINK>; <LINK REF="STD-Wollersheim-1991" TYPE="STUDY">Wollersheim 1991</LINK>a). Daily doses of nicardipine ranged from 30 to 100 mg, with a mean of 68 mg/d. Two trials compared nisoldipine versus placebo (<LINK REF="STD-Challenor-1987" TYPE="STUDY">Challenor 1987</LINK>; <LINK REF="STD-Gjorup-1986a" TYPE="STUDY">Gjorup 1986a</LINK>), providing daily dosages of 10 mg and 20 mg, respectively. Three trials compared diltiazem versus placebo (<LINK REF="STD-Kahan-1985b" TYPE="STUDY">Kahan 1985b</LINK>; <LINK REF="STD-Rhedda-1985" TYPE="STUDY">Rhedda 1985</LINK>; <LINK REF="STD-Teixeira-da-Costa" TYPE="STUDY">Teixeira da Costa</LINK>), giving a mean dosage of 240 mg/d (dosages ranged from 180 mg to 360 mg, with a median dose of 180 mg/d). Individual studies compared Bay K 9320, amlodipine, isradipine, or verapamil (<LINK REF="STD-Muller_x002d_Buhl-1983" TYPE="STUDY">Muller-Buhl 1983</LINK>; <LINK REF="STD-La-Civita-1997" TYPE="STUDY">La Civita 1997</LINK>; <LINK REF="STD-Leppert-1989" TYPE="STUDY">Leppert 1989</LINK>; <LINK REF="STD-Kinney-1982" TYPE="STUDY">Kinney 1982</LINK>, respectively) versus placebo.</P></INCLUDED_STUDIES_DESCR><EXCLUDED_STUDIES_DESCR MODIFIED="2017-11-22 20:23:37 -0500" MODIFIED_BY="[Empty name]"><P>We excluded 30 additional articles (see <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>). We excluded 10 studies because they lacked a placebo (<LINK REF="STD-Della-Bella-1997" TYPE="STUDY">Della Bella 1997</LINK>; <LINK REF="STD-Dziadzio-1999" TYPE="STUDY">Dziadzio 1999</LINK>; <LINK REF="STD-Leppert-1993" TYPE="STUDY">Leppert 1993</LINK>; <LINK REF="STD-Myrdal-1994" TYPE="STUDY">Myrdal 1994</LINK>; <LINK REF="STD-Park-2013" TYPE="STUDY">Park 2013</LINK>; <LINK REF="STD-Rademaker-1989" TYPE="STUDY">Rademaker 1989</LINK>; <LINK REF="STD-Rademaker-1992" TYPE="STUDY">Rademaker 1992</LINK>; <LINK REF="STD-Ringqvist-1993" TYPE="STUDY">Ringqvist 1993</LINK>; <LINK REF="STD-Varela_x002d_Aguilar-1997" TYPE="STUDY">Varela-Aguilar 1997</LINK> <LINK REF="STD-Wu-2008" TYPE="STUDY">Wu 2008</LINK>); another four studies because they did not present placebo data (<LINK REF="STD-Codella-1989" TYPE="STUDY">Codella 1989</LINK>; <LINK REF="STD-La-Civita-1996" TYPE="STUDY">La Civita 1996</LINK>; <LINK REF="STD-Rademaker-1989" TYPE="STUDY">Rademaker 1989</LINK>; <LINK REF="STD-Varela_x002d_Aguilar-1997" TYPE="STUDY">Varela-Aguilar 1997</LINK>); nine trials because they were not randomized (<LINK REF="STD-Creager-1984" TYPE="STUDY">Creager 1984</LINK>; <LINK REF="STD-Garcia-Hernandez2004" TYPE="STUDY">Garcia Hernandez2004</LINK>; <LINK REF="STD-Joseph-1988" TYPE="STUDY">Joseph 1988</LINK>; <LINK REF="STD-Kallenberg-1991" TYPE="STUDY">Kallenberg 1991</LINK>; <LINK REF="STD-Lewis-1987" TYPE="STUDY">Lewis 1987</LINK>; <LINK REF="STD-Pisenti-1984" TYPE="STUDY">Pisenti 1984</LINK>; <LINK REF="STD-Smith-1985" TYPE="STUDY">Smith 1985</LINK>; <LINK REF="STD-Vayssairat-1989" TYPE="STUDY">Vayssairat 1989</LINK>; <LINK REF="STD-Wollersheim-1987" TYPE="STUDY">Wollersheim 1987</LINK>); one trial because researchers gave participants placebo and treatment simultaneously (<LINK REF="STD-Schmidt-1989" TYPE="STUDY">Schmidt 1989</LINK>); two studies because they were not of adequate duration (duration &lt; 1 week: <LINK REF="STD-Weber-1990" TYPE="STUDY">Weber 1990</LINK>; <LINK REF="STD-Kahan-1983b" TYPE="STUDY">Kahan 1983b</LINK>); one study because study authors reported an insufficient washout duration of one day (<LINK REF="STD-Winston-1983" TYPE="STUDY">Winston 1983</LINK>); and three were excluded because they were meta-analyzes (<LINK REF="STD-Ennis-2016" TYPE="STUDY">Ennis 2016</LINK>; <LINK REF="STD-Thompson-2001" TYPE="STUDY">Thompson 2001</LINK>; <LINK REF="STD-Thompson-2005" TYPE="STUDY">Thompson 2005</LINK>).</P><P>We have not currently included seven studies because we were unable to locate the articles or full data (<LINK REF="STD-EUCTR2009_x002d_018194_x002d_31_x002d_GB" TYPE="STUDY">EUCTR2009-018194-31-GB</LINK>; <LINK REF="STD-Kahan-1982" TYPE="STUDY">Kahan 1982</LINK>; <LINK REF="STD-Kahan-1983a" TYPE="STUDY">Kahan 1983a</LINK>; <LINK REF="STD-Redondo-1986" TYPE="STUDY">Redondo 1986</LINK>; <LINK REF="STD-van-Heereveld-1988" TYPE="STUDY">van Heereveld 1988</LINK>; <LINK REF="STD-Wasir-1983" TYPE="STUDY">Wasir 1983</LINK>; <LINK REF="STD-Wise-1987" TYPE="STUDY">Wise 1987</LINK>). See <LINK TAG="AWAITING_STUDIES" TYPE="SECTION">Studies awaiting classification</LINK>.</P><P>As of July 2017, we found two studies in Clinicaltrials.gov that were ongoing: One study compared 10% nifedipine versus 5% sildenafil (and placebo) (<LINK REF="STD-Vera_x002d_Kellet-2017" TYPE="STUDY">Vera-Kellet 2017</LINK>); the other compared diltiazem versus nitroglycerin and placebo (<LINK REF="STD-Nazarinia-2016" TYPE="STUDY">Nazarinia 2016</LINK>).</P></EXCLUDED_STUDIES_DESCR></STUDY_DESCRIPTION><STUDY_QUALITY MODIFIED="2017-11-29 09:37:53 -0500" MODIFIED_BY="[Empty name]"><P>The most commonly encountered biases were lack of random sequence generation (in 78% of studies) and concealment of allocation (in 70% of studies), followed by performance, attrition, and selective reporting biases, respectively. See <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>, <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>, and <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK> for additional details on risk of bias of included studies.</P><ALLOCATION MODIFIED="2017-11-24 21:04:31 -0500" MODIFIED_BY="[Empty name]"><P>We judged allocation sequence generation as "high risk" for <LINK REF="STD-Rhedda-1985" TYPE="STUDY">Rhedda 1985</LINK>. See <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>. Although an independent collaborator performed randomization by using computer-generated random numbers, randomization did not produce groups with equal baseline characteristics. At completion of the trial, researchers reported that the control group had more severe RP than the active treatment group. Nine of the 38 included studies adequately described allocation sequence and concealment, and we rated them as having "low risk" (<LINK REF="STD-Corbin-1986" TYPE="STUDY">Corbin 1986</LINK>; <LINK REF="STD-French-Co_x002d_op-1991" TYPE="STUDY">French Co-op 1991</LINK>; <LINK REF="STD-Kahan-1985a" TYPE="STUDY">Kahan 1985a</LINK>; <LINK REF="STD-Kahan-1987" TYPE="STUDY">Kahan 1987</LINK>; <LINK REF="STD-Nilsson-1987" TYPE="STUDY">Nilsson 1987</LINK>; <LINK REF="STD-Rhedda-1985" TYPE="STUDY">Rhedda 1985</LINK>; <LINK REF="STD-Rodeheffer-1983" TYPE="STUDY">Rodeheffer 1983</LINK>; <LINK REF="STD-RTSI-2000" TYPE="STUDY">RTSI 2000</LINK>; <LINK REF="STD-Sarkozi--1986" TYPE="STUDY">Sarkozi 1986</LINK>). Methods of concealment used by these trials included automated computer generation, tables of random numbers, block randomization, and randomization by a third party co-ordinating center. The remainder of these studies failed to adequately describe how the allocation sequence and concealment were generated; we rated them as having "unclear risk of bias."</P></ALLOCATION><BLINDING MODIFIED="2017-11-29 09:37:53 -0500" MODIFIED_BY="[Empty name]"><P>Investigators stated that most (34/38; 89%) of the included RCTs were "double-blind"; we assumed that these RCTs had adequate blinding and classified them as "low risk." Four studies (<LINK REF="STD-Hawkins-1985" TYPE="STUDY">Hawkins 1985</LINK>; <LINK REF="STD-Kirch-1987" TYPE="STUDY">Kirch 1987</LINK>; <LINK REF="STD-Leppert-1989" TYPE="STUDY">Leppert 1989</LINK>; <LINK REF="STD-Rodeheffer-1983" TYPE="STUDY">Rodeheffer 1983</LINK>) were "single-blind," at least for some part of the trial. Therefore, we rated performance bias for these trials as showing "unclear risk", as seen in <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>.</P><P>With regard to blinding of outcome assessments, in some studies participants kept diaries for assessment of outcomes of interest (frequency, severity and duration of RP). Some studies used patient global assessments. Outcomes assessments appeared to be adequately blinded as all studies were blinded and 89% were double blind. </P></BLINDING><EXCLUSIONS MODIFIED="2017-11-28 10:51:21 -0500" MODIFIED_BY="[Empty name]"><P>We found incomplete outcome data due to attrition in approximately 40% of the included trials. We assessed risk of bias due to incomplete outcome data as "unclear" in eight studies (<LINK REF="STD-Aldoori-1986" TYPE="STUDY">Aldoori 1986</LINK>; <LINK REF="STD-Challenor-1987" TYPE="STUDY">Challenor 1987</LINK>; <LINK REF="STD-Constantini-1987" TYPE="STUDY">Constantini 1987</LINK>; <LINK REF="STD-French-Co_x002d_op-1991" TYPE="STUDY">French Co-op 1991</LINK>; <LINK REF="STD-Muller_x002d_Buhl-1983" TYPE="STUDY">Muller-Buhl 1983</LINK>; <LINK REF="STD-RTSI-2000" TYPE="STUDY">RTSI 2000</LINK>; <LINK REF="STD-Sauza-1984" TYPE="STUDY">Sauza 1984</LINK>; <LINK REF="STD-Teixeira-da-Costa" TYPE="STUDY">Teixeira da Costa</LINK>). These studies reported attrition with unclear effects on outcomes (i.e., it was clear whether attrition occurred in treatment or placebo phase in cross-over studies, losses from groups were equal in small trials, dropout was uneven in larger trials). We classified eight trials as having "high risk" of bias with regard to attrition (<LINK REF="STD-Bravard-1983" TYPE="STUDY">Bravard 1983</LINK>; <LINK REF="STD-Constantini-1987" TYPE="STUDY">Constantini 1987</LINK>; <LINK REF="STD-Gjorup-1986b" TYPE="STUDY">Gjorup 1986b</LINK>; <LINK REF="STD-Hawkins-1985" TYPE="STUDY">Hawkins 1985</LINK>; <LINK REF="STD-Rhedda-1985" TYPE="STUDY">Rhedda 1985</LINK>; <LINK REF="STD-RTSI-2000" TYPE="STUDY">RTSI 2000</LINK>; Sarkozi 1986; <LINK REF="STD-Waller-1986" TYPE="STUDY">Waller 1986</LINK>). These trials reported high dropout rates, unequal dropout between treatment and placebo groups, and exclusion from analyses (due to missing data from subjective diary assessments or non-compliance of participants). We classified the remaining 20 trials as having "low risk" of bias due to attrition; they had minimal or equal loss to follow-up and treated participants on an intention-to-treat (ITT) basis.</P></EXCLUSIONS><SELECTIVE_REPORTING MODIFIED="2017-11-14 07:19:18 -0500" MODIFIED_BY="[Empty name]"><P>We rated selective reporting bias as "low risk" for most trials. Two trials did not report all proposed outcomes (<LINK REF="STD-Hawkins-1985" TYPE="STUDY">Hawkins 1985</LINK>; <LINK REF="STD-RTSI-2000" TYPE="STUDY">RTSI 2000</LINK>). <LINK REF="STD-Hawkins-1985" TYPE="STUDY">Hawkins 1985</LINK> noted that the severity of attacks on a 5-point Likert scale was parallel to that on a 10-cm VAS scale but did not report actual results; <LINK REF="STD-RTSI-2000" TYPE="STUDY">RTSI 2000</LINK> did not report all minor outcomes mentioned in the methods. We classified risk of reporting bias as "unclear" for these two trials.</P></SELECTIVE_REPORTING><OTHER_BIAS_SOURCES MODIFIED="2017-11-28 10:51:21 -0500" MODIFIED_BY="[Empty name]"><P>Other potential risks of bias considered were possible carryover effects in cross-over trials, and similarity of baseline characteristics in parallel trials. Overall, we judged these sources of bias as "low risk" for 18 trials (<LINK REF="STD-Aldoori-1986" TYPE="STUDY">Aldoori 1986</LINK>; <LINK REF="STD-Corbin-1986" TYPE="STUDY">Corbin 1986</LINK>; <LINK REF="STD-Ferri-1992" TYPE="STUDY">Ferri 1992</LINK>; <LINK REF="STD-Finch-1988" TYPE="STUDY">Finch 1988</LINK>; <LINK REF="STD-French-Co_x002d_op-1991" TYPE="STUDY">French Co-op 1991</LINK>; <LINK REF="STD-Kahan-1985a" TYPE="STUDY">Kahan 1985a</LINK>; <LINK REF="STD-Kirch-1987" TYPE="STUDY">Kirch 1987</LINK>; <LINK REF="STD-La-Civita-1997" TYPE="STUDY">La Civita 1997</LINK>; <LINK REF="STD-Malamet-1984" TYPE="STUDY">Malamet 1984</LINK>; <LINK REF="STD-Meyrick-Thomas-1987" TYPE="STUDY">Meyrick Thomas 1987</LINK>; <LINK REF="STD-Muller_x002d_Buhl-1983" TYPE="STUDY">Muller-Buhl 1983</LINK>; <LINK REF="STD-Nilsson-1987" TYPE="STUDY">Nilsson 1987</LINK>; <LINK REF="STD-Rhedda-1985" TYPE="STUDY">Rhedda 1985</LINK>; <LINK REF="STD-Rodeheffer-1983" TYPE="STUDY">Rodeheffer 1983</LINK>; <LINK REF="STD-RTSI-2000" TYPE="STUDY">RTSI 2000</LINK>; Sarkozi 1986; <LINK REF="STD-Sauza-1984" TYPE="STUDY">Sauza 1984</LINK>; <LINK REF="STD-Teixeira-da-Costa" TYPE="STUDY">Teixeira da Costa</LINK>). See <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>. For remaining included studies, we judged risk of bias for this domain as "unclear" owing to lack of sufficient information. Carryover bias was determined to be present if: there was no washout between treatments in a crossover trial (inadequate washout) and/or the baseline RP characteristics were dissimilar at the second treatment or the baseline characteristics for RP were not provided. CCBs are fast in their onset and rapidly washout when discontinued so the washout did not have to be for very long (such as one to two weeks) for patients to be assumed to be in steady state.</P></OTHER_BIAS_SOURCES></STUDY_QUALITY><INTERVENTION_EFFECTS MODIFIED="2017-11-24 20:06:58 -0500" MODIFIED_BY="[Empty name]"><SUBSECTION><HEADING LEVEL="3">Primary outcomes</HEADING><SUBSECTION><HEADING LEVEL="4">Comparison 1. All calcium channel blockers (CCBs) versus placebo for all subsets of Raynaud's phenomenon (RP)</HEADING><P>See <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>.</P><SUBSECTION><HEADING LEVEL="5">Frequency of attacks</HEADING><SUBSECTION><HEADING LEVEL="6">Average number of attacks/week in 528 participants from 23 studies</HEADING><P>See <LINK REF="STD-Aldoori-1986" TYPE="STUDY">Aldoori 1986</LINK>; <LINK REF="STD-Challenor-1987" TYPE="STUDY">Challenor 1987</LINK>; <LINK REF="STD-Challenor-1989" TYPE="STUDY">Challenor 1989</LINK>; <LINK REF="STD-Corbin-1986" TYPE="STUDY">Corbin 1986</LINK>; <LINK REF="STD-Ettinger-1984" TYPE="STUDY">Ettinger 1984</LINK>; <LINK REF="STD-Ferri-1992" TYPE="STUDY">Ferri 1992</LINK>; <LINK REF="STD-Finch-1988" TYPE="STUDY">Finch 1988</LINK>; <LINK REF="STD-French-Co_x002d_op-1991" TYPE="STUDY">French Co-op 1991</LINK>; <LINK REF="STD-Gjorup-1986a" TYPE="STUDY">Gjorup 1986a</LINK>; <LINK REF="STD-Hawkins-1985" TYPE="STUDY">Hawkins 1985</LINK>; <LINK REF="STD-Kahan-1985a" TYPE="STUDY">Kahan 1985a</LINK>; <LINK REF="STD-Kahan-1985b" TYPE="STUDY">Kahan 1985b</LINK>; <LINK REF="STD-Kahan-1985c" TYPE="STUDY">Kahan 1985c</LINK>; <LINK REF="STD-Kahan-1987" TYPE="STUDY">Kahan 1987</LINK>; <LINK REF="STD-Kirch-1987" TYPE="STUDY">Kirch 1987</LINK>; <LINK REF="STD-Malamet-1984" TYPE="STUDY">Malamet 1984</LINK>; <LINK REF="STD-Meyrick-Thomas-1987" TYPE="STUDY">Meyrick Thomas 1987</LINK>; <LINK REF="STD-Rodeheffer-1983" TYPE="STUDY">Rodeheffer 1983</LINK>; <LINK REF="STD-Rupp-1987" TYPE="STUDY">Rupp 1987</LINK>; <LINK REF="STD-Sarkozi--1986" TYPE="STUDY">Sarkozi 1986</LINK>; <LINK REF="STD-Smith-1982" TYPE="STUDY">Smith 1982</LINK>; <LINK REF="STD-Waller-1986" TYPE="STUDY">Waller 1986</LINK>; and <LINK REF="STD-Wigley-1987" TYPE="STUDY">Wigley 1987</LINK> (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>).</P><P>When we considered all trials regardless of the class or type of CCB, dose, or RP type, we found that the weighted mean difference (WMD) for the frequency of attacks per week was -6.07 (95% confidence interval [CI] - 6.53 to -5.61). The negative sign in the WMD indicates that the intervention (CCBs) reduced the number of Raynaud's attacks per week when compared with placebo. This was equivalent to a relative reduction of 44% (95% CI -48% to -41%) in the frequency of attacks per week with CCBs. However, significant statistical heterogeneity (I² = 98%) was present. Excluding <LINK REF="STD-Kahan-1985c" TYPE="STUDY">Kahan 1985c</LINK> - a short trial of two weeks per arm that showed a very large effect for CCBs compared with the remaining trials - reduced heterogeneity to I² = 77. As a result, the new WMD was -2.93 (95% CI -3.44 to -2.43) (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>).</P><P>We did not include in the analysis <LINK REF="STD-RTSI-2000" TYPE="STUDY">RTSI 2000</LINK>, which used a different scale of measure (geometric mean), provided an imprecise P value, and was much larger and longer than the other trials. This parallel trial compared effects of nifedipine versus placebo (77 participants took nifedipine, and 81 took placebo) in participants with primary RP and found a 66% reduction in frequency of attacks with nifedipine (P &lt; 0.001) after one year. Additionally, participants taking nifedipine reported greater improvement in their RP symptoms compared with participants taking placebo (P &lt; 0.001). Overall, effects of nifedipine on the frequency of attacks reported in this trial were consistent with the overall conclusion of this meta-analysis.</P><P>Examination of the funnel plot of the frequency of attacks (<LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>) showed an asymmetrical distribution of treatment effects around the mean estimate of effect (<LINK REF="REF-Egger-1997" TYPE="REFERENCE">Egger 1997</LINK>), with more studies showing benefit for CCBs.</P></SUBSECTION></SUBSECTION><SUBSECTION><HEADING LEVEL="5">Duration of attacks</HEADING><SUBSECTION><HEADING LEVEL="6">Average duration per attack measured in minutes in 69 participants from six studies</HEADING><P>See <LINK REF="STD-Aldoori-1986" TYPE="STUDY">Aldoori 1986</LINK>; <LINK REF="STD-Ettinger-1984" TYPE="STUDY">Ettinger 1984</LINK>; <LINK REF="STD-Meyrick-Thomas-1987" TYPE="STUDY">Meyrick Thomas 1987</LINK>; <LINK REF="STD-Finch-1988" TYPE="STUDY">Finch 1988</LINK>; <LINK REF="STD-Kirch-1987" TYPE="STUDY">Kirch 1987</LINK>; and <LINK REF="STD-Malamet-1984" TYPE="STUDY">Malamet 1984</LINK> (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>).</P><P>The WMD for the average duration of attacks in the six trials was -1.67 minutes (95% CI -3.29 to 0) with considerable heterogeneity (I² = 89). This was equal to a small relative percent reduction of 9% (95% CI -18% to 0%).</P></SUBSECTION></SUBSECTION><SUBSECTION><HEADING LEVEL="5">Severity of attacks</HEADING><SUBSECTION><HEADING LEVEL="6">Average severity per attack assessed on a 10-cm visual analogue scale (0 = no symptoms, 10 = maximal severity) in 374 participants from 16 studies</HEADING><P>See <LINK REF="STD-Challenor-1989" TYPE="STUDY">Challenor 1989</LINK>; <LINK REF="STD-Ettinger-1984" TYPE="STUDY">Ettinger 1984</LINK>; <LINK REF="STD-Ferri-1992" TYPE="STUDY">Ferri 1992</LINK>; <LINK REF="STD-Finch-1988" TYPE="STUDY">Finch 1988</LINK>; <LINK REF="STD-French-Co_x002d_op-1991" TYPE="STUDY">French Co-op 1991</LINK>; <LINK REF="STD-Gjorup-1986a" TYPE="STUDY">Gjorup 1986a</LINK>; <LINK REF="STD-Hawkins-1985" TYPE="STUDY">Hawkins 1985</LINK>; <LINK REF="STD-Kahan-1985a" TYPE="STUDY">Kahan 1985a</LINK>; <LINK REF="STD-Kahan-1985b" TYPE="STUDY">Kahan 1985b</LINK>; <LINK REF="STD-Kahan-1985c" TYPE="STUDY">Kahan 1985c</LINK>; <LINK REF="STD-Kahan-1987" TYPE="STUDY">Kahan 1987</LINK>; <LINK REF="STD-Kirch-1987" TYPE="STUDY">Kirch 1987</LINK>; <LINK REF="STD-Malamet-1984" TYPE="STUDY">Malamet 1984</LINK>; <LINK REF="STD-Rupp-1987" TYPE="STUDY">Rupp 1987</LINK>; <LINK REF="STD-Smith-1982" TYPE="STUDY">Smith 1982</LINK>; and <LINK REF="STD-Wigley-1987" TYPE="STUDY">Wigley 1987</LINK> (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>).</P><P>The pooled WMD was -0.62 cm (95% CI -0.72 to - 0.51) with significant heterogeneity (I² = 92%). The negative sign in the WMD indicates that the severity of attacks was less among the active treatment group than the placebo group. Absolute risk difference was -6% (95% CI -11% to -8%) and relative percent change was -9% (95% CI -11% to -8%).</P><P>Examination of the funnel plot (<LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>) for severity of attacks showed some asymmetry with a few outliers in the direction of effect.</P></SUBSECTION></SUBSECTION><SUBSECTION><HEADING LEVEL="5">Pain</HEADING><SUBSECTION><HEADING LEVEL="6">Average pain per attack measured on a 10-cm visual analogue scale (0 = no pain, 10 = maximal pain) in 62 participants from 4 studies</HEADING><P>See <LINK REF="STD-Aldoori-1986" TYPE="STUDY">Aldoori 1986</LINK>; <LINK REF="STD-Ettinger-1984" TYPE="STUDY">Ettinger 1984</LINK>; <LINK REF="STD-Malamet-1984" TYPE="STUDY">Malamet 1984</LINK>; and <LINK REF="STD-Rupp-1987" TYPE="STUDY">Rupp 1987</LINK> (<LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>).</P><P>The pooled summary WMD for pain in these studies was -1.47 cm (95% CI -2.21 to -0.74). The negative sign indicates that pain was less in the active treatment group. Absolute risk reduction was -15% (95% CI -22 % to -7%) and relative percent change was -47% (95% CI -71% to -24%). Heterogeneity was moderate (I² = 77%).</P></SUBSECTION></SUBSECTION><SUBSECTION><HEADING LEVEL="5">Patient global</HEADING><SUBSECTION><HEADING LEVEL="6">Disability due to Raynaud's assessed on a 10-cm visual analogue scale (0 = no disability, 10 = maximal disability) in 96 participants from two studies</HEADING><P>See <LINK REF="STD-Challenor-1987" TYPE="STUDY">Challenor 1987</LINK> and <LINK REF="STD-French-Co_x002d_op-1991" TYPE="STUDY">French Co-op 1991</LINK> (<LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>).</P><P>The WMD for patient global was -0.37 (95% CI -0.73 to 0). We did not calculate the number needed to treat for an additional beneficial outcome (NNTB) for this non-significant result, but absolute risk difference was -4% (95% CI -7% to 0%) and relative percent change was -9% (95% CI -19% to 0%).</P></SUBSECTION></SUBSECTION><SUBSECTION><HEADING LEVEL="5">Withdrawals</HEADING><SUBSECTION><HEADING LEVEL="6">Numbers of participants who dropped out of studies owing to adverse treatment effects among a total of 63 participants from two studies</HEADING><P>See <LINK REF="STD-Constantini-1987" TYPE="STUDY">Constantini 1987</LINK> and <LINK REF="STD-Sarkozi--1986" TYPE="STUDY">Sarkozi 1986</LINK> (<LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK>).</P><P>The pooled summary risk ratio (RR) of withdrawals from two parallel trials that reported this outcome was 1.32 (95% CI 0.51 to 3.33); 8 out of 32 withdrew from active treatment compared with 6 out of 31 from placebo treatment. Absolute risk difference was 6% (95% CI -14% to 26%) and relative percent change was 30% (95% CI -49% to 233%). We did not calculate the number needed to treat for an additional harmful outcome (NNTH) because withdrawals did not differ statistically between the two groups.</P><P>We did not analyze withdrawals for cross-over trials but did notice that overall withdrawals were more frequent with CCBs than with placebo. From 10 cross-over trials with 281 participants that reported withdrawals, 39 participants withdrew while on active treatment compared with 15 while taking placebo (see <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>).</P></SUBSECTION></SUBSECTION><SUBSECTION><HEADING LEVEL="5">Serious adverse events</HEADING><SUBSECTION><HEADING LEVEL="6">Number of participants who died or withdrew and were hospitalized as a result of adverse effects of treatment</HEADING><P>Investigators reported no serious adverse events</P><P><U><B>Note: </B></U><LINK REF="STD-Wollersheim-1991" TYPE="STUDY">Wollersheim 1991</LINK> met the inclusion criteria of this review, but the only outcome that could be included in the meta-analysis was withdrawals. For the other reported outcomes - frequency, duration, and severity of attacks - trial authors reported no statistically significant differences between groups but provided no estimates of variance. This trial used medium-dose nicardipine and included a mixture of participants with primary and secondary RP. If we had been able to include in our meta-analysis trial data on frequency, duration, and severity of attacks, we expect that the non-significant results would decrease observed effects of CCBs on these outcomes. Also, we did not include <LINK REF="STD-RTSI-2000" TYPE="STUDY">RTSI 2000</LINK> in the meta-analysis, as this trial reported geometric mean differences and did not report the P value with enough precision for calculation of a standard error.</P><P>Subgroup analyses included the following comparisons.</P></SUBSECTION></SUBSECTION></SUBSECTION><SUBSECTION><HEADING LEVEL="4">Comparison 2. CCBs versus placebo by RP type (primary vs secondary)</HEADING><SUBSECTION><HEADING LEVEL="5">Frequency of attacks</HEADING><SUBSECTION><HEADING LEVEL="6">Average number of attacks/week in 528 participants from 12 studies</HEADING><P>See <LINK REF="STD-Challenor-1989" TYPE="STUDY">Challenor 1989</LINK>; <LINK REF="STD-Corbin-1986" TYPE="STUDY">Corbin 1986</LINK>; <LINK REF="STD-Ettinger-1984" TYPE="STUDY">Ettinger 1984</LINK>; <LINK REF="STD-Kahan-1985a" TYPE="STUDY">Kahan 1985a</LINK>; <LINK REF="STD-Kahan-1985b" TYPE="STUDY">Kahan 1985b</LINK>; <LINK REF="STD-Kahan-1987" TYPE="STUDY">Kahan 1987</LINK>; <LINK REF="STD-Kirch-1987" TYPE="STUDY">Kirch 1987</LINK>; <LINK REF="STD-Malamet-1984" TYPE="STUDY">Malamet 1984</LINK>; <LINK REF="STD-Meyrick-Thomas-1987" TYPE="STUDY">Meyrick Thomas 1987</LINK>; <LINK REF="STD-Rodeheffer-1983" TYPE="STUDY">Rodeheffer 1983</LINK>; <LINK REF="STD-Rupp-1987" TYPE="STUDY">Rupp 1987</LINK>; and <LINK REF="STD-Sarkozi--1986" TYPE="STUDY">Sarkozi 1986</LINK> (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>).</P><P>In 226 people with primary RP, CCBs reduced the frequency of attacks per week by 3.02 (95% CI -3.65 to -2.38) compared with placebo. In 102 people with secondary RP, CCBs reduced the average number of attacks over a one-week period by 3.42 (95% CI -4.33 to -2.51) compared with placebo. These differences between groups were not statistically significant (P = 0.48; I² = 48%).<BR/></P></SUBSECTION></SUBSECTION><SUBSECTION><HEADING LEVEL="5">Severity of attacks</HEADING><SUBSECTION><HEADING LEVEL="6">Average severity per attack assessed on a 10-cm visual analogue scale (0 = no symptoms, 10 = maximal severity) in 253 participants from 10 studies</HEADING><P>See <LINK REF="STD-Challenor-1989" TYPE="STUDY">Challenor 1989</LINK>; <LINK REF="STD-French-Co_x002d_op-1991" TYPE="STUDY">French Co-op 1991</LINK>; <LINK REF="STD-Gjorup-1986a" TYPE="STUDY">Gjorup 1986a</LINK>; <LINK REF="STD-Hawkins-1985" TYPE="STUDY">Hawkins 1985</LINK>; <LINK REF="STD-Kahan-1985a" TYPE="STUDY">Kahan 1985a</LINK>; <LINK REF="STD-Kahan-1985b" TYPE="STUDY">Kahan 1985b</LINK>; <LINK REF="STD-Kahan-1987" TYPE="STUDY">Kahan 1987</LINK>; <LINK REF="STD-Kirch-1987" TYPE="STUDY">Kirch 1987</LINK>; <LINK REF="STD-Malamet-1984" TYPE="STUDY">Malamet 1984</LINK>; and <LINK REF="STD-Rupp-1987" TYPE="STUDY">Rupp 1987</LINK> (<LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>).</P><P>Compared with placebo, CCBs reduced the severity of attacks by 0.95 on a 10-cm scale (95% CI -1.11 to -0.79; I² = 96%) in 184 people with primary Raynaud's. In 69 people with secondary RP, CCBs reduced the severity of attacks by 0.48 (95% CI -0.61 to -0.35; I² = 94%) compared with placebo.</P><P>The difference between these subgroups was statistically significant (P &lt; 0.0001; I² = 95%).</P></SUBSECTION></SUBSECTION></SUBSECTION><SUBSECTION><HEADING LEVEL="4">Comparison 3. Nifedipine versus placebo by RP type (primary vs secondary)</HEADING><SUBSECTION><HEADING LEVEL="5">Frequency of attacks</HEADING><SUBSECTION><HEADING LEVEL="6">Average number of attacks/week in 233 participants from nine studies</HEADING><P>See <LINK REF="STD-Challenor-1989" TYPE="STUDY">Challenor 1989</LINK>; <LINK REF="STD-Corbin-1986" TYPE="STUDY">Corbin 1986</LINK>; <LINK REF="STD-Ettinger-1984" TYPE="STUDY">Ettinger 1984</LINK>; <LINK REF="STD-Kahan-1985a" TYPE="STUDY">Kahan 1985a</LINK>; <LINK REF="STD-Kirch-1987" TYPE="STUDY">Kirch 1987</LINK>; <LINK REF="STD-Malamet-1984" TYPE="STUDY">Malamet 1984</LINK>; <LINK REF="STD-Meyrick-Thomas-1987" TYPE="STUDY">Meyrick Thomas 1987</LINK>; <LINK REF="STD-Rodeheffer-1983" TYPE="STUDY">Rodeheffer 1983</LINK> and <LINK REF="STD-Sarkozi--1986" TYPE="STUDY">Sarkozi 1986</LINK> (<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>).</P><P>Among 90 participants with primary RP, nifedipine reduced the frequency of attacks by 4.42 (95% CI -5.35 to -3.50) compared with placebo. In 60 participants with secondary RP, nifedipine reduced the frequency of attacks by 4.19 (95% CI -5.47 to -2.91) compared with placebo. However, heterogeneity was substantial (I² = 98% and I² = 87%, respectively).</P><P>The difference between these subgroups was not statistically significant (P = 0.77).</P></SUBSECTION></SUBSECTION><SUBSECTION><HEADING LEVEL="5">Severity of attacks</HEADING><SUBSECTION><HEADING LEVEL="6">Average severity per attack assessed on a 10-cm visual analogue scale (0 = no symptoms, 10 = maximal severity) in 39 participants from four trials</HEADING><P>See <LINK REF="STD-Challenor-1989" TYPE="STUDY">Challenor 1989</LINK>; <LINK REF="STD-Kahan-1985a" TYPE="STUDY">Kahan 1985a</LINK>; <LINK REF="STD-Kirch-1987" TYPE="STUDY">Kirch 1987</LINK>; and <LINK REF="STD-Malamet-1984" TYPE="STUDY">Malamet 1984</LINK> (<LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK>).</P><P>In 27 participants with primary RP, nifedipine when compared with placebo reduced the severity of attacks (WMD 1.74, 95% CI -2.09 to -1.39). In 27 participants with secondary RP, nifedipine did not appear to be any more beneficial than placebo (WMD 0.01, 95% CI -0.32 to 0.34). However, heterogeneity was substantial (I² = 98% and I² = 96%, respectively).</P><P>The difference between these subgroups was statistically significant (P &lt; 0.0001; I² = 97%).</P></SUBSECTION></SUBSECTION></SUBSECTION><SUBSECTION><HEADING LEVEL="4">Comparison 4. CCBs versus placebo for primary and secondary RP by CCB class (dihydropyridine class vs non-dihydropyridine class)</HEADING><P>For frequency and severity of attacks, we had enough data to perform a subgroup analysis by CCB class (dihydropyridine vs non-dihydropyridine). We further analyzed the data for these outcomes by type of dihydropyridine CCB (i.e., nifedipine vs placebo, nicardipine vs placebo, and nisoldipine vs placebo).</P><SUBSECTION><HEADING LEVEL="5">Frequency of attacks (average/week)</HEADING><SUBSECTION><HEADING LEVEL="6">Average number of attacks/week in 528 participants from 23 studies</HEADING><P>See <LINK REF="STD-Aldoori-1986" TYPE="STUDY">Aldoori 1986</LINK>; <LINK REF="STD-Challenor-1987" TYPE="STUDY">Challenor 1987</LINK>; <LINK REF="STD-Challenor-1989" TYPE="STUDY">Challenor 1989</LINK>; <LINK REF="STD-Corbin-1986" TYPE="STUDY">Corbin 1986</LINK>; <LINK REF="STD-Ettinger-1984" TYPE="STUDY">Ettinger 1984</LINK>; <LINK REF="STD-Ferri-1992" TYPE="STUDY">Ferri 1992</LINK>; <LINK REF="STD-Finch-1988" TYPE="STUDY">Finch 1988</LINK>; <LINK REF="STD-French-Co_x002d_op-1991" TYPE="STUDY">French Co-op 1991</LINK>; <LINK REF="STD-Gjorup-1986a" TYPE="STUDY">Gjorup 1986a</LINK>; <LINK REF="STD-Hawkins-1985" TYPE="STUDY">Hawkins 1985</LINK>; <LINK REF="STD-Kahan-1985a" TYPE="STUDY">Kahan 1985a</LINK>; <LINK REF="STD-Kahan-1985b" TYPE="STUDY">Kahan 1985b</LINK>; <LINK REF="STD-Kahan-1985c" TYPE="STUDY">Kahan 1985c</LINK>; <LINK REF="STD-Kahan-1987" TYPE="STUDY">Kahan 1987</LINK>; <LINK REF="STD-Kirch-1987" TYPE="STUDY">Kirch 1987</LINK>; <LINK REF="STD-Malamet-1984" TYPE="STUDY">Malamet 1984</LINK>; <LINK REF="STD-Meyrick-Thomas-1987" TYPE="STUDY">Meyrick Thomas 1987</LINK>; <LINK REF="STD-Rodeheffer-1983" TYPE="STUDY">Rodeheffer 1983</LINK>; <LINK REF="STD-Rupp-1987" TYPE="STUDY">Rupp 1987</LINK>; <LINK REF="STD-Sarkozi--1986" TYPE="STUDY">Sarkozi 1986</LINK>; <LINK REF="STD-Smith-1982" TYPE="STUDY">Smith 1982</LINK>; <LINK REF="STD-Waller-1986" TYPE="STUDY">Waller 1986</LINK>; and <LINK REF="STD-Wigley-1987" TYPE="STUDY">Wigley 1987</LINK> (<LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>).</P><P>Of the 23 studies included in this analysis, 22 used the dihydropyridine class of CCBs, and only one used the non-dihydropyridine class (<LINK REF="STD-Kahan-1985b" TYPE="STUDY">Kahan 1985b</LINK>). The WMD for frequency of attacks in the dihydropyridine class of CCBs compared with placebo was -6.13 (95% CI -6.60 to -5.67).</P><P>We further analyzed the data for frequency of attacks by dihydropyridine CCB type. Among 22 studies using the dihydropyridine class, 15 used nifedipine, 4 nicardipine, and 2 nisoldipine. In trials comparing nifedipine versus placebo, nifedipine reduced the number of attacks by 8.62 (95% CI -9.20 to -8.03; I² = 98%) in 290 people; nicardipine reduced the frequency of attacks by 1.92 (95% CI -2.80 to -1.04; I² = 50%) in 150 people; and nisoldipine reduced the frequency of attacks by 3.00 per week (95% CI -4.57 to -1.43; I² = 0%) in 39 people (<LINK REF="CMP-004.02" TYPE="ANALYSIS">Analysis 4.2</LINK>).</P></SUBSECTION></SUBSECTION><SUBSECTION><HEADING LEVEL="5">Severity of attacks</HEADING><SUBSECTION><HEADING LEVEL="6">Average severity per attack assessed on a 10-cm visual analogue scale (0 = no symptoms, 10 = maximal severity) in 374 participants from 16 studies</HEADING><P>See <LINK REF="STD-Challenor-1989" TYPE="STUDY">Challenor 1989</LINK>; <LINK REF="STD-Ettinger-1984" TYPE="STUDY">Ettinger 1984</LINK>; <LINK REF="STD-Ferri-1992" TYPE="STUDY">Ferri 1992</LINK>; <LINK REF="STD-Finch-1988" TYPE="STUDY">Finch 1988</LINK>; <LINK REF="STD-French-Co_x002d_op-1991" TYPE="STUDY">French Co-op 1991</LINK>; <LINK REF="STD-Gjorup-1986a" TYPE="STUDY">Gjorup 1986a</LINK>; <LINK REF="STD-Hawkins-1985" TYPE="STUDY">Hawkins 1985</LINK>; <LINK REF="STD-Kahan-1985a" TYPE="STUDY">Kahan 1985a</LINK>; <LINK REF="STD-Kahan-1985b" TYPE="STUDY">Kahan 1985b</LINK>; <LINK REF="STD-Kahan-1985c" TYPE="STUDY">Kahan 1985c</LINK>; <LINK REF="STD-Kahan-1987" TYPE="STUDY">Kahan 1987</LINK>; <LINK REF="STD-Kirch-1987" TYPE="STUDY">Kirch 1987</LINK>; <LINK REF="STD-Malamet-1984" TYPE="STUDY">Malamet 1984</LINK>; <LINK REF="STD-Rupp-1987" TYPE="STUDY">Rupp 1987</LINK>; <LINK REF="STD-Smith-1982" TYPE="STUDY">Smith 1982</LINK>; and <LINK REF="STD-Wigley-1987" TYPE="STUDY">Wigley 1987</LINK> (<LINK REF="CMP-004.03" TYPE="ANALYSIS">Analysis 4.3</LINK>).</P><P>Only 1 of the 16 trials providing data on severity used the non-dihydropyridine class, and 15 used the dihydropyridine class. The WMD for severity of attacks in the 15 trials comparing dihydropyridine CCBs versus placebo was -0.60 (95% CI -0.71 to -0.50). Heterogeneity was substantial (I² = 92%).</P><P>Further analysis of data by dihydropyridine CCB type shows that when compared with placebo, nifedipine reduced the severity of attacks by 0.79 (95% CI -0.96 to -0.61; I² = 94%) in 189 people; nicardipine reduced the severity of attacks by 0.47 (95% CI -0.61 to -0.33; I² = 91%) in 150 people; and nisoldipine reduced the severity of attacks by 0.79 (95% CI -1.36 to -0.22) in 19 people (<LINK REF="CMP-004.04" TYPE="ANALYSIS">Analysis 4.4</LINK>).</P></SUBSECTION></SUBSECTION></SUBSECTION><SUBSECTION><HEADING LEVEL="4">Comparison 5. CCBs versus placebo in comparison by CCB dose for RP (both primary and secondary RP included)</HEADING><P>Most of the included trials used low-dose CCBs (refer to <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK> for dosage ranges), and few used high-dose CCBs. Hence, for this subgroup analysis, we examined low-dose CCBs versus placebo, and medium/high-dose CCBs versus placebo<I>.</I></P><SUBSECTION><HEADING LEVEL="5">Frequency of attacks</HEADING><SUBSECTION><HEADING LEVEL="6">Average number of attacks/week in 528 participants from 23 studies</HEADING><P>See <LINK REF="STD-Aldoori-1986" TYPE="STUDY">Aldoori 1986</LINK>; <LINK REF="STD-Challenor-1987" TYPE="STUDY">Challenor 1987</LINK>; <LINK REF="STD-Challenor-1989" TYPE="STUDY">Challenor 1989</LINK>; <LINK REF="STD-Corbin-1986" TYPE="STUDY">Corbin 1986</LINK>; <LINK REF="STD-Ettinger-1984" TYPE="STUDY">Ettinger 1984</LINK>; <LINK REF="STD-Ferri-1992" TYPE="STUDY">Ferri 1992</LINK>; <LINK REF="STD-Finch-1988" TYPE="STUDY">Finch 1988</LINK>; <LINK REF="STD-French-Co_x002d_op-1991" TYPE="STUDY">French Co-op 1991</LINK>; <LINK REF="STD-Gjorup-1986a" TYPE="STUDY">Gjorup 1986a</LINK>; <LINK REF="STD-Hawkins-1985" TYPE="STUDY">Hawkins 1985</LINK>; <LINK REF="STD-Kahan-1985a" TYPE="STUDY">Kahan 1985a</LINK>; <LINK REF="STD-Kahan-1985b" TYPE="STUDY">Kahan 1985b</LINK>; <LINK REF="STD-Kahan-1985c" TYPE="STUDY">Kahan 1985c</LINK>; <LINK REF="STD-Kahan-1987" TYPE="STUDY">Kahan 1987</LINK>; <LINK REF="STD-Kirch-1987" TYPE="STUDY">Kirch 1987</LINK>; <LINK REF="STD-Malamet-1984" TYPE="STUDY">Malamet 1984</LINK>; <LINK REF="STD-Meyrick-Thomas-1987" TYPE="STUDY">Meyrick Thomas 1987</LINK>; <LINK REF="STD-Rodeheffer-1983" TYPE="STUDY">Rodeheffer 1983</LINK>; <LINK REF="STD-Rupp-1987" TYPE="STUDY">Rupp 1987</LINK>; <LINK REF="STD-Sarkozi--1986" TYPE="STUDY">Sarkozi 1986</LINK>; <LINK REF="STD-Smith-1982" TYPE="STUDY">Smith 1982</LINK>; <LINK REF="STD-Waller-1986" TYPE="STUDY">Waller 1986</LINK>; and <LINK REF="STD-Wigley-1987" TYPE="STUDY">Wigley 1987</LINK> (<LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK>).</P><P>When we examined the frequency of attacks by CCB dose versus placebo, we found that the pooled WMD for frequency of attacks with low-dose CCBs was -3.00 (95% CI -3.63 to -2.37; I² = 68%) compared with -9.50 (95% CI -10.17 to -8.83; I² = 92%) with medium/high-dose CCBs. However, medium/high-dose CCBs showed substantial heterogeneity (I² = 99%). A sensitivity analysis of medium/high-dose CCBs versus placebo that excluded <LINK REF="STD-Kahan-1985a" TYPE="STUDY">Kahan 1985a</LINK> and <LINK REF="STD-Kahan-1985c" TYPE="STUDY">Kahan 1985c</LINK>, whose treatment effect was much larger than that noted in the remaining studies, eliminated heterogeneity and revealed that the WMD for frequency of attacks between CCBs and placebo was -1.74 (95% CI -2.63 to -0.85; I² = 0%).</P><P>Differences between subgroups by dosage were statistically significant (P &lt; 0.0001; I² = 98%).</P></SUBSECTION></SUBSECTION><SUBSECTION><HEADING LEVEL="5">Duration of attacks</HEADING><SUBSECTION><HEADING LEVEL="6">Average duration per attack measured in minutes in 69 participants from six studies</HEADING><P>See <LINK REF="STD-Aldoori-1986" TYPE="STUDY">Aldoori 1986</LINK>; <LINK REF="STD-Ettinger-1984" TYPE="STUDY">Ettinger 1984</LINK>; <LINK REF="STD-Finch-1988" TYPE="STUDY">Finch 1988</LINK>; <LINK REF="STD-Kirch-1987" TYPE="STUDY">Kirch 1987</LINK>; <LINK REF="STD-Malamet-1984" TYPE="STUDY">Malamet 1984</LINK>; and <LINK REF="STD-Meyrick-Thomas-1987" TYPE="STUDY">Meyrick Thomas 1987</LINK> (<LINK REF="CMP-005.02" TYPE="ANALYSIS">Analysis 5.2</LINK>).</P><P>The pooled WMD for the duration of attacks with low-dose CCBs was 2.24 (95% CI -0.24 to 4.73) compared with placebo for 56 participants. However, heterogeneity was substantial (I² = 92%). The WMD for the duration of attacks with medium-dose CCBs was -4.60 (95% CI -6.76 to -2.45) compared with placebo for 82 participants.</P><P>Differences between these subgroups were statistically significant (P &lt; 0.0001; I² = 94%).</P></SUBSECTION></SUBSECTION><SUBSECTION><HEADING LEVEL="5">Severity of attacks</HEADING><SUBSECTION><HEADING LEVEL="6">Average severity per attack assessed on a 10-cm visual analogue scale (0 = no symptoms, 10 = maximal severity) in 374 participants from 16 studies</HEADING><P>See <LINK REF="STD-Challenor-1989" TYPE="STUDY">Challenor 1989</LINK>; <LINK REF="STD-Ettinger-1984" TYPE="STUDY">Ettinger 1984</LINK>; <LINK REF="STD-Ferri-1992" TYPE="STUDY">Ferri 1992</LINK>; <LINK REF="STD-Finch-1988" TYPE="STUDY">Finch 1988</LINK>; <LINK REF="STD-French-Co_x002d_op-1991" TYPE="STUDY">French Co-op 1991</LINK>; <LINK REF="STD-Gjorup-1986a" TYPE="STUDY">Gjorup 1986a</LINK>; <LINK REF="STD-Hawkins-1985" TYPE="STUDY">Hawkins 1985</LINK>; <LINK REF="STD-Kahan-1985a" TYPE="STUDY">Kahan 1985a</LINK>; <LINK REF="STD-Kahan-1985b" TYPE="STUDY">Kahan 1985b</LINK>; <LINK REF="STD-Kahan-1985c" TYPE="STUDY">Kahan 1985c</LINK>; <LINK REF="STD-Kahan-1987" TYPE="STUDY">Kahan 1987</LINK>; <LINK REF="STD-Kirch-1987" TYPE="STUDY">Kirch 1987</LINK>; <LINK REF="STD-Malamet-1984" TYPE="STUDY">Malamet 1984</LINK>; <LINK REF="STD-Rupp-1987" TYPE="STUDY">Rupp 1987</LINK>; <LINK REF="STD-Smith-1982" TYPE="STUDY">Smith 1982</LINK>; and <LINK REF="STD-Wigley-1987" TYPE="STUDY">Wigley 1987</LINK> (<LINK REF="CMP-005.03" TYPE="ANALYSIS">Analysis 5.3</LINK>).</P><P>The WMD for severity of attacks was -0.56 (95% CI -0.68 to -0.45; I² = 94%) when low-dose CCBs were compared with placebo in 217 people, and -0.91 (95% CI -1.18 to -0.64; I² = 90%) when medium/high-dose CCBs were compared with placebo in 157 people.</P><P>Differences between these subgroups were statistically significant (P = 0.02; I² = 81%).</P></SUBSECTION></SUBSECTION><SUBSECTION><HEADING LEVEL="5">Pain</HEADING><SUBSECTION><HEADING LEVEL="6">Average pain per attack measured on a 10-point visual analogue scale (0 = no pain, 10 = maximal pain) in 62 participants from four studies</HEADING><P>See <LINK REF="STD-Aldoori-1986" TYPE="STUDY">Aldoori 1986</LINK>; <LINK REF="STD-Ettinger-1984" TYPE="STUDY">Ettinger 1984</LINK>; <LINK REF="STD-Malamet-1984" TYPE="STUDY">Malamet 1984</LINK>; and <LINK REF="STD-Rupp-1987" TYPE="STUDY">Rupp 1987</LINK> (<LINK REF="CMP-005.04" TYPE="ANALYSIS">Analysis 5.4</LINK>).</P><P>The WMD for pain was -3.04 (95% CI -4.34 to -1.75; I² = 59%) for 36 participants with low-dose CCBs, and -0.73 (95% CI -1.62 to 0.16) for 26 participants with medium-dose CCBs when each was compared with placebo.</P><P>Again, differences between these subgroups were statistically significant (P = 0.04; I² = 88%).</P></SUBSECTION></SUBSECTION><SUBSECTION><HEADING LEVEL="5">Patient global</HEADING><SUBSECTION><HEADING LEVEL="6">Disability due to Raynaud's assessed on a 10-cm visual analogue scale (0 = no disability, 10 = maximal disability) in 96 participants from two studies</HEADING><P>See <LINK REF="STD-Challenor-1987" TYPE="STUDY">Challenor 1987</LINK> and <LINK REF="STD-French-Co_x002d_op-1991" TYPE="STUDY">French Co-op 1991</LINK> (<LINK REF="CMP-005.05" TYPE="ANALYSIS">Analysis 5.5</LINK>).</P><P><LINK REF="STD-Challenor-1987" TYPE="STUDY">Challenor 1987</LINK> compared a low-dose CCB versus placebo in 36 people and reported that the WMD for patient global was -0.20 (95% CI -0.63 to 0.23). <LINK REF="STD-French-Co_x002d_op-1991" TYPE="STUDY">French Co-op 1991</LINK> compared a high-dose CCB versus placebo in 60 people and reported that the WMD for patient global was -0.74 (95% CI -1.37 to -0.11). Differences between these two trials were not statistically significant (P = 0.16; I² = 48%).</P></SUBSECTION></SUBSECTION></SUBSECTION></SUBSECTION><SUBSECTION><HEADING LEVEL="3">Minor outcomes</HEADING><P>See <LINK REF="CMP-006.01" TYPE="ANALYSIS">Analysis 6.1</LINK> to <LINK REF="CMP-006.02" TYPE="ANALYSIS">Analysis 6.2</LINK> (<LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>).</P><P>For our minor outcomes, trials reported general improvement, treatment preference, changes in digital ulcers, and side effects.</P><SUBSECTION><HEADING LEVEL="4">General improvement</HEADING><P>Three parallel RCTs reported on and analyzed general improvement (<LINK REF="STD-Constantini-1987" TYPE="STUDY">Constantini 1987</LINK>; <LINK REF="STD-Sarkozi--1986" TYPE="STUDY">Sarkozi 1986</LINK>; <LINK REF="STD-Sauza-1984" TYPE="STUDY">Sauza 1984</LINK>). For these trials, the risk ratio of improvement was 2.38 (95% CI 1.35 to 4.20; I² = 12%). Data from cross-over trials were not analyzed; however, more participants from these trials reported improvement while receiving active treatment over placebo (nine cross-over trials with 109 participants reported 76 cases of general improvement on active treatment vs 29 cases on placebo).</P></SUBSECTION><SUBSECTION><HEADING LEVEL="4">Treatment preference</HEADING><P>Four cross-over trials with a total of 89 participants reported treatment preference (<LINK REF="STD-Corbin-1986" TYPE="STUDY">Corbin 1986</LINK>; <LINK REF="STD-Gjorup-1986a" TYPE="STUDY">Gjorup 1986a</LINK>; <LINK REF="STD-Gjorup-1986b" TYPE="STUDY">Gjorup 1986b</LINK>; <LINK REF="STD-Rupp-1987" TYPE="STUDY">Rupp 1987</LINK>). Of the these 89 participants, 61 preferred active treatment and 17 indicated a preference for placebo.</P></SUBSECTION><SUBSECTION><HEADING LEVEL="4">Changes in digital ulcers</HEADING><P>Only one study considered changes in digital ulceration (<LINK REF="STD-Meyrick-Thomas-1987" TYPE="STUDY">Meyrick Thomas 1987</LINK>). This study reported 18 new digital ulcers in six patients taking placebo and nine new ulcers among three patients taking nifedipine.</P></SUBSECTION><SUBSECTION><HEADING LEVEL="4">Side effects</HEADING><P>Three parallel trials reported side effects and thus were meta-analyzed for this outcome (<LINK REF="STD-Constantini-1987" TYPE="STUDY">Constantini 1987</LINK>; <LINK REF="STD-Sarkozi--1986" TYPE="STUDY">Sarkozi 1986</LINK>; <LINK REF="STD-Sauza-1984" TYPE="STUDY">Sauza 1984</LINK>). The RR for side effects was 1.12 (95% CI 0.87 to 1.45). Hence, side effects were more common with CCBs than with placebo. This was also true for the cross-over trials: Of 573 participants from 26 cross-over trials, 265 experienced side effects on active treatment compared with 85 on placebo.</P></SUBSECTION></SUBSECTION><SUBSECTION><HEADING LEVEL="3">Results from the search of regulatory websites</HEADING><P>On March 8, 2016, we searched for black box warnings on websites for FDA MedWatch, European Medicines Evaluation Agency, Australian Adverse Drug Reactions Bulletin, and UK Medicines and Healthcare products Regulatory agencies. We found no black box warnings for nifedipine, nicardipine, nisoldipine, diltiazem, verapamil, amlodipine, isradipine, or BAY K 9320.</P></SUBSECTION></INTERVENTION_EFFECTS></RESULTS><DISCUSSION MODIFIED="2017-11-24 21:06:08 -0500" MODIFIED_BY="[Empty name]"><SUMMARY_OF_RESULTS MODIFIED="2017-11-24 21:05:36 -0500" MODIFIED_BY="[Empty name]"><P>For this review, we identified 38 studies with 982 participants and considered all subsets of Raynaud's phenomenon (RP) (both primary and secondary). However, not all studies reported all outcomes of interest. We used the Cochrane risk of bias assessment tool as well as the GRADE approach to evaluate the quality of evidence. In addition, we examined effects of calcium channel blockers (CCBs) by class, type, and dose, as well as by Raynaud's type (primary vs secondary). The most frequently encountered risk of bias types were incomplete outcome data and lack of reporting of methods used for randomization generation and allocation. For most outcomes, we downgraded evidence for small sample sizes because included trials did not always report all outcomes. Overall, evidence quality ranged from low to moderate (three moderate quality and three low quality).</P><SUBSECTION><HEADING LEVEL="3">Major outcomes</HEADING><SUBSECTION><HEADING LEVEL="4">CCBs (all) versus placebo for all RP subsets</HEADING><P>When we examined CCBs compared with placebo for all RP subsets, we found that CCBs (given for between 2 and 20 weeks) were superior in reducing the frequency, severity, and pain of attacks, as seen in <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>. Reductions in frequency and severity of Raynaud's attacks were small to moderate and were based on evidence of moderate quality derived from 23 trials with 528 participants, and from 18 trials with 415 participants, respectively. Reduced frequency of attacks with CCBs remained after a post hoc sensitivity analysis was performed to address some of the observed heterogeneity. Other plausible explanations for the remainder of the heterogeneity noted for these outcomes included variations in the duration of trials, in CCB dose and type, and in methodological rigor.</P><P>Evidence of low quality from four studies with 62 participants shows that CCBs were better than placebo for reducing pain associated with Raynaud's attacks. The impact of CCBs on the duration of attacks and on patient global, although favoring CCBs, was uncertain because evidence on small numbers of participants was obtained from a limited number of trials measuring and reporting these outcomes.</P><P>Two parallel studies with 69 participants analyzed withdrawals due to adverse events and found that withdrawals were more common with CCBs than with placebo; however, this evidence was of low quality and differences may not have been important. For cross-over trials, we did not analyze withdrawals (because of the challenges involved in analyzing dichotomous outcomes from cross-over trials), but we noted that overall, more withdrawals were reported with CCBs than with placebo. These studies did not report serious adverse events (leading to withdrawal followed by hospitalization or death) directly attributed to treatment.</P></SUBSECTION><SUBSECTION><HEADING LEVEL="4">CCBs versus placebo by RP type (primary vs secondary)</HEADING><P>Examination of all CCBs versus placebo by RP type revealed that CCBs (when compared with placebo) had a similar effect in both subgroups with regard to reducing the frequency of attacks (a reduction of three attacks/week). However, the number of participants with primary RP was much larger than the number with secondary RP. Hence, this difference in sample sizes may have affected observed effect estimates. Another comparison revealed that CCBs were superior to placebo in primary RP with regard to reducing the severity of attacks (-0.91 cm vs -0.48 cm, respectively). The smaller treatment effect sizes noted in secondary RP with regard to RP severity are consistent with those reported in clinical practice owing to the more severe nature of the disease in this subpopulation.</P></SUBSECTION><SUBSECTION><HEADING LEVEL="4">Nifedipine versus placebo by RP type (primary or secondary)</HEADING><P>Comparison of nifedipine versus placebo by RP type showed that nifedipine was slightly better in reducing the frequency of attacks in primary RP (-4.42 vs -4.19, respectively); and nifedipine was much more effective in reducing the severity of attacks in primary than in secondary RP (-1.74 cm vs 0.01 cm, respectively). However, sample sizes for these subgroup analyses were very small, likely making analyses underpowered to detect the true effects of treatment. In general, improvement in secondary RP may be less than in primary RP, as the condition in the former group is likely more severe and potentially less reversible with fixed vascular changes - not just vasospasm.</P></SUBSECTION><SUBSECTION><HEADING LEVEL="4">Subgroup analysis by CCB class: dihydropyridines (most common class of CCBs) versus placebo for all RP subsets</HEADING><P>Comparison of only the dihydropyridine class of CCBs versus placebo for all RP subsets yielded similar results to those obtained when all CCBs were compared with placebo; this was expected because all trials but one used the dihydropyridine class of CCBs.</P><P>Nifedipine, nicardipine, and nisoldipine were analyzed separately versus placebo for frequency and severity of attacks. All three CCBs were superior to placebo in decreasing both the frequency and the severity of attacks. Nifedipine was used by most of the included trials and led to the largest reduction in frequency of attacks. Nifedipine also had a larger effect estimate with regard to severity of attacks when compared with nicardipine - the second most commonly used CCB. Nisoldipine was used by only two trials and had a larger effect size on severity of attacks, but this effect estimate was likely imprecise owing to the small sample size. Overall, nifedipine appeared to be the most beneficial treatment with regard to reducing the frequency and severity of attacks.</P></SUBSECTION><SUBSECTION><HEADING LEVEL="4">CCBs (by dose) versus placebo for all RP subsets</HEADING><P>Comparison of CCBs versus placebo by CCB dose (low, medium/high) revealed that higher doses were superior to lower doses in reducing the frequency, duration, and severity of attacks, as well as in improving patient global. In addition, although most trials used low-dose CCBs, and fewer used medium to high doses, results show that higher doses had larger treatment effects and hence appeared more beneficial with regard to the frequency, duration, and severity of attacks, as well as improved patient global. Although significant heterogeneity was evident, low-dose CCBs reduced the frequency of attacks per week by 3.0 and the severity of attacks by 0.56 cm (on a scale of 0 to 10 cm), and medium/high-dose CCBs reduced the frequency of attacks by 9.5 and severity by 0.91 cm. In addition, medium/high-dose CCBs were superior to placebo in reducing the average duration of attacks (mean difference [WMD] -4.60, 95% CI -6.76 to -2.45), but low-dose CCBs compared with placebo did not produce this effect (WMD 2.24, 95% CI -0.24 to 4.73). Higher doses of CCBs were better in reducing disability due to RP (patient global): A study comparing a high-dose CCB versus placebo in 60 participants found a reduction of 0.74 cm (95% CI -1.37 to -0.11) with CCBs, but another trial using a low-dose CCB versus placebo in 36 participants found a reduction of 0.20 cm (95% CI -0.63 to 0.23).</P><P>Researchers found a larger reduction in pain with low-dose CCBs versus placebo than with higher-dose CCBs versus placebo. However, overall sample sizes were small, and a larger number of trial participants used low-dose CCBs compared with placebo.</P><P>Overall, higher doses of CCBs compared with placebo appear to be more beneficial with regard to the primary outcomes examined. Larger treatment effect estimates of CCBs at higher doses are consistent with findings reported in clinical practice, but dosages generally are based on patient tolerability.</P></SUBSECTION></SUBSECTION><SUBSECTION><HEADING LEVEL="3">Heterogeneity and publication bias</HEADING><P>We explored explanations for the presence of heterogeneity in treatment effects by performing subgroup and sensitivity analyses. Overall, we observed heterogeneity with most outcomes that was partially explained by differences in the type and dose of CCBs, as well as by differences in disease type (primary vs secondary RP) and study duration, with most trials being of very short duration. Other plausible factors that may have contributed to heterogeneity but were not explored include differences in inclusion criteria of trials, rigor in trial methods, trial type (cross-over vs parallel), and differences in the time of year trials were performed. To our knowledge, only one study reported that concomitant medications were continued during the trial. Hence, we do not believe that use of concomitant vasodilator medications was a significant confounder in the observed results.</P><P>For major outcomes reported in at least 10 trials (frequency and severity of attacks), we examined funnel plots to assess for publication bias. Both funnel plots showed some asymmetry around the mean effect estimate but did not indicate publication bias as a major concern. Plausible explanations for the presence of asymmetry in these funnel plots include the presence of significant heterogeneity, differences in the quality and size of trials, differences in methods (i.e., parallel vs cross-over design), and possibly selective reporting.</P></SUBSECTION><SUBSECTION><HEADING LEVEL="3">Minor outcomes</HEADING><P>With regard to our minor outcomes, analysis of three parallel trials showed that CCBs were associated with more general improvement in patients' Raynaud's condition. We were unable to meta-analyze dichotomous outcomes from cross-over trials, but we did examine overall trends. Cross-over trials also reported that more participants reported improvement while taking CCBs than placebo, and more participants preferred active treatment over placebo. One trial reporting changes in digital ulceration found that nine participants developed 18 new digital ulcers while taking placebo, and three participants developed six new digital ulcers while taking nifedipine. Results from this trial suggest that CCBs such as nifedipine may be useful for prevention of digital ulcers. However, participants who took CCBs reported more side effects than were reported by those who took placebo, but none of these reported adverse effects were serious.</P></SUBSECTION><SUBSECTION><HEADING LEVEL="3">Conclusions from this review and meta-analysis</HEADING><P>Overall, although they were associated with more non-serious side effects, CCBs were preferred to placebo and were better in reducing the frequency, duration, and severity of Raynaud's attacks when given over 2 to 20 weeks. In addition, CCBs produced a potentially clinically important mean improvement in pain, and more participants taking CCBs reported general improvement. In particular, CCBs showed greater benefit at higher doses in reducing the frequency and severity of attacks for patients with primary RP. It is important to note that researchers reported no serious adverse events directly related to treatment with CCBs. These findings indicate that CCBs, particularly those in the dihydropyridine class (i.e., nifedipine and nicardipine), given at higher doses may be beneficial for the management of RP (especially among patients with primary RP) requiring pharmacological intervention (although most people with RP, especially primary RP, do not require pharmacological treatment). Some clinically important outcomes of interest (i.e., changes in average duration of attacks, pain, and patient global) were measured or reported by only a few trials. Hence, effect estimates for these outcomes were imprecise but appeared to favor CCBs. The findings of this review may be generalizable to other members of the dihydropyridine class of CCBs, such as amlodipine, bepridil, felodipine, isradipine, and nisoldipine.</P></SUBSECTION></SUMMARY_OF_RESULTS><APPLICABILITY_OF_FINDINGS MODIFIED="2017-11-24 20:18:31 -0500" MODIFIED_BY="[Empty name]"><P>Most of the trials included in this review were small and included a mixture of patients with primary and secondary RP. Fewer trials enrolled patients with secondary RP, which makes it more difficult to generalize the results of this review to these patients. Review results indicate that CCBs (particularly those in the dihydropyridine class) may be beneficial in the management of RP, especially primary RP. Furthermore, both nifedipine and nicardipine - the most commonly used dihydropyridines - proved superior to placebo in reducing the frequency and severity of RP attacks. However, several concerns must be addressed to guide clinicians in using or interpreting the findings of this review.</P><UL><LI>The overall quality of evidence ranged from low to moderate, with evidence for three outcomes being of low quality and three of moderate quality. Many trials included in the meta-analyses were not methodologically rigorous. This variation in the quality of the evidence requires cautious interpretation and use of review findings, especially in clinical practice.</LI><LI>Most trials had small sample sizes. As a result, we were unable to conduct subgroup analysis for all major outcomes of this review. The overall small sample size was a problem, especially for some outcomes such as duration and patient global, which were not measured or reported by many trials. For outcomes with small sample sizes, results often have large confidence intervals and are imprecise.</LI><LI>Most included trials were of the cross-over design. Potential carryover effects between active treatment and placebo are possible with this method. We were unable to estimate a period effect. Results may be biased.</LI><LI>The dosage of CCBs used was highly variable, with most trials using low-dose CCBs. We found evidence of higher efficacy for medium/high versus.low doses of CCBs in RP treatment. Hence, suboptimal doses in most included trials may be responsible for the non-significant findings observed for some outcomes. Clinicians may start with low doses of CCBs and may increase dosage to achieve a desired effect (if not obtained with low dose), as long as the patient can tolerate it and no serious side effects develop.</LI><LI>Most included trials include a mixture of patients with primary and secondary RP. Only seven trials exclusively included patients with primary RP, and even fewer included only those with secondary RP. Consistent with the findings of this study, patients with primary RP often respond better to medication, possibly as a result of the milder nature of their disease. Only a few studies including patients with secondary RP reported the important outcomes of interest. Most trials did not stratify randomization between primary and secondary RP (or within secondary RP between systemic sclerosis, which is the most severe form of secondary RP, and other connective tissue disorders). This could have introduced bias, as groups may not have been equal with respect to the proportion of primary and secondary RP between treatment arms (for parallel designed studies).</LI><LI>Another problem could be the variability of treatment duration between trials. However, CCBs are fast acting, and most patients respond to treatment quickly. Thus efficacy of CCBs would be expected in short trials, but longer trials may report increased dropout and greater regression to the mean and/or attenuation of benefit for other reasons.</LI><LI>Included trials showed high variability in outcome measurements and scales used. To allow for ease of interpretation, we converted all results to the most commonly used scales. For instance, for severity of attacks, we converted the results of all trials to a 10-cm visual analogue scale score. This variability in the scales of measure likely contributed to some of the observed heterogeneity.</LI><LI>Last, significant statistical heterogeneity was seen with most outcomes. Some heterogeneity was partially reduced by subgroup and sensitivity analyses. However, heterogeneity often remained and is likely a result of the different factors discussed above.</LI></UL></APPLICABILITY_OF_FINDINGS><QUALITY_OF_EVIDENCE MODIFIED="2017-11-14 06:14:08 -0500" MODIFIED_BY="[Empty name]"><P>We assessed the quality of evidence from trials included in this review using the GRADE approach (<LINK REF="REF-Grade-2008" TYPE="REFERENCE">Grade 2008</LINK>). Many trials, particularly older ones from the 1980s (when reporting was less standardized and protocols were not registered) failed to fully describe their methods. The deficiency that we most commonly encountered when assessing risk of bias in these trials was lack of full descriptions of random sequence generation and allocation concealment. Most publications noted that the study was "randomized" and "double-blind" without providing further details.</P><P>We downgraded outcomes of frequency of attacks and severity of attacks to moderate quality owing to concerns about inconsistency of results across trials. We downgraded evidence on patient global assessment to moderate quality for concerns about imprecision due to the small sample size. We downgraded evidence on duration of attacks and pain to low quality for concerns about both inconsistency and imprecision. We downgraded evidence quality to low for withdrawals due to adverse events, given the small sample size (imprecision) and high attrition rate noted in the two studies that reported this outcome.</P><P>Given the moderate to low quality of evidence on major outcomes, one should use caution, but trial results do mirror what is seen in clinical practice; hence they have face validity despite methodological flaws.</P></QUALITY_OF_EVIDENCE><POTENTIAL_BIASES MODIFIED="2017-11-24 21:06:08 -0500" MODIFIED_BY="[Empty name]"><P>We performed an extensive and sensitive electronic search of all important databases to ensure retrieval of as many studies as possible. In addition, at least two review authors performed most of the steps of the review and consulted with a third review author regarding disagreements. </P><P>Some subgroup analyses were post hoc which may have introduced bias as many trials did not stratify randomization on the analyses of interest. We did plan to study: primary vs. secondary RP and RP from systemic sclerosis (as the scleroderma patients are more difficult to treat and have more severe and complicated RP), we planned to study subsets of CCBs (dihydropyridines and nifedipine in particular as we knew the bulk of the data was from nifedipine), but studying some other subgroups post hoc may have been biased. Overall, we did not identify any major biases in the review process.</P></POTENTIAL_BIASES><AGREEMENT MODIFIED="2017-11-14 06:16:37 -0500" MODIFIED_BY="[Empty name]"><P>The findings of this review, although broader in scope, are similar to those of our 2005 meta-analysis - <LINK REF="STD-Thompson-2005" TYPE="STUDY">Thompson 2005</LINK> - and of a recent meta-analysis - <LINK REF="STD-Ennis-2016" TYPE="STUDY">Ennis 2016</LINK> - on the use of oral vasodilators (including CCBs) for primary RP. Both of these meta-analyses noted reduced frequency of attacks among patients with primary RP when treated with CCBs. <LINK REF="STD-Thompson-2005" TYPE="STUDY">Thompson 2005</LINK> found that CCBs decreased the frequency of attacks in patients with primary RP by a mean of 2.8 to 5 attacks per week, and <LINK REF="STD-Ennis-2016" TYPE="STUDY">Ennis 2016</LINK> noted a decrease of 0.6 to 2.8 attacks per week. In the current review, when review authors considered both primary and secondary RP, we found an average decrease in the frequency of six attacks per week (and an average decrease of three attacks per week with exclusion of <LINK REF="STD-Kahan-1985c" TYPE="STUDY">Kahan 1985c</LINK>). When considering only primary RP, we found an average decrease of three attacks per week. This difference between our study and <LINK REF="STD-Ennis-2016" TYPE="STUDY">Ennis 2016</LINK> may be due to the fact that <LINK REF="STD-Ennis-2016" TYPE="STUDY">Ennis 2016</LINK> included all trials examining CCBs versus placebo or other treatments. We limited our review to trials examining only CCBs versus placebo and no other oral vasodilators from other classes of medications.</P><P>The <LINK REF="STD-Thompson-2001" TYPE="STUDY">Thompson 2001</LINK> meta-analysis shows that CCBs significantly reduced both the frequency and the severity of attacks in patients with systemic sclerosis. This review did not find that CCBs significantly reduced any of the reported major outcomes in patients with secondary RP. Differences between these reviews are likely due to the fact that review authors for <LINK REF="STD-Thompson-2001" TYPE="STUDY">Thompson 2001</LINK> included a larger number of trials (any trials with over 75% of trial participants with systemic sclerosis) and performed subset analyses of data from trials that included participants with systemic sclerosis, if data could be extracted. In our current review of secondary RP, we included only trials in which all participants had secondary RP of any origin, resulting in very small numbers of trials and participants. We included any trial of participants with secondary RP in which nearly all had connective tissue disease.</P></AGREEMENT></DISCUSSION><CONCLUSIONS MODIFIED="2017-11-24 21:07:12 -0500" MODIFIED_BY="[Empty name]"><IMPLICATIONS_PRACTICE MODIFIED="2017-11-24 21:06:47 -0500" MODIFIED_BY="[Empty name]"><P>This review is the largest and most comprehensive systematic review conducted to investigate the efficacy of calcium channel blockers (CCBs) for the management of Raynaud's phenomenon (RP). Evidence of low to moderate quality assembled for this review indicates that CCBs (such as nifedipine) may be effective in reducing the frequency and severity of Raynaud's attacks, especially in primary RP. In addition, results of this review show that higher doses may be more useful than lower doses (although in clinical practice, dose is based on desired outcome and patient tolerability). Adverse effects were more common with CCBs, but none were considered serious. Longer-term treatment effects of CCBs for RP are unknown, as most trials have had a very short duration. However, CCBs are used routinely over the long term for patients with RP who require drug treatment with ongoing effectiveness for long periods of time, often as needed or on a regular basis. Harms include side effects such as hypotension, flushing, and peripheral edema which can lead to discontinuation of treatment in some patients. However, serious adverse events within the trials (most of which were relatively short duration) were rare and did not differ from placebo, or not reported.</P></IMPLICATIONS_PRACTICE><IMPLICATIONS_RESEARCH MODIFIED="2017-11-24 21:07:12 -0500" MODIFIED_BY="[Empty name]"><P>In many randomized controlled trials undertaken to study RP, the placebo effect may be great, so the sample size may need to be adjusted upward.</P><P>Most of the included studies were older and smaller studies that had methodological deficiencies. Larger studies that are more methodologically robust would allow for better estimation of the true effect of CCBs, but likely no further trials are needed to examine current use of CCBs in patients with RP. Head-to-head comparisons of CCBs and other treatments for RP could clarify the relative positioning of other agents and/or reveal relative effects of various RP treatments via a network meta-analysis. In addition, not all included trials reported all outcomes of interest. Future trials should use standardized outcome measurements (a minimum core set) and similar time frames (i.e. frequency of RP attacks over one week); these trials need to be registered and should report all outcomes studied within the trial to yield more accurate estimations of treatment effect.</P><P>Additionally, most included trials were of the cross-over design with potential carryover effects between placebo and active treatment, which could introduce bias against the active treatment effect. Differences in the number of RP attacks between individuals can be very skewed, so an advantage can be gained by using cross-over trials with fast-acting and fast-washing out medications for RP treatment; also, a sample size (cost and feasibility) advantage and having each patient act as his or her own control can reduce variability between patients in the number of RP attacks.</P><P>Response to treatment differs between patients with primary and secondary RP. Secondary RP is more difficult to manage, as the disease is more severe. When possible, researchers should report the results of primary and secondary RP subsets separately. More important, future studies should include use of the validated Raynaud's condition score (RCS) to allow for more consistent comparison between trials (<LINK REF="REF-Khanna-2009" TYPE="REFERENCE">Khanna 2009</LINK>; <LINK REF="REF-Merkel-2002" TYPE="REFERENCE">Merkel 2002</LINK>). Use of various scales for measurement of outcomes likely contributes to heterogeneity.</P></IMPLICATIONS_RESEARCH></CONCLUSIONS></BODY><ACKNOWLEDGEMENTS MODIFIED="2017-11-12 16:24:03 -0500" MODIFIED_BY="[Empty name]"><P>We are grateful to Ingrid Tows and the German Cochrane Centre for their services in translating a German study.</P><P>We also thank our reviewers for their valuable feedback and contributions to this review.</P></ACKNOWLEDGEMENTS><CONFLICT_OF_INTEREST MODIFIED="2017-11-29 09:50:00 -0500" MODIFIED_BY="[Empty name]"><P>JP: has consulted for Actelion, Mediquest, Pfizer, and United Therapeutics in the area of Raynaud's phenomenon and/or digital ulcers.</P><P>PTu: grants/honoraria from Bristol Myers and UCB.</P><P>FR: none known.</P><P>PTi: none known.</P><P>SH: none known.</P><P>LM: none known.</P><P>EG: none known.</P><P>GW: none known.</P></CONFLICT_OF_INTEREST><CONTRIBUTIONS MODIFIED="2017-11-28 10:39:57 -0500" MODIFIED_BY="[Empty name]"><P>Pope J - Guarantor, coordinator; conceiving the review, designing search strategies, screening search results, obtaining and screening data on unpublished studies, providing general advice on the review, securing funding for the review, performing previous work that was the foundation of the current review.</P><P>Rirash F- collected data, assisted in designing the review, undertook searches, organized retrieval of papers, screened retrieved papers against inclusion criteria, appraised quality of papers, extracted data from papers, obtained and screened data on unpublished studies, managed data, entered data into RevMan version 5 (2014), analyzed and interpreted data, participated in writing the review.</P><P>Tingey P - collected data, assisted in designing the review, undertook searches, organized retrieval of papers, screened retrieved papers against inclusion criteria, appraised quality of papers, extracted data from papers, obtained and screened data on unpublished studies, managed data, entered data into RevMan version 5 (2014), analyzed and interpreted data, participated in writing the review.</P><P>Harding S - collected data, assisted in designing the review, undertook searches, organized retrieval of papers, screened retrieved papers against inclusion criteria, appraised quality of papers, extracted data from papers, obtained and screened data on unpublished studies, managed data, entered data into RevMan version 5 (2014), analyzed and interpreted data, participated in writing the review.</P><P>Maxwell L - advised on and assisted with methods, data extraction, and calculations; commented on draft versions of the review.</P><P>Ghogomu E - advised on and assisted with methods, data extraction, and calculations; commented on draft versions of the review.</P><P>Wells GA - advised on methods, commented on draft versions of the review.</P><P>Tugwell P - advised on methods, interpreted data, commented on draft versions of the review.</P></CONTRIBUTIONS><PRO_REV_DIFF MODIFIED="2017-11-28 11:16:10 -0500" MODIFIED_BY="[Empty name]"><P>We used a generic protocol for pharmacological interventions for Raynaud's (<LINK REF="REF-Pope-2015" TYPE="REFERENCE">Pope 2015</LINK>). We have adjusted the text to reflect the specific interventions and controls assessed in this review. We added some post hoc analyses in this review that were not included in the registered protocol. We did plan to study: primary vs. secondary RP and RP from systemic sclerosis (as the scleroderma patients are more difficult to treat and have more severe and complicated RP), we planned to study subsets of CCBs (dihydropyridines and nifedipine in particular as we knew the bulk of the data was from nifedipine). All other subgroup analysis were post-hoc.</P></PRO_REV_DIFF><PUBLIC_NOTES MODIFIED_BY="Jordi Pardo Pardo"/></MAIN_TEXT><STUDIES_AND_REFERENCES MODIFIED="2017-11-29 14:53:30 +0000" MODIFIED_BY="Jordi Pardo Pardo">
<STUDIES MODIFIED="2017-11-14 08:05:45 -0500" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2017-11-14 07:44:43 -0500" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Aldoori-1986" MODIFIED="2017-11-14 07:30:58 -0500" MODIFIED_BY="[Empty name]" NAME="Aldoori 1986" YEAR="1986">
<REFERENCE MODIFIED="2017-11-14 07:30:58 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Aldoori M, Campebell WB, Dieppe PA</AU>
<TI>Nifedipine in the treatment of Raynaud's syndrome</TI>
<SO>Cardiovascualr Research</SO>
<YR>1986</YR>
<VL>20</VL>
<NO>6</NO>
<PG>466-70</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7191702"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7191701"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bravard-1983" MODIFIED="2017-11-14 07:31:14 -0500" MODIFIED_BY="[Empty name]" NAME="Bravard 1983" YEAR="1983">
<REFERENCE MODIFIED="2017-11-14 07:31:14 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bravard P, Moore N</AU>
<TI>Nifedipine for Raynaud's phenomenon</TI>
<SO>Lancet</SO>
<YR>1983</YR>
<VL>1</VL>
<NO>8316</NO>
<PG>130-1</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7191704"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7191703"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Challenor-1987" MODIFIED="2017-11-14 07:31:57 -0500" MODIFIED_BY="[Empty name]" NAME="Challenor 1987" YEAR="1987">
<REFERENCE MODIFIED="2017-11-14 07:31:57 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Challenor VF, Waller DG, Francis DA, Francis JL, Mani R, Roath S</AU>
<TI>Nisodipine in primary Raynaud's phenomenon</TI>
<SO>European Journal of Clinical Pharmacology</SO>
<YR>1987</YR>
<VL>33</VL>
<NO>1</NO>
<PG>27-30</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7191706"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7191705"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Challenor-1989" MODIFIED="2017-11-14 07:32:16 -0500" MODIFIED_BY="[Empty name]" NAME="Challenor 1989" YEAR="1989">
<REFERENCE MODIFIED="2017-11-14 07:32:16 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Challenor VF, Waller DG, Hayward RA, Griffin MJ, Roath OS</AU>
<TI>Vibrotactile sensation and response to nifedipine dose titration in primary Raynaud's phenomenon</TI>
<SO>Angiology</SO>
<YR>1989</YR>
<VL>40</VL>
<NO>2</NO>
<PG>120-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7191708"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7191707"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Constantini-1987" MODIFIED="2017-11-14 07:32:48 -0500" MODIFIED_BY="[Empty name]" NAME="Constantini 1987" YEAR="1987">
<REFERENCE MODIFIED="2017-11-14 07:32:48 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Constantini A, Martelli E, Bavera P, Agus GB</AU>
<TI>Slow release nifedipine in the treatment of Raynaud's phenomenon</TI>
<SO>International Journal of Angiology</SO>
<YR>1987</YR>
<VL>6</VL>
<NO>4</NO>
<PG>359-63</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7191710"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7191709"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Corbin-1986" MODIFIED="2017-11-14 07:32:35 -0500" MODIFIED_BY="[Empty name]" NAME="Corbin 1986" YEAR="1986">
<REFERENCE MODIFIED="2017-11-14 07:32:35 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Corbin DOC, Wood DA, Macintyre CCA, Housley E</AU>
<TI>A randomized double blind cross-over trial of nifedipine in the treatment of primary Raynaud's phenomenon</TI>
<SO>European Heart Journal</SO>
<YR>1986</YR>
<VL>7</VL>
<NO>2</NO>
<PG>165-70</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7191712"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7191711"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ettinger-1984" MODIFIED="2017-11-14 07:33:12 -0500" MODIFIED_BY="[Empty name]" NAME="Ettinger 1984" YEAR="1984">
<REFERENCE MODIFIED="2017-11-14 07:33:12 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ettinger WH, Wise RA, Schaffhauser D, Wigley FM</AU>
<TI>Controlled double-blind trial of dazoxiben and nifedipine in the treatment of Raynaud's phenomenon</TI>
<SO>American Journal of Medicine</SO>
<YR>1984</YR>
<VL>77</VL>
<NO>3</NO>
<PG>451-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7191714"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7191713"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ferri-1992" MODIFIED="2017-11-14 07:33:29 -0500" MODIFIED_BY="[Empty name]" NAME="Ferri 1992" YEAR="1992">
<REFERENCE MODIFIED="2017-11-14 07:33:29 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ferri C, Cecchetti R, Cini G, Gambini I, La Civita L, Bernini L, et al</AU>
<TI>Slow-releasing nicardipine in the treatment of Raynaud's phenomena without underlying diseases</TI>
<SO>Clinical Rheumatology</SO>
<YR>1992</YR>
<VL>11</VL>
<NO>1</NO>
<PG>76-80</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7191716"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7191715"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Finch-1988" MODIFIED="2017-11-14 07:33:46 -0500" MODIFIED_BY="[Empty name]" NAME="Finch 1988" YEAR="1988">
<REFERENCE MODIFIED="2017-11-14 07:33:46 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Finch MB, Copland S, Passmore AP, Johnston GD</AU>
<TI>A double-blind cross-over study of nifedipine retard in patients with Raynaud's phenomenon</TI>
<SO>Clinical Rheumatology</SO>
<YR>1988</YR>
<VL>7</VL>
<NO>3</NO>
<PG>359-65</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7191718"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7191717"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-French-Co_x002d_op-1991" MODIFIED="2017-11-14 07:34:04 -0500" MODIFIED_BY="[Empty name]" NAME="French Co-op 1991" YEAR="1991">
<REFERENCE MODIFIED="2017-11-14 07:34:04 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>French Cooperative Multicenter Group for Raynaud's Phenomenon* Paris France</AU>
<TI>Controlled multicenter double-blind trial of nicardipine in the treatment of primary Raynaud phenomenon</TI>
<SO>American Heart Journal</SO>
<YR>1991</YR>
<VL>122</VL>
<NO>1</NO>
<PG>352-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7191720"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7191719"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gjorup-1986a" MODIFIED="2017-11-14 07:34:17 -0500" MODIFIED_BY="[Empty name]" NAME="Gjorup 1986a" YEAR="1986">
<REFERENCE MODIFIED="2017-11-14 07:34:17 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gjorup T, Hartling OJ, Kelbaek H, Nielsen SL</AU>
<TI>Controlled double blind trial of nisoldipine in the treatment of idiopathic Raynaud's phenomenon</TI>
<SO>European Journal of Clinical Pharmacology</SO>
<YR>1986</YR>
<VL>31</VL>
<NO>4</NO>
<PG>387-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7191722"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7191721"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gjorup-1986b" MODIFIED="2017-11-14 07:34:31 -0500" MODIFIED_BY="[Empty name]" NAME="Gjorup 1986b" YEAR="1986">
<REFERENCE MODIFIED="2017-11-14 07:34:31 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gjorup T, Kelbaek H, Hartling OJ, Nielsen SL</AU>
<TI>Controlled double-blind trial of the clinical effect of nifedipine in the treatment of idiopathic Raynaud's phenomenon</TI>
<SO>American Heart Journal</SO>
<YR>1986</YR>
<VL>111</VL>
<NO>4</NO>
<PG>742-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7191724"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7191723"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hawkins-1985" MODIFIED="2017-11-14 07:34:47 -0500" MODIFIED_BY="[Empty name]" NAME="Hawkins 1985" YEAR="1985">
<REFERENCE MODIFIED="2017-11-14 07:34:47 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hawkins SJ, Black CM, Hall ND, McGregor A, Ring EF, Maddison PJ</AU>
<TI>Clinical and laboratory effects of nifedipine in Raynaud's phenomenon</TI>
<SO>Rheumatology International</SO>
<YR>1986</YR>
<VL>6</VL>
<NO>2</NO>
<PG>85-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7191726"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7191725"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kahan-1985a" MODIFIED="2017-11-14 07:35:00 -0500" MODIFIED_BY="[Empty name]" NAME="Kahan 1985a" YEAR="1985">
<REFERENCE MODIFIED="2017-11-14 07:35:00 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kahan A, Foult JM, Weber S, Amor B, Menkes CJ, Degeorges M</AU>
<TI>Nifedipine and alpha-adrenergic blockade in Raynaud's phenomenon</TI>
<SO>European Heart Journal</SO>
<YR>1985</YR>
<VL>6</VL>
<NO>8</NO>
<PG>702-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7191728"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7191727"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kahan-1985b" MODIFIED="2017-11-14 07:35:13 -0500" MODIFIED_BY="[Empty name]" NAME="Kahan 1985b" YEAR="1985">
<REFERENCE MODIFIED="2017-11-14 07:35:13 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kahan A, Amor B, Menkes CJ</AU>
<TI>A randomised double-blind trial of diltiazem in the treatment of Raynaud's phenomenon</TI>
<SO>Annals of Rheumatic Diseases</SO>
<YR>1985</YR>
<VL>44</VL>
<NO>1</NO>
<PG>30-3</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7191730"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7191729"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kahan-1985c" MODIFIED="2017-11-14 07:35:36 -0500" MODIFIED_BY="[Empty name]" NAME="Kahan 1985c" YEAR="1985">
<REFERENCE MODIFIED="2017-11-14 07:35:36 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kahan A, Weber S, Amor B, Menkes CJ, Hodara M, Degeorges M</AU>
<TI>Nifedipine and Raynaud's phenomenon associated with connective tissue diseases</TI>
<SO>International Journal of Angiology</SO>
<YR>1985</YR>
<VL>4</VL>
<NO>2</NO>
<PG>221-3</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7191732"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7191731"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kahan-1987" MODIFIED="2017-11-14 07:35:54 -0500" MODIFIED_BY="[Empty name]" NAME="Kahan 1987" YEAR="1987">
<REFERENCE MODIFIED="2017-11-14 07:35:54 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kahan A, Amor B, Menkes CJ, Weber S, Guerin F, Degeorges M</AU>
<TI>Nicardipine in the treatment of Raynaud's phenomenon: a randomized double-blind trial</TI>
<SO>Angiology</SO>
<YR>1987</YR>
<VL>38</VL>
<NO>4</NO>
<PG>333-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7191734"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7191733"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kallenberg-1987" MODIFIED="2017-11-14 07:37:17 -0500" MODIFIED_BY="[Empty name]" NAME="Kallenberg 1987" YEAR="1987">
<REFERENCE MODIFIED="2017-11-14 07:37:17 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kallenberg Cees GM, Wouda AA, Kuitert JJ, Tijssen J, Wesseling H</AU>
<TI>Nifedipine in Raynaud's phenomenon: relationship between immediate, short term and long term effects</TI>
<SO>Journal of Rheumatology</SO>
<YR>1986</YR>
<VL>14</VL>
<NO>2</NO>
<PG>284-90</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7191736"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7191735"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kinney-1982" MODIFIED="2017-11-14 07:37:36 -0500" MODIFIED_BY="[Empty name]" NAME="Kinney 1982" YEAR="1982">
<REFERENCE MODIFIED="2017-11-14 07:37:36 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kinney EL, Nicholas GG, Gallow J, Pontoriero C, Zelis R</AU>
<TI>The treatment of severe Raynaud's phenomenon with verapamil</TI>
<SO>Journal of Clinical Pharmacology</SO>
<YR>1982</YR>
<VL>22</VL>
<NO>1</NO>
<PG>74-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7191738"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7191737"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kirch-1987" MODIFIED="2015-05-06 15:11:49 -0400" MODIFIED_BY="[Empty name]" NAME="Kirch 1987" YEAR="1987">
<REFERENCE MODIFIED="2015-05-06 15:11:49 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kirch W, Linder HR, Hutt HJ, Ohnhaus EE, Mahler F</AU>
<TI>Ketanserin versus nifedipine in secondary Raynaud's phenomenon</TI>
<SO>VASA</SO>
<YR>1987</YR>
<VL>16</VL>
<NO>1</NO>
<PG>77-80</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7191740"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7191739"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-La-Civita-1997" MODIFIED="2017-11-14 07:38:02 -0500" MODIFIED_BY="[Empty name]" NAME="La Civita 1997" YEAR="1997">
<REFERENCE MODIFIED="2017-11-14 07:38:02 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>La Civita L, Pitaro N, Rossi M, Giuggioli D, Gambini I, Cini G, et al</AU>
<TI>Amlodipine in the treatment of Raynaud's phenomenon: a double-blind placebo-controlled crossover study</TI>
<SO>Clinical Drug Investigation</SO>
<YR>1997</YR>
<VL>23</VL>
<NO>Suppl 1</NO>
<PG>126-31</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7191742"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7191741"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Leppert-1989" MODIFIED="2015-06-06 14:13:10 -0400" MODIFIED_BY="[Empty name]" NAME="Leppert 1989" YEAR="1989">
<REFERENCE MODIFIED="2015-06-06 14:13:10 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Leppert J, Jonasson T, Nilsson H, Ringqvist I</AU>
<TI>The effect of isradipine, a new calcium-channel antagonist, in patients with primary Raynaud's phenomenon: a single-blind dose response study</TI>
<SO>Cardiovascular Drugs and Therapy</SO>
<YR>1989</YR>
<VL>3</VL>
<NO>3</NO>
<PG>397-401</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7191744"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7191743"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Malamet-1984" MODIFIED="2017-11-14 07:38:41 -0500" MODIFIED_BY="[Empty name]" NAME="Malamet 1984" YEAR="1984">
<REFERENCE MODIFIED="2017-11-14 07:38:41 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Malamet R, Wise RA, Ettinger WH, Wigley FM</AU>
<TI>Nifedipine in the treatment of Rayaud's phenomenon: evidence for platelet activation</TI>
<SO>American Journal of Medicine</SO>
<YR>1985</YR>
<VL>78</VL>
<NO>4</NO>
<PG>602-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7191746"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7191745"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Meyrick-Thomas-1987" MODIFIED="2017-11-14 07:39:12 -0500" MODIFIED_BY="[Empty name]" NAME="Meyrick Thomas 1987" YEAR="1987">
<REFERENCE MODIFIED="2017-11-14 07:39:12 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Meyrick-Thomas RH, Rademaker M, Grimes SM, Mackay A, Kovacs IB, Cook ED, et al</AU>
<TI>Nifedipine in the treatment of Raynaud's phenomenon in patients with systemic sclerosis</TI>
<SO>British Journal of Dermatology</SO>
<YR>1987</YR>
<VL>117</VL>
<NO>2</NO>
<PG>237-41</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7191748"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7191747"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Muller_x002d_Buhl-1983" MODIFIED="2017-11-14 07:39:30 -0500" MODIFIED_BY="[Empty name]" NAME="Muller-Buhl 1983" YEAR="1983">
<REFERENCE MODIFIED="2017-11-14 07:39:30 -0500" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Muller-Buhl U, Diehm C, Scheuermann W, Morl H</AU>
<TI>Calcium antagonists in the treatment of Raynaud's phenomenon</TI>
<TO>Calciumantagonisten zur Behandlung des Raynaud-phenomens</TO>
<SO>Deutsche Medicinische Wochenschrift</SO>
<YR>1983</YR>
<VL>108</VL>
<NO>47</NO>
<PG>1795-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7191750"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7191749"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nilsson-1987" MODIFIED="2017-11-14 07:39:53 -0500" MODIFIED_BY="[Empty name]" NAME="Nilsson 1987" YEAR="1987">
<REFERENCE MODIFIED="2017-11-14 07:39:53 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nilsson H, Jonason T, Leppert J, Ringqvist I</AU>
<TI>The effect of the calcium-entry blocker nifedipine on cold-induced digital vasospasm. A double-blind crossover study versus placebo</TI>
<SO>Acta Medica Scandinavica</SO>
<YR>1987</YR>
<VL>221</VL>
<NO>1</NO>
<PG>53-60</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7191752"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7191751"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rhedda-1985" MODIFIED="2017-11-14 07:40:10 -0500" MODIFIED_BY="[Empty name]" NAME="Rhedda 1985" YEAR="1985">
<REFERENCE MODIFIED="2017-11-14 07:40:10 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rhedda A, McCans J, Willan AR, Ford PM</AU>
<TI>A double blind placebo controlled crossover randomized trial of diltiazem in Raynaud's phenomenon</TI>
<SO>Journal of Rheumatology</SO>
<YR>1985</YR>
<VL>12</VL>
<NO>4</NO>
<PG>724-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7191754"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7191753"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rodeheffer-1983" MODIFIED="2017-11-14 07:40:28 -0500" MODIFIED_BY="[Empty name]" NAME="Rodeheffer 1983" YEAR="1983">
<REFERENCE MODIFIED="2017-11-14 07:40:28 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rodeheffer RJ, Rommer JA, Wigley F, Smith CR</AU>
<TI>Controlled double-blind trial of nifedipine in the treatment of Raynaud's phenomenon</TI>
<SO>New England Journal of Medicine</SO>
<YR>1983</YR>
<VL>308</VL>
<NO>15</NO>
<PG>880-3</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7191756"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7191755"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-RTSI-2000" MODIFIED="2017-11-14 07:40:46 -0500" MODIFIED_BY="[Empty name]" NAME="RTSI 2000" YEAR="2000">
<REFERENCE MODIFIED="2017-11-14 07:40:46 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ranayd's Treatment Study Investigators (RTSI)</AU>
<TI>Comparison of sustained-release nifedipine and temperature biofeedback treatment of primary Raynaud phenomenon</TI>
<SO>Archives of Internal Medicine</SO>
<YR>2000</YR>
<VL>160</VL>
<NO>8</NO>
<PG>1101-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7191758"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7191757"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rupp-1987" MODIFIED="2017-11-14 07:41:12 -0500" MODIFIED_BY="[Empty name]" NAME="Rupp 1987" YEAR="1987">
<REFERENCE MODIFIED="2017-11-14 07:41:12 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rupp PAF, Mellinger S, Kohler J, Dorsey JK, Furst DE</AU>
<TI>Nicardipine for the treatment of Raynaud's phenomena: a double blind crossover trial of a new calcium entry blocker</TI>
<SO>Journal of Rheumatology</SO>
<YR>1987</YR>
<VL>14</VL>
<NO>4</NO>
<PG>745-50</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7191760"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7191759"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sarkozi--1986" MODIFIED="2017-11-14 07:41:37 -0500" MODIFIED_BY="[Empty name]" NAME="Sarkozi  1986" YEAR="1986">
<REFERENCE MODIFIED="2017-11-14 07:41:37 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sarkozi J, Bookman AA, Mahon W, Ramsay C, Detsky AS, Keystone AC</AU>
<TI>Nifedipine in the treatment of idiopathic Raynaud's syndrome</TI>
<SO>Journal of Rheumatology</SO>
<YR>1986</YR>
<VL>13</VL>
<NO>2</NO>
<PG>331-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7191762"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7191761"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sauza-1984" MODIFIED="2017-11-14 07:42:45 -0500" MODIFIED_BY="[Empty name]" NAME="Sauza 1984" YEAR="1984">
<REFERENCE MODIFIED="2017-11-14 07:42:45 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sauza J, Kraus A, Gonzalez-Amaro R, Alarcon-Segovia D</AU>
<TI>Effect of calcium channel blocker Nifedipine on Raynaud's phenomenon: a controlled double blind trial</TI>
<SO>Journal of Rheumatology</SO>
<YR>1984</YR>
<VL>11</VL>
<NO>3</NO>
<PG>362-4</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7191764"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7191763"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Smith-1982" MODIFIED="2017-11-14 07:43:42 -0500" MODIFIED_BY="[Empty name]" NAME="Smith 1982" YEAR="1982">
<REFERENCE MODIFIED="2017-11-14 07:43:42 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Smith CD, McKendry RJR</AU>
<TI>Controlled trial of nifedipine in the treatment of Raynaud's phenomenon</TI>
<SO>The Lancet</SO>
<YR>1982</YR>
<VL>2</VL>
<NO>8311</NO>
<PG>1299-301</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7191766"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7191765"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Teixeira-da-Costa" MODIFIED="2017-11-14 07:43:10 -0500" MODIFIED_BY="[Empty name]" NAME="Teixeira da Costa" YEAR="1987">
<REFERENCE MODIFIED="2017-11-14 07:43:10 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Teixeira da Costa J, Melo Gomez JA, Espirito Santo J, Viana Queiros M</AU>
<TI>Inefficacy of diltiazem in the treatment of Raynaud's phenomenon with associated connective tissue disease: a double blind placebo controlled study</TI>
<SO>Journal of Rheumatology</SO>
<YR>1987</YR>
<VL>14</VL>
<NO>4</NO>
<PG>858-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7191768"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7191767"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Waller-1986" MODIFIED="2017-11-14 07:43:22 -0500" MODIFIED_BY="[Empty name]" NAME="Waller 1986" YEAR="1986">
<REFERENCE MODIFIED="2017-11-14 07:43:22 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Waller DG, Challenor VF, Francis DA, Roath OS</AU>
<TI>Clinical and rheological effects of nifedipine in Raynaud's phenomenon</TI>
<SO>British Journal of Clinical Pharmacology</SO>
<YR>1986</YR>
<VL>22</VL>
<NO>4</NO>
<PG>449-54</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7191770"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7191769"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-White-1986" MODIFIED="2017-11-14 07:44:08 -0500" MODIFIED_BY="[Empty name]" NAME="White 1986" YEAR="1986">
<REFERENCE MODIFIED="2017-11-14 07:44:08 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>White CJ, Phillips WA, Abrahams LA, Watson TD, Singleton PT</AU>
<TI>Objective benefit of nifedipine in the treatment of Raynaud's phenomenon</TI>
<SO>American Journal of Medicine</SO>
<YR>1986</YR>
<VL>80</VL>
<NO>4</NO>
<PG>263-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7191772"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7191771"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wigley-1987" MODIFIED="2017-11-14 07:44:30 -0500" MODIFIED_BY="[Empty name]" NAME="Wigley 1987" YEAR="1987">
<REFERENCE MODIFIED="2017-11-14 07:44:30 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wigley FM, Wise RA, Malamet R, Scott TE</AU>
<TI>Nicardipine in the treatment of Raynaud's phenomenon - dissociation of platelet activation from vasospasm</TI>
<SO>Arthritis and Rheumatism</SO>
<YR>1987</YR>
<VL>30</VL>
<NO>3</NO>
<PG>281-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7191774"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7191773"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wollersheim-1991" MODIFIED="2017-11-14 07:44:43 -0500" MODIFIED_BY="[Empty name]" NAME="Wollersheim 1991" YEAR="1991">
<REFERENCE MODIFIED="2017-11-14 07:44:43 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wollersheim H, Thien T</AU>
<TI>Double-blind placebo-controlled crossover study of oral nicardipine in the treatment of Raynaud's phenomenon</TI>
<SO>Journal of Cardiovascular Pharmacology</SO>
<YR>1991</YR>
<VL>18</VL>
<NO>6</NO>
<PG>813-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7191776"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7191775"/></IDENTIFIERS>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2017-11-14 08:04:24 -0500" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="MIX" ID="STD-Codella-1989" MODIFIED="2015-06-06 15:06:28 -0400" MODIFIED_BY="[Empty name]" NAME="Codella 1989" YEAR="1989">
<REFERENCE MODIFIED="2015-06-06 15:06:26 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Codella O, Caramaschi P, Olivieri O, Perbellini L, Perbellini A, Bambara LM, Corrocher R, et al</AU>
<TI>Controlled comparison of ketanserin and nifedipine in Raynaud's phenomenon</TI>
<SO>Angiology</SO>
<YR>1989</YR>
<VL>40</VL>
<NO>2</NO>
<PG>114-21</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7191778"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7191777"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Creager-1984" MODIFIED="2017-11-14 07:47:03 -0500" MODIFIED_BY="[Empty name]" NAME="Creager 1984" YEAR="1984">
<REFERENCE MODIFIED="2017-11-14 07:47:03 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Codella O, Caramaschi P, Olivieri O, Perbellini L, Perbellini A, Bambara LM, et al</AU>
<TI>Controlled comparison of ketanserin and nifedipine in Raynaud's phenomenon</TI>
<SO>Angiology</SO>
<YR>1989</YR>
<VL>40</VL>
<NO>2</NO>
<PG>114-21</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7191780"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-11-14 07:46:01 -0500" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Creager MA, Pariser KM, Winston EM, Basmussen HM, Miller KB, Coffman JD</AU>
<TI>Nifedipine-induced fingertip vasodilation in patients with Raynaud's phenomenon</TI>
<SO>American Heart Journal</SO>
<YR>1984</YR>
<VL>108</VL>
<PG>370-3</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7191781"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7191779"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Della-Bella-1997" MODIFIED="2017-11-14 07:47:26 -0500" MODIFIED_BY="[Empty name]" NAME="Della Bella 1997" YEAR="1997]">
<REFERENCE MODIFIED="2017-11-14 07:47:26 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Della Bella S, Molteni M, Mascagni B, Zulian C, Compasso S, Scorza R</AU>
<TI>Cytokine production in scleroderma patients: effects of therapy with either iloprost or nifedipine</TI>
<SO>Clinical and Experimental Rheumatology</SO>
<YR>1997</YR>
<VL>15</VL>
<PG>135-41</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7191783"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7191782"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dziadzio-1999" MODIFIED="2017-11-14 07:51:32 -0500" MODIFIED_BY="[Empty name]" NAME="Dziadzio 1999" YEAR="1999">
<REFERENCE MODIFIED="2017-11-14 07:51:32 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dziadzio M, Denton CP, Smith R, Howell K, Blann A, Bowers E, et al</AU>
<TI>Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen week, randomized, parallel-group, controlled trial</TI>
<SO>Arthritis &amp; Rheumatology</SO>
<YR>1999</YR>
<VL>42</VL>
<NO>12</NO>
<PG>2646-55</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7191785"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7191784"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ennis-2016" MODIFIED="2017-11-14 07:51:56 -0500" MODIFIED_BY="[Empty name]" NAME="Ennis 2016" YEAR="2014">
<REFERENCE MODIFIED="2017-11-14 07:51:56 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ennis H, Anderson ME, Wilkinson J, Herrick AL</AU>
<TI>Calcium channel blockers for primary Raynaud&#8217;s phenomenon</TI>
<SO>Cochrane Database of Systematic Reviews 2014</SO>
<YR>2014</YR>
<VL>Jan 30</VL>
<NO>1</NO>
<PG>Art. No.: CD002069. DOI: 10.1002/14651858.CD002069.pub4</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7191787"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7191786"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Garcia-Hernandez2004" MODIFIED="2017-11-14 07:53:00 -0500" MODIFIED_BY="[Empty name]" NAME="Garcia Hernandez2004" YEAR="2004">
<REFERENCE MODIFIED="2017-11-14 07:53:00 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Garcia Hernandez FJ, Ocana Medina C, Mateos Romero L, Molinillo Lopez J, Arias Zambrano A, Gonzalez Leon R, Sanchez Roman J</AU>
<TI>Iloprost for severe Raynaud's phenomenon and ischaemic ulcers related with systemic diseases</TI>
<TO>Iloprost en el fenomeno de Raynaud grave y las ulceras isquemicas de las enfermedades sistemicas</TO>
<SO>Medicina Clinica</SO>
<YR>2004</YR>
<VL>122</VL>
<NO>13</NO>
<PG>501-4</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7191789"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7191788"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Joseph-1988" MODIFIED="2017-11-14 07:53:17 -0500" MODIFIED_BY="[Empty name]" NAME="Joseph 1988" YEAR="1988">
<REFERENCE MODIFIED="2017-11-14 07:53:17 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Joseph BZ, Organek HW, Grant A, Axelrod DA</AU>
<TI>Effects of nifedipine therapy on pulmonary Raynaud's in primary Sjogren's syndrome</TI>
<SO>Clinical and Experimental Rheumatology</SO>
<YR>1988</YR>
<VL>6</VL>
<PG>409-10</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7191791"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7191790"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kahan-1983b" MODIFIED="2017-11-14 07:53:33 -0500" MODIFIED_BY="[Empty name]" NAME="Kahan 1983b" YEAR="1983">
<REFERENCE MODIFIED="2017-11-14 07:53:33 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kahan A, Weber S, Amor B, Menkes CJ, Saporta L, Hodara M, et al</AU>
<TI>Calcium entry blocking agents in digital vasospasm (Raynaud's phenomenon)</TI>
<SO>European Heart Journal</SO>
<YR>1983</YR>
<VL>4</VL>
<NO>Suppl C</NO>
<PG>123-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7191793"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7191792"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kallenberg-1991" MODIFIED="2017-11-14 07:53:57 -0500" MODIFIED_BY="[Empty name]" NAME="Kallenberg 1991" YEAR="1991">
<REFERENCE MODIFIED="2017-11-14 07:53:57 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kallenberg CGM, Wouda AA, Meems L, Wesseling H</AU>
<TI>Once daily felodipine in patients with primary Raynaud's phenomenon</TI>
<SO>European Journal of Clinical Pharmacology</SO>
<YR>1991</YR>
<VL>40</VL>
<PG>313-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7191795"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7191794"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-La-Civita-1996" MODIFIED="2017-11-14 07:54:11 -0500" MODIFIED_BY="[Empty name]" NAME="La Civita 1996" YEAR="1996">
<REFERENCE MODIFIED="2017-11-14 07:54:11 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>La Civita L, Giuggioli D, Grazia Del Chicca M, Longombardo G, Pasero G, Ferri C</AU>
<TI>Effect of isradipine on endothelin-1 plasma concentrations in patients with Raynaud's phenomenon</TI>
<SO>Annals of Rheumatic Diseases</SO>
<YR>1996</YR>
<VL>55</VL>
<PG>331-4</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7191797"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7191796"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Leppert-1993" MODIFIED="2017-11-14 07:54:22 -0500" MODIFIED_BY="[Empty name]" NAME="Leppert 1993" YEAR="1993">
<REFERENCE MODIFIED="2017-11-14 07:54:22 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Leppert J, Nilsson H, Myrdal U, Edvinsson L, Hedner T, Ringqvist I</AU>
<TI>Sympathetic activation after two weeks of nifedipine treatment in primary Raynaud's patients and controls</TI>
<SO>Cardiovascular Drugs and Therapy</SO>
<YR>1993</YR>
<VL>7</VL>
<PG>901-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7191799"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7191798"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lewis-1987" MODIFIED="2017-11-14 07:54:39 -0500" MODIFIED_BY="[Empty name]" NAME="Lewis 1987" YEAR="1987">
<REFERENCE MODIFIED="2017-11-14 07:54:39 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lewis P, Psaila JV, Morgan RH, Davies WT, Woodcock JP</AU>
<TI>Nifedipine in patients with Raynaud's syndrome - effects on radial artery blood flow</TI>
<SO>European Heart Journal</SO>
<YR>1987</YR>
<VL>8</VL>
<NO>Suppl K</NO>
<PG>83-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7191801"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7191800"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Myrdal-1994" MODIFIED="2017-11-14 07:55:06 -0500" MODIFIED_BY="[Empty name]" NAME="Myrdal 1994" YEAR="1994">
<REFERENCE MODIFIED="2017-11-14 07:55:06 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Myrdal U, Leppert J, Edvinsson L, Ekman R, Hednar T, Nilsson H, et al</AU>
<TI>Magnesium sulphate infusion decreases circulating calcitonin gene-related peptide (CG Raynaud's phenomenon) in women with primary Raynaud's phenomenon</TI>
<SO>Clinical Physiology</SO>
<YR>1994</YR>
<VL>14</VL>
<PG>539-46</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7191803"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7191802"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nilsson-1990" MODIFIED="2017-11-14 07:55:53 -0500" MODIFIED_BY="[Empty name]" NAME="Nilsson 1990" YEAR="1990">
<REFERENCE MODIFIED="2017-11-14 07:55:53 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nilsson H, Blychert E, Jonasson T, Leppert J, Ringqvist I</AU>
<TI>The effect of felodipine on cold-induced digital vasospasm</TI>
<SO>Journal of Cardiovascular Pharmacology</SO>
<YR>1990</YR>
<VL>15</VL>
<NO>Suppl.4</NO>
<PG>S108-10</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7191805"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7191804"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Park-2013" MODIFIED="2017-11-14 07:56:17 -0500" MODIFIED_BY="[Empty name]" NAME="Park 2013" YEAR="2013">
<REFERENCE MODIFIED="2017-11-14 07:56:17 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Park JK, Lee EY, Yoon MJ, Lee W, Kim YK, Park CSY, et al</AU>
<TI>Head to head comparison of Udenafil versus amlodipine in the treatment of secondary Raynaud's phenomenon: a double-blind, randomized cross-over study</TI>
<SO>Scientific Abstracts</SO>
<YR>2013</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7191807"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7191806"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pisenti-1984" MODIFIED="2017-11-14 07:57:22 -0500" MODIFIED_BY="[Empty name]" NAME="Pisenti 1984" YEAR="1984">
<REFERENCE MODIFIED="2017-11-14 07:57:22 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pisenti L, Hart LL</AU>
<TI>DIAS rounds. Nifedipine and prazosin in Raynaud's phenomenon</TI>
<SO>Drug Intelligence &amp; Clinical Pharmacy</SO>
<YR>1984</YR>
<VL>8</VL>
<NO>13</NO>
<PG>213-4</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7191809"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7191808"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rademaker-1989" MODIFIED="2017-11-14 07:57:46 -0500" MODIFIED_BY="[Empty name]" NAME="Rademaker 1989" YEAR="1989">
<REFERENCE MODIFIED="2017-11-14 07:57:46 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rademaker M, Cooke ED, Almond NE, Beacham JA, Smith RE, Mant TGK, et al</AU>
<TI>Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: a double blind randomised study</TI>
<SO>British Medical Journal</SO>
<YR>1989</YR>
<VL>298</VL>
<PG>561-4</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7191811"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7191810"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rademaker-1992" MODIFIED="2017-11-14 07:57:55 -0500" MODIFIED_BY="[Empty name]" NAME="Rademaker 1992" YEAR="1992">
<REFERENCE MODIFIED="2017-11-14 07:57:55 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rademaker M, Meyrick-Thomas RH, Kirby JD, Kovacs IB</AU>
<TI>The anti-platelet effect of nifedipine in patients with systemic sclerosis</TI>
<SO>Clinical and Experimental Rheumatology</SO>
<YR>1992</YR>
<VL>10</VL>
<PG>57-62</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7191813"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7191812"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ringqvist-1993" MODIFIED="2017-11-14 07:58:12 -0500" MODIFIED_BY="[Empty name]" NAME="Ringqvist 1993" YEAR="1993">
<REFERENCE MODIFIED="2017-11-14 07:58:12 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ringqvist I, Hedner T, Leppert J, Niklasson U, Edvinsson L</AU>
<TI>Effects of cold pressor test on circulating arterial natriuretic peptide 99-126 (ANP) in patients with Raynaud's phenomenon and influence of treatment with magnesium sulphate and nifedipine</TI>
<SO>Clinical Physiology</SO>
<YR>1993</YR>
<VL>13</VL>
<PG>271-80</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7191815"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7191814"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schmidt-1989" MODIFIED="2017-11-14 07:58:22 -0500" MODIFIED_BY="[Empty name]" NAME="Schmidt 1989" YEAR="1989">
<REFERENCE MODIFIED="2017-11-14 07:58:22 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schmidt JF, Valentin N, Levin Nielsen S</AU>
<TI>The clinical effect of felodipine and nifedipine in Raynaud's phenomenon</TI>
<SO>European Journal of Clinical Pharmacology</SO>
<YR>1989</YR>
<VL>37</VL>
<PG>191-2</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7191817"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7191816"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shcherbakov-1987" MODIFIED="2017-11-14 07:58:51 -0500" MODIFIED_BY="[Empty name]" NAME="Shcherbakov 1987" YEAR="1987">
<REFERENCE MODIFIED="2017-11-14 07:58:51 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shcherbakov AB, Guseva NG, Mach ES</AU>
<TI>Treatment of Raynaud's syndrome with calcium entry blockers</TI>
<SO>Terapevticheskii Arkhiv</SO>
<YR>1987</YR>
<VL>59</VL>
<NO>4</NO>
<PG>89-92</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7191819"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7191818"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Smith-1985" MODIFIED="2017-11-14 07:59:09 -0500" MODIFIED_BY="[Empty name]" NAME="Smith 1985" YEAR="1985">
<REFERENCE MODIFIED="2017-11-14 07:59:09 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Smith CR, Rodeheffer RJ</AU>
<TI>Treatment of Raynaud's phenomenon with calcium channel blockers</TI>
<SO>American Journal of Medicine</SO>
<YR>1985</YR>
<VL>78</VL>
<NO>Suppl 2b</NO>
<PG>39-42</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7191821"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7191820"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Thompson-2001" MODIFIED="2017-11-14 07:59:39 -0500" MODIFIED_BY="[Empty name]" NAME="Thompson 2001" YEAR="2001">
<REFERENCE MODIFIED="2017-11-14 07:59:39 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thompson AE 1, Shea B, Welch V, Fenlon D, Pope JE</AU>
<TI>Calcium-channel blockers for Raynaud&#8217;s phenomenon in systemic sclerosis</TI>
<SO>Arthritis &amp; Rheumatology</SO>
<YR>2011</YR>
<VL>44</VL>
<NO>8</NO>
<PG>1841-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7191823"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7191822"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Thompson-2005" MODIFIED="2015-06-06 15:01:56 -0400" MODIFIED_BY="[Empty name]" NAME="Thompson 2005" YEAR="2005">
<REFERENCE MODIFIED="2015-06-06 15:01:56 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thompson AE, Pope JE</AU>
<TI>Calcium channel blockers for primary Raynaud&#8217;s phenomenon: a meta-analysis</TI>
<SO>Rheumatology</SO>
<YR>2005</YR>
<VL>44</VL>
<NO>2</NO>
<PG>145-50</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7191825"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7191824"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Varela_x002d_Aguilar-1997" NAME="Varela-Aguilar 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Verela-Aguilar JM, Sanchez-Roman J, Talegon Melendez A, Castillo Palma J</AU>
<TI>Comparative study of misoprostol and nifedipine for the treatment of Raynaud's phenomenon secondary to systemic diseases. Doppler-duplex hemodynamic evaluation</TI>
<TO>Estudio comparativo de misoprostol y nifedipino en el tratamiento del fenomeno de Raynaud secundario a enfermedades sistemacis. Valoracion hemodinamica mediante Doppler-duplex</TO>
<SO>Revista Clinica Espanol</SO>
<YR>1997</YR>
<VL>197</VL>
<NO>2</NO>
<PG>77-83</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7191827"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7191826"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vayssairat-1989" NAME="Vayssairat 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vayssairat M, Blaison N, Baudot N, Evenou P, Gilard M, Mathieu J-F</AU>
<TI>Effect of nifedipine on cold stress post-ischemic reactive hyperemia in Raynaud's phenomenon</TI>
<TO>Action de la nifedipine sur la reaction d'hyperhemie post-ischemique au froid dans le phenomene de Raynaud</TO>
<SO>Journal des Maladies Vasculaires</SO>
<YR>1989</YR>
<VL>14</VL>
<NO>4</NO>
<PG>299-302</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7191829"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7191828"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Weber-1990" MODIFIED="2017-11-14 08:00:06 -0500" MODIFIED_BY="[Empty name]" NAME="Weber 1990" YEAR="1990">
<REFERENCE MODIFIED="2017-11-14 08:00:06 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Weber A, Bounameaux H</AU>
<TI>Effects of low-dose nifedipine on a cold provocation test in patients with Raynaud's disease</TI>
<SO>Journal of Cardiovascular Pharmacology</SO>
<YR>1990</YR>
<VL>15</VL>
<PG>853-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7191831"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7191830"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Winston-1983" MODIFIED="2017-11-14 08:01:06 -0500" MODIFIED_BY="[Empty name]" NAME="Winston 1983" YEAR="1983">
<REFERENCE MODIFIED="2017-11-14 08:01:06 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Winston EL, Pariser MK, Miller KB, Salem SN, Creager MA</AU>
<TI>Nifedipine as a therapeutic modality for Raynaud's phenomenon</TI>
<SO>Arthritis &amp; Rheumatology</SO>
<YR>1983</YR>
<VL>26</VL>
<NO>10</NO>
<PG>1177-80</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7191833"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7191832"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wollersheim-1987" MODIFIED="2017-11-14 08:01:32 -0500" MODIFIED_BY="[Empty name]" NAME="Wollersheim 1987" YEAR="1987">
<REFERENCE MODIFIED="2017-11-14 08:01:32 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wollersheim H, Thien T, van't Laar A</AU>
<TI>Nifedipine in primary Raynaud's phenomenon and in scleroderma: oral versus sublingual hemodynamic effects</TI>
<SO>Journal of Clinical Pharmacology</SO>
<YR>1987</YR>
<VL>27</VL>
<PG>907-13</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7191835"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7191834"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wu-2008" MODIFIED="2017-11-14 08:04:24 -0500" MODIFIED_BY="[Empty name]" NAME="Wu 2008" YEAR="2008">
<REFERENCE MODIFIED="2017-11-14 08:04:24 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wu YJ, Luo SF, Yang SH, Chen JY, Yu KH, See LC</AU>
<TI>Vascular response of Raynaud's phenomenon to nifedipine or herbal (Duhuo-Tisheng Tang with Danggui-Sini Tang): a preliminary study</TI>
<SO>Chan Gung Medicine Journal</SO>
<YR>2008</YR>
<VL>31</VL>
<NO>5</NO>
<PG>492-501</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7191837"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7191836"/></IDENTIFIERS>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2017-11-14 08:04:56 -0500" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-EUCTR2009_x002d_018194_x002d_31_x002d_GB" MODIFIED="2016-03-06 16:23:01 -0500" MODIFIED_BY="[Empty name]" NAME="EUCTR2009-018194-31-GB" YEAR="">
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7191838"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kahan-1982" MODIFIED="2015-06-27 12:31:43 -0400" MODIFIED_BY="[Empty name]" NAME="Kahan 1982" YEAR="1982">
<REFERENCE MODIFIED="2015-06-27 12:31:43 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kahan A, Weber S, Amor B, Saporta L, Hodara M, Degeorges M</AU>
<TI>Controlled study of nifedipine in the treatment of Raynaud's phenomenon</TI>
<TO>Etude controllee de la nifedipine dans le traitement du phenomene de Raynaud</TO>
<SO>Revue du Rhumatism</SO>
<YR>1982</YR>
<VL>49</VL>
<NO>5</NO>
<PG>337-43</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7191840"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7191839"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kahan-1983a" MODIFIED="2015-06-27 10:48:12 -0400" MODIFIED_BY="[Empty name]" NAME="Kahan 1983a" YEAR="1983">
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7191841"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Redondo-1986" MODIFIED="2017-03-31 11:23:48 -0400" MODIFIED_BY="Jordi Pardo Pardo" NAME="Redondo 1986" YEAR="1986">
<REFERENCE MODIFIED="2017-03-31 11:23:48 -0400" MODIFIED_BY="Jordi Pardo Pardo" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Redondo FR, Noguerado A, Asensio JP, Bote L, Alvaro-Gracia JL, Castellanos M</AU>
<TI>Nifedipine treatment of Raynaud's phenomenon: a double blind controlled clinical study</TI>
<SO>Revista Espanola de Reumatologia</SO>
<YR>1986</YR>
<VL>13</VL>
<PG>121-3</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7191843"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7191842"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-van-Heereveld-1988" MODIFIED="2015-06-27 11:42:40 -0400" MODIFIED_BY="[Empty name]" NAME="van Heereveld 1988" YEAR="1988">
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7191844"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wasir-1983" MODIFIED="2017-11-14 08:04:56 -0500" MODIFIED_BY="[Empty name]" NAME="Wasir 1983" YEAR="1983">
<REFERENCE MODIFIED="2017-11-14 08:04:56 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wasir HS, Singh G, Kaul R, Sachdeva, Kahan WA, Chhina GS, et al</AU>
<TI>A comparative study of trifluoperazine a calmodulin inhibitor, nifedipine, dipyridamole and intraarterial reserpine in the treatment of raynaud's phenomenon: a double blind randomised controlled trial [abstract]</TI>
<SO>Indian Heart Journal</SO>
<YR>1983</YR>
<VL>35</VL>
<NO>5</NO>
<PG>306</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7191846"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7191845"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wise-1987" MODIFIED="2015-06-27 12:10:20 -0400" MODIFIED_BY="[Empty name]" NAME="Wise 1987" YEAR="1987">
<REFERENCE MODIFIED="2015-06-27 12:10:19 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wise RA, Malamet R, Wigley FM</AU>
<TI>Acute effects of nifedipine on digital blood flow in human subjects with Raynaud's phenomenon: a double blind placebo controlled trial</TI>
<SO>Journal of Rheumatology</SO>
<YR>1987</YR>
<VL>14</VL>
<NO>2</NO>
<PG>278-83</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7191848"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7191847"/></IDENTIFIERS>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES MODIFIED="2017-11-14 08:05:45 -0500" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Nazarinia-2016" MODIFIED="2017-11-14 08:05:26 -0500" MODIFIED_BY="[Empty name]" NAME="Nazarinia 2016" YEAR="2016">
<REFERENCE MODIFIED="2017-11-14 08:05:26 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nazarinia MA</AU>
<TI>Assessing and Comparing the Effect of Diltiazem Gel Versus Nitroglycerin Ointment in Healing Process of Scleroderma Digital Ulcers</TI>
<SO>Clinicaltrials.gov</SO>
<YR>2017</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7191850"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2017-07-23 13:38:18 -0400" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7191849"/><IDENTIFIER MODIFIED="2017-07-23 13:38:18 -0400" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT02801305"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Vera_x002d_Kellet-2017" MODIFIED="2017-11-14 08:05:45 -0500" MODIFIED_BY="[Empty name]" NAME="Vera-Kellet 2017" YEAR="2017">
<REFERENCE MODIFIED="2017-11-14 08:05:45 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Vera-Kellet C</AU>
<TI>Color Doppler Ultrasound Comparison of Topical 10% Nifedipine Versus 5% Sildenafil in Secondary Raynaud: A Randomized, Double-blind, Placebo-controlled Pilot Study</TI>
<SO>Clinicaltrials.gov</SO>
<YR>2017</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7191852"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2017-07-23 13:19:37 -0400" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7191851"/><IDENTIFIER MODIFIED="2017-07-23 13:19:37 -0400" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT03027674  "/></IDENTIFIERS>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2017-11-22 20:18:13 -0500" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2017-11-22 20:18:13 -0500" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Cates-2008" MODIFIED="2017-11-22 20:18:13 -0500" MODIFIED_BY="[Empty name]" NAME="Cates 2008" TYPE="COMPUTER_PROGRAM">
<AU>Cates, C, MD</AU>
<TI>Visual Rx</TI>
<YR>2016</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Deeks-2011" MODIFIED="2017-11-14 08:06:42 -0500" MODIFIED_BY="[Empty name]" NAME="Deeks 2011" TYPE="BOOK_SECTION">
<AU>Deeks JJ, Higgins JPT, Altman DG, editors</AU>
<TI>Chapter 9: Analysing data and undertaking meta-analyses</TI>
<SO>Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011)</SO>
<PB>The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Egger-1997" MODIFIED="2017-11-14 08:07:01 -0500" MODIFIED_BY="[Empty name]" NAME="Egger 1997" TYPE="JOURNAL_ARTICLE">
<AU>Egger M, Zellweger-Zahner T, Scheider M, Junker C, Lengeler Antes G</AU>
<TI>Language bias in randomised controlled trials published in English and German</TI>
<SO>Lancet</SO>
<YR>1997</YR>
<VL>350</VL>
<NO>907</NO>
<PG>326-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Garc_x00ed_a_x002d_Carrasco-2008" MODIFIED="2017-11-14 08:07:33 -0500" MODIFIED_BY="[Empty name]" NAME="García-Carrasco 2008" TYPE="JOURNAL_ARTICLE">
<AU>García-Carrasco M, Jiménez-Hernández M, Escárcega RO, Mendoza-Pinto C, Pardo-Santos R, Levy R</AU>
<TI>Treatment of Raynaud's phenomenon</TI>
<SO>Autoimmunity Reviews</SO>
<YR>2008</YR>
<VL>8</VL>
<NO>1</NO>
<PG>62-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Goundry-2012" MODIFIED="2017-11-14 08:07:51 -0500" MODIFIED_BY="[Empty name]" NAME="Goundry 2012" TYPE="JOURNAL_ARTICLE">
<AU>Goundry B, Bell L, Langtree M, Moorthy A</AU>
<TI>Diagnosis and management of Raynaud&#8217;s phenomenon</TI>
<SO>British Medical Journal</SO>
<YR>2012</YR>
<VL>344</VL>
<NO>e289</NO>
<PG>doi: 10.1136/bmj.e289.</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Grade-2008" MODIFIED="2015-06-15 18:05:25 -0400" MODIFIED_BY="[Empty name]" NAME="Grade 2008" TYPE="JOURNAL_ARTICLE">
<AU>Grading Working Group</AU>
<TI>Grading quality of evidence and strength of recommendations</TI>
<SO>British Medical Journal</SO>
<YR>2008</YR>
<VL>336</VL>
<NO>7653</NO>
<PG>1106-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hansteen-1976" MODIFIED="2017-11-14 08:08:14 -0500" MODIFIED_BY="[Empty name]" NAME="Hansteen 1976" TYPE="JOURNAL_ARTICLE">
<AU>Hansteen V</AU>
<TI>Medical treatment in Raynaud's disease</TI>
<SO>Acta Chirurgica Scandinavica Supplementum</SO>
<YR>1976</YR>
<VL>465</VL>
<PG>87-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Herrick-2005" MODIFIED="2017-11-14 08:08:26 -0500" MODIFIED_BY="[Empty name]" NAME="Herrick 2005" TYPE="JOURNAL_ARTICLE">
<AU>Herrick AL</AU>
<TI>Pathogenesis of Raynaud's phenomenon</TI>
<SO>Rheumatology</SO>
<YR>2005</YR>
<VL>44</VL>
<NO>5</NO>
<PG>587-96</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" MODIFIED="2017-11-14 08:08:42 -0500" MODIFIED_BY="[Empty name]" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>British Medical Journal</SO>
<YR>2003</YR>
<VL>327</VL>
<NO>7414</NO>
<PG>557-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2017-11-14 08:10:11 -0500" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Green S, editors</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011)</TI>
<SO>The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Khanna-2009" MODIFIED="2017-11-14 08:10:40 -0500" MODIFIED_BY="[Empty name]" NAME="Khanna 2009" TYPE="JOURNAL_ARTICLE">
<AU>Khanna PP, Maranian P, Gregory J, Khanna D</AU>
<TI>The minimally important difference and patient acceptable symptom state for the Raynaud&#8217;s condition score in patients with Raynaud&#8217;s phenomenon in a large randomized controlled clinical trial</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2009</YR>
<VL>69</VL>
<NO>3</NO>
<PG>588-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-LeRoy-1992" MODIFIED="2017-11-14 08:22:48 -0500" MODIFIED_BY="[Empty name]" NAME="LeRoy 1992" TYPE="JOURNAL_ARTICLE">
<AU>LeRoy EC, Medsger TA</AU>
<TI>Raynaud's phenomenon: a proposal for classification</TI>
<SO>Clinical and Experimental Rheumatology</SO>
<YR>1992</YR>
<VL>10</VL>
<NO>5</NO>
<PG>485-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Levien-2010" MODIFIED="2017-11-14 08:11:15 -0500" MODIFIED_BY="[Empty name]" NAME="Levien 2010" TYPE="JOURNAL_ARTICLE">
<AU>Levien TL</AU>
<TI>Advances in the treatment of Raynaud's phenomenon</TI>
<SO>Dove Press Journal: Vascular Health and Risk Management 2010</SO>
<YR>2010</YR>
<VL>24</VL>
<NO>6</NO>
<PG>167-77</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Masi-1980" MODIFIED="2017-11-14 08:11:40 -0500" MODIFIED_BY="[Empty name]" NAME="Masi 1980" TYPE="JOURNAL_ARTICLE">
<AU>Masi AT, Rodnan GP, Medsger TA Jr, et al</AU>
<TI>ACR Preliminary criteria for the classification of systemic sclerosis (scleroderma). Special article</TI>
<SO>Arthritis &amp; Rheumatism</SO>
<YR>1980</YR>
<VL>23</VL>
<PG>581-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Maundrell-2015" MODIFIED="2017-11-14 08:14:40 -0500" MODIFIED_BY="[Empty name]" NAME="Maundrell 2015" TYPE="BOOK">
<AU>Maundrell A, Proudman SM</AU>
<TI>Epidemiology of Raynaud&#8217;s Phenomenon</TI>
<SO>Epidemiology of Raynaud's Phenomenon</SO>
<YR>2015</YR>
<NO>1st ed</NO>
<PG>21-35</PG>
<EN>1st</EN>
<PB>Springer</PB>
<CY>New York, NY</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Merkel-2002" MODIFIED="2017-11-14 08:15:31 -0500" MODIFIED_BY="[Empty name]" NAME="Merkel 2002" TYPE="JOURNAL_ARTICLE">
<AU>Merkel PA, Herlyn K, Martin RW, Anderson JJ, Mayes MD, Bell P,.et al</AU>
<TI>Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon</TI>
<SO>Arthritis &amp; Rheumatism</SO>
<YR>2002</YR>
<VL>46</VL>
<NO>9</NO>
<PG>2410-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ortonne-1989" MODIFIED="2017-11-14 08:15:56 -0500" MODIFIED_BY="[Empty name]" NAME="Ortonne 1989" TYPE="JOURNAL_ARTICLE">
<AU>Ortonne JP, Torzuoli C, Dujardin P, Fraitag B</AU>
<TI>Ketanserin in the treatment of systemic sclerosis: a double-blind controlled trial</TI>
<SO>British Journal of Dermatology</SO>
<YR>1989</YR>
<VL>120</VL>
<NO>2</NO>
<PG>261-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pope-2015" MODIFIED="2017-11-14 08:16:29 -0500" MODIFIED_BY="[Empty name]" NAME="Pope 2015" TYPE="COCHRANE_PROTOCOL">
<AU>Pope J, Rirash F, Tingey PC, Harding SE, Maxwell LJ, Tanjong GE, et al</AU>
<TI>Drug interventions versus placebo for the treatment of Raynaud&#8217;s phenomenon: generic protocol</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2015</YR>
<NO>8</NO>
<IDENTIFIERS MODIFIED="2017-04-18 10:51:20 -0400" MODIFIED_BY="Jordi Pardo Pardo"><IDENTIFIER MODIFIED="2017-04-18 10:51:20 -0400" MODIFIED_BY="Jordi Pardo Pardo" TYPE="DOI" VALUE="10.1002/14651858.CD011813"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Sch_x00fc_nemann-2011" MODIFIED="2017-11-14 08:17:02 -0500" MODIFIED_BY="[Empty name]" NAME="Schünemann 2011" TYPE="OTHER">
<AU>Schünemann H, Oxman AD, Vist GE, Higgins JBT, Deeks JJ, et al, editors</AU>
<TI>Chapter 12: Interpreting results and drawing conclusions</TI>
<SO>In: Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Silman-1990" MODIFIED="2015-06-06 15:15:43 -0400" MODIFIED_BY="[Empty name]" NAME="Silman 1990" TYPE="JOURNAL_ARTICLE">
<AU>Silman A, Holligan S, Brennan P, Maddison P</AU>
<TI>Prevalence of symptoms of Raynaud&#8217;s phenomenon in general practice</TI>
<SO>British Medical Journal</SO>
<YR>1190</YR>
<VL>301</VL>
<NO>6752</NO>
<PG>590-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sterne-2011" MODIFIED="2017-11-14 08:17:20 -0500" MODIFIED_BY="[Empty name]" NAME="Sterne 2011" TYPE="JOURNAL_ARTICLE">
<AU>Sterne JAC, et al</AU>
<TI>Reccomendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials</TI>
<SO>British Medical Journal</SO>
<YR>2011</YR>
<VL>343</VL>
<NO>d4002</NO>
<PG>doi: 10.1136/bmj.d4002</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sturgill-1998" MODIFIED="2015-06-06 14:59:54 -0400" MODIFIED_BY="[Empty name]" NAME="Sturgill 1998" TYPE="JOURNAL_ARTICLE">
<AU>Sturgill MG, Seibold JR</AU>
<TI>Rational use of calcium-channel antagonists in Raynaud&#8217;s phenomenon</TI>
<SO>Current Opinion in Rheumatology</SO>
<YR>1998</YR>
<VL>10</VL>
<NO>6</NO>
<PG>584&#8211;8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-The-Cochrane-Collaboration-2014." MODIFIED="2017-11-22 19:52:35 -0500" MODIFIED_BY="[Empty name]" NAME="The Cochrane Collaboration 2014." TYPE="COMPUTER_PROGRAM">
<AU>Cochrane Collaboration 2014</AU>
<TI>Review Manager 5 (RevMan 5).Version 5.3</TI>
<CY>Copenhagen: Nordic Cochrane Centre</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wigley-2002" MODIFIED="2017-11-14 08:17:39 -0500" MODIFIED_BY="[Empty name]" NAME="Wigley 2002" TYPE="JOURNAL_ARTICLE">
<AU>Wigley FM</AU>
<TI>Raynaud's phenomenon</TI>
<SO>New England Journal of Medicine</SO>
<YR>2002</YR>
<VL>347</VL>
<NO>13</NO>
<PG>1001-8</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES MODIFIED="2017-11-14 08:17:56 -0500" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Kahan-1983" MODIFIED="2017-11-14 08:17:56 -0500" MODIFIED_BY="[Empty name]" NAME="Kahan 1983" TYPE="JOURNAL_ARTICLE">
<AU>Kahan A, Amor B, Menkes C, Webber S</AU>
<TI>Nifedipine in digital ulceration in scleroderma</TI>
<SO>Arthritis &amp; Rheumatism</SO>
<YR>1983</YR>
<VL>26</VL>
<NO>6</NO>
<PG>809</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-van-Heereveld-1988" MODIFIED="2015-06-27 11:42:13 -0400" MODIFIED_BY="[Empty name]" NAME="van Heereveld 1988" TYPE="JOURNAL_ARTICLE">
<AU>van Heereveld H, Wollersheim H, Gough K, Thien T</AU>
<TI>Intravenous nicardipine in Raynaud's phenomenon: a controlled trial</TI>
<SO>Journal of Cardiovascular Pharmacology</SO>
<YR>1988</YR>
<VL>11</VL>
<NO>1</NO>
<PG>68-74</PG>
<IDENTIFIERS/>
</REFERENCE>
</PENDING_REFERENCES>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES><CHARACTERISTICS_OF_STUDIES MODIFIED="2017-11-29 09:38:40 -0500" MODIFIED_BY="[Empty name]"><CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2017-11-29 09:38:40 -0500" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO"><INCLUDED_CHAR MODIFIED="2017-11-13 21:19:44 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Aldoori-1986"><CHAR_METHODS MODIFIED="2017-11-13 21:19:00 -0500" MODIFIED_BY="[Empty name]"><P>Randomized double-blind controlled trial</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2017-11-13 21:19:44 -0500" MODIFIED_BY="[Empty name]"><P>13 patients (10 women and 3 men)</P><P>Median age 50 (range 25 to 68)</P><P>10 patients with diagnosis of Raynaud's, 3 with evidence of scleroderma</P><P>Mean duration of symptoms 9 years (range 2 to 30)</P><P>All but 2 treated previously for disease.</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2017-11-12 16:27:50 -0500" MODIFIED_BY="[Empty name]"><P>Each received nifedipine 20 mg initial dose or identical placebo for 3 weeks followed by cross-over to 10 mg nifedipine/8 hours or placebo.</P><P>Two courses of treatment were separated by 1 week of washover.</P><P>Duration 7 weeks (two 3-week treatment periods and 1 week of washover)</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2017-11-13 02:47:31 -0500" MODIFIED_BY="[Empty name]"><P>Mean number and duration of attacks</P><P>Severity of attacks (mild/moderate/severe)</P><P>Severity of pain (10-cm analogue scale)</P><P>Overall grading of symptoms (mild/moderate/severe)</P><P>Patient and observer opinions on treatment</P><P>Side effects</P><P>Patient preference for each period of treatment (1 or 2)</P></CHAR_OUTCOMES><CHAR_NOTES/></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2017-11-12 16:36:28 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bravard-1983"><CHAR_METHODS MODIFIED="2017-11-12 16:32:58 -0500" MODIFIED_BY="[Empty name]"><P>Randomized double-blind placebo-controlled cross-over study</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2014-09-15 19:41:43 -0400" MODIFIED_BY="[Empty name]"><P>9 patients with multiple sclerosis</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2017-11-12 16:33:36 -0500" MODIFIED_BY="[Empty name]"><P>10 mg nifedipine 3× daily or matching placebo</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2017-11-12 16:33:46 -0500" MODIFIED_BY="[Empty name]"><P>Numbers of attacks, outings; preference</P></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2017-11-12 16:36:28 -0500" MODIFIED_BY="[Empty name]"><P>2/9 excluded owing to incomplete diary data, and 2 others owing to different temperatures between treatment periods; thus results for 5/9 participants </P></CHAR_NOTES></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2017-11-13 21:19:25 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Challenor-1987"><CHAR_METHODS MODIFIED="2017-11-13 21:19:16 -0500" MODIFIED_BY="[Empty name]"><P>Randomized placebo-controlled double-blind trial</P><P>3-Way cross-over design</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2017-11-13 02:38:40 -0500" MODIFIED_BY="[Empty name]"><P>36 participants with primary Raynaud's (32 female, 4 male)</P><P>Mean age 47 years (range 19 to 67)</P><P>Mean Raynaud's phenomenon duration 26.2 years (range 2 to 60 years)</P><P>Vasoactive drugs discontinued before entry and other concomitant drug discontinued in 19 patients</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2017-11-13 21:19:25 -0500" MODIFIED_BY="[Empty name]"><P>Nisoldipine 5 mg, 10 mg daily or matching placebo before food</P><P>3-Way cross-over each with duration of 4 weeks</P><P>Total study length 3 months</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2017-11-13 02:40:33 -0500" MODIFIED_BY="[Empty name]"><P>Daily Raynaud's phenomenon attacks</P><P>Severity</P><P>Number of times outdoors</P><P>Subjective response to treatment on 1 to 5 scale (1 = much better, 2 = better, 3 = same, 4 = worse, 5 = much worse) and 10-cm visual analogue scale (from 0 = much better to 10 = much worse)</P></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2017-11-13 02:49:25 -0500" MODIFIED_BY="[Empty name]"><P>Length of washover not clear</P><P>Mean ambient temperature similar during all treatment periods</P></CHAR_NOTES></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2017-11-13 21:20:57 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Challenor-1989"><CHAR_METHODS MODIFIED="2017-11-13 21:20:50 -0500" MODIFIED_BY="[Empty name]"><P>Double-blind randomized placebo-controlled (double-dummy) trial<BR/>Cross-over design</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2017-11-13 21:20:57 -0500" MODIFIED_BY="[Empty name]"><P>N = 24 patients with primary Raynaud's phenomenon - 22 female, 2 male<BR/>Mean age 37.7 ± 2.9 years, range 17 to 61<BR/>Mean duration of disease 21.0 ± 3.3 years<BR/>3 smokers<BR/>4 dropouts</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2017-11-13 02:52:35 -0500" MODIFIED_BY="[Empty name]"><P>Continuation of concurrent treatments unchanged<BR/>Patients randomized to receive nifedipine or placebo<BR/>Dose increased after 3 weeks<BR/>After a further 3 weeks, patients crossed over to the opposite treatment for 6 weeks, with dose increasing as before</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2017-11-13 02:54:04 -0500" MODIFIED_BY="[Empty name]"><P>Subjective and objective assessments<BR/>Daily participant record of episodes, number of attacks, duration, and severity, as well as number of visits outdoors, unwanted effects, and improvement<BR/>Vibration perception, skin temperature, and blood plasma measurements</P></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2015-06-04 17:54:21 -0400" MODIFIED_BY="[Empty name]"/></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2017-11-13 21:21:33 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Constantini-1987"><CHAR_METHODS MODIFIED="2017-11-13 21:21:33 -0500" MODIFIED_BY="[Empty name]"><P>Randomized double-blind placebo-controlled trial<BR/>Parallel design</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2017-11-13 03:12:27 -0500" MODIFIED_BY="[Empty name]"><P>N = 24 patients with Raynaud's phenomenon - 19 women and 5 men<BR/>Mean age 41 years, range 19 to 63<BR/>Mean disease duration 3 years<BR/>6 idiopathic Raynaud's phenomenon, 6 connective tissue disease, 1 AVD, 1 IA<BR/>7 dropouts</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2017-11-13 02:59:43 -0500" MODIFIED_BY="[Empty name]"><P>2 groups of 12 participants<BR/>1 group treated with nifedipine 20 mg for a month, the other group treated with matching placebo for a month</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2017-11-13 03:12:39 -0500" MODIFIED_BY="[Empty name]"><P>Clinical and instrumental parameters evaluated at beginning and end of treatment<BR/>Entity and frequency of ischemic attacks<BR/>Skin trophism stage and degree of pain <BR/>Capillaroscopy</P></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2015-06-04 17:54:59 -0400" MODIFIED_BY="[Empty name]"/></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2017-11-14 06:51:48 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Corbin-1986"><CHAR_METHODS MODIFIED="2017-11-13 03:15:20 -0500" MODIFIED_BY="[Empty name]"><P>Double-blind placebo-controlled randomized<BR/>Cross-over design<BR/></P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2017-11-13 21:22:10 -0500" MODIFIED_BY="[Empty name]"><P>N = 24 patients, all referred to peripheral vascular clinic, Royal Infirmary of Edinburgh<BR/>Mean age 31 years, range 17 to 49 <BR/>All with Raynaud's phenomenon for mean of 9.5 years<BR/>5 smokers<BR/>2 dropouts</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2017-11-13 03:17:27 -0500" MODIFIED_BY="[Empty name]"><P>Participants given a supply of nifedipine capsules or an identical supply of placebo for first week. Dose increased weekly for 3 weeks, then held constant<BR/>Doses decreased if participants could not tolerate higher dose<BR/>Participants randomized in blocks of 4 to receive either nifedipine for 4 weeks followed by placebo for 4 weeks, or vice versa<BR/>Total study duration 8 weeks</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2017-11-14 06:51:48 -0500" MODIFIED_BY="[Empty name]"><P>Participant diary used to record attacks<BR/>Efficacy, FSP, side effects, drug compliance, and ambient daily temperature also recorded</P></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2015-06-07 20:33:38 -0400" MODIFIED_BY="[Empty name]"/></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2017-11-14 06:54:14 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ettinger-1984"><CHAR_METHODS MODIFIED="2017-11-13 03:23:37 -0500" MODIFIED_BY="[Empty name]"><P>Randomized double-blind placebo-controlled cross-over study</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2017-11-13 03:24:33 -0500" MODIFIED_BY="[Empty name]"><P>25 patients with Raynaud's</P><P>Mean age 36.7 ± 2.5 years, range 21 to 60</P><P>Mean disease duration 9.5 ± 1.4 years</P><P>6 primary Raynaud's phenomenon</P><P>16 secondary Raynaud's phenomenon</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2017-11-13 03:25:29 -0500" MODIFIED_BY="[Empty name]"><P>Nifedipine</P><P>Dazoxiben</P><P>Placebo</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2017-11-14 06:54:14 -0500" MODIFIED_BY="[Empty name]"><P>Participant diary used to record Raynaud's phenomenon with number, duration, severity, pain, overall response to treatment, and side effects</P></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2017-11-13 03:26:29 -0500" MODIFIED_BY="[Empty name]"><P>Intervention with 3 arms; number of participants with placebo divided by 2 to avoid double-counting </P></CHAR_NOTES></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2017-11-14 08:20:35 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ferri-1992"><CHAR_METHODS MODIFIED="2017-11-14 08:20:35 -0500" MODIFIED_BY="[Empty name]"><P>Randomized double-blind placebo-controlled trial</P><P>Cross-over design<BR/></P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2017-11-13 03:30:36 -0500" MODIFIED_BY="[Empty name]"><P>21 participants - 18 women and 3 men </P><P>Mean age 46 ± 12 years, range 22 to 65 </P><P>All patients with active Raynaud's phenomenon<BR/>From outpatient rheumatology unit of the University of Pisa<BR/>All patients with typical Raynaud's phenomenon in both hands, and at least 1 attack daily during 2 weeks preceding the study<BR/>3 dropouts</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2017-11-13 03:32:28 -0500" MODIFIED_BY="[Empty name]"><P>During month preceding the trial, no treatment with NSAIDs, dipyridamole vasodilators, and other drugs interfering with sympathetic nervous system functions </P><P>Entry into 8-week study; given placebo or nicardipine twice daily for 3 weeks followed by 2-week washout period and cross-over for the next 3 weeks</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2017-11-14 06:52:18 -0500" MODIFIED_BY="[Empty name]"><P>Participants given an instruction booklet and a clinical diary for recording subjective symptom variations and other parameters such as body weight, blood pressure, and side effects Complete history and careful physical examination performed at entry followed by clinical screening<BR/>Participant diary used to record number of attacks each day, severity of discomfort by VAS, and degree of hand disability</P><P>Changes in digital blood flow evaluated</P></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2015-06-04 17:56:28 -0400" MODIFIED_BY="[Empty name]"/></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2017-11-13 03:39:53 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Finch-1988"><CHAR_METHODS MODIFIED="2017-11-13 03:36:53 -0500" MODIFIED_BY="[Empty name]"><P>Randomized double-blind placebo-controlled prospective study<BR/>Cross-over design</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2017-11-13 03:37:47 -0500" MODIFIED_BY="[Empty name]"><P>N = 15 patients - 11 female, 4 male<BR/>Mean age 53, ranging from 15 to 74<BR/>Mean disease duration 8.3 years<BR/>3 patients with scleroderma, 1 with systemic lupus erythematosus, 1 with limited scleroderma (CREST), 8 with primary Raynaud's phenomenon<BR/>No dropouts</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2017-11-13 03:39:13 -0500" MODIFIED_BY="[Empty name]"><P>Study duration 7 weeks<BR/>For 1 week, all participants given placebo, followed by random assignment to placebo or nifedipine for 2 weeks<BR/>Then 2-week washout period and final 2-week cross-over period</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2017-11-13 03:39:53 -0500" MODIFIED_BY="[Empty name]"><P>Daily record kept by participant of number, duration, and severity of attacks, as well as side effects <BR/>During assessments, heart rate, finger blood flow, blood work, digital systolic pressure, and blood pressure recorded</P></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2015-06-04 17:58:13 -0400" MODIFIED_BY="[Empty name]"/></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2017-11-13 03:44:49 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-French-Co_x002d_op-1991"><CHAR_METHODS MODIFIED="2017-11-13 03:41:51 -0500" MODIFIED_BY="[Empty name]"><P>Randomized multicenter double-blind placebo-controlled<BR/>Cross-over design<BR/></P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2017-11-13 03:42:49 -0500" MODIFIED_BY="[Empty name]"><P>N = 69 patients - 18 men and 51 women<BR/>Average age 38 ± 15 years, ranging from 18 to 64<BR/>Mean disease duration 15 ± 11 years<BR/>9 dropouts</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2017-11-13 03:44:37 -0500" MODIFIED_BY="[Empty name]"><P>Prospective study protocol<BR/>4 treatment periods, 5 hospital visits<BR/>Period 1: single-blind placebo period (patient eligibility assessed) </P><P>Period 2: participants randomly assigned to receive either nicardipine or placebo </P><P>Period 3: single-blind washout period with placebo </P><P>Period 4: double-blind cross-over from period 2 </P><P>Periods 2 and 4 each for 2 weeks; periods 1 and 3 each for 1 week<BR/>Total study duration 6 weeks</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2017-11-13 03:44:49 -0500" MODIFIED_BY="[Empty name]"><P>Number of crises, intensity, and overall disability of each incident recorded in diary</P></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2015-06-04 17:58:55 -0400" MODIFIED_BY="[Empty name]"/></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2017-11-14 06:54:33 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gjorup-1986a"><CHAR_METHODS MODIFIED="2017-11-13 21:25:49 -0500" MODIFIED_BY="[Empty name]"><P>Double-blind placebo-controlled randomized trial<BR/>Cross-over design<BR/></P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2017-11-13 21:25:59 -0500" MODIFIED_BY="[Empty name]"><P>N = 19 patients - 15 female, 4 male</P><P>Median age 40 years, range 22 to 60 <BR/>All with typical Raynaud's phenomenon<BR/>Selected from files of general practitioners in hospital area<BR/>Study completed by all patients</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2017-11-13 03:48:29 -0500" MODIFIED_BY="[Empty name]"><P>3-Week periods of active and placebo treatment </P><P>Participants assigned to receive nisoldipine or placebo during first period </P><P>Study conducted during March and April<BR/>Total study duration 6 weeks</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2017-11-14 06:54:33 -0500" MODIFIED_BY="[Empty name]"><P>Participant diary used to record daily number of attacks, grade of the most severe attack (on a scale from 1 to 10), whether the day had been better or worse than expected, and overall evaluation of preferred treatment</P><P>Side effects also recorded</P></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2015-06-04 17:59:59 -0400" MODIFIED_BY="[Empty name]"/></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2017-11-13 21:26:36 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gjorup-1986b"><CHAR_METHODS MODIFIED="2017-11-13 21:26:36 -0500" MODIFIED_BY="[Empty name]"><P>Double-blind placebo-controlled randomized trial<BR/>Cross-over design<BR/></P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2017-11-13 03:52:23 -0500" MODIFIED_BY="[Empty name]"><P>N = 26 patients - 21 women, 5 men<BR/>Median age 38 years, range 22 to 61<BR/>Patients selected from files of general practitioners in hospital area<BR/>All with typical Raynaud's phenomenon<BR/>Median duration of symptoms 14 years<BR/>12 tobacco users<BR/>5 dropouts</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2017-11-13 03:53:02 -0500" MODIFIED_BY="[Empty name]"><P>Cross-over trial comprising 2 periods of treatment each for 2 weeks <BR/>Participants randomly allocated to receive either nifedipine or placebo and crossed over for the second treatment period<BR/>Total study duration 4 weeks</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2017-11-13 03:53:38 -0500" MODIFIED_BY="[Empty name]"><P>Daily record of number of attacks<BR/>Most severe attack graded<BR/>Days compared with participant expectations<BR/>Subjective overall evaluation at completion of treatment</P></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2015-06-04 18:00:25 -0400" MODIFIED_BY="[Empty name]"/></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2017-11-22 21:00:44 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hawkins-1985"><CHAR_METHODS MODIFIED="2017-11-13 03:57:28 -0500" MODIFIED_BY="[Empty name]"><P>Randomized controlled trial</P><P>Double-blinding not explicitly stated but given benefit of the doubt</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2017-11-22 21:00:44 -0500" MODIFIED_BY="[Empty name]"><P>71 entering the study and 57 completing the study - 49 female, 8 male</P><P>At least 2 attacks during last 2 weeks before enrollment</P><P>Mean age 49 years, range 17 to 78</P><P>Mean duration of Raynaud's 14.7 years, range 1 to 52</P><P>20 with idiopathic Raynaud's</P><P>25 with systemic sclerosis</P><P>4 with seropositive rheumatoid arthritis</P><P>3 with mixed connective tissue disease</P><P>3 with systemic lupus erythematosus</P><P>1 with Sjogren's syndrome and seropositive polyarthritis</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2017-11-13 04:01:20 -0500" MODIFIED_BY="[Empty name]"><P>Following 2-week run-in period without therapy</P><P>Randomized to either 10 mg nifedipine 4×/d or placebo</P><P>Underwent 4 consecutive periods of treatment with alternating nifedipine and placebo</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2017-11-13 04:01:48 -0500" MODIFIED_BY="[Empty name]"><P>Number of attacks per week</P><P>Severity on a 10-cm visual analogue scale and on a 5-point scale (none, mild, moderate, severe, and very severe)</P><P>BP, presence of digital ulcers</P><P>Thermal stress test</P></CHAR_OUTCOMES><CHAR_NOTES/></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2017-11-14 06:52:51 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kahan-1985a"><CHAR_METHODS MODIFIED="2017-11-13 21:28:16 -0500" MODIFIED_BY="[Empty name]"><P>Placebo-controlled double-blind randomized trial<BR/>Cross-over design<BR/></P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2017-11-13 04:05:55 -0500" MODIFIED_BY="[Empty name]"><P>N = 15 patients - 13 women and 2 men </P><P>Mean age 41 </P><P>With symptomatic bilateral Raynaud's phenomenon: 7 systemic sclerosis, 1 rheumatoid arthritis, 2 systemic lupus erythematosus, 5 Raynaud's phenomenon<BR/>0 dropouts</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2017-11-13 04:06:56 -0500" MODIFIED_BY="[Empty name]"><P>Each participant given placebo 3 times daily for 1 week, then matched capsules of nifedipine 3 times daily for 1 week, then placebo 3 times daily for another week, then prazosin 3 times daily for 1 week, and finally placebo yet again 3 times daily for 1 week </P><P>During the study, no other vasoactive medication taken<BR/>Total study duration 5 weeks</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2017-11-14 06:52:51 -0500" MODIFIED_BY="[Empty name]"><P>Participants diary used to record vasospastic attacks - frequency, severity (10-cm visual analogue scale), and subjective assessments</P></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2015-06-04 18:01:46 -0400" MODIFIED_BY="[Empty name]"/></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2017-11-13 04:12:23 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kahan-1985b"><CHAR_METHODS MODIFIED="2017-11-13 04:10:01 -0500" MODIFIED_BY="[Empty name]"><P>Double-blind randomized placebo-controlled prospective study<BR/>Cross-over design</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2017-11-13 04:10:57 -0500" MODIFIED_BY="[Empty name]"><P>N = 16 patients - 14 women and 2 men<BR/>Mean age 41.5 years, range 18 to 57<BR/>7 with systemic sclerosis, 2 rheumatoid arthritis, 1 systemic lupus erythematosus, 6 idiopathic Raynaud's phenomenon<BR/>Mean disease duration 12.8 years<BR/>No dropouts<BR/></P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2017-11-13 04:11:45 -0500" MODIFIED_BY="[Empty name]"><P>Each participant given placebo in a single-blind fashion for 1 week<BR/>Participants randomized to receive placebo or diltiazem in a double-blind fashion for 2 weeks, then crossed over for the last 2 weeks<BR/>Total study duration 5 weeks</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2017-11-13 04:12:23 -0500" MODIFIED_BY="[Empty name]"><P>Participant diary used to record frequency, severity, and number of attacks<BR/>Participants asked about overall effectiveness of treatments<BR/>Side effects recorded</P></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2015-06-04 18:03:17 -0400" MODIFIED_BY="[Empty name]"/></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2017-11-14 06:53:05 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kahan-1985c"><CHAR_METHODS MODIFIED="2017-11-13 21:29:37 -0500" MODIFIED_BY="[Empty name]"><P>Double-blind randomized placebo-controlled trial<BR/>Cross-over design</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2017-11-13 04:15:19 -0500" MODIFIED_BY="[Empty name]"><P>N = 30 patients - 26 female and 4 male<BR/>Mean age 42.9 years<BR/>All with Raynaud's phenomenon - 10 associated with progressive systemic sclerosis, 5 systemic lupus erythematosus, 3 rheumatoid arthritis, 12 idiopathic Raynaud's phenomenon<BR/>No dropouts</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2017-11-13 04:15:48 -0500" MODIFIED_BY="[Empty name]"><P>For 2 consecutive weeks, participants given 20 mg nifedipine and placebo 3× daily in random order</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2017-11-14 06:53:05 -0500" MODIFIED_BY="[Empty name]"><P>Participant diary used to record weekly frequency of attacks and side effects</P></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2015-06-04 18:03:43 -0400" MODIFIED_BY="[Empty name]"/></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2017-11-14 06:55:15 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kahan-1987"><CHAR_METHODS MODIFIED="2017-11-13 21:30:17 -0500" MODIFIED_BY="[Empty name]"><P>Double-blind randomized placebo-controlled trial<BR/>Cross-over design<BR/></P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2017-11-13 04:19:11 -0500" MODIFIED_BY="[Empty name]"><P>20 patients - 16 women and 4 men</P><P>Age 18 to 68 years </P><P>15 with progressive systemic sclerosis, 2 with rheumatoid arthritis, 3 with idiopathic Raynaud's phenomenon<BR/>0 dropouts</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2017-11-13 04:20:31 -0500" MODIFIED_BY="[Empty name]"><P>No vasoactive medication during the study<BR/>Initial 1-week baseline observation period of no therapy, followed by 2 treatment periods, each of 2-week duration, separated by a 1-week baseline observation period<BR/>Total study duration 6 weeks</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2017-11-14 06:55:15 -0500" MODIFIED_BY="[Empty name]"><P>During each period, standardized participant diary used to record digital vasospastic attacks</P><P>Severity of Raynaud's phenomenon assessed at the end of each period on a 4-point clinical scale</P><P>Last day of each period - inquiries made about side effects related to treatment; blood pressure, and pulse rate recorded; complete blood counts, erythrocyte sedimentation rate, serum creatinine, serum aspartate, aminotransferase, alkaline phosphatase, and serum total protein measured before the study and on last day of 2 treatment periods</P></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2015-06-04 18:06:25 -0400" MODIFIED_BY="[Empty name]"/></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2017-11-13 04:26:11 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kallenberg-1987"><CHAR_METHODS MODIFIED="2017-11-13 04:23:52 -0500" MODIFIED_BY="[Empty name]"><P>Double-blind randomized cross-over trial</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2017-11-13 04:26:04 -0500" MODIFIED_BY="[Empty name]"><P>16 patients</P><P>8 with primary Raynaud's - 6 female and 2 male</P><P>Mean age 34 years, range 25 to 47</P><P>Duration of disease 20 years, range 3 to 37</P><P>8 with secondary Raynaud's - 5 female and 3 male </P><P>Mean age 44 years, range 28 to 63 </P><P>Duration of disease 17 years, range 9 to 24 </P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2017-11-13 04:26:11 -0500" MODIFIED_BY="[Empty name]"><P>Nifedipine or placebo</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2014-10-03 13:25:35 -0400" MODIFIED_BY="[Empty name]"><P>Side effects</P></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2015-06-07 21:00:26 -0400" MODIFIED_BY="[Empty name]"/></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2017-11-13 21:31:18 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kinney-1982"><CHAR_METHODS MODIFIED="2017-11-13 21:31:18 -0500" MODIFIED_BY="[Empty name]"><P>Double-blind randomized placebo-controlled trial<BR/>Cross-over design<BR/></P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2017-11-13 04:29:28 -0500" MODIFIED_BY="[Empty name]"><P>16 patients - 10 progressive systemic sclerosis, 2 mixed connective tissue disease, 2 with systemic lupus erythematosus, 2 with Raynaud's disease<BR/>2 dropouts</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2017-11-13 04:31:00 -0500" MODIFIED_BY="[Empty name]"><P>No vasoactive drug other than the one being tested (verapamil) </P><P>All study participants non-smokers except for 1 participant who continued to smoke 4 cigarettes a day throughout the duration of the experiment </P><P>Concomitant medications not changed during this study </P><P>Verapamil administered orally for 3 weeks followed by increased dosage for 3 weeks </P><P>Last 6 weeks of study - treatment groups crossed over<BR/>Total study duration 12 weeks</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2017-11-13 04:31:59 -0500" MODIFIED_BY="[Empty name]"><P>Participants interviewed and examined at start of the study and every 3 weeks thereafter </P><P>Diary analysis to ascertain whether participants had at least 1 episode of Raynaud's phenomenon on a given day </P><P>Pulse volume, total blood flow in the tip of the finger, skin temperature, and cold pressor testing measured</P></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2015-06-04 18:07:28 -0400" MODIFIED_BY="[Empty name]"/></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2017-11-14 06:55:44 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kirch-1987"><CHAR_METHODS MODIFIED="2017-11-13 21:32:10 -0500" MODIFIED_BY="[Empty name]"><P>Single-blind placebo-controlled randomized trial<BR/>Cross-over design</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2017-11-13 04:34:40 -0500" MODIFIED_BY="[Empty name]"><P>N = 10 patients - 5 male, 5 female</P><P>Age 18 to 60 years<BR/>Typical Raynaud's phenomenon and related connective tissue disorders<BR/>No dropouts</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2017-11-13 04:35:45 -0500" MODIFIED_BY="[Empty name]"><P>Participants given no drugs other than ketanserin, nifedipine, or placebo<BR/>Initially received placebo orally during washout period of 4 weeks, then randomly assigned to receive either nifedipine or ketanserin orally for 4 weeks<BR/>Then, a 2-week lasting placebo phase interconnected with a cross-over to the final 4-week lasting therapy phase<BR/>Total study duration 14 weeks</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2017-11-14 06:55:44 -0500" MODIFIED_BY="[Empty name]"><P>Participant diary used to record possible adverse effects and frequency, duration, and severity of attacks<BR/>Severity assessed on a 3-point scale<BR/>Patient treatment rating on a 3-point scale<BR/>Laboratory parameters performed including blood cell count, erythrocyte sedimentation rate, and biochemical analysis of renal and hepatic function<BR/>Skin temperature recordings and videomicroscopy performed, thereby monitoring flowmetry, a standard cold provocation test, and typical morphological changes in skin capillaries</P></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2015-06-04 18:09:39 -0400" MODIFIED_BY="[Empty name]"/></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2017-11-13 21:33:06 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-La-Civita-1997"><CHAR_METHODS MODIFIED="2017-11-13 21:33:06 -0500" MODIFIED_BY="[Empty name]"><P>Does not explicitly say "randomized" but appears to be given the benefit of the doubt<BR/>Double-blind placebo-controlled trial<BR/>Cross-over design</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2017-11-13 04:41:49 -0500" MODIFIED_BY="[Empty name]"><P>N = 24 patients - 20 women, 4 men<BR/>Age 22 to 63 years, mean age 45<BR/>15 with primary Raynaud's phenomenon, 9 with suspected secondary Raynaud's phenomenon<BR/>Active Raynaud's phenomenon in all patients, with mean duration of 3.5 years <BR/>4 dropouts</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2017-11-13 04:42:30 -0500" MODIFIED_BY="[Empty name]"><P>Trial lasting 7 weeks <BR/>Participants given placebo or amlodipine for 3 weeks, followed by a 1-week washout period, then crossed over to alternate treatment for 3 weeks</P><P>Total treatment duration 7 weeks</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2017-11-13 04:43:02 -0500" MODIFIED_BY="[Empty name]"><P>Participant diary used to record subjective symptoms, blood pressure, number and severity of daily episodes, and adverse events<BR/>Blood flow and radial blood flow examined</P></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2015-06-04 18:09:53 -0400" MODIFIED_BY="[Empty name]"/></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2017-11-13 04:49:05 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Leppert-1989"><CHAR_METHODS MODIFIED="2017-11-13 04:45:26 -0500" MODIFIED_BY="[Empty name]"><P>Single-blind dose response study<BR/>Cross-over design</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2017-11-13 04:47:00 -0500" MODIFIED_BY="[Empty name]"><P>10 female patients </P><P>Mean age 43 ± 7 years </P><P>All with disabling primary Raynaud's phenomenon</P><P>All with finger cytosolic pressure at 10°C below 50% of the value at 30°C </P><P>All with severe Raynaud's phenomenon for a mean period of 12 ± 6 years<BR/>0 dropouts</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2017-11-13 04:47:55 -0500" MODIFIED_BY="[Empty name]"><P>Total duration of treatment 9 weeks </P><P>After an initial placebo run-in period of 3 weeks, participants given isradipine capsules at a dose of 1.25 mg twice daily for 3 weeks, followed by 2.5 mg for a further 3 weeks </P><P>No vasoactive compounds other than isradipine taken</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2017-11-13 04:49:05 -0500" MODIFIED_BY="[Empty name]"><P>Finger systolic pressure measured<BR/>At the end of each period, finger systolic blood pressure measured and participants questioned regarding side effects </P><P>Participant assessment of effectiveness of therapy on a 0 to 100 mm visual analogue scale</P></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2015-06-04 18:10:24 -0400" MODIFIED_BY="[Empty name]"/></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2017-11-13 21:15:43 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Malamet-1984"><CHAR_METHODS MODIFIED="2017-11-13 21:13:11 -0500" MODIFIED_BY="[Empty name]"><P>Double-blind cross-over randomized placebo-controlled trial</P><P>Placebo, nifedipine (2 10-mg capsules 3× daily), and dazoxiben (100 mg 4× daily)</P><P>10-Week study with 6 treatment periods</P><P>2-Week single-blind placebo run-in period</P><P>3 2-week double-blind cross-over treatment periods (separated by 1-week single-blind washout periods)</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2017-11-13 21:15:43 -0500" MODIFIED_BY="[Empty name]"><P>13 patients - 7 female and 2 male </P><P>Mean age 34.6 ± 4.0 years, range 21 to 55 </P><P>Duration of Raynaud's 11.4 ± 2.6 years, range 1 to 22 </P><P>8 patients with secondary Raynaud's (associated with connective tissue disease), 1 with primary Raynaud's </P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2017-11-13 21:13:58 -0500" MODIFIED_BY="[Empty name]"><P>Placebo</P><P>Nifedipine (2 10-mg capsules 3× daily)</P><P>Daxoziben (100 mg 4× daily)</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2017-11-13 21:14:04 -0500" MODIFIED_BY="[Empty name]"><P>Number of Raynaud's attacks</P><P>Severity of attacks (3-point scale)</P><P>Pain intensity (VAS scale)</P><P>Duration of episodes (minutes)</P></CHAR_OUTCOMES><CHAR_NOTES/></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2017-11-14 08:21:23 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Meyrick-Thomas-1987"><CHAR_METHODS MODIFIED="2017-11-13 21:34:49 -0500" MODIFIED_BY="[Empty name]"><P>Double-blind placebo-controlled randomized trial<BR/>Cross-over design<BR/></P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2017-11-13 21:35:11 -0500" MODIFIED_BY="[Empty name]"><P>10 patients with diagnosis of systemic sclerosis; 1 dropout</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2017-11-14 08:21:23 -0500" MODIFIED_BY="[Empty name]"><P>Participants randomly allocated to group A or B. Following a 4-week run-in period during which they received no medication, participants given either oral nifedipine or placebo for 6 weeks. Following a 4-week drug-free washout period, participants crossed over to alternative treatment for 6 weeks after completion, with final 4-week drug-free washout period<BR/>Total study duration 20 weeks</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2017-11-13 21:39:11 -0500" MODIFIED_BY="[Empty name]"><P>Clinical and laboratory assessments performed at regular intervals throughout the trial; in addition, participants completed diary cards recording duration, severity, pain, and date of each attack and any side effects of treatment. Clinical assessment including evaluating compliance, recording lying and standing blood pressures and new digital ulcers, presenting inquiry regarding side effects, and checking completion of diary cards. Venous blood flow taken</P></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2015-06-04 18:11:31 -0400" MODIFIED_BY="[Empty name]"/></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2017-11-13 21:43:29 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Muller_x002d_Buhl-1983"><CHAR_METHODS MODIFIED="2017-11-13 21:41:54 -0500" MODIFIED_BY="[Empty name]"><P>Randomized double-blind placebo-controlled trial<BR/>Parallel design</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2017-11-13 21:42:44 -0500" MODIFIED_BY="[Empty name]"><P>N = 24 patients - 10 women, 14 men </P><P>3 with collagen disease, 21 with primary Raynaud's phenomenon<BR/>Mean age 43.5 for drug, 43 for placebo<BR/>No dropouts</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2017-11-13 21:42:57 -0500" MODIFIED_BY="[Empty name]"><P>Treatment with calcium antagonist Bay K 9320 or placebo lasting 3 weeks<BR/></P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2017-11-13 21:43:29 -0500" MODIFIED_BY="[Empty name]"><P>Effectiveness, severity, and frequency recorded<BR/>Subjective improvement </P></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2015-06-04 18:12:53 -0400" MODIFIED_BY="[Empty name]"/></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2017-11-13 21:46:31 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nilsson-1987"><CHAR_METHODS MODIFIED="2017-11-13 21:44:58 -0500" MODIFIED_BY="[Empty name]"><P>Randomized double-blind placebo-controlled trial</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2017-11-13 21:45:28 -0500" MODIFIED_BY="[Empty name]"><P>28 patients - 24 female and 4 male</P><P>Average age 47.5 years</P><P>Mean duration of symptoms 17.5 years</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2017-11-13 21:46:27 -0500" MODIFIED_BY="[Empty name]"><P>Nifedipine 10 mg for 1 week and 20 mg (2 10-mg capsules/d) for the next week or placebo 3×/d for 2 weeks during first treatment period, followed by 1-week washover period </P><P>Second period - participants crossed over to opposite treatment</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2017-11-13 21:46:31 -0500" MODIFIED_BY="[Empty name]"><P>Changes in symptoms</P><P>Side effects</P></CHAR_OUTCOMES><CHAR_NOTES/></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2017-11-13 21:53:55 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rhedda-1985"><CHAR_METHODS MODIFIED="2017-11-13 21:49:27 -0500" MODIFIED_BY="[Empty name]"><P>Double-blind placebo-controlled randomized trial<BR/>Cross-over design</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2017-11-13 21:50:19 -0500" MODIFIED_BY="[Empty name]"><P>30 patients - 7 male and 23 female </P><P>All with typical features of Raynaud's </P><P>All with primary disease and ANF-negative without signs or symptoms to suggest connective tissue disorder </P><P>11 with secondary disease </P><P>8 dropouts</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2017-11-13 21:52:49 -0500" MODIFIED_BY="[Empty name]"><P>Study including a 2-week drug-free baseline period, a 4-week treatment period when participants received diltiazem or placebo, a 4-week observation period when no drugs were taken, and finally a 4-week treatment period when patients were crossed-over to receive the opposite drug from the first treatment period, and finally, a terminal 2-week observation period<BR/>Total study duration 16 weeks</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2017-11-13 21:53:55 -0500" MODIFIED_BY="[Empty name]"><P>Participant diary used to record number of episodes of vasospasm per day and duration of each attack </P><P>Side effects reported </P><P>At end of study, participants asked to identify period of active drug therapy </P><P>Temperatures and barometric pressures recorded throughout the study</P></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2015-06-04 18:13:52 -0400" MODIFIED_BY="[Empty name]"/></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2017-11-14 06:56:33 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rodeheffer-1983"><CHAR_METHODS MODIFIED="2017-11-13 21:57:45 -0500" MODIFIED_BY="[Empty name]"><P>Prospective randomized double-blind placebo-controlled trial<BR/>Cross-over design<BR/></P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2017-11-13 21:59:04 -0500" MODIFIED_BY="[Empty name]"><P>N = 15 patients - 3 men and 12 women from outpatient rheumatology clinics at Johns Hopkins Hospital, the Good Samaritan Hospital, and the University of Maryland Hospital<BR/>Mean age 34.1 years, range 20 to 52<BR/>1 patient with systemic lupus erythematosus, 9 with systemic sclerosis, the rest with symptomatic Raynaud's phenomenon related to cold or stress</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2017-11-13 21:59:49 -0500" MODIFIED_BY="[Empty name]"><P>Study protocol 7 weeks </P><P>First 2-week period - all given placebo, then randomly assigned to nifedipine or placebo for next 2 weeks, then placebo for 1 week, finally crossed-over to the other treatment for last 2 weeks</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2017-11-14 06:56:33 -0500" MODIFIED_BY="[Empty name]"><P>Diary used by participants to keep record of vasospastic attacks<BR/>Digital artery systolic pressure measured<BR/>Overall effectiveness assessed<BR/>Frequency, severity, and duration recorded</P></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2015-06-04 18:15:40 -0400" MODIFIED_BY="[Empty name]"/></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2017-11-14 01:46:07 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-RTSI-2000"><CHAR_METHODS MODIFIED="2017-11-14 01:45:04 -0500" MODIFIED_BY="[Empty name]"><P>Randomized controlled trial</P><P>Double-masked for nifedipine and placebo</P><P>77 participants randomized to nifedipine, 81 to placebo</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2017-11-14 01:45:21 -0500" MODIFIED_BY="[Empty name]"><P>With primary Raynaud's phenomenon and history of 2 or more attacks the previous cold season</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2017-11-14 01:45:27 -0500" MODIFIED_BY="[Empty name]"><P>Nifedipine 30 to 60 mg per day or matching placebo</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2017-11-14 01:46:07 -0500" MODIFIED_BY="[Empty name]"><P>Primary outcome: self-reported color chart-verified Raynaud's phenomenon attacks during 1 winter month after 1 year of treatment</P><P>Secondary outcomes: verified attacks at 2 months, all attacks at 2 months and 1 year, quality of life</P></CHAR_OUTCOMES><CHAR_NOTES/></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2017-11-14 06:57:03 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rupp-1987"><CHAR_METHODS MODIFIED="2017-11-14 01:50:52 -0500" MODIFIED_BY="[Empty name]"><P>Double-blind randomized trial<BR/>Cross-over design</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2017-11-14 01:52:32 -0500" MODIFIED_BY="[Empty name]"><P>N = 30 patients - 28 women and 2 men</P><P>28 participants at start of study<BR/>Source: Outpatient Rheumatology Clinic at the University of Iowa Hospitals and Clinics<BR/>Patients with systemic Raynaud's vasospasms, at least 3 attacks per week during the month preceding start of the study<BR/>2 patients excluded before the trial began; 1 dropout</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2017-11-14 01:53:35 -0500" MODIFIED_BY="[Empty name]"><P>Complete history and examination for participants, who received placebo or nicardipine for 4 weeks followed by a cross-over for the next 4 weeks<BR/>Total study duration 8 weeks</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2017-11-14 06:57:03 -0500" MODIFIED_BY="[Empty name]"><P>Participant diary used to record vasospastic attacks and side effects. Severity rated on an ordinal scale from 0 to 4. Pain associated with vasospasm recorded on a 15-cm visual analogue scale. Daily number of episodes recorded. Variables recorded on a diary sheet; after completion of each 4-week trial, participants evaluated in the human physiology laboratory. At study end, participants asked to give subjective evaluation of treatment periods. Used 15-cm horizontal visual analogue scale to rate degree of pain with cold challenge with immersion of the right hand in ice for 90 seconds</P></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2015-06-04 18:16:31 -0400" MODIFIED_BY="[Empty name]"/></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2017-11-14 02:01:28 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sarkozi--1986"><CHAR_METHODS MODIFIED="2017-11-14 01:59:35 -0500" MODIFIED_BY="[Empty name]"><P>Randomized double-blind placebo-controlled trial</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2017-11-14 02:00:57 -0500" MODIFIED_BY="[Empty name]"><P>39 patients - 29 female and 10 male </P><P>With idiopathic Raynaud's syndrome</P><P>At least 2 attacks/week in the previous 3 months </P><P>Mean disease duration 8.86 years</P><P>Mean age 39.9 years</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2017-11-14 02:01:10 -0500" MODIFIED_BY="[Empty name]"><P>Nifedipine 10 mg 3×/d or matching placebo</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2017-11-14 02:01:28 -0500" MODIFIED_BY="[Empty name]"><P>Frequency of attacks</P><P>Severity of attacks</P><P>Change in pulse amplitude of digital blood flow and time to return to baseline</P><P>Side effects</P><P>Treatment compliance</P></CHAR_OUTCOMES><CHAR_NOTES/></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2017-11-14 02:07:15 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sauza-1984"><CHAR_METHODS MODIFIED="2017-11-14 02:04:43 -0500" MODIFIED_BY="[Empty name]"><P>Parallel double-blind randomized controlled trial</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2017-11-14 02:06:40 -0500" MODIFIED_BY="[Empty name]"><P>25 patients entering the trial, 18 completing the 10-week study</P><P>17/18 completing the trial female </P><P>Mean age 41 years, range 24 to 71 </P><P>Only 1 with primary Raynaud's, 17 with secondary Raynaud's, 10 with recurrent digital pitting scars, none given vasodilators for at least 2 weeks before start of the study</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2017-11-14 02:07:04 -0500" MODIFIED_BY="[Empty name]"><P>10 given nifedipine (30 mg to 60 mg/d)</P><P>8 given matching placebo</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2017-11-14 02:07:15 -0500" MODIFIED_BY="[Empty name]"><P>Number of Raynaud's attacks during previous 2 weeks</P><P>Intensity of attacks</P><P>Side effects</P><P>Improvements</P></CHAR_OUTCOMES><CHAR_NOTES/></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2017-11-14 02:12:05 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Smith-1982"><CHAR_METHODS MODIFIED="2017-11-14 02:09:32 -0500" MODIFIED_BY="[Empty name]"><P>Double-blind randomized placebo-controlled trial<BR/>Cross-over design<BR/></P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2017-11-14 02:11:09 -0500" MODIFIED_BY="[Empty name]"><P>N = 17 patients, all female<BR/>Mean age 41 years, range 16 to 67<BR/>All with typical Raynaud's phenomenon with mean duration of 9.9 years<BR/>5 with idiopathic Raynaud's phenomenon, Raynaud's phenomenon secondary to systemic sclerosis, and RP secondary to systemic lupus erythematosus (in 1 patient)<BR/></P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2017-11-14 02:11:37 -0500" MODIFIED_BY="[Empty name]"><P>After 2 weeks of baseline, participants randomized to receive placebo or nifedipine for 2 weeks followed by a cross-over for 2 weeks<BR/>Total study duration 6 weeks</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2017-11-14 02:12:05 -0500" MODIFIED_BY="[Empty name]"><P>Frequency, severity (10-cm visual analogue scale), drug effectiveness (10-cm visual analogue scale) recorded in a participant diary<BR/>Blood pressure, heart rate, side effects, and skin temperature recovery times measured during visits</P></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2015-06-04 18:19:36 -0400" MODIFIED_BY="[Empty name]"/></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2017-11-14 08:21:54 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Teixeira-da-Costa"><CHAR_METHODS MODIFIED="2017-11-14 02:14:23 -0500" MODIFIED_BY="[Empty name]"><P>Double-blind randomized placebo-controlled trial<BR/>Cross-over study</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2017-11-14 02:14:56 -0500" MODIFIED_BY="[Empty name]"><P>N = 15 patients, 14 with associated connective tissue disorder<BR/>1 dropout, 2 exclusions due to incomplete data</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2017-11-14 02:15:55 -0500" MODIFIED_BY="[Empty name]"><P>Study carried out in 2 treatment periods, each of 2 weeks separated by a 1-week washout period from beginning of February to end of March<BR/>Participants given diltiazem or placebo. During second treatment period, each group crossed-over to opposite treatment<BR/>Total study duration 5 weeks</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2017-11-14 08:21:54 -0500" MODIFIED_BY="[Empty name]"><P>Subjective criteria: weekly frequency of vasospastic attacks recorded daily by participant; participant evaluation of effectiveness of study agent on 5-point clinical scale, taking frequency, severity, and duration into account<BR/>Objective: digital rheography recorded after 5 minutes of immersion of the hands in water at 30 degrees Celsius, and after 5 minutes of immersion at 5 degrees Celsius. Digital rheography performed immediately before start of the study, on the last day of first treatment, and on the last day of second treatment</P></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2015-06-04 18:20:46 -0400" MODIFIED_BY="[Empty name]"/></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2017-11-14 02:23:08 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Waller-1986"><CHAR_METHODS MODIFIED="2017-11-14 02:19:49 -0500" MODIFIED_BY="[Empty name]"><P>Double-blind randomized placebo-controlled trial<BR/>Cross-over design</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2017-11-14 02:21:31 -0500" MODIFIED_BY="[Empty name]"><P>N = 34 patients - 8 male and 26 female<BR/>28 with primary Raynaud's phenomenon, 4 with Raynaud's phenomenon secondary to systemic sclerosis, 2 with Raynaud's phenomenon secondary to RA<BR/>Mean age 45 years, range 14 to 77 </P><P>Mean duration of Raynaud's disease 14.7 years<BR/>10 smokers<BR/>5 dropouts</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2017-11-14 02:22:30 -0500" MODIFIED_BY="[Empty name]"><P>Concurrent medication unchanged in 16 participants<BR/>Participants randomized after 2-week run-in period to receive a new biphasic release formulation of nifedipine or placebo </P><P>Each period 4 weeks with 2-week washout period between<BR/>Total study duration 12 weeks</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2017-11-14 02:23:08 -0500" MODIFIED_BY="[Empty name]"><P>Participant diary used to record episodes, number of attacks, severity, side effects, and improvement<BR/>Nifedipine concentration in blood plasma also recorded</P></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2015-06-04 18:21:35 -0400" MODIFIED_BY="[Empty name]"/></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2017-11-14 02:27:00 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-White-1986"><CHAR_METHODS MODIFIED="2017-11-14 02:25:17 -0500" MODIFIED_BY="[Empty name]"><P>Double-blind randomized placebo-controlled trial<BR/>Cross-over design</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2017-11-14 02:26:18 -0500" MODIFIED_BY="[Empty name]"><P>N = 11 patients - 8 women, 3 men<BR/>Age range from 28 to 81 </P><P>Also included 21 healthy control participants<BR/>Primary Raynaud's phenomenon in 6 participants, Raynaud's phenomenon secondary to systemic disease in 5 participants<BR/>0 dropouts</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2017-11-14 02:26:50 -0500" MODIFIED_BY="[Empty name]"><P>Participants given nifedipine or placebo for 1 week, then crossed over to receive opposite treatment for 1 week<BR/>Total study duration 2 weeks</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2017-11-14 02:27:00 -0500" MODIFIED_BY="[Empty name]"><P>Baseline digital temperature, pill counts, and subjective change in symptoms measured</P></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2015-06-04 18:25:12 -0400" MODIFIED_BY="[Empty name]"/></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2017-11-14 02:32:14 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wigley-1987"><CHAR_METHODS MODIFIED="2017-11-14 02:28:29 -0500" MODIFIED_BY="[Empty name]"><P>Randomized double-blind placebo-controlled trial<BR/>Cross-over design</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2017-11-14 02:30:16 -0500" MODIFIED_BY="[Empty name]"><P>N = 25 patients - 21 female, 4 male </P><P>Mean age 39 ± 2.6 years, range 22 to 65<BR/>19 of Caucasian descent<BR/>Average disease duration 4.75 ± 0.8 years<BR/>10 with primary Raynaud's phenomenon, 15 with Raynaud's phenomenon secondary to connective tissue disorder<BR/>No dropouts during cross-over phase, 2 dropouts during parallel phase</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2017-11-14 02:31:45 -0500" MODIFIED_BY="[Empty name]"><P>Participants randomly assigned to receive nicardipine or placebo for first 2 weeks followed by a second 2-week period with agent not taken <BR/>Continuation of agent from the second treatment period for an additional 4 weeks in a parallel design<BR/>Total study duration 4 weeks</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2017-11-14 02:32:14 -0500" MODIFIED_BY="[Empty name]"><P>Participant diary used to record frequency and severity<BR/>Finger systolic pressure and venous sampling performed<BR/>Beta-thromboglobulin and platelet factor 4 measured</P></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2015-06-04 18:26:03 -0400" MODIFIED_BY="[Empty name]"/></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2017-11-14 02:36:44 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wollersheim-1991"><CHAR_METHODS MODIFIED="2017-11-14 02:34:22 -0500" MODIFIED_BY="[Empty name]"><P>Randomized double-blind placebo-controlled cross-over trial</P><P>Washout period of 2 weeks separating cross-over phases </P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2017-11-14 02:35:49 -0500" MODIFIED_BY="[Empty name]"><P>25 patients - 10 male and 15 female </P><P>Mean age 41.2 ± 10.7 years</P><P>16 with primary and 9 with secondary Raynaud's phenomenon</P><P>Mean duration of disease 6.5 ± 6.1 years</P><P>10 smokers</P><P>Mean attack rate in the winter 7.2 ± 2.9/d, range 2 to 14 attacks/d </P><P>8 with skin lesions, 3 who had undergone sympathectomy</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2017-11-14 02:36:21 -0500" MODIFIED_BY="[Empty name]"><P>Nicardipine 30 mg 3× per day or matching placebo capsules for 3 weeks, then cross-over to opposite treatment after 2-week washout period for another 3 weeks</P><P>Trial preceded by 3-week baseline period without medication</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2017-11-14 02:36:44 -0500" MODIFIED_BY="[Empty name]"><P>Frequency, duration, and severity of attacks</P><P>Treatment preference</P><P>Drug effectiveness (rated on a 5-point scale: much worse, worse, no difference, better, or much better) </P><P>Ischemic attack changes</P><P>Side effects</P><P>Objective measurements: weight, systolic blood pressure, temperature, diastolic blood pressure, heart rate</P></CHAR_OUTCOMES><CHAR_NOTES/></INCLUDED_CHAR><FOOTNOTES><P>ANF: XXX.</P><P>AVD: atrioventricular dissociation.</P><P>BP: blood pressure.</P><P>CREST: calcinosis, Raynaud phenomenon, esophageal dysmotility, sclerodactyly, and telangiectasia.</P><P>FSP: XXX.</P><P>IA: intracranial aneurysm.</P><P>NSAIDs: non-steroidal anti-inflammatory drugs.</P><P>RA: rheumatoid arthritis.</P><P>VAS: visual analogue scale.</P></FOOTNOTES></CHARACTERISTICS_OF_INCLUDED_STUDIES><CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2017-11-22 21:03:38 -0500" MODIFIED_BY="[Empty name]" SORT_BY="STUDY"><EXCLUDED_CHAR STUDY_ID="STD-Codella-1989"><CHAR_REASON_FOR_EXCLUSION><P>No placebo</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2015-06-26 14:47:13 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Creager-1984"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-06-26 14:47:13 -0400" MODIFIED_BY="[Empty name]"><P>Not a randomized controlled trial</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR STUDY_ID="STD-Della-Bella-1997"><CHAR_REASON_FOR_EXCLUSION><P>No placebo</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR STUDY_ID="STD-Dziadzio-1999"><CHAR_REASON_FOR_EXCLUSION><P>No placebo</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2017-11-22 21:03:38 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ennis-2016"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-11-22 21:03:38 -0500" MODIFIED_BY="[Empty name]"><P>A meta-analysis</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR STUDY_ID="STD-Garcia-Hernandez2004"><CHAR_REASON_FOR_EXCLUSION><P>Not a randomized controlled trial</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2014-08-17 17:14:15 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Joseph-1988"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-17 17:14:15 -0400" MODIFIED_BY="[Empty name]"><P>Not a randomized controlled trial</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR STUDY_ID="STD-Kahan-1983b"><CHAR_REASON_FOR_EXCLUSION><P>Duration &lt; 1 week</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2017-11-14 02:39:31 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kallenberg-1991"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-11-14 02:39:31 -0500" MODIFIED_BY="[Empty name]"><P>Not a randomized dose-finding study</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2017-11-14 02:39:38 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-La-Civita-1996"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-11-14 02:39:38 -0500" MODIFIED_BY="[Empty name]"><P>No placebo data presented</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR STUDY_ID="STD-Leppert-1993"><CHAR_REASON_FOR_EXCLUSION><P>No placebo</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2017-11-14 02:39:48 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lewis-1987"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-11-14 02:39:48 -0500" MODIFIED_BY="[Empty name]"><P>Not a randomized controlled trial</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR STUDY_ID="STD-Myrdal-1994"><CHAR_REASON_FOR_EXCLUSION><P>No placebo</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2015-06-26 14:51:50 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nilsson-1990"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-06-26 14:51:50 -0400" MODIFIED_BY="[Empty name]"><P>Not a randomized controlled trial</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2013-06-18 11:11:18 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Park-2013"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-18 11:11:18 -0400" MODIFIED_BY="[Empty name]"><P>No placebo</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2015-06-26 14:33:33 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pisenti-1984"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-06-26 14:33:33 -0400" MODIFIED_BY="[Empty name]"><P>Not a randomized controlled trial</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR STUDY_ID="STD-Rademaker-1989"><CHAR_REASON_FOR_EXCLUSION><P>No placebo data presented</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR STUDY_ID="STD-Rademaker-1992"><CHAR_REASON_FOR_EXCLUSION><P>No placebo</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR STUDY_ID="STD-Ringqvist-1993"><CHAR_REASON_FOR_EXCLUSION><P>No placebo</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR STUDY_ID="STD-Schmidt-1989"><CHAR_REASON_FOR_EXCLUSION><P>No separation of placebo and treatment data</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2017-11-14 02:40:06 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Shcherbakov-1987"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-11-14 02:40:06 -0500" MODIFIED_BY="[Empty name]"><P>Open-label study</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR STUDY_ID="STD-Smith-1985"><CHAR_REASON_FOR_EXCLUSION><P>Not a randomized controlled trial</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2017-11-14 02:40:22 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Thompson-2001"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-11-14 02:40:22 -0500" MODIFIED_BY="[Empty name]"><P>Meta-analysis performed</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2017-11-14 02:40:26 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Thompson-2005"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-11-14 02:40:26 -0500" MODIFIED_BY="[Empty name]"><P>Meta-analysis performed</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2017-11-14 02:40:29 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Varela_x002d_Aguilar-1997"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-11-14 02:40:29 -0500" MODIFIED_BY="[Empty name]"><P>No placebo data presented</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR STUDY_ID="STD-Vayssairat-1989"><CHAR_REASON_FOR_EXCLUSION><P>Not a randomized controlled trial</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR STUDY_ID="STD-Weber-1990"><CHAR_REASON_FOR_EXCLUSION><P>Duration &lt; 1 week</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2014-09-08 13:42:37 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Winston-1983"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-08 13:42:37 -0400" MODIFIED_BY="[Empty name]"><P>Insufficient "washout" period of 1 day </P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2017-11-14 02:40:43 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wollersheim-1987"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-11-14 02:40:43 -0500" MODIFIED_BY="[Empty name]"><P>Not a randomized controlled trial</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2015-06-26 15:31:39 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wu-2008"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-06-26 15:31:39 -0400" MODIFIED_BY="[Empty name]"><P>Non-randomized, no placebo</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><FOOTNOTES/></CHARACTERISTICS_OF_EXCLUDED_STUDIES><CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2017-11-14 02:47:29 -0500" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO"><AWAITING_CHAR MODIFIED="2017-11-14 02:43:19 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-EUCTR2009_x002d_018194_x002d_31_x002d_GB"><CHAR_METHODS MODIFIED="2017-11-14 02:41:57 -0500" MODIFIED_BY="[Empty name]"><P>Open-label clinical trial</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2017-11-14 02:42:18 -0500" MODIFIED_BY="[Empty name]"><P>Patients with PRP (primary Raynaud's phenomenon) with Raynaud&#8217;s phenomenon for at least 2 years</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2016-03-06 16:23:01 -0500" MODIFIED_BY="[Empty name]"><P>Amlodipine gel or placebo</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2017-11-14 02:43:19 -0500" MODIFIED_BY="[Empty name]"><P>Main objective: to determine the efficacy of amlodipine maleate gel in improving digital blood flow</P><P>Primary endpoint: to improve symptoms by increasing blood flow to finger extremities</P><P>Secondary objective: to ascertain the practicality of amlodipine maleate gel application; to establish short-term side effect profile</P></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2016-03-06 16:23:01 -0500" MODIFIED_BY="[Empty name]"/></AWAITING_CHAR><AWAITING_CHAR MODIFIED="2017-11-14 02:43:39 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kahan-1982"><CHAR_METHODS MODIFIED="2017-11-14 02:43:27 -0500" MODIFIED_BY="[Empty name]"><P>Double-blind placebo-controlled study</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2017-11-14 02:43:30 -0500" MODIFIED_BY="[Empty name]"><P>46 with Raynaud's phenomenon</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2015-06-27 12:33:30 -0400" MODIFIED_BY="[Empty name]"><P>Nifedipine or placebo</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2015-06-27 12:33:42 -0400" MODIFIED_BY="[Empty name]"><P>Frequency of attacks</P></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2017-11-14 02:43:39 -0500" MODIFIED_BY="[Empty name]"><P>Abstract only; data not available</P></CHAR_NOTES></AWAITING_CHAR><AWAITING_CHAR MODIFIED="2017-11-14 02:43:52 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kahan-1983a"><CHAR_METHODS MODIFIED="2017-11-14 02:43:42 -0500" MODIFIED_BY="[Empty name]"><P>Unknown</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2015-06-27 10:49:27 -0400" MODIFIED_BY="[Empty name]"><P>Patients with scleroderma</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2015-06-27 10:49:05 -0400" MODIFIED_BY="[Empty name]"><P>Nifedipine </P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2017-11-14 02:43:52 -0500" MODIFIED_BY="[Empty name]"><P>Unknown; abstract not available</P></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2015-06-27 11:30:42 -0400" MODIFIED_BY="[Empty name]"><P>Unable to obtain data</P></CHAR_NOTES></AWAITING_CHAR><AWAITING_CHAR MODIFIED="2017-11-14 02:43:59 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Redondo-1986"><CHAR_METHODS MODIFIED="2017-11-14 02:43:59 -0500" MODIFIED_BY="[Empty name]"><P>Double-blind controlled clinical study</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2015-06-07 21:17:15 -0400" MODIFIED_BY="[Empty name]"><P>Not yet assessed</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2015-06-07 21:17:16 -0400" MODIFIED_BY="[Empty name]"><P>Not yet assessed</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2015-06-07 21:17:18 -0400" MODIFIED_BY="[Empty name]"><P>Not yet assessed</P></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2015-06-07 21:17:41 -0400" MODIFIED_BY="[Empty name]"><P>Unable to locate Spanish study</P></CHAR_NOTES></AWAITING_CHAR><AWAITING_CHAR MODIFIED="2017-11-14 02:44:49 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-van-Heereveld-1988"><CHAR_METHODS MODIFIED="2017-11-14 02:44:08 -0500" MODIFIED_BY="[Empty name]"><P>Double-blind placebo-controlled cross-over study</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2017-11-14 02:44:18 -0500" MODIFIED_BY="[Empty name]"><P>12 Raynaud patients, 12 healthy volunteers</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2017-11-14 02:44:28 -0500" MODIFIED_BY="[Empty name]"><P>Intravenously administered</P><P>Nicardipine (5 mg/h during 85 minutes)</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2017-11-14 02:44:36 -0500" MODIFIED_BY="[Empty name]"><P>Blood pressure</P><P>Skin temperature</P><P>Heart rate</P></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2017-11-14 02:44:49 -0500" MODIFIED_BY="[Empty name]"><P>No report on any of the outcomes of interest for this review</P></CHAR_NOTES></AWAITING_CHAR><AWAITING_CHAR MODIFIED="2017-11-14 02:46:57 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wasir-1983"><CHAR_METHODS MODIFIED="2017-11-14 02:44:53 -0500" MODIFIED_BY="[Empty name]"><P>Double-blind randomised controlled trial</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2015-06-27 11:50:22 -0400" MODIFIED_BY="[Empty name]"><P>52 patients with primary or secondary Raynaud's phenomenon</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2017-11-14 02:45:22 -0500" MODIFIED_BY="[Empty name]"><P>Intra-arterial reserpine injection or sublingually administered nifedipine, orally administered trifluoperazine or dipyridamole, weekly on a long-term basis</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2017-11-14 02:46:54 -0500" MODIFIED_BY="[Empty name]"><P>Besides the usual biochemical and immunological investigations, special tests including skin temperature, recovery time after a cold stress test, measurement of digital blood flow by strain-gauge digital plethysmography, and radioisotopically determined glomerular filtration rate. Digital blood flow and skin temperature recovery times studied after 45 minutes, 2 hours, 6 hours, and 24 hours of intra-arterial reserpine injection or sublingually administered nifedipine, orally administered trifluoperazine or dipyridamole; and weekly on a long-term basis </P><P>Raynaud's frequency, severity, and duration of attacks</P></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2017-11-14 02:46:57 -0500" MODIFIED_BY="[Empty name]"><P>Abstract only; data unavailable</P></CHAR_NOTES></AWAITING_CHAR><AWAITING_CHAR MODIFIED="2017-11-14 02:47:29 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wise-1987"><CHAR_METHODS MODIFIED="2017-11-14 02:47:11 -0500" MODIFIED_BY="[Empty name]"><P>Double-blind placebo-controlled trial</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2017-11-14 02:47:20 -0500" MODIFIED_BY="[Empty name]"><P>21 participants with Raynaud's phenomenon</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2017-11-14 02:47:25 -0500" MODIFIED_BY="[Empty name]"><P>Nifedipne or placebo</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2017-11-14 02:47:29 -0500" MODIFIED_BY="[Empty name]"><P>Perfusion pressure and digital blood flow</P></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2015-06-27 12:14:27 -0400" MODIFIED_BY="[Empty name]"><P>Outcomes of interest not reported</P></CHAR_NOTES></AWAITING_CHAR><FOOTNOTES/></CHARACTERISTICS_OF_AWAITING_STUDIES><CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2017-11-23 21:11:07 -0500" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO"><ONGOING_CHAR MODIFIED="2017-11-23 21:03:55 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nazarinia-2016"><CHAR_STUDY_NAME MODIFIED="2017-11-23 20:56:35 -0500" MODIFIED_BY="[Empty name]"><P>Assessing and Comparing the Effect of Diltiazem Gel Versus Nitroglycerin Ointment in Healing Process of Scleroderma Digital Ulcers</P></CHAR_STUDY_NAME><CHAR_METHODS MODIFIED="2017-11-23 20:57:03 -0500" MODIFIED_BY="[Empty name]"><P>Randomized parallel assignment</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2017-11-23 20:57:41 -0500" MODIFIED_BY="[Empty name]"><P>90 patients with scleroderma</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2017-11-23 20:59:17 -0500" MODIFIED_BY="[Empty name]"><P>About 60 patients will be considered to be in control group receiving vaseline ointment as the placebo applying 2 times daily on their ulcers for 8 weeks.</P><P>Experimental:</P><P>Diltiazem Gel 2%</P><P>About 30 patients will receive Diltiazem Gel 2% applying 2 times daily for 8 weeks on their digital ulcers.</P><P>Experimental: Nitroglycerin Ointment 2%</P><P>About 30 patients will receive nitroglycerin 2% applying 2 times daily for 8 weeks on their digital ulcers.</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2017-11-23 21:02:03 -0500" MODIFIED_BY="[Empty name]"><P>Primary Outcome Measures:</P><UL><LI>Assessing the effect of topical diltiazem on scleroderma digital ulcers' healing process according to their site and comparing it with topical nitroglycerin [ Time Frame: 10 months ]</LI></UL><P>Secondary Outcome Measures:</P><UL><LI>To see if there is any significant difference in mean diameters of scleroderma digital ulcers between patients receiving placebo and ones treated with diltiazem gel [ Time Frame: 6 months ]</LI><LI>To see if the patients, receiving diltiazem gel, develop significantly less numbers of new ulcers during the study [ Time Frame: 6 months ]</LI><LI>To see if there is any significant difference in mean diameters of scleroderma digital ulcers between patients receiving placebo and ones treated with nitroglycerin ointment [ Time Frame: 6 months ]</LI><LI>To see if ones receiving nitroglycerin ointment develop significantly less numbers of new ulcers during the study [ Time Frame: 6 months ]</LI><LI>To see if ones receiving diltiazem gel have difference in mean diameters of ulcers and numbers of new ones with group receiving nitroglycerin ointment [ Time Frame: 6 months ]</LI><LI>To compare the difference in mean diameter of digital ulcers according to their site in each experimental group [ Time Frame: 1 month ]</LI></UL></CHAR_OUTCOMES><CHAR_STARTING_DATE MODIFIED="2017-11-23 21:02:32 -0500" MODIFIED_BY="[Empty name]"><P>June 2016</P></CHAR_STARTING_DATE><CHAR_CONTACT_INFORMATION MODIFIED="2017-11-23 21:03:55 -0500" MODIFIED_BY="[Empty name]"><P>Rheumatology Reseach Center, Shiraz University of Medical Sciences, Shiraz, Iran.Shiraz, Fars, Iran, Islamic Republic of</P></CHAR_CONTACT_INFORMATION><CHAR_NOTES MODIFIED="2017-11-23 21:03:53 -0500" MODIFIED_BY="[Empty name]"/></ONGOING_CHAR><ONGOING_CHAR MODIFIED="2017-11-23 21:11:07 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Vera_x002d_Kellet-2017"><CHAR_STUDY_NAME MODIFIED="2017-11-23 21:05:57 -0500" MODIFIED_BY="[Empty name]"><P>Color Doppler Ultrasound Comparison of Topical 10% Nifedipine Versus 5% Sildenafil in Secondary Raynaud: A Randomized, Double-blind, Placebo-controlled Pilot Study</P></CHAR_STUDY_NAME><CHAR_METHODS MODIFIED="2017-11-23 21:06:16 -0500" MODIFIED_BY="[Empty name]"><P>A randomized, double-blind, placebo-controlled pilot study took place in 10 patients with secondary RP. Topical 10% nifedipine on one hand and 5% sildenafil on the other hand were applied. The thumbs didn't receive any cream and served as a control group. The primary outcome was the improvement of blood flow and vessel diameter of the digital arteries measured by high frequency color Doppler ultrasound before and 1 hour after treatment.</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2017-11-23 21:07:24 -0500" MODIFIED_BY="[Empty name]"><P>10 patients with clinical diagnosis of secondary Raynaud´s phenomenon associated with a connective tissue disease</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2017-11-23 21:09:01 -0500" MODIFIED_BY="[Empty name]"><P>Experimental: 10% nifedipine cream</P><P>Patient hands (right versus left) were randomized to treatment with topical sildenafil or nifedipine cream. The thumbs of both hands didn't receive any cream so that each subject served as her own control. Subjects were instructed to apply 5 grams of 10% nifedipine cream in one hand and 5 grams of 5% sildenafil cream to the opposite hand. Vinyl gloves were supplied to improve the absorption of the cream into the hand, leaving the thumb of both hands out of the glove without any cream.</P><P>Active Comparator: 5% sildenafil cream</P><P>Patient hands (right versus left) were randomized to treatment with topical sildenafil or nifedipine cream. The thumbs of both hands didn't receive any cream so that each subject served as her own control. Subjects were instructed to apply 5 grams of topical10% nifedipine cream in one hand and 5 grams of topical 5% sildenafil cream to the opposite hand. Vinyl gloves were supplied to improve the absorption of the cream into the hand, leaving the thumb of both hands out of the glove without any cream.</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2017-11-23 21:09:23 -0500" MODIFIED_BY="[Empty name]"><P>Primary Outcome Measures:Improvement of blood flow in the digital arteries (peak systolic velocity ) of the dorsal arterial arch of the proximal nail fold of the index, middle and thumb fingers of both hands [ Time Frame: Outcome measure will be assessed the same day of the study and the data will be presented after the data is analyzed (12 weeks) ]The peak systolic velocity peak is measured with Doppler sonography in centimeters/second<BR/><BR/>Secondary Outcome Measures:Improvement of the diameter (mm) of the dorsal arterial arch of the proximal nail fold of the of the index, middle and thumb fingers of both hands. [ Time Frame: Outcome measure will be assessed the same day of the study and the data will be presented after the data is analyzed (12 weeks) ]The diameter is measured with Doppler sonography in millimeters</P></CHAR_OUTCOMES><CHAR_STARTING_DATE MODIFIED="2017-11-23 21:09:41 -0500" MODIFIED_BY="[Empty name]"><P>August 2016</P></CHAR_STARTING_DATE><CHAR_CONTACT_INFORMATION MODIFIED="2017-11-23 21:11:07 -0500" MODIFIED_BY="[Empty name]"><P>Responsible Party:Pontificia Universidad Catolica de Chile</P></CHAR_CONTACT_INFORMATION><CHAR_NOTES MODIFIED="2017-11-23 21:10:43 -0500" MODIFIED_BY="[Empty name]"/></ONGOING_CHAR><FOOTNOTES/></CHARACTERISTICS_OF_ONGOING_STUDIES></CHARACTERISTICS_OF_STUDIES><QUALITY_ITEMS MODIFIED="2017-11-29 09:38:40 -0500" MODIFIED_BY="[Empty name]"><QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2017-11-14 08:21:33 -0500" MODIFIED_BY="[Empty name]" NO="1"><NAME>Random sequence generation (selection bias)</NAME><DESCRIPTION><P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P></DESCRIPTION><QUALITY_ITEM_DATA><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-14 06:58:07 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Aldoori-1986"><DESCRIPTION><P>Evidence insufficient for judgement of risk</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-14 06:58:16 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bravard-1983"><DESCRIPTION><P>Evidence insufficient for judgement of risk</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-14 06:58:28 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Challenor-1987"><DESCRIPTION><P>Evidence insufficient for judgement of risk</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-14 06:58:37 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Challenor-1989"><DESCRIPTION><P>Evidence insufficient for judgement of risk</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-14 06:58:52 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Constantini-1987"><DESCRIPTION><P>Evidence insufficient for judgement of risk</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-13 03:19:19 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Corbin-1986"><DESCRIPTION><P>Participants randomized in blocks of 4 to receive either nifedipine for 4 weeks followed by placebo for 4 weeks, or vice versa</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-14 08:20:19 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ettinger-1984"><DESCRIPTION><P>Information insufficient for judgement of low or high risk of bias</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-14 06:59:27 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ferri-1992"><DESCRIPTION><P>Evidence insufficient for judgement of risk</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-14 06:59:35 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Finch-1988"><DESCRIPTION><P>Evidence insufficient for judgement of risk</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-13 03:45:02 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-French-Co_x002d_op-1991"><DESCRIPTION><P>"Patients were randomly assigned....enters were unaware of randomization code."</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-14 06:59:47 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gjorup-1986a"><DESCRIPTION><P>Evidence insufficient for judgement of risk</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-14 06:59:58 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gjorup-1986b"><DESCRIPTION><P>Evidence insufficient for judgement of risk</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-14 08:20:54 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hawkins-1985"><DESCRIPTION><P>Evidence insufficient for judgement of risk</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-13 04:08:08 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kahan-1985a"><DESCRIPTION><P>"Randomization sequence was determined using a table of random numbers."</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-14 07:00:20 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kahan-1985b"><DESCRIPTION><P>"randomized double cross-over protocol"</P><P>Evidence insufficient for judgement of risk</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-14 07:00:31 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kahan-1985c"><DESCRIPTION><P>Evidence insufficient for judgement of risk</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-10-21 17:03:36 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kahan-1987"><DESCRIPTION><P>Based on a table of random numbers</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-14 07:00:42 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kallenberg-1987"><DESCRIPTION><P>Evidence insufficient for judgement of risk</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-01 21:41:22 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kinney-1982"><DESCRIPTION><P>"computer-generated randomization schedule"</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-14 07:01:01 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kirch-1987"><DESCRIPTION><P>Evidence insufficient for judgement of risk</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-14 07:01:13 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-La-Civita-1997"><DESCRIPTION><P>Evidence insufficient for judgement of risk</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-14 07:01:24 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Leppert-1989"><DESCRIPTION><P>Evidence insufficient for judgement of risk</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-14 07:01:40 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Malamet-1984"><DESCRIPTION><P>Evidence insufficient for judgement of risk</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-14 07:01:47 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Meyrick-Thomas-1987"><DESCRIPTION><P>"random order, cross-over design"</P><P>Evidence insufficient for judgement of risk</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-14 07:01:58 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Muller_x002d_Buhl-1983"><DESCRIPTION><P>No information provided for judgement of risk</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-14 07:21:48 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nilsson-1987"><DESCRIPTION><P>"Randomization was made in blocks of 6."</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-14 07:22:14 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-RTSI-2000"><DESCRIPTION><P>"Co-ordinating center generated a set of allocations for each clinical center using an Autonomated Telephone Randomization System."</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-13 21:54:35 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Rhedda-1985"><DESCRIPTION><P>Randomization via computer-generated random numbers by an independent collaborator </P><P>However, findings showing that 1 group had more severe disease than the other, despite this randomization</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-10-21 17:51:58 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rodeheffer-1983"><DESCRIPTION><P>"Table of random numbers used" for randomization</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-14 08:21:33 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rupp-1987"><DESCRIPTION><P>Evidence insufficient for judgement of risk</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-18 12:59:25 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sarkozi--1986"><DESCRIPTION><P>"randomization sequence determined from a table of random numbers"</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-14 07:02:36 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sauza-1984"><DESCRIPTION><P>Evidence insufficient for judgement of risk</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-14 07:02:43 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Smith-1982"><DESCRIPTION><P>Evidence insufficient for judgement of risk</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-14 07:02:56 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Teixeira-da-Costa"><DESCRIPTION><P>Evidence insufficient for judgement of risk</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-14 07:03:17 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Waller-1986"><DESCRIPTION><P>Evidence insufficient for judgement of risk</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-14 07:03:25 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-White-1986"><DESCRIPTION><P>Evidence insufficient for judgement of risk</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-14 07:03:37 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wigley-1987"><DESCRIPTION><P>Evidence insufficient for judgement of risk</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-14 07:03:49 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wollersheim-1991"><DESCRIPTION><P>Information insufficient for judgement of risk</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY></QUALITY_ITEM_DATA></QUALITY_ITEM><QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2017-11-14 08:21:41 -0500" MODIFIED_BY="[Empty name]" NO="2"><NAME>Allocation concealment (selection bias)</NAME><DESCRIPTION><P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P></DESCRIPTION><QUALITY_ITEM_DATA><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-14 06:58:12 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Aldoori-1986"><DESCRIPTION><P>Evidence insufficient for judgement of risk</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-14 06:58:20 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bravard-1983"><DESCRIPTION><P>Evidence insufficient for judgement of risk</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-14 06:58:33 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Challenor-1987"><DESCRIPTION><P>Evidence insufficient for judgement of risk</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-14 06:58:40 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Challenor-1989"><DESCRIPTION><P>Evidence insufficient for judgement of risk</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-14 06:58:56 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Constantini-1987"><DESCRIPTION><P>Evidence insufficient for judgement of risk</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-13 03:19:31 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Corbin-1986"><DESCRIPTION><P>Block randomization concealing allocation</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-14 08:20:25 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ettinger-1984"><DESCRIPTION><P>Information insufficient for judgement of low or high risk of bias</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-14 06:59:31 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ferri-1992"><DESCRIPTION><P>Evidence insufficient for judgement of risk</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-14 06:59:40 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Finch-1988"><DESCRIPTION><P>Evidence insufficient for judgement of risk</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-13 03:45:08 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-French-Co_x002d_op-1991"><DESCRIPTION><P>Assignment by third party through random generation</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-14 06:59:51 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gjorup-1986a"><DESCRIPTION><P>Evidence insufficient for judgement of risk</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-14 07:00:02 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gjorup-1986b"><DESCRIPTION><P>Evidence insufficient for judgement of risk</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-14 08:21:00 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hawkins-1985"><DESCRIPTION><P>Evidence insufficient for judgement of risk</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-10-27 20:37:18 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kahan-1985a"><DESCRIPTION><P>Likely occurred</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-14 07:00:24 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kahan-1985b"><DESCRIPTION><P>Evidence insufficient for judgement of risk</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-14 07:00:35 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kahan-1985c"><DESCRIPTION><P>Evidence insufficient for judgement of risk</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-13 04:22:39 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kahan-1987"><DESCRIPTION><P>"Randomization sequence was determined with a table of random numbers."</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-14 07:00:46 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kallenberg-1987"><DESCRIPTION><P>Evidence insufficient for judgement of risk</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-13 04:32:17 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kinney-1982"><DESCRIPTION><P>Likely occurred on the basis of computer generation</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-14 07:01:05 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kirch-1987"><DESCRIPTION><P>Evidence insufficient for judgement of risk</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-14 07:01:17 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-La-Civita-1997"><DESCRIPTION><P>Evidence insufficient for judgement of risk</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-14 07:01:28 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Leppert-1989"><DESCRIPTION><P>Evidence insufficient for judgement of risk</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-14 07:01:44 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Malamet-1984"><DESCRIPTION><P>Evidence insufficient for judgement of risk</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-14 07:21:12 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Meyrick-Thomas-1987"><DESCRIPTION><P>"Patient[s] were randomly allocated to Group A or B."</P><P>Evidence insufficient for judgement of risk</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-14 07:02:03 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Muller_x002d_Buhl-1983"><DESCRIPTION><P>No information provided for judgement of risk</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-13 21:46:56 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nilsson-1987"><DESCRIPTION><P>Blind allocation based on blocking</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-14 01:47:04 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-RTSI-2000"><DESCRIPTION><P>Allocations generated in block sizes varying randomly to balance the number of participants allocated to each treatment</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-13 21:54:52 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rhedda-1985"><DESCRIPTION><P>Participants unaware of randomization group, which was confirmed at the conclusion of the trial</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-13 22:00:40 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rodeheffer-1983"><DESCRIPTION><P>Likely occurred on basis of table of random numbers</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-14 08:21:41 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rupp-1987"><DESCRIPTION><P>Evidence insufficient for judgement of risk</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-14 02:01:51 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sarkozi--1986"><DESCRIPTION><P>Allocation blind, based on a table of random numbers</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-14 07:02:40 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sauza-1984"><DESCRIPTION><P>Evidence insufficient for judgement of risk</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-14 07:02:47 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Smith-1982"><DESCRIPTION><P>Evidence insufficient for judgement of risk</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-14 07:03:00 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Teixeira-da-Costa"><DESCRIPTION><P>Evidence insufficient for judgement of risk</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-14 07:03:21 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Waller-1986"><DESCRIPTION><P>Evidence insufficient for judgement of risk</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-14 07:03:29 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-White-1986"><DESCRIPTION><P>Evidence insufficient for judgement of risk</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-14 07:03:41 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wigley-1987"><DESCRIPTION><P>Evidence insufficient for judgement of risk</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-14 02:37:12 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wollersheim-1991"><DESCRIPTION><P>"A sheet detailing the assignment of all periods for all medication sets was provided in sealed envelopes to be opened only in the event of a serious adverse event."</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY></QUALITY_ITEM_DATA></QUALITY_ITEM><QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2017-11-14 07:22:01 -0500" MODIFIED_BY="[Empty name]" NO="7"><NAME>Blinding of participants and personnel (performance bias)</NAME><DESCRIPTION><P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P></DESCRIPTION><QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1"><NAME>All outcomes</NAME></QUALITY_ITEM_DATA_ENTRY_GROUP><QUALITY_ITEM_DATA><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2017-11-12 16:30:05 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Aldoori-1986"><DESCRIPTION><P>Double-blind cross-over study</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2017-11-12 16:37:31 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bravard-1983"><DESCRIPTION><P>Described as a double-blind study</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2017-11-13 02:42:14 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Challenor-1987"><DESCRIPTION><P>Double-blind study</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2017-11-13 02:55:00 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Challenor-1989"><DESCRIPTION><P>Double-dummy RCT: "Patients were randomized to receive either a 10-mg sustained-release formulation of nifedipine twice daily before food or a matching placebo."</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2017-11-13 03:13:20 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Constantini-1987"><DESCRIPTION><P>Double-blind investigation</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2017-11-13 03:19:48 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Corbin-1986"><DESCRIPTION><P>Double-blind: "Patients were given a supply of 5 mg nifedipine capsules or an identical placebo (supplied by Bayer UK Limited)."</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2017-11-13 03:27:26 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ettinger-1984"><DESCRIPTION><P>"Double-blind" study</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2017-11-13 03:34:26 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ferri-1992"><DESCRIPTION><P>"Double-blind cross-over"</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2017-11-13 03:40:34 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Finch-1988"><DESCRIPTION><P>Double-blind cross-over</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2017-11-13 03:45:16 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-French-Co_x002d_op-1991"><DESCRIPTION><P>Double-blind cross-over with identical appearing treatment and placebo tablets</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2017-11-13 03:50:15 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gjorup-1986a"><DESCRIPTION><P>"Double-blind cross-over study"</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2017-11-13 03:54:19 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gjorup-1986b"><DESCRIPTION><P>"Double-blind" - "randomly allocated to receive either 20mg nifedipine or placebo in equivalent numbers"</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2017-11-13 04:02:49 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hawkins-1985"><DESCRIPTION><P>Does not explicitly state double-blinding</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2017-11-13 04:08:29 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kahan-1985a"><DESCRIPTION><P>Double-blind cross-over study; dependent variables quantified before the code was broken</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2017-11-13 04:13:10 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kahan-1985b"><DESCRIPTION><P>Double-blind cross-over study</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2017-11-13 04:16:44 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kahan-1985c"><DESCRIPTION><P>Double-blind study </P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2017-11-13 04:22:48 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kahan-1987"><DESCRIPTION><P>"Double-blind cross-over study"</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2017-11-13 04:26:50 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kallenberg-1987"><DESCRIPTION><P>Double-blind study</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2017-11-13 04:32:34 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kinney-1982"><DESCRIPTION><P>"The study was double-blinded." </P><P>"Placebo-treated patients received equivalent numbers of capsules."</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2017-11-13 04:39:00 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kirch-1987"><DESCRIPTION><P>Single-blind study - patients unaware of their treatment arm</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2017-11-13 04:43:55 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-La-Civita-1997"><DESCRIPTION><P>"Double-blind"</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2017-11-13 04:49:58 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Leppert-1989"><DESCRIPTION><P>Single-blind study; participants unaware of their treatment arm</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2017-11-13 21:16:49 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Malamet-1984"><DESCRIPTION><P>Double-blind study</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2017-11-13 21:40:19 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Meyrick-Thomas-1987"><DESCRIPTION><P>"Double-blind..received either nifedipine or identical placebo capsules 3× daily (Group A or B)"</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2017-11-13 21:44:04 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Muller_x002d_Buhl-1983"><DESCRIPTION><P>Double-blind</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2017-11-13 21:47:18 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nilsson-1987"><DESCRIPTION><P>Double-blind cross-over study; code broken only after conclusion of treatment</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2017-11-14 01:47:11 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-RTSI-2000"><DESCRIPTION><P>Double-blind study</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2017-11-13 21:55:04 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rhedda-1985"><DESCRIPTION><P>Double-blind study; blinding likely successful</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2017-11-14 07:22:01 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rodeheffer-1983"><DESCRIPTION><P>"Double-blind.....received a supply of placebo capsules or matching 10mg nifedipine"</P><P>Last few weeks single-blind, with participants unaware of the their treatment arm</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2017-11-14 01:58:10 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rupp-1987"><DESCRIPTION><P>Double-blind cross-over study </P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2017-11-14 02:02:09 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sarkozi--1986"><DESCRIPTION><P>Double-blind RCT, with blinding likely maintained</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2017-11-14 02:07:51 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sauza-1984"><DESCRIPTION><P>Double-blind study</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2017-11-14 02:12:48 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Smith-1982"><DESCRIPTION><P>Double-blind</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2017-11-14 02:18:11 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Teixeira-da-Costa"><DESCRIPTION><P>Double-blind</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2017-11-14 02:23:44 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Waller-1986"><DESCRIPTION><P>Double-blind</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2017-11-14 02:27:35 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-White-1986"><DESCRIPTION><P>Double-blind study</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2017-11-14 02:32:49 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wigley-1987"><DESCRIPTION><P>Double-blind study</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2017-11-14 02:37:31 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wollersheim-1991"><DESCRIPTION><P>Double-blind; matching treatment and placebo capsules given</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY></QUALITY_ITEM_DATA></QUALITY_ITEM><QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2017-11-28 11:03:18 -0500" MODIFIED_BY="[Empty name]" NO="3"><NAME>Blinding (performance bias and detection bias)</NAME><DESCRIPTION><P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P></DESCRIPTION><QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1"><NAME>All outcomes</NAME></QUALITY_ITEM_DATA_ENTRY_GROUP><QUALITY_ITEM_DATA/></QUALITY_ITEM><QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2017-11-29 09:38:40 -0500" MODIFIED_BY="[Empty name]" NO="8"><NAME>Blinding of outcome assessment (detection bias)</NAME><DESCRIPTION><P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P></DESCRIPTION><QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1"><NAME>All outcomes</NAME></QUALITY_ITEM_DATA_ENTRY_GROUP><QUALITY_ITEM_DATA><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-11-14 06:53:28 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Aldoori-1986"><DESCRIPTION><P>Diary used by participants to record subjective assessments during treatment</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-11-14 06:53:37 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bravard-1983"><DESCRIPTION><P>Participant diary used for subjective assessments</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-11-14 06:53:49 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Challenor-1987"><DESCRIPTION><P>Participant diary used to record number of attacks, severity, subjective improvement</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-11-14 06:53:59 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Challenor-1989"><DESCRIPTION><P>Participant diary used to record episodes of Raynaud&#8217;s phenomenon, noting number of attacks, duration, and severity</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-11-29 09:38:40 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Constantini-1987"><DESCRIPTION><P>Low riskUnclear riskHigh risk</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-11-14 06:54:07 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Corbin-1986"><DESCRIPTION><P>Participant diary used to record daily attacks of Raynaud's phenomenon. Participants asked to assess their response to each treatment in relation to pretrial status</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-11-13 03:27:48 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ettinger-1984"><DESCRIPTION><P>"Double-blind" study</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-11-23 20:35:26 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ferri-1992"><DESCRIPTION><P>Participant diary used to record subjective assessments, i.e., number of attacks, severity, etc</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-11-13 03:41:01 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Finch-1988"><DESCRIPTION><P>"Patients kept a daily diary of number, duration and severity of attacks."</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-11-13 03:45:42 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-French-Co_x002d_op-1991"><DESCRIPTION><P>"recorded by patients number of crises..intensity and overall disability"</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-11-13 03:50:39 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gjorup-1986a"><DESCRIPTION><P>"Patients recorded number of attacks, severity, and efficacy."</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-11-13 03:55:13 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gjorup-1986b"><DESCRIPTION><P>Participant-recorded number and severity of attacks and evaluation of treatment efficacy</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-11-13 04:03:25 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hawkins-1985"><DESCRIPTION><P>Subjective participant assessments of number and severity of attacks</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-11-14 06:55:03 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kahan-1985a"><DESCRIPTION><P>Participant diary used to record subjective assessments </P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-11-13 04:13:54 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kahan-1985b"><DESCRIPTION><P>"Patients kept a record to attacks...severity, and effectiveness."</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-11-13 04:17:39 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kahan-1985c"><DESCRIPTION><P>Number of attacks reported by participants</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-11-14 07:20:46 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kahan-1987"><DESCRIPTION><P>"Patients kept a record of their digital vasospastic attacks...quantified before the drug code was broken."</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-11-14 06:55:21 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kallenberg-1987"><DESCRIPTION><P>Participant diary used to record subjective assessments</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-11-14 06:55:30 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kinney-1982"><DESCRIPTION><P>Participant diary used to record subjective assessments and to check compliance</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-11-13 04:39:41 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kirch-1987"><DESCRIPTION><P>Participant diary used to record attack frequency and duration and adverse effects</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-11-13 04:44:20 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-La-Civita-1997"><DESCRIPTION><P>Participant diary used for subjective assessments</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-11-13 04:50:23 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Leppert-1989"><DESCRIPTION><P>Subjective participant assessment of outcomes</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-11-14 06:56:04 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Malamet-1984"><DESCRIPTION><P>Participant diary used to record subjective assessments</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-11-13 21:40:53 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Meyrick-Thomas-1987"><DESCRIPTION><P>"Patient recorded duration, severity, and date of each attack."</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-11-29 09:38:22 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Muller_x002d_Buhl-1983"><DESCRIPTION><P>Double-blind</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-11-13 21:47:51 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nilsson-1987"><DESCRIPTION><P>Participant assessment of changes in symptoms and side effects</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-11-14 01:48:35 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-RTSI-2000"><DESCRIPTION><P>Self-reports of participants with color charts to identify attacks</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-11-14 06:56:26 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rhedda-1985"><DESCRIPTION><P>Participant diary used to record subjective assessments (frequency of attacks, duration, side effects)</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-11-14 06:56:39 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rodeheffer-1983"><DESCRIPTION><P>Diary used by participants to record subjective assessments</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-11-14 08:21:48 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rupp-1987"><DESCRIPTION><P>Participant assessment of attacks, severity, and side effects</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-11-14 02:02:30 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sarkozi--1986"><DESCRIPTION><P>Subjective assessments by participants</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-11-14 02:08:21 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sauza-1984"><DESCRIPTION><P>Participant subjective assessments</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-11-14 02:13:24 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Smith-1982"><DESCRIPTION><P>Participant diary used to record daily attacks, severity, side effects, and drug effectiveness</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-11-14 02:18:41 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Teixeira-da-Costa"><DESCRIPTION><P>Subjective participant assessment of frequency, severity, and duration of attacks and overall effectiveness of treatment</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-11-14 02:24:01 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Waller-1986"><DESCRIPTION><P>"Patients were requested to keep a daily record of episodes of Raynaud's phenomenon noting the number of attacks and their severity and evaluate overall disease."</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-11-14 02:27:59 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-White-1986"><DESCRIPTION><P>Participants asked to assessed treatment efficacy subjectively</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-11-14 07:22:40 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wigley-1987"><DESCRIPTION><P>"Subjects kept a daily diary of the frequency and severity of attacks."</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-11-14 06:57:24 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wollersheim-1991"><DESCRIPTION><P>Participant diary used for subjective assessments; participants unaware of allocation</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY></QUALITY_ITEM_DATA></QUALITY_ITEM><QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2017-11-14 07:02:15 -0500" MODIFIED_BY="[Empty name]" NO="4"><NAME>Incomplete outcome data (attrition bias)</NAME><DESCRIPTION><P>Attrition bias due to amount, nature or handling of incomplete outcome data</P></DESCRIPTION><QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1"><NAME>All outcomes</NAME></QUALITY_ITEM_DATA_ENTRY_GROUP><QUALITY_ITEM_DATA><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-12 16:32:22 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Aldoori-1986"><DESCRIPTION><P>Four participants who reported &lt; 2 attacks during first course of treatment excluded from mean and severity analysis of number of attacks but included in other analyses</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-14 06:53:43 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bravard-1983"><DESCRIPTION><P>4/9 participants excluded owing to incomplete diary or to differences in temperature between 2 study periods</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-13 02:45:51 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Challenor-1987"><DESCRIPTION><P>4/36 dropouts</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-13 02:57:27 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Challenor-1989"><DESCRIPTION><P>Two participant withdrawals from the study for personal reasons unrelated to treatment </P><P>Two participant treatment discontinuations after 5 and 7 days of 40 mg sustained-release nifedipine due to unwanted effects - the latter included in the analysis</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-13 03:56:26 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Constantini-1987"><DESCRIPTION><P>7/24 dropouts: 3 from treatment group (2 for side effects and 1 for incorrect application of treatment) and 4 from placebo group (for side effects)</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-13 03:23:13 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Corbin-1986"><DESCRIPTION><P>One participant with unrelated illness during first week of trial and withdrawn; youngest participant,tolerating placebo in full doses and unable to tolerate even the starting dose of nifedipine; thus, only 22 participants completing 4 weeks of treatment with nifedipine and placebo</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-13 03:28:03 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ettinger-1984"><DESCRIPTION><P>19/25 completing the study</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-13 03:56:39 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ferri-1992"><DESCRIPTION><P>3/21 lost to follow-up (1 from placebo group for non-compliance, 2 from treatment group for side effects)</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-10-21 19:04:10 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Finch-1988"><DESCRIPTION><P>No loss to follow-up</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-13 03:56:49 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-French-Co_x002d_op-1991"><DESCRIPTION><P>6 weeks: 9 dropouts (5 from placebo group and 2 from treatment group for side effects; 2 for personal reasons)</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-13 03:50:42 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gjorup-1986a"><DESCRIPTION><P>No loss to follow-up</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-13 03:57:06 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gjorup-1986b"><DESCRIPTION><P>5 lost to follow-up (4 from treatment group for side effects)</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-13 04:03:46 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hawkins-1985"><DESCRIPTION><P>14/71 dropouts - 6 due to intercurrent illness, 8 due to drug side effects (7 from nifedipine and 1 from placebo)</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-13 04:09:04 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kahan-1985a"><DESCRIPTION><P>None detected</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-13 04:13:57 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kahan-1985b"><DESCRIPTION><P>None detected</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-13 04:17:45 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kahan-1985c"><DESCRIPTION><P>No losses to follow-up reported</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-13 04:23:08 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kahan-1987"><DESCRIPTION><P>No losses to follow-up</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-13 04:27:37 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kallenberg-1987"><DESCRIPTION><P>Only 1/16 dropouts</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-14 06:55:39 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kinney-1982"><DESCRIPTION><P>2/16 participants with completed diary excluded from analysis</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-13 04:39:47 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kirch-1987"><DESCRIPTION><P>No losses to follow-up</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-13 04:44:31 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-La-Civita-1997"><DESCRIPTION><P>4/24 dropouts (2 for inadequate compliance, 2 for intercurrent disease)</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-13 04:50:26 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Leppert-1989"><DESCRIPTION><P>No dropouts</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-06 15:09:53 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Malamet-1984"><DESCRIPTION><P>No missing data</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-13 21:41:01 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Meyrick-Thomas-1987"><DESCRIPTION><P>1 dropout</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-14 07:02:15 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Muller_x002d_Buhl-1983"><DESCRIPTION><P>No information provided for judgement of risk</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-13 21:48:06 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nilsson-1987"><DESCRIPTION><P>1/28 (1 participant on nifedipine with dropout due to side effects)</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-14 01:50:13 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-RTSI-2000"><DESCRIPTION><P>Siimilar dropout rates between treatment and placebo. Complete outcome data provided for 73% and 75% on nifedipine and placebo, respectively </P><P>At 2 months, 27/157 dropouts</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-13 21:56:01 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Rhedda-1985"><DESCRIPTION><P>11/30 participants with no analyzable data or dropping out</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-13 22:01:37 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rodeheffer-1983"><DESCRIPTION><P>None</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-14 01:59:11 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rupp-1987"><DESCRIPTION><P>1/28 dropouts while taking placebo for side effects</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-14 02:04:13 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sarkozi--1986"><DESCRIPTION><P>5/20 lost from nifedipine arm (1 loss to follow-up, 1 dropout due to severe side effects, 2 exclusions owing to non-compliance)</P><P>2/19 lost from placebo arm (1 pregnancy, 1 exclusion for non-compliance)</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-14 02:08:57 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sauza-1984"><DESCRIPTION><P>18/25 completing the 10-week trial (7 exclusions due to compliance issues, failure to attend follow-up appointments, or modifications in treatment programs)</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-14 02:13:27 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Smith-1982"><DESCRIPTION><P>None</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-14 02:19:12 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Teixeira-da-Costa"><DESCRIPTION><P>3/15 participants excluded (1 dropout due to side effects, 2 others with incomplete diary records excluded from analyses)</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-14 02:24:13 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Waller-1986"><DESCRIPTION><P>5/34 - "Five patients (three primary, two secondary) withdrew from the study because of unwanted effects on starting active treatment."</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-14 02:28:03 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-White-1986"><DESCRIPTION><P>No missing data</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-14 02:33:16 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wigley-1987"><DESCRIPTION><P>No dropouts during cross-over period of the study</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-14 02:38:43 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wollersheim-1991"><DESCRIPTION><P>Only 3 dropouts; no data provided (2 from treatment group and 1 from placebo group)</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY></QUALITY_ITEM_DATA></QUALITY_ITEM><QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2017-11-14 07:02:18 -0500" MODIFIED_BY="[Empty name]" NO="5"><NAME>Selective reporting (reporting bias)</NAME><DESCRIPTION><P>Reporting bias due to selective outcome reporting</P></DESCRIPTION><QUALITY_ITEM_DATA><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-12 16:32:29 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Aldoori-1986"><DESCRIPTION><P>None detected</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-12 16:39:47 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bravard-1983"><DESCRIPTION><P>None detected</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-13 02:45:56 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Challenor-1987"><DESCRIPTION><P>None detected</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-23 17:39:29 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Challenor-1989"><DESCRIPTION><P>No evidence of selective reporting</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-23 18:48:14 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Constantini-1987"><DESCRIPTION><P>None detected</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-23 19:54:10 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Corbin-1986"><DESCRIPTION><P>None detected</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-13 03:28:07 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ettinger-1984"><DESCRIPTION><P>All outcome data reported</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-13 03:35:59 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ferri-1992"><DESCRIPTION><P>None detected</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-13 03:41:09 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Finch-1988"><DESCRIPTION><P>None detected</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-13 03:46:03 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-French-Co_x002d_op-1991"><DESCRIPTION><P>None detected</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-13 03:50:45 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gjorup-1986a"><DESCRIPTION><P>None detected</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-13 03:55:34 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gjorup-1986b"><DESCRIPTION><P>None detected</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-13 04:03:56 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hawkins-1985"><DESCRIPTION><P>Severity of attacks not reported on a 5-point Likert scale as proposed</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-13 04:09:06 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kahan-1985a"><DESCRIPTION><P>None detected</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-13 04:14:00 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kahan-1985b"><DESCRIPTION><P>None detected</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-13 04:17:56 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kahan-1985c"><DESCRIPTION><P>None detected</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-13 04:23:11 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kahan-1987"><DESCRIPTION><P>None detected</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-13 04:27:41 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kallenberg-1987"><DESCRIPTION><P>None detected</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-13 04:33:22 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kinney-1982"><DESCRIPTION><P>None detected</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-13 04:39:49 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kirch-1987"><DESCRIPTION><P>None detected</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-13 04:44:34 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-La-Civita-1997"><DESCRIPTION><P>None detected</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-13 04:50:30 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Leppert-1989"><DESCRIPTION><P>None detected</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-13 21:17:34 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Malamet-1984"><DESCRIPTION><P>None detected</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-13 21:41:03 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Meyrick-Thomas-1987"><DESCRIPTION><P>None detected</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-14 07:02:18 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Muller_x002d_Buhl-1983"><DESCRIPTION><P>No information provided for judgement of risk</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-13 21:48:10 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nilsson-1987"><DESCRIPTION><P>None detected</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-14 01:50:30 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-RTSI-2000"><DESCRIPTION><P>Not all minor outcomes reported</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-13 21:56:04 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rhedda-1985"><DESCRIPTION><P>None detected</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-13 22:01:39 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rodeheffer-1983"><DESCRIPTION><P>None detected</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-14 01:59:16 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rupp-1987"><DESCRIPTION><P>None detected</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-14 02:04:17 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sarkozi--1986"><DESCRIPTION><P>None detected</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-14 02:09:02 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sauza-1984"><DESCRIPTION><P>None detected</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-14 02:13:29 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Smith-1982"><DESCRIPTION><P>None detected</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-14 02:19:15 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Teixeira-da-Costa"><DESCRIPTION><P>None detected</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-14 02:24:22 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Waller-1986"><DESCRIPTION><P>None detected</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-14 02:28:06 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-White-1986"><DESCRIPTION><P>None detected</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-14 02:33:19 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wigley-1987"><DESCRIPTION><P>None detected</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-14 02:38:51 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wollersheim-1991"><DESCRIPTION><P>All prespecified outcomes reported</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY></QUALITY_ITEM_DATA></QUALITY_ITEM><QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2017-11-14 08:20:30 -0500" MODIFIED_BY="[Empty name]" NO="6"><NAME>Other bias</NAME><DESCRIPTION><P>Bias due to problems not covered elsewhere in the table</P></DESCRIPTION><QUALITY_ITEM_DATA><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-12 16:32:35 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Aldoori-1986"><DESCRIPTION><P>Washover period included</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-14 06:58:25 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bravard-1983"><DESCRIPTION><P>Evidence insufficient for judgement of risk</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-04 17:54:05 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Challenor-1987"><DESCRIPTION><P>Length of washover not clear</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-14 06:58:48 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Challenor-1989"><DESCRIPTION><P>Evidence insufficient for judgement of risk</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-14 06:59:09 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Constantini-1987"><DESCRIPTION><P>Evidence insufficient for judgement of risk</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-13 03:23:04 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Corbin-1986"><DESCRIPTION><P>Baseline characteristics similar between groups</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-14 08:20:30 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ettinger-1984"><DESCRIPTION><P>Information insufficient for judgement of low or high risk of bias</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-13 03:36:29 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ferri-1992"><DESCRIPTION><P>Washout of 2 weeks included between cross-overs</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-13 03:41:23 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Finch-1988"><DESCRIPTION><P>Washout period of 2 weeks included between cross-overs</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-13 03:46:14 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-French-Co_x002d_op-1991"><DESCRIPTION><P>Washover period of 1 week included</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-13 03:50:50 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gjorup-1986a"><DESCRIPTION><P>No mention of a washout period between cross-over phases</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-13 03:55:40 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gjorup-1986b"><DESCRIPTION><P>No mention of a washout period between cross-over phases</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-13 04:04:01 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hawkins-1985"><DESCRIPTION><P>No mention of washout period between cross-over phases</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-13 04:09:31 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kahan-1985a"><DESCRIPTION><P>Cross-over phases separated by 1-week placebo period</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-13 04:14:05 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kahan-1985b"><DESCRIPTION><P>No mention of a washout period between cross-over phases</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-13 04:18:00 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kahan-1985c"><DESCRIPTION><P>No mention of a washout period between cross-over phases</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-13 04:23:37 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kahan-1987"><DESCRIPTION><P>Treatment periods separated by 1-week baseline observation (washout) periods</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-14 07:00:54 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kallenberg-1987"><DESCRIPTION><P>Evidence insufficient for judgement of risk</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-14 07:00:57 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kinney-1982"><DESCRIPTION><P>Evidence insufficient for judgement of risk</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-13 04:40:04 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kirch-1987"><DESCRIPTION><P>Washout period of 2 weeks separating cross-over periods</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-13 04:44:50 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-La-Civita-1997"><DESCRIPTION><P>Washout period of 1 week separating cross-over periods</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-14 07:01:36 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Leppert-1989"><DESCRIPTION><P>Evidence insufficient for judgement of risk</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-13 21:17:47 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Malamet-1984"><DESCRIPTION><P>1-Week single-blind washout period between cross-over phases</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-13 21:41:31 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Meyrick-Thomas-1987"><DESCRIPTION><P>Cross-over phases separated by a 4-week drug-free washout period</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-14 07:02:23 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Muller_x002d_Buhl-1983"><DESCRIPTION><P>No information provided for judgement of risk</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-13 21:48:35 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nilsson-1987"><DESCRIPTION><P>Cross-over phases separated by 1-week washout period </P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-14 01:50:35 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-RTSI-2000"><DESCRIPTION><P>Two groups with similar baseline characteristics</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-13 21:56:29 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rhedda-1985"><DESCRIPTION><P>A 4-week observation period with no drugs taken used to separate cross-over phases</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-13 22:01:53 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rodeheffer-1983"><DESCRIPTION><P>Placebo period of 1 week used to separate cross-over phases</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-14 01:59:22 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rupp-1987"><DESCRIPTION><P>No mention of a washover period</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-14 02:04:30 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sarkozi--1986"><DESCRIPTION><P>Similar baseline characteristics among groups</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-14 02:09:07 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sauza-1984"><DESCRIPTION><P>Two groups with similar baseline characteristics</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-14 02:13:34 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Smith-1982"><DESCRIPTION><P>No mention of a washover period</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-14 02:19:28 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Teixeira-da-Costa"><DESCRIPTION><P>Washout period of 1 week separating cross-over phases</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-14 02:24:36 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Waller-1986"><DESCRIPTION><P>Washout period of 2 weeks separating cross-over phases</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-14 02:28:10 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-White-1986"><DESCRIPTION><P>No mention of a washout period</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-14 07:03:45 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wigley-1987"><DESCRIPTION><P>Evidence insufficient for judgement of risk</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-14 02:39:05 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wollersheim-1991"><DESCRIPTION><P>Washout period of 2 weeks separating cross-over phases</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY></QUALITY_ITEM_DATA></QUALITY_ITEM></QUALITY_ITEMS><SOF_TABLES MODIFIED="2017-11-23 21:15:48 -0500" MODIFIED_BY="[Empty name]"><SOF_TABLE ID="SOF-01" MODIFIED="2017-11-23 21:15:48 -0500" MODIFIED_BY="[Empty name]" NO="1" READONLY="YES"><TITLE MODIFIED="2017-11-14 07:12:49 -0500" MODIFIED_BY="[Empty name]">Calcium channel blockers compared with placebo for treatment of Raynaud's phenomenon</TITLE><TABLE COLS="7" ROWS="14"><TR><TD COLSPAN="7"><P/><P>Calcium channel blockers (CCBs) compared with placebo for treatment of Raynaud's phenomenon</P></TD></TR><TR><TD COLSPAN="7"><P><B>Patient or population:</B> patients with Raynaud's phenomenon<BR/><B>Settings:</B> outpatient settings<BR/><B>Intervention:</B> calcium channel blockers (CCBs) (all)<BR/><B>Comparison: </B>placebo</P></TD></TR><TR><TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP"><P>Outcomes</P></TH><TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP"><P>Illustrative comparative risks* (95% CI)</P></TH><TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP"><P>Relative effect<BR/>(95% CI)</P></TH><TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP"><P>No. of participants<BR/>(studies)</P></TH><TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP"><P>Quality of the evidence<BR/>(GRADE)</P></TH><TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP"><P>Comments</P></TH></TR><TR><TH ALIGN="LEFT" VALIGN="TOP"><P>Assumed risk</P></TH><TH ALIGN="LEFT" VALIGN="TOP"><P>Corresponding risk</P></TH></TR><TR><TH ALIGN="LEFT" VALIGN="TOP"><P><B>Placebo</B></P></TH><TH ALIGN="LEFT" VALIGN="TOP"><P>CCBs (all)</P></TH></TR><TR><TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP"><P><B>Frequency of attacks </B><BR/>Average number of attacks/week<BR/>Follow-up: 4 to 20 weeks</P></TD><TD ROWSPAN="1" VALIGN="TOP"><P>Mean frequency of attacks in control groups:</P><P><B>13.7 attacks</B><SUP>a</SUP></P></TD><TD ROWSPAN="1" VALIGN="TOP"><P>Mean frequency of attacks in intervention groups:</P><P><B>6.13 lower</B></P><P>(6.60 to 5.67 lower)<SUP>b</SUP></P><P/><P/><P/><P/></TD><TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP"><P/></TD><TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP"><P>528<BR/>(23 studies)</P></TD><TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP"><P>&#8853;&#8853;&#8853;&#8861;</P><P><B>moderate</B><SUP>c</SUP></P><P/></TD><TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP"><P>Note: Excluding a study with a very large reduction in frequency of attacks changed the mean difference to -2.93 per week (95% CI -3.44 to -2.43).<BR/>NNTB: N/A<SUP>d</SUP></P><P>Absolute risk difference: N/A<SUP>d</SUP></P><P>Relative percent change: -44% (95% CI -48% to -41%)</P></TD></TR><TR><TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP"><P><B>Duration of attacks</B></P><P>Average duration per attack measured in minutes<BR/>Follow-up: 2 to 20 weeks</P></TD><TD ROWSPAN="1" VALIGN="TOP"><P>Mean duration of attacks in control groups:<BR/><B>18.8</B> <B>minutes</B><SUP>a</SUP></P></TD><TD ROWSPAN="1" VALIGN="TOP"><P>Mean duration of attacks in intervention groups:<BR/><B>1.67 fewer minutes</B><BR/></P><P>(-3.29 to 0)</P><P/><P/></TD><TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP"><P/></TD><TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP"><P>69<BR/>(6 studies)</P></TD><TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP"><P>&#8853;&#8853;&#8861;&#8861;</P><P><B>low</B><SUP>c,e</SUP></P><P/></TD><TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP"><P>NNTB: N/A<SUP>d</SUP></P><P>Absolute risk difference: N/A<SUP>d</SUP></P><P>Relative percent change: -9% (95% CI -18% to 0%)</P></TD></TR><TR><TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP"><P><B>Severity of attacks</B><BR/>Average severity per attack assessed on a 10-cm visual analogue scale (0 = no symptoms, 10 = maximal severity)<BR/>Follow-up: 2 to 12 weeks</P></TD><TD ROWSPAN="1" VALIGN="TOP"><P>Mean severity of attacks in control groups:<BR/><B>6.7 cm</B><SUP>a</SUP></P><P/></TD><TD ROWSPAN="1" VALIGN="TOP"><P>Mean severity of attacks in intervention groups:<BR/><B>0.62 lower</B><BR/>(0.72 to 0.51 lower)</P><P/><P/><P/><P/><P/></TD><TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP"><P/></TD><TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP"><P>415<BR/>(18 studies)</P><P/></TD><TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP"><P>&#8853;&#8853;&#8853;&#8861;</P><P><B>moderate</B><SUP>c</SUP></P><P/></TD><TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP"><P>NNTB: N/A<SUP>d</SUP></P><P>Absolute risk difference: -6% (95% CI -7% to -5%)</P><P>Relative percent change: -9% (95% CI -11% to -8%)</P></TD></TR><TR><TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP"><P><B>Pain</B></P><P>Average pain per attack, measured on a 10-cm visual analogue scale (0 = no pain, 10 = maximal pain)<BR/>Follow-up: 2 to 10 weeks</P></TD><TD ROWSPAN="1" VALIGN="TOP"><P>Mean pain in control groups:<BR/><B>3.13 cm</B><SUP>a</SUP></P></TD><TD ROWSPAN="1" VALIGN="TOP"><P>Mean pain in intervention groups:<BR/><B>1.47 lower</B><BR/>(2.21 to 0.74 lower)</P><P/><P/><P/></TD><TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP"><P/></TD><TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP"><P>62<BR/>(4 studies)</P></TD><TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP"><P>&#8853;&#8853;&#8861;&#8861;</P><P><B>low</B><SUP>c,e</SUP></P></TD><TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP"><P>N/A<SUP>d</SUP></P><P>Absolute risk difference: -15% (95% CI -22% to -7%)</P><P>Relative percent change: -47% (95% CI -71% to -24%)</P></TD></TR><TR><TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP"><P><B>Patient global </B><BR/>Disability due to Raynaud's assessed on a 10-cm visual analogue scale (0 = no disability, 10 = maximal disability)</P><P>Follow-up: 5 weeks</P></TD><TD ROWSPAN="1" VALIGN="TOP"><P>Mean patient global in control group:</P><P><B>3.9 cm</B><SUP>a</SUP></P></TD><TD ROWSPAN="1" VALIGN="TOP"><P>Mean patient global in intervention groups:<BR/><B>0.37 lower</B><BR/>(0.73 lower to 0)</P><P/><P/></TD><TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP"><P/></TD><TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP"><P>92<BR/>(2)</P></TD><TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP"><P>&#8853;&#8853;&#8853;&#8861;</P><P><B>moderate</B><SUP>e</SUP></P></TD><TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP"><P>NNTB: N/A<SUP>f</SUP></P><P>Absolute risk difference: -4% (95% CI -7% to 0%)</P><P>Relative percent change: -9% (95% CI -19% to 0%)</P><P/></TD></TR><TR><TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP"><P><B>Number of withdrawals due to adverse events</B><BR/>Number of participants who dropped out of studies owing to adverse treatment effects<BR/>Follow-up: 2 to 20 weeks</P></TD><TD ROWSPAN="1" VALIGN="TOP"><P><B>194 per 1000</B></P><P/></TD><TD ROWSPAN="1" VALIGN="TOP"><P><B>252 per 1000</B><BR/>(99 to 645)</P></TD><TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP"><P><B>RR 1.30</B><BR/>(0.51 to 3.33)</P></TD><TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP"><P>63<BR/>(2 studies)</P></TD><TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP"><P>&#8853;&#8853;&#8861;&#8861;</P><P><B>low</B><SUP>e,g</SUP></P><P/></TD><TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP"><P>NNTH: N/A<SUP>f</SUP></P><P>Absolute risk reduction: 6% (95% CI -14% to 26%)</P><P>Relative percent change: 30% (95% CI -49% to 233%)</P></TD></TR><TR><TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP"><P><B>Serious adverse events</B><BR/>Number of participants who died or withdrew and were hospitalized as a result of adverse effects of treatment</P></TD><TD ROWSPAN="1" VALIGN="TOP"><P>See comment.</P></TD><TD ROWSPAN="1" VALIGN="TOP"><P>See comment.</P></TD><TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP"><P>Not estimable</P></TD><TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP"><P>0<BR/>(0)</P></TD><TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP"><P>See comment.</P></TD><TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP"><P>No serious adverse events reported</P></TD></TR><TR><TD COLSPAN="7"><P>*The basis for the <B>assumed risk</B> (eg, median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>CCB: calcium channel blocker; CI: confidence interval; NNTB: number needed to treat for an additional beneficial outcome; NNTH: number needed to treat for an additional harmful outcome; RR: risk ratio.</P></TD></TR><TR><TD COLSPAN="7"><P>GRADE Working Group grades of evidence.<BR/><B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/><B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/><B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/><B>Very low quality:</B> We are very uncertain about the estimate.<BR/></P></TD></TR></TABLE><FOOTNOTES><P><SUP>a</SUP>Final value: weighted mean of scores in placebo group across studies in the meta-analysis.<BR/><SUP>b</SUP>With exclusion of <LINK REF="STD-Kahan-1985c" TYPE="STUDY">Kahan 1985c</LINK>, CCBs leading to reduced frequency of attacks per week by 2.93 (95% CI -3.44 to -2.43).<BR/><SUP>c</SUP>Downgraded 1 level for significant statistical heterogeneity (I² &gt; 50%).<BR/><SUP>d</SUP>N/A value not calculated.<BR/><SUP>e</SUP>Downgraded 1 level for imprecision (total population size &lt; 400 for continuous outcomes; total number of events &lt; 300 for dichotomous outcomes).<BR/><SUP>f</SUP>NNTB (number needed to benefit) and NNTH (number needed to harm) calculated only for statistically significant outcomes.<BR/><SUP>g</SUP>Downgraded 1 level for inclusion of studies with high risk of bias due to attrition.</P></FOOTNOTES></SOF_TABLE></SOF_TABLES><ADDITIONAL_TABLES MODIFIED="2016-02-14 14:31:41 -0500" MODIFIED_BY="[Empty name]"/><ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2017-11-22 21:08:46 -0500" MODIFIED_BY="[Empty name]"><COMPARISON ID="CMP-001" MODIFIED="2017-11-14 03:10:42 -0500" MODIFIED_BY="[Empty name]" NO="1"><NAME>CCBs vs placebo (generic inverse variance method)</NAME><IV_OUTCOME CHI2="969.137869656359" CI_END="-5.611865258823822" CI_START="-6.531557871604291" CI_STUDY="95" CI_TOTAL="95" DF="22" EFFECT_SIZE="-6.0717115652140565" ESTIMABLE="YES" I2="97.72994114781618" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" MODIFIED="2017-11-14 03:10:09 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.6653345369377348E-15" P_Q="1.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="25.9" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="23" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="511" TOTAL_2="513" WEIGHT="100.0" Z="25.87894221822023"><NAME>Frequency of attacks (average/week)</NAME><GROUP_LABEL_1>CCBs</GROUP_LABEL_1><GROUP_LABEL_2>Placebo</GROUP_LABEL_2><GRAPH_LABEL_1>Favours CCBs</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2><EFFECT_MEASURE>Mean Difference</EFFECT_MEASURE><IV_DATA CI_END="-2.32127311138369" CI_START="-10.27872688861631" EFFECT_SIZE="-6.3" ESTIMABLE="YES" ESTIMATE="-6.3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2017-03-31 11:15:04 -0400" MODIFIED_BY="Jordi Pardo Pardo" ORDER="569" SE="2.03" STUDY_ID="STD-Aldoori-1986" TOTAL_1="9" TOTAL_2="9" WEIGHT="1.3357867985552305"/><IV_DATA CI_END="2.0047593025302612" CI_START="-2.424759302530261" EFFECT_SIZE="-0.21" ESTIMABLE="YES" ESTIMATE="-0.21" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2017-03-31 11:15:05 -0400" MODIFIED_BY="Jordi Pardo Pardo" ORDER="572" SE="1.13" STUDY_ID="STD-Challenor-1987" TOTAL_1="36" TOTAL_2="36" WEIGHT="4.3109435493509665"/><IV_DATA CI_END="-0.9988349349961474" CI_START="-4.801165065003852" EFFECT_SIZE="-2.9" ESTIMABLE="YES" ESTIMATE="-2.9" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2017-03-31 11:15:05 -0400" MODIFIED_BY="Jordi Pardo Pardo" ORDER="574" SE="0.97" STUDY_ID="STD-Challenor-1989" TOTAL_1="22" TOTAL_2="22" WEIGHT="5.850402612569081"/><IV_DATA CI_END="-4.5748403373151385" CI_START="-8.965159662684862" EFFECT_SIZE="-6.77" ESTIMABLE="YES" ESTIMATE="-6.77" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-09-08 12:26:04 -0400" MODIFIED_BY="[Empty name]" ORDER="1158" SE="1.12" STUDY_ID="STD-Corbin-1986" TOTAL_1="23" TOTAL_2="23" WEIGHT="4.388268349941204"/><IV_DATA CI_END="0.44273949402729107" CI_START="-6.142739494027291" EFFECT_SIZE="-2.85" ESTIMABLE="YES" ESTIMATE="-2.85" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2017-03-31 11:15:06 -0400" MODIFIED_BY="Jordi Pardo Pardo" ORDER="1159" SE="1.68" STUDY_ID="STD-Ettinger-1984" TOTAL_1="19" TOTAL_2="19" WEIGHT="1.950341488862758"/><IV_DATA CI_END="-2.002091839422862" CI_START="-11.997908160577138" EFFECT_SIZE="-7.0" ESTIMABLE="YES" ESTIMATE="-7.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2017-03-31 11:15:06 -0400" MODIFIED_BY="Jordi Pardo Pardo" ORDER="1164" SE="2.55" STUDY_ID="STD-Ferri-1992" TOTAL_1="18" TOTAL_2="18" WEIGHT="0.84654268637697"/><IV_DATA CI_END="0.0671164441329255" CI_START="-9.027116444132925" EFFECT_SIZE="-4.48" ESTIMABLE="YES" ESTIMATE="-4.48" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2017-03-31 11:15:07 -0400" MODIFIED_BY="Jordi Pardo Pardo" ORDER="1166" SE="2.32" STUDY_ID="STD-Finch-1988" TOTAL_1="15" TOTAL_2="15" WEIGHT="1.0227117676438482"/><IV_DATA CI_END="0.37397658995103533" CI_START="-2.1739765899510353" EFFECT_SIZE="-0.9" ESTIMABLE="YES" ESTIMATE="-0.9" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-27 00:26:27 -0400" MODIFIED_BY="[Empty name]" ORDER="577" SE="0.65" STUDY_ID="STD-French-Co_x002d_op-1991" TOTAL_1="60" TOTAL_2="60" WEIGHT="13.028742764890524"/><IV_DATA CI_END="-0.5852406974697386" CI_START="-5.014759302530261" EFFECT_SIZE="-2.8" ESTIMABLE="YES" ESTIMATE="-2.8" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2017-03-31 11:15:08 -0400" MODIFIED_BY="Jordi Pardo Pardo" ORDER="1169" SE="1.13" STUDY_ID="STD-Gjorup-1986a" TOTAL_1="19" TOTAL_2="19" WEIGHT="4.3109435493509665"/><IV_DATA CI_END="-1.0064237702035639" CI_START="-3.5935762297964358" EFFECT_SIZE="-2.3" ESTIMABLE="YES" ESTIMATE="-2.3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2017-03-31 11:15:41 -0400" MODIFIED_BY="Jordi Pardo Pardo" ORDER="1171" SE="0.66" STUDY_ID="STD-Hawkins-1985" TOTAL_1="57" TOTAL_2="57" WEIGHT="12.636923365854562"/><IV_DATA CI_END="-8.028443578706534" CI_START="-12.771556421293466" EFFECT_SIZE="-10.4" ESTIMABLE="YES" ESTIMATE="-10.4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2017-03-31 11:16:10 -0400" MODIFIED_BY="Jordi Pardo Pardo" ORDER="1173" SE="1.21" STUDY_ID="STD-Kahan-1985a" TOTAL_1="15" TOTAL_2="15" WEIGHT="3.759745794799705"/><IV_DATA CI_END="0.025141654954888182" CI_START="-6.325141654954888" EFFECT_SIZE="-3.15" ESTIMABLE="YES" ESTIMATE="-3.15" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2017-03-31 11:15:09 -0400" MODIFIED_BY="Jordi Pardo Pardo" ORDER="1175" SE="1.62" STUDY_ID="STD-Kahan-1985b" TOTAL_1="16" TOTAL_2="16" WEIGHT="2.097486594332513"/><IV_DATA CI_END="-20.352820528812167" CI_START="-22.58717947118783" EFFECT_SIZE="-21.47" ESTIMABLE="YES" ESTIMATE="-21.47" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2017-03-31 11:16:09 -0400" MODIFIED_BY="Jordi Pardo Pardo" ORDER="600" SE="0.57" STUDY_ID="STD-Kahan-1985c" TOTAL_1="30" TOTAL_2="30" WEIGHT="16.942578695494763"/><IV_DATA CI_END="-0.9656410576243384" CI_START="-5.4343589423756615" EFFECT_SIZE="-3.2" ESTIMABLE="YES" ESTIMATE="-3.2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-09-08 20:12:40 -0400" MODIFIED_BY="[Empty name]" ORDER="1178" SE="1.14" STUDY_ID="STD-Kahan-1987" TOTAL_1="20" TOTAL_2="20" WEIGHT="4.235644673873691"/><IV_DATA CI_END="6.294322926915717" CI_START="-2.094322926915716" EFFECT_SIZE="2.1" ESTIMABLE="YES" ESTIMATE="2.1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2017-03-31 11:15:11 -0400" MODIFIED_BY="Jordi Pardo Pardo" ORDER="601" SE="2.14" STUDY_ID="STD-Kirch-1987" TOTAL_1="10" TOTAL_2="10" WEIGHT="1.2019922740340307"/><IV_DATA CI_END="3.2902743060447897" CI_START="-10.39027430604479" EFFECT_SIZE="-3.55" ESTIMABLE="YES" ESTIMATE="-3.55" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2017-03-31 11:15:11 -0400" MODIFIED_BY="Jordi Pardo Pardo" ORDER="604" SE="3.49" STUDY_ID="STD-Malamet-1984" TOTAL_1="7" TOTAL_2="7" WEIGHT="0.45193748968943165"/><IV_DATA CI_END="2.23152040583352" CI_START="-6.4315204058335205" EFFECT_SIZE="-2.1" ESTIMABLE="YES" ESTIMATE="-2.1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2017-03-31 11:15:12 -0400" MODIFIED_BY="Jordi Pardo Pardo" ORDER="608" SE="2.21" STUDY_ID="STD-Meyrick-Thomas-1987" TOTAL_1="9" TOTAL_2="9" WEIGHT="1.1270538723953742"/><IV_DATA CI_END="0.16676110330325877" CI_START="-4.066761103303259" EFFECT_SIZE="-1.95" ESTIMABLE="YES" ESTIMATE="-1.95" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-09-09 15:08:21 -0400" MODIFIED_BY="[Empty name]" ORDER="610" SE="1.08" STUDY_ID="STD-Rodeheffer-1983" TOTAL_1="15" TOTAL_2="15" WEIGHT="4.719344837248154"/><IV_DATA CI_END="-0.5292352951507471" CI_START="-4.370764704849253" EFFECT_SIZE="-2.45" ESTIMABLE="YES" ESTIMATE="-2.45" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2017-03-31 11:15:13 -0400" MODIFIED_BY="Jordi Pardo Pardo" ORDER="611" SE="0.98" STUDY_ID="STD-Rupp-1987" TOTAL_1="27" TOTAL_2="27" WEIGHT="5.731615804004839"/><IV_DATA CI_END="11.760202275124898" CI_START="-9.760202275124898" EFFECT_SIZE="1.0" ESTIMABLE="YES" ESTIMATE="1.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-27 00:31:50 -0400" MODIFIED_BY="[Empty name]" ORDER="576" SE="5.49" STUDY_ID="STD-Sarkozi--1986" TOTAL_1="15" TOTAL_2="17" WEIGHT="0.18263522079111372"/><IV_DATA CI_END="-5.087660866127308" CI_START="-11.712339133872693" EFFECT_SIZE="-8.4" ESTIMABLE="YES" ESTIMATE="-8.4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2017-03-31 11:16:09 -0400" MODIFIED_BY="Jordi Pardo Pardo" ORDER="614" SE="1.69" STUDY_ID="STD-Smith-1982" TOTAL_1="17" TOTAL_2="17" WEIGHT="1.9273288113743385"/><IV_DATA CI_END="-0.3636392568513407" CI_START="-4.636360743148659" EFFECT_SIZE="-2.5" ESTIMABLE="YES" ESTIMATE="-2.5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2017-03-31 11:15:14 -0400" MODIFIED_BY="Jordi Pardo Pardo" ORDER="616" SE="1.09" STUDY_ID="STD-Waller-1986" TOTAL_1="27" TOTAL_2="27" WEIGHT="4.633148571808978"/><IV_DATA CI_END="0.42835354005667003" CI_START="-4.62835354005667" EFFECT_SIZE="-2.1" ESTIMABLE="YES" ESTIMATE="-2.1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2017-03-31 11:15:15 -0400" MODIFIED_BY="Jordi Pardo Pardo" ORDER="618" SE="1.29" STUDY_ID="STD-Wigley-1987" TOTAL_1="25" TOTAL_2="25" WEIGHT="3.3078804267569537"/></IV_OUTCOME><IV_OUTCOME CHI2="90.48618493084655" CI_END="-2.426098804265753" CI_START="-3.435243580461762" CI_STUDY="95" CI_TOTAL="95" DF="21" EFFECT_SIZE="-2.9306711923637576" ESTIMABLE="YES" I2="76.79203735238798" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" MODIFIED="2017-11-14 03:10:19 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.3302436929762962E-10" P_Q="1.0" P_Z="5.0289354023590044E-30" Q="0.0" RANDOM="NO" SCALE="25.9" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="22" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="481" TOTAL_2="483" WEIGHT="100.00000000000001" Z="11.383916605532416"><NAME>Frequency of attacks (average/week)</NAME><GROUP_LABEL_1>CCBs</GROUP_LABEL_1><GROUP_LABEL_2>Placebo</GROUP_LABEL_2><GRAPH_LABEL_1>Favours CCBs</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2><EFFECT_MEASURE>Mean Difference</EFFECT_MEASURE><IV_DATA CI_END="-2.32127311138369" CI_START="-10.27872688861631" EFFECT_SIZE="-6.3" ESTIMABLE="YES" ESTIMATE="-6.3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-31 12:52:32 -0500" MODIFIED_BY="[Empty name]" ORDER="569" SE="2.03" STUDY_ID="STD-Aldoori-1986" TOTAL_1="9" TOTAL_2="9" WEIGHT="1.6082690475760946"/><IV_DATA CI_END="2.0047593025302612" CI_START="-2.424759302530261" EFFECT_SIZE="-0.21" ESTIMABLE="YES" ESTIMATE="-0.21" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-31 12:52:32 -0500" MODIFIED_BY="[Empty name]" ORDER="572" SE="1.13" STUDY_ID="STD-Challenor-1987" TOTAL_1="36" TOTAL_2="36" WEIGHT="5.190317110311166"/><IV_DATA CI_END="-0.9988349349961474" CI_START="-4.801165065003852" EFFECT_SIZE="-2.9" ESTIMABLE="YES" ESTIMATE="-2.9" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-31 12:52:32 -0500" MODIFIED_BY="[Empty name]" ORDER="574" SE="0.97" STUDY_ID="STD-Challenor-1989" TOTAL_1="22" TOTAL_2="22" WEIGHT="7.043804780695426"/><IV_DATA CI_END="-4.5748403373151385" CI_START="-8.965159662684862" EFFECT_SIZE="-6.77" ESTIMABLE="YES" ESTIMATE="-6.77" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-31 12:52:32 -0500" MODIFIED_BY="[Empty name]" ORDER="1158" SE="1.12" STUDY_ID="STD-Corbin-1986" TOTAL_1="23" TOTAL_2="23" WEIGHT="5.283415113326152"/><IV_DATA CI_END="0.44273949402729107" CI_START="-6.142739494027291" EFFECT_SIZE="-2.85" ESTIMABLE="YES" ESTIMATE="-2.85" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-31 12:52:32 -0500" MODIFIED_BY="[Empty name]" ORDER="1159" SE="1.68" STUDY_ID="STD-Ettinger-1984" TOTAL_1="19" TOTAL_2="19" WEIGHT="2.3481844948116235"/><IV_DATA CI_END="-2.002091839422862" CI_START="-11.997908160577138" EFFECT_SIZE="-7.0" ESTIMABLE="YES" ESTIMATE="-7.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-31 12:52:32 -0500" MODIFIED_BY="[Empty name]" ORDER="1164" SE="2.55" STUDY_ID="STD-Ferri-1992" TOTAL_1="18" TOTAL_2="18" WEIGHT="1.0192258236303462"/><IV_DATA CI_END="0.0671164441329255" CI_START="-9.027116444132925" EFFECT_SIZE="-4.48" ESTIMABLE="YES" ESTIMATE="-4.48" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-31 12:52:32 -0500" MODIFIED_BY="[Empty name]" ORDER="1166" SE="2.32" STUDY_ID="STD-Finch-1988" TOTAL_1="15" TOTAL_2="15" WEIGHT="1.2313309895504472"/><IV_DATA CI_END="0.37397658995103533" CI_START="-2.1739765899510353" EFFECT_SIZE="-0.9" ESTIMABLE="YES" ESTIMATE="-0.9" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-31 12:52:32 -0500" MODIFIED_BY="[Empty name]" ORDER="577" SE="0.65" STUDY_ID="STD-French-Co_x002d_op-1991" TOTAL_1="60" TOTAL_2="60" WEIGHT="15.686428208654023"/><IV_DATA CI_END="-0.5852406974697386" CI_START="-5.014759302530261" EFFECT_SIZE="-2.8" ESTIMABLE="YES" ESTIMATE="-2.8" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-31 12:52:32 -0500" MODIFIED_BY="[Empty name]" ORDER="1169" SE="1.13" STUDY_ID="STD-Gjorup-1986a" TOTAL_1="19" TOTAL_2="19" WEIGHT="5.190317110311166"/><IV_DATA CI_END="-1.0064237702035639" CI_START="-3.5935762297964358" EFFECT_SIZE="-2.3" ESTIMABLE="YES" ESTIMATE="-2.3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-31 12:52:32 -0500" MODIFIED_BY="[Empty name]" ORDER="1171" SE="0.66" STUDY_ID="STD-Hawkins-1985" TOTAL_1="57" TOTAL_2="57" WEIGHT="15.214683007705062"/><IV_DATA CI_END="-8.028443578706534" CI_START="-12.771556421293466" EFFECT_SIZE="-10.4" ESTIMABLE="YES" ESTIMATE="-10.4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-31 12:52:32 -0500" MODIFIED_BY="[Empty name]" ORDER="1173" SE="1.21" STUDY_ID="STD-Kahan-1985a" TOTAL_1="15" TOTAL_2="15" WEIGHT="4.526682547746962"/><IV_DATA CI_END="0.025141654954888182" CI_START="-6.325141654954888" EFFECT_SIZE="-3.15" ESTIMABLE="YES" ESTIMATE="-3.15" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-31 12:52:32 -0500" MODIFIED_BY="[Empty name]" ORDER="1175" SE="1.62" STUDY_ID="STD-Kahan-1985b" TOTAL_1="16" TOTAL_2="16" WEIGHT="2.5253451905793036"/><IV_DATA CI_END="-0.9656410576243384" CI_START="-5.4343589423756615" EFFECT_SIZE="-3.2" ESTIMABLE="YES" ESTIMATE="-3.2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-31 12:52:32 -0500" MODIFIED_BY="[Empty name]" ORDER="1178" SE="1.14" STUDY_ID="STD-Kahan-1987" TOTAL_1="20" TOTAL_2="20" WEIGHT="5.09965829344131"/><IV_DATA CI_END="6.294322926915717" CI_START="-2.094322926915716" EFFECT_SIZE="2.1" ESTIMABLE="YES" ESTIMATE="2.1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-31 12:52:32 -0500" MODIFIED_BY="[Empty name]" ORDER="601" SE="2.14" STUDY_ID="STD-Kirch-1987" TOTAL_1="10" TOTAL_2="10" WEIGHT="1.447182268791232"/><IV_DATA CI_END="3.2902743060447897" CI_START="-10.39027430604479" EFFECT_SIZE="-3.55" ESTIMABLE="YES" ESTIMATE="-3.55" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-31 12:52:32 -0500" MODIFIED_BY="[Empty name]" ORDER="604" SE="3.49" STUDY_ID="STD-Malamet-1984" TOTAL_1="7" TOTAL_2="7" WEIGHT="0.544126560385902"/><IV_DATA CI_END="2.23152040583352" CI_START="-6.4315204058335205" EFFECT_SIZE="-2.1" ESTIMABLE="YES" ESTIMATE="-2.1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-31 12:52:32 -0500" MODIFIED_BY="[Empty name]" ORDER="608" SE="2.21" STUDY_ID="STD-Meyrick-Thomas-1987" TOTAL_1="9" TOTAL_2="9" WEIGHT="1.356957457496023"/><IV_DATA CI_END="0.16676110330325877" CI_START="-4.066761103303259" EFFECT_SIZE="-1.95" ESTIMABLE="YES" ESTIMATE="-1.95" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-31 12:52:32 -0500" MODIFIED_BY="[Empty name]" ORDER="610" SE="1.08" STUDY_ID="STD-Rodeheffer-1983" TOTAL_1="15" TOTAL_2="15" WEIGHT="5.682026678803434"/><IV_DATA CI_END="-0.5292352951507471" CI_START="-4.370764704849253" EFFECT_SIZE="-2.45" ESTIMABLE="YES" ESTIMATE="-2.45" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-31 12:52:32 -0500" MODIFIED_BY="[Empty name]" ORDER="611" SE="0.98" STUDY_ID="STD-Rupp-1987" TOTAL_1="27" TOTAL_2="27" WEIGHT="6.9007870867933425"/><IV_DATA CI_END="11.760202275124898" CI_START="-9.760202275124898" EFFECT_SIZE="1.0" ESTIMABLE="YES" ESTIMATE="1.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-31 12:52:32 -0500" MODIFIED_BY="[Empty name]" ORDER="576" SE="5.49" STUDY_ID="STD-Sarkozi--1986" TOTAL_1="15" TOTAL_2="17" WEIGHT="0.21989030952638927"/><IV_DATA CI_END="-5.087660866127308" CI_START="-11.712339133872693" EFFECT_SIZE="-8.4" ESTIMABLE="YES" ESTIMATE="-8.4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-31 12:52:32 -0500" MODIFIED_BY="[Empty name]" ORDER="614" SE="1.69" STUDY_ID="STD-Smith-1982" TOTAL_1="17" TOTAL_2="17" WEIGHT="2.3204775456588798"/><IV_DATA CI_END="-0.3636392568513407" CI_START="-4.636360743148659" EFFECT_SIZE="-2.5" ESTIMABLE="YES" ESTIMATE="-2.5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-31 12:52:32 -0500" MODIFIED_BY="[Empty name]" ORDER="616" SE="1.09" STUDY_ID="STD-Waller-1986" TOTAL_1="27" TOTAL_2="27" WEIGHT="5.578247553367835"/><IV_DATA CI_END="0.42835354005667003" CI_START="-4.62835354005667" EFFECT_SIZE="-2.1" ESTIMABLE="YES" ESTIMATE="-2.1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-31 12:52:32 -0500" MODIFIED_BY="[Empty name]" ORDER="618" SE="1.29" STUDY_ID="STD-Wigley-1987" TOTAL_1="25" TOTAL_2="25" WEIGHT="3.9826428208378855"/></IV_OUTCOME><IV_OUTCOME CHI2="43.592613195383" CI_END="-0.03637931218662316" CI_START="-3.294365406355406" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_SIZE="-1.6653723592710148" ESTIMABLE="YES" I2="88.53016684824583" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" MODIFIED="2016-01-31 12:53:30 -0500" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="2.8019394471279213E-8" P_Q="1.0" P_Z="0.04509849034792966" Q="0.0" RANDOM="NO" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="69" TOTAL_2="69" WEIGHT="100.00000000000001" Z="2.003734669624155"><NAME>Duration of attacks (minutes)</NAME><GROUP_LABEL_1>CCBs</GROUP_LABEL_1><GROUP_LABEL_2>Placebo</GROUP_LABEL_2><GRAPH_LABEL_1>CCBs</GRAPH_LABEL_1><GRAPH_LABEL_2>Placebo</GRAPH_LABEL_2><EFFECT_MEASURE>Mean Difference</EFFECT_MEASURE><IV_DATA CI_END="-17.52429172522556" CI_START="-49.27570827477444" EFFECT_SIZE="-33.4" ESTIMABLE="YES" ESTIMATE="-33.4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-17 15:32:18 -0500" MODIFIED_BY="[Empty name]" ORDER="570" SE="8.1" STUDY_ID="STD-Aldoori-1986" TOTAL_1="9" TOTAL_2="9" WEIGHT="1.0528639154954074"/><IV_DATA CI_END="-1.2604453794795316" CI_START="-6.199554620520468" EFFECT_SIZE="-3.73" ESTIMABLE="YES" ESTIMATE="-3.73" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-09-16 10:47:00 -0400" MODIFIED_BY="[Empty name]" ORDER="1160" SE="1.26" STUDY_ID="STD-Ettinger-1984" TOTAL_1="19" TOTAL_2="19" WEIGHT="43.51121283424897"/><IV_DATA CI_END="-1.0901530657047687" CI_START="-17.74984693429523" EFFECT_SIZE="-9.42" ESTIMABLE="YES" ESTIMATE="-9.42" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-09-08 16:34:35 -0400" MODIFIED_BY="[Empty name]" ORDER="1167" SE="4.25" STUDY_ID="STD-Finch-1988" TOTAL_1="15" TOTAL_2="15" WEIGHT="3.824409771385671"/><IV_DATA CI_END="6.267552819747472" CI_START="1.1324471802525289" EFFECT_SIZE="3.7" ESTIMABLE="YES" ESTIMATE="3.7" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-09-09 13:00:55 -0400" MODIFIED_BY="[Empty name]" ORDER="602" SE="1.31" STUDY_ID="STD-Kirch-1987" TOTAL_1="10" TOTAL_2="10" WEIGHT="40.25313297340113"/><IV_DATA CI_END="-1.3864958011234547" CI_START="-11.813504198876544" EFFECT_SIZE="-6.6" ESTIMABLE="YES" ESTIMATE="-6.6" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-09-09 13:31:31 -0400" MODIFIED_BY="[Empty name]" ORDER="605" SE="2.66" STUDY_ID="STD-Malamet-1984" TOTAL_1="7" TOTAL_2="7" WEIGHT="9.762903710731765"/><IV_DATA CI_END="1.8965630182735573" CI_START="-23.896563018273557" EFFECT_SIZE="-11.0" ESTIMABLE="YES" ESTIMATE="-11.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-09-09 14:26:03 -0400" MODIFIED_BY="[Empty name]" ORDER="609" SE="6.58" STUDY_ID="STD-Meyrick-Thomas-1987" TOTAL_1="9" TOTAL_2="9" WEIGHT="1.595476794737061"/></IV_OUTCOME><IV_OUTCOME CHI2="187.00095349243026" CI_END="-0.5093952201934386" CI_START="-0.7231830497121683" CI_STUDY="95" CI_TOTAL="95" DF="15" EFFECT_SIZE="-0.6162891349528035" ESTIMABLE="YES" I2="91.97865052564708" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" MODIFIED="2017-11-14 03:10:31 -0500" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.1102230246251565E-16" P_Q="1.0" P_Z="1.3117227249799898E-29" Q="0.0" RANDOM="NO" SCALE="1.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="16" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="374" TOTAL_2="374" WEIGHT="100.0" Z="11.300030607822949"><NAME>Severity of attacks (average, on a 10-cm VAS)</NAME><GROUP_LABEL_1>CCBs</GROUP_LABEL_1><GROUP_LABEL_2>Placebo</GROUP_LABEL_2><GRAPH_LABEL_1>Favours CCBs</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2><EFFECT_MEASURE>Risk Difference</EFFECT_MEASURE><IV_DATA CI_END="-0.18840756324658858" CI_START="-1.0115924367534115" EFFECT_SIZE="-0.6" ESTIMABLE="YES" ESTIMATE="-0.6" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-26 15:06:13 -0400" MODIFIED_BY="[Empty name]" ORDER="575" SE="0.21" STUDY_ID="STD-Challenor-1989" TOTAL_1="22" TOTAL_2="22" WEIGHT="6.744832879993221"/><IV_DATA CI_END="1.2931578619118635" CI_START="-3.2931578619118635" EFFECT_SIZE="-1.0" ESTIMABLE="YES" ESTIMATE="-1.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-09-08 12:51:14 -0400" MODIFIED_BY="[Empty name]" ORDER="1161" SE="1.17" STUDY_ID="STD-Ettinger-1984" TOTAL_1="19" TOTAL_2="19" WEIGHT="0.21728915918452849"/><IV_DATA CI_END="-1.490409364019586" CI_START="-2.5095906359804143" EFFECT_SIZE="-2.0" ESTIMABLE="YES" ESTIMATE="-2.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-12-13 19:15:17 -0500" MODIFIED_BY="[Empty name]" ORDER="1165" SE="0.26" STUDY_ID="STD-Ferri-1992" TOTAL_1="18" TOTAL_2="18" WEIGHT="4.4001054734867004"/><IV_DATA CI_END="-0.6052136858747794" CI_START="-2.094786314125221" EFFECT_SIZE="-1.35" ESTIMABLE="YES" ESTIMATE="-1.35" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-09-08 16:44:42 -0400" MODIFIED_BY="[Empty name]" ORDER="1168" SE="0.38" STUDY_ID="STD-Finch-1988" TOTAL_1="15" TOTAL_2="15" WEIGHT="2.059883171798483"/><IV_DATA CI_END="-0.029608643710387017" CI_START="-0.9703913562896129" EFFECT_SIZE="-0.5" ESTIMABLE="YES" ESTIMATE="-0.5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-27 00:05:23 -0400" MODIFIED_BY="[Empty name]" ORDER="578" SE="0.24" STUDY_ID="STD-French-Co_x002d_op-1991" TOTAL_1="60" TOTAL_2="60" WEIGHT="5.164012673744809"/><IV_DATA CI_END="-0.2216104444833843" CI_START="-1.3583895555166157" EFFECT_SIZE="-0.79" ESTIMABLE="YES" ESTIMATE="-0.79" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-02-03 18:59:40 -0500" MODIFIED_BY="[Empty name]" ORDER="1170" SE="0.29" STUDY_ID="STD-Gjorup-1986a" TOTAL_1="19" TOTAL_2="19" WEIGHT="3.536826753956017"/><IV_DATA CI_END="-0.6568061226281907" CI_START="-1.3231938773718093" EFFECT_SIZE="-0.99" ESTIMABLE="YES" ESTIMATE="-0.99" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-02-03 18:59:44 -0500" MODIFIED_BY="[Empty name]" ORDER="1172" SE="0.17" STUDY_ID="STD-Hawkins-1985" TOTAL_1="57" TOTAL_2="57" WEIGHT="10.292288235560587"/><IV_DATA CI_END="-2.7572154866477767" CI_START="-4.4427845133522235" EFFECT_SIZE="-3.6" ESTIMABLE="YES" ESTIMATE="-3.6" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-02-03 18:59:50 -0500" MODIFIED_BY="[Empty name]" ORDER="1174" SE="0.43" STUDY_ID="STD-Kahan-1985a" TOTAL_1="15" TOTAL_2="15" WEIGHT="1.6086918875484102"/><IV_DATA CI_END="-0.8436212491213679" CI_START="-3.1563787508786323" EFFECT_SIZE="-2.0" ESTIMABLE="YES" ESTIMATE="-2.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-02-03 18:59:52 -0500" MODIFIED_BY="[Empty name]" ORDER="1176" SE="0.59" STUDY_ID="STD-Kahan-1985b" TOTAL_1="16" TOTAL_2="16" WEIGHT="0.8544875897951768"/><IV_DATA CI_END="-0.5100090038649865" CI_START="-1.4899909961350135" EFFECT_SIZE="-1.0" ESTIMABLE="YES" ESTIMATE="-1.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-02-03 18:59:55 -0500" MODIFIED_BY="[Empty name]" ORDER="1177" SE="0.25" STUDY_ID="STD-Kahan-1987" TOTAL_1="20" TOTAL_2="20" WEIGHT="4.759154080123216"/><IV_DATA CI_END="1.0323931570626104" CI_START="0.2876068429373897" EFFECT_SIZE="0.66" ESTIMABLE="YES" ESTIMATE="0.66" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-02-03 18:59:57 -0500" MODIFIED_BY="[Empty name]" ORDER="603" SE="0.19" STUDY_ID="STD-Kirch-1987" TOTAL_1="10" TOTAL_2="10" WEIGHT="8.239532687193933"/><IV_DATA CI_END="0.4339675860860488" CI_START="-3.093967586086049" EFFECT_SIZE="-1.33" ESTIMABLE="YES" ESTIMATE="-1.33" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-02-03 18:59:59 -0500" MODIFIED_BY="[Empty name]" ORDER="606" SE="0.9" STUDY_ID="STD-Malamet-1984" TOTAL_1="7" TOTAL_2="7" WEIGHT="0.36721867902185307"/><IV_DATA CI_END="-0.09556320537593518" CI_START="-0.4444367946240648" EFFECT_SIZE="-0.27" ESTIMABLE="YES" ESTIMATE="-0.27" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-02-03 19:00:01 -0500" MODIFIED_BY="[Empty name]" ORDER="612" SE="0.089" STUDY_ID="STD-Rupp-1987" TOTAL_1="27" TOTAL_2="27" WEIGHT="37.551714430968445"/><IV_DATA CI_END="-1.6944129655655804" CI_START="-3.1055870344344196" EFFECT_SIZE="-2.4" ESTIMABLE="YES" ESTIMATE="-2.4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-02-03 19:00:03 -0500" MODIFIED_BY="[Empty name]" ORDER="615" SE="0.36" STUDY_ID="STD-Smith-1982" TOTAL_1="17" TOTAL_2="17" WEIGHT="2.295116743886582"/><IV_DATA CI_END="-0.5884075632465886" CI_START="-1.4115924367534114" EFFECT_SIZE="-1.0" ESTIMABLE="YES" ESTIMATE="-1.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-02-03 19:00:05 -0500" MODIFIED_BY="[Empty name]" ORDER="617" SE="0.21" STUDY_ID="STD-Waller-1986" TOTAL_1="27" TOTAL_2="27" WEIGHT="6.744832879993221"/><IV_DATA CI_END="0.37039135628961295" CI_START="-0.570391356289613" EFFECT_SIZE="-0.1" ESTIMABLE="YES" ESTIMATE="-0.1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-02-03 19:00:07 -0500" MODIFIED_BY="[Empty name]" ORDER="619" SE="0.24" STUDY_ID="STD-Wigley-1987" TOTAL_1="25" TOTAL_2="25" WEIGHT="5.164012673744809"/></IV_OUTCOME><IV_OUTCOME CHI2="10.844447438021737" CI_END="-0.7374175154045095" CI_START="-2.206471841470634" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_SIZE="-1.4719446784375718" ESTIMABLE="YES" I2="72.33607321031688" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" MODIFIED="2017-11-14 03:10:42 -0500" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.012597477319962858" P_Q="1.0" P_Z="8.578334593756844E-5" Q="0.0" RANDOM="NO" SCALE="36.91" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="62" TOTAL_2="62" WEIGHT="100.0" Z="3.927640395299003"><NAME>Pain (10-cm visual analogue scale)</NAME><GROUP_LABEL_1>CCBs</GROUP_LABEL_1><GROUP_LABEL_2>Placebo</GROUP_LABEL_2><GRAPH_LABEL_1>Favours CCBs</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2><EFFECT_MEASURE>Std. Mean Difference</EFFECT_MEASURE><IV_DATA CI_END="-1.188825931131161" CI_START="-4.011174068868839" EFFECT_SIZE="-2.6" ESTIMABLE="YES" ESTIMATE="-2.6" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-12-13 14:23:14 -0500" MODIFIED_BY="[Empty name]" ORDER="571" SE="0.72" STUDY_ID="STD-Aldoori-1986" TOTAL_1="9" TOTAL_2="9" WEIGHT="27.09284089801222"/><IV_DATA CI_END="0.9987719079412423" CI_START="-2.0587719079412423" EFFECT_SIZE="-0.53" ESTIMABLE="YES" ESTIMATE="-0.53" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-12-13 18:06:51 -0500" MODIFIED_BY="[Empty name]" ORDER="1162" SE="0.78" STUDY_ID="STD-Ettinger-1984" TOTAL_1="19" TOTAL_2="19" WEIGHT="23.085024197122834"/><IV_DATA CI_END="0.2675798313424306" CI_START="-1.9275798313424306" EFFECT_SIZE="-0.83" ESTIMABLE="YES" ESTIMATE="-0.83" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-12-13 18:09:21 -0500" MODIFIED_BY="[Empty name]" ORDER="607" SE="0.56" STUDY_ID="STD-Malamet-1984" TOTAL_1="7" TOTAL_2="7" WEIGHT="44.7861247497753"/><IV_DATA CI_END="-2.156860145818109" CI_START="-8.70313985418189" EFFECT_SIZE="-5.43" ESTIMABLE="YES" ESTIMATE="-5.43" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-02-03 19:02:53 -0500" MODIFIED_BY="[Empty name]" ORDER="613" SE="1.67" STUDY_ID="STD-Rupp-1987" TOTAL_1="27" TOTAL_2="27" WEIGHT="5.036010155089653"/></IV_OUTCOME><IV_OUTCOME CHI2="1.93368700265252" CI_END="-0.017995301367367933" CI_START="-0.72863599836738" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_SIZE="-0.373315649867374" ESTIMABLE="YES" I2="48.28532235939643" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" MODIFIED="2016-02-13 19:35:20 -0500" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.164355900179179" P_Q="1.0" P_Z="0.0394725050120816" Q="0.0" RANDOM="NO" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="96" TOTAL_2="96" WEIGHT="100.0" Z="2.0592269249257633"><NAME>Patient global</NAME><GROUP_LABEL_1>CCBs</GROUP_LABEL_1><GROUP_LABEL_2>Placebo</GROUP_LABEL_2><GRAPH_LABEL_1>Favours CCBs</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2><EFFECT_MEASURE>Std. Mean Difference</EFFECT_MEASURE><IV_DATA CI_END="0.2311920765988119" CI_START="-0.6311920765988119" EFFECT_SIZE="-0.2" ESTIMABLE="YES" ESTIMATE="-0.2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-02-02 19:58:51 -0500" MODIFIED_BY="[Empty name]" ORDER="573" SE="0.22" STUDY_ID="STD-Challenor-1987" TOTAL_1="36" TOTAL_2="36" WEIGHT="67.90450928381964"/><IV_DATA CI_END="-0.1128115249471826" CI_START="-1.3671884750528174" EFFECT_SIZE="-0.74" ESTIMABLE="YES" ESTIMATE="-0.74" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-17 17:37:11 -0500" MODIFIED_BY="[Empty name]" ORDER="579" SE="0.32" STUDY_ID="STD-French-Co_x002d_op-1991" TOTAL_1="60" TOTAL_2="60" WEIGHT="32.09549071618037"/></IV_OUTCOME><DICH_OUTCOME CHI2="1.3344741214343134" CI_END="3.332007130323157" CI_START="0.5078632913522062" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3008474576271185" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="6" I2="25.064114474907573" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="0.5227059221035039" LOG_CI_START="-0.2942531770893441" LOG_EFFECT_SIZE="0.11422637250707986" METHOD="MH" MODIFIED="2016-02-13 19:35:20 -0500" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.24801097235140634" P_Q="1.0" P_Z="0.5836367992598746" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="32" TOTAL_2="31" WEIGHT="100.0" Z="0.5480802562079908"><NAME>Number of withdrawals (due to treatment)</NAME><GROUP_LABEL_1>calcium channel blockers</GROUP_LABEL_1><GROUP_LABEL_2>Placebo</GROUP_LABEL_2><GRAPH_LABEL_1>Favours CCB</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2><DICH_DATA CI_END="2.657721666524914" CI_START="0.21164744490926812" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.4245094969145651" LOG_CI_START="-0.674386970131165" LOG_EFFECT_SIZE="-0.12493873660829995" MODIFIED="2016-01-30 17:07:57 -0500" MODIFIED_BY="[Empty name]" ORDER="330" O_E="0.0" SE="0.6454972243679028" STUDY_ID="STD-Constantini-1987" TOTAL_1="12" TOTAL_2="12" VAR="0.41666666666666663" WEIGHT="66.10169491525424"/><DICH_DATA CI_END="10.803239118692582" CI_START="0.5221234981497506" EFFECT_SIZE="2.375" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="1.0335539888632717" LOG_CI_START="-0.282226760941501" LOG_EFFECT_SIZE="0.3756636139608854" MODIFIED="2016-01-30 17:07:57 -0500" MODIFIED_BY="[Empty name]" ORDER="129" O_E="0.0" SE="0.7728961256550789" STUDY_ID="STD-Sarkozi--1986" TOTAL_1="20" TOTAL_2="19" VAR="0.5973684210526315" WEIGHT="33.898305084745765"/></DICH_OUTCOME></COMPARISON><COMPARISON ID="CMP-002" MODIFIED="2017-11-22 21:08:46 -0500" MODIFIED_BY="[Empty name]" NO="2"><NAME>Subgroup analysis by RP type</NAME><IV_OUTCOME CHI2="116.2010965116717" CI_END="-2.6289447789806095" CI_START="-3.668637420056455" CI_STUDY="95" CI_TOTAL="95" DF="20" EFFECT_SIZE="-3.148791099518532" ESTIMABLE="YES" I2="82.78845845659372" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" MODIFIED="2017-11-22 21:08:46 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.2212453270876722E-15" P_Q="0.48128768806765754" P_Z="1.65838753330059E-32" Q="0.4959442202084846" RANDOM="NO" SCALE="15.54" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="15" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="311" TOTAL_2="313" WEIGHT="100.0" Z="11.87181077575097"><NAME>Frequency of attacks (average/week)</NAME><GROUP_LABEL_1>CCBs</GROUP_LABEL_1><GROUP_LABEL_2>Placebo</GROUP_LABEL_2><GRAPH_LABEL_1>Favours CCBs</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2><EFFECT_MEASURE>Mean Difference</EFFECT_MEASURE><IV_SUBGROUP CHI2="73.23497794139452" CI_END="-2.3848841398463074" CI_START="-3.6522748663206253" DF="11" EFFECT_SIZE="-3.0185795030834663" ESTIMABLE="YES" I2="84.97985483275133" ID="CMP-002.01.01" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2017-11-14 03:11:11 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="2.952205147011E-11" P_Z="9.985294614582063E-21" STUDIES="12" TAU2="0.0" TOTAL_1="209" TOTAL_2="211" WEIGHT="67.29594405930189" Z="9.336200726310574"><NAME>CCBs vs placebo for primary RP</NAME><IV_DATA CI_END="2.0047593025302612" CI_START="-2.424759302530261" EFFECT_SIZE="-0.21" ESTIMABLE="YES" ESTIMATE="-0.21" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-24 15:39:46 -0500" MODIFIED_BY="[Empty name]" ORDER="572" SE="1.13" STUDY_ID="STD-Challenor-1987" TOTAL_1="36" TOTAL_2="36" WEIGHT="5.509305809464168"/><IV_DATA CI_END="-0.9988349349961474" CI_START="-4.801165065003852" EFFECT_SIZE="-2.9" ESTIMABLE="YES" ESTIMATE="-2.9" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-12-25 13:23:45 -0500" MODIFIED_BY="[Empty name]" ORDER="574" SE="0.97" STUDY_ID="STD-Challenor-1989" TOTAL_1="22" TOTAL_2="22" WEIGHT="7.476705907221591"/><IV_DATA CI_END="-4.5748403373151385" CI_START="-8.965159662684862" EFFECT_SIZE="-6.77" ESTIMABLE="YES" ESTIMATE="-6.77" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-17 11:52:13 -0500" MODIFIED_BY="[Empty name]" ORDER="1158" SE="1.12" STUDY_ID="STD-Corbin-1986" TOTAL_1="23" TOTAL_2="23" WEIGHT="5.60812546883354"/><IV_DATA CI_END="2.0511470572738797" CI_START="-3.71114705727388" EFFECT_SIZE="-0.83" ESTIMABLE="YES" ESTIMATE="-0.83" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-24 10:45:16 -0500" MODIFIED_BY="[Empty name]" ORDER="884" SE="1.47" STUDY_ID="STD-Ettinger-1984" TOTAL_1="3" TOTAL_2="3" WEIGHT="3.255510476238972"/><IV_DATA CI_END="0.37397658995103533" CI_START="-2.1739765899510353" EFFECT_SIZE="-0.9" ESTIMABLE="YES" ESTIMATE="-0.9" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-12-25 13:23:45 -0500" MODIFIED_BY="[Empty name]" ORDER="577" SE="0.65" STUDY_ID="STD-French-Co_x002d_op-1991" TOTAL_1="60" TOTAL_2="60" WEIGHT="16.65049133279241"/><IV_DATA CI_END="-0.5852406974697386" CI_START="-5.014759302530261" EFFECT_SIZE="-2.8" ESTIMABLE="YES" ESTIMATE="-2.8" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-12-25 13:23:45 -0500" MODIFIED_BY="[Empty name]" ORDER="1169" SE="1.13" STUDY_ID="STD-Gjorup-1986a" TOTAL_1="19" TOTAL_2="19" WEIGHT="5.509305809464168"/><IV_DATA CI_END="-10.774066628600899" CI_START="-18.025933371399102" EFFECT_SIZE="-14.4" ESTIMABLE="YES" ESTIMATE="-14.4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-25 20:46:04 -0500" MODIFIED_BY="[Empty name]" ORDER="887" SE="1.85" STUDY_ID="STD-Kahan-1985a" TOTAL_1="5" TOTAL_2="5" WEIGHT="2.055466059343986"/><IV_DATA CI_END="3.2832923470804687E-4" CI_START="-7.800328329234707" EFFECT_SIZE="-3.9" ESTIMABLE="YES" ESTIMATE="-3.9" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-23 15:34:43 -0500" MODIFIED_BY="[Empty name]" ORDER="904" SE="1.99" STUDY_ID="STD-Kahan-1985b" TOTAL_1="6" TOTAL_2="6" WEIGHT="1.7764280164906932"/><IV_DATA CI_END="-2.824858345045112" CI_START="-9.175141654954889" EFFECT_SIZE="-6.0" ESTIMABLE="YES" ESTIMATE="-6.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-24 12:54:39 -0500" MODIFIED_BY="[Empty name]" ORDER="891" SE="1.62" STUDY_ID="STD-Kahan-1987" TOTAL_1="3" TOTAL_2="3" WEIGHT="2.680548920936135"/><IV_DATA CI_END="-2.24962665144036" CI_START="-5.15037334855964" EFFECT_SIZE="-3.7" ESTIMABLE="YES" ESTIMATE="-3.7" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-24 09:28:52 -0500" MODIFIED_BY="[Empty name]" ORDER="610" SE="0.74" STUDY_ID="STD-Rodeheffer-1983" TOTAL_1="5" TOTAL_2="5" WEIGHT="12.846662870899916"/><IV_DATA CI_END="0.18475029866527448" CI_START="-5.224750298665274" EFFECT_SIZE="-2.52" ESTIMABLE="YES" ESTIMATE="-2.52" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-24 16:49:35 -0500" MODIFIED_BY="[Empty name]" ORDER="899" SE="1.38" STUDY_ID="STD-Rupp-1987" TOTAL_1="12" TOTAL_2="12" WEIGHT="3.693988966658683"/><IV_DATA CI_END="11.760202275124898" CI_START="-9.760202275124898" EFFECT_SIZE="1.0" ESTIMABLE="YES" ESTIMATE="1.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-12-25 13:23:45 -0500" MODIFIED_BY="[Empty name]" ORDER="576" SE="5.49" STUDY_ID="STD-Sarkozi--1986" TOTAL_1="15" TOTAL_2="17" WEIGHT="0.233404420957621"/></IV_SUBGROUP><IV_SUBGROUP CHI2="42.47017435006869" CI_END="-2.5077091967533036" CI_START="-4.325752241571748" DF="8" EFFECT_SIZE="-3.416730719162526" ESTIMABLE="YES" I2="81.16325133478746" ID="CMP-002.01.02" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2017-11-14 03:11:19 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.1050749766372547E-6" P_Z="1.7464354298369014E-13" STUDIES="9" TAU2="0.0" TOTAL_1="102" TOTAL_2="102" WEIGHT="32.70405594069812" Z="7.366898350967196"><NAME>CCBs vs placebo for secondary RP</NAME><IV_DATA CI_END="-0.5024561841175155" CI_START="-6.617543815882485" EFFECT_SIZE="-3.56" ESTIMABLE="YES" ESTIMATE="-3.56" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-24 10:59:00 -0500" MODIFIED_BY="[Empty name]" ORDER="885" SE="1.56" STUDY_ID="STD-Ettinger-1984" TOTAL_1="15" TOTAL_2="15" WEIGHT="2.8907103008320156"/><IV_DATA CI_END="-6.540036015459946" CI_START="-10.459963984540055" EFFECT_SIZE="-8.5" ESTIMABLE="YES" ESTIMATE="-8.5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-24 11:30:17 -0500" MODIFIED_BY="[Empty name]" ORDER="886" SE="1.0" STUDY_ID="STD-Kahan-1985a" TOTAL_1="10" TOTAL_2="10" WEIGHT="7.034832588104794"/><IV_DATA CI_END="-0.5920378162329429" CI_START="-4.707962183767057" EFFECT_SIZE="-2.65" ESTIMABLE="YES" ESTIMATE="-2.65" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-24 12:37:49 -0500" MODIFIED_BY="[Empty name]" ORDER="889" SE="1.05" STUDY_ID="STD-Kahan-1985b" TOTAL_1="10" TOTAL_2="10" WEIGHT="6.380800533428384"/><IV_DATA CI_END="-0.6628385365421416" CI_START="-4.857161463457858" EFFECT_SIZE="-2.76" ESTIMABLE="YES" ESTIMATE="-2.76" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-24 13:03:54 -0500" MODIFIED_BY="[Empty name]" ORDER="892" SE="1.07" STUDY_ID="STD-Kahan-1987" TOTAL_1="17" TOTAL_2="17" WEIGHT="6.144495229369197"/><IV_DATA CI_END="6.294322926915717" CI_START="-2.094322926915716" EFFECT_SIZE="2.1" ESTIMABLE="YES" ESTIMATE="2.1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-12-25 13:30:40 -0500" MODIFIED_BY="[Empty name]" ORDER="601" SE="2.14" STUDY_ID="STD-Kirch-1987" TOTAL_1="10" TOTAL_2="10" WEIGHT="1.5361238073422991"/><IV_DATA CI_END="3.2902743060447897" CI_START="-10.39027430604479" EFFECT_SIZE="-3.55" ESTIMABLE="YES" ESTIMATE="-3.55" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-12-25 13:30:52 -0500" MODIFIED_BY="[Empty name]" ORDER="604" SE="3.49" STUDY_ID="STD-Malamet-1984" TOTAL_1="7" TOTAL_2="7" WEIGHT="0.5775677201422643"/><IV_DATA CI_END="2.23152040583352" CI_START="-6.4315204058335205" EFFECT_SIZE="-2.1" ESTIMABLE="YES" ESTIMATE="-2.1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-12-25 13:30:59 -0500" MODIFIED_BY="[Empty name]" ORDER="608" SE="2.21" STUDY_ID="STD-Meyrick-Thomas-1987" TOTAL_1="9" TOTAL_2="9" WEIGHT="1.440353921521835"/><IV_DATA CI_END="3.948744896346283" CI_START="-2.0487448963462835" EFFECT_SIZE="0.95" ESTIMABLE="YES" ESTIMATE="0.95" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-24 10:06:19 -0500" MODIFIED_BY="[Empty name]" ORDER="907" SE="1.53" STUDY_ID="STD-Rodeheffer-1983" TOTAL_1="9" TOTAL_2="9" WEIGHT="3.005182873298643"/><IV_DATA CI_END="0.3247502986652746" CI_START="-5.084750298665274" EFFECT_SIZE="-2.38" ESTIMABLE="YES" ESTIMATE="-2.38" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-24 16:51:12 -0500" MODIFIED_BY="[Empty name]" ORDER="900" SE="1.38" STUDY_ID="STD-Rupp-1987" TOTAL_1="15" TOTAL_2="15" WEIGHT="3.693988966658683"/></IV_SUBGROUP></IV_OUTCOME><IV_OUTCOME CHI2="263.60497159947295" CI_END="-0.567601233547893" CI_START="-0.7685187156027002" CI_STUDY="95" CI_TOTAL="95" DF="13" EFFECT_SIZE="-0.6680599745752966" ESTIMABLE="YES" I2="95.06837829304962" I2_Q="95.03960941482559" ID="CMP-002.02" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" MODIFIED="2017-11-14 03:11:29 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="4.440892098500626E-16" P_Q="7.123903571049084E-6" P_Z="7.844675369828611E-39" Q="20.159702806242638" RANDOM="NO" SCALE="11.87" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="253" TOTAL_2="253" WEIGHT="100.0" Z="13.033942853446165"><NAME>Severity of attacks (average, on a 10-cm VAS)</NAME><GROUP_LABEL_1>CCBs</GROUP_LABEL_1><GROUP_LABEL_2>Placebo</GROUP_LABEL_2><GRAPH_LABEL_1>Favours CCBs</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2><EFFECT_MEASURE>Mean Difference</EFFECT_MEASURE><IV_SUBGROUP CHI2="161.34177722955002" CI_END="-0.7900433711136435" CI_START="-1.106667696052541" DF="7" EFFECT_SIZE="-0.9483555335830923" ESTIMABLE="YES" I2="95.66138410013873" ID="CMP-002.02.01" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2016-02-07 17:40:44 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="-8.881784197001252E-16" P_Z="7.855450110299337E-32" STUDIES="8" TAU2="0.0" TOTAL_1="184" TOTAL_2="184" WEIGHT="40.26677981901999" Z="11.740997415285948"><NAME>Primary RP: CCBs vs placebo</NAME><IV_DATA CI_END="-0.18840756324658858" CI_START="-1.0115924367534115" EFFECT_SIZE="-0.6" ESTIMABLE="YES" ESTIMATE="-0.6" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-12-25 14:08:38 -0500" MODIFIED_BY="[Empty name]" ORDER="575" SE="0.21" STUDY_ID="STD-Challenor-1989" TOTAL_1="22" TOTAL_2="22" WEIGHT="5.957179561928233"/><IV_DATA CI_END="-0.029608643710387017" CI_START="-0.9703913562896129" EFFECT_SIZE="-0.5" ESTIMABLE="YES" ESTIMATE="-0.5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-12-25 14:08:38 -0500" MODIFIED_BY="[Empty name]" ORDER="578" SE="0.24" STUDY_ID="STD-French-Co_x002d_op-1991" TOTAL_1="60" TOTAL_2="60" WEIGHT="4.5609656021013025"/><IV_DATA CI_END="-0.2216104444833843" CI_START="-1.3583895555166157" EFFECT_SIZE="-0.79" ESTIMABLE="YES" ESTIMATE="-0.79" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-12-25 14:08:38 -0500" MODIFIED_BY="[Empty name]" ORDER="1170" SE="0.29" STUDY_ID="STD-Gjorup-1986a" TOTAL_1="19" TOTAL_2="19" WEIGHT="3.123800459940964"/><IV_DATA CI_END="-0.6568061226281907" CI_START="-1.3231938773718093" EFFECT_SIZE="-0.99" ESTIMABLE="YES" ESTIMATE="-0.99" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-12-25 14:08:38 -0500" MODIFIED_BY="[Empty name]" ORDER="1172" SE="0.17" STUDY_ID="STD-Hawkins-1985" TOTAL_1="57" TOTAL_2="57" WEIGHT="9.090367428409515"/><IV_DATA CI_END="-4.053612245256382" CI_START="-5.386387754743618" EFFECT_SIZE="-4.72" ESTIMABLE="YES" ESTIMATE="-4.72" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-02-07 17:40:44 -0500" MODIFIED_BY="[Empty name]" ORDER="1174" SE="0.34" STUDY_ID="STD-Kahan-1985a" TOTAL_1="5" TOTAL_2="5" WEIGHT="2.2725918571023787"/><IV_DATA CI_END="2.6878991567121515" CI_START="-8.28789915671215" EFFECT_SIZE="-2.8" ESTIMABLE="YES" ESTIMATE="-2.8" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-02-07 17:40:40 -0500" MODIFIED_BY="[Empty name]" ORDER="1176" SE="2.8" STUDY_ID="STD-Kahan-1985b" TOTAL_1="6" TOTAL_2="6" WEIGHT="0.033509135035846314"/><IV_DATA CI_END="-1.1792082835557873" CI_START="-2.0807917164442125" EFFECT_SIZE="-1.63" ESTIMABLE="YES" ESTIMATE="-1.63" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-24 14:54:44 -0500" MODIFIED_BY="[Empty name]" ORDER="1177" SE="0.23" STUDY_ID="STD-Kahan-1987" TOTAL_1="3" TOTAL_2="3" WEIGHT="4.9661931697738195"/><IV_DATA CI_END="0.12359423752640869" CI_START="-0.5035942375264086" EFFECT_SIZE="-0.19" ESTIMABLE="YES" ESTIMATE="-0.19" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-24 16:55:09 -0500" MODIFIED_BY="[Empty name]" ORDER="612" SE="0.16" STUDY_ID="STD-Rupp-1987" TOTAL_1="12" TOTAL_2="12" WEIGHT="10.262172604727931"/></IV_SUBGROUP><IV_SUBGROUP CHI2="82.10349156368022" CI_END="-0.34912887916677215" CI_START="-0.6090908153308884" DF="5" EFFECT_SIZE="-0.47910984724883027" ESTIMABLE="YES" I2="93.91012500835977" ID="CMP-002.02.02" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2016-01-24 16:57:20 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="4.440892098500626E-16" P_Z="5.032182355147314E-13" STUDIES="6" TAU2="0.0" TOTAL_1="69" TOTAL_2="69" WEIGHT="59.73322018098001" Z="7.224427230403232"><NAME>Secondary RP: CCBs vs placebo</NAME><IV_DATA CI_END="-2.1672154866477764" CI_START="-3.852784513352223" EFFECT_SIZE="-3.01" ESTIMABLE="YES" ESTIMATE="-3.01" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-24 12:02:15 -0500" MODIFIED_BY="[Empty name]" ORDER="888" SE="0.43" STUDY_ID="STD-Kahan-1985a" TOTAL_1="10" TOTAL_2="10" WEIGHT="1.4208308203409143"/><IV_DATA CI_END="-0.06922629128576041" CI_START="-2.9307737087142396" EFFECT_SIZE="-1.5" ESTIMABLE="YES" ESTIMATE="-1.5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-24 12:43:54 -0500" MODIFIED_BY="[Empty name]" ORDER="890" SE="0.73" STUDY_ID="STD-Kahan-1985b" TOTAL_1="10" TOTAL_2="10" WEIGHT="0.49298483520554526"/><IV_DATA CI_END="-0.5418434574841547" CI_START="-0.9181565425158452" EFFECT_SIZE="-0.73" ESTIMABLE="YES" ESTIMATE="-0.73" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-24 14:55:36 -0500" MODIFIED_BY="[Empty name]" ORDER="893" SE="0.096" STUDY_ID="STD-Kahan-1987" TOTAL_1="17" TOTAL_2="17" WEIGHT="28.506035013133143"/><IV_DATA CI_END="1.0323931570626104" CI_START="0.2876068429373897" EFFECT_SIZE="0.66" ESTIMABLE="YES" ESTIMATE="0.66" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-12-25 14:09:50 -0500" MODIFIED_BY="[Empty name]" ORDER="603" SE="0.19" STUDY_ID="STD-Kirch-1987" TOTAL_1="10" TOTAL_2="10" WEIGHT="7.277330157369391"/><IV_DATA CI_END="0.4339675860860488" CI_START="-3.093967586086049" EFFECT_SIZE="-1.33" ESTIMABLE="YES" ESTIMATE="-1.33" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-12-25 14:09:56 -0500" MODIFIED_BY="[Empty name]" ORDER="606" SE="0.9" STUDY_ID="STD-Malamet-1984" TOTAL_1="7" TOTAL_2="7" WEIGHT="0.3243353317049815"/><IV_DATA CI_END="-0.11440396170059405" CI_START="-0.545596038299406" EFFECT_SIZE="-0.33" ESTIMABLE="YES" ESTIMATE="-0.33" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-24 16:57:20 -0500" MODIFIED_BY="[Empty name]" ORDER="901" SE="0.11" STUDY_ID="STD-Rupp-1987" TOTAL_1="15" TOTAL_2="15" WEIGHT="21.711704023226037"/></IV_SUBGROUP></IV_OUTCOME></COMPARISON><COMPARISON ID="CMP-003" MODIFIED="2017-11-22 21:08:46 -0500" MODIFIED_BY="[Empty name]" NO="3"><NAME>Subgroup analysis: nifedipine versus placebo by RP type</NAME><IV_OUTCOME CHI2="83.52140172452015" CI_END="-3.5931454387664026" CI_START="-5.094428056015941" CI_STUDY="95" CI_TOTAL="95" DF="11" EFFECT_SIZE="-4.343786747391172" ESTIMABLE="YES" I2="86.82972295378678" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" MODIFIED="2017-11-14 03:11:59 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="3.055333763768431E-13" P_Q="0.7722507597599847" P_Z="8.139960090901088E-30" Q="0.08377092937075217" RANDOM="NO" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="133" TOTAL_2="135" WEIGHT="99.99999999999999" Z="11.341855935169292"><NAME>Frequency of attacks: nifedipine vs placebo by RP type</NAME><GROUP_LABEL_1>Nifedipine</GROUP_LABEL_1><GROUP_LABEL_2>Placebo</GROUP_LABEL_2><GRAPH_LABEL_1>Favours Nifedipine</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2><EFFECT_MEASURE>Mean Difference</EFFECT_MEASURE><IV_SUBGROUP CHI2="43.84516943917927" CI_END="-3.49742020938642" CI_START="-5.350593630157895" DF="5" EFFECT_SIZE="-4.424006919772157" ESTIMABLE="YES" I2="88.59623519773174" ID="CMP-003.01.01" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2016-01-25 19:23:26 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="2.4900587480836123E-8" P_Z="8.13467681115956E-21" STUDIES="6" TAU2="0.0" TOTAL_1="73" TOTAL_2="75" WEIGHT="65.6285466449085" Z="9.35788753812336"><NAME>Nifedipine vs placebo for primary RP</NAME><IV_DATA CI_END="-0.9988349349961474" CI_START="-4.801165065003852" EFFECT_SIZE="-2.9" ESTIMABLE="YES" ESTIMATE="-2.9" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-17 12:47:11 -0500" MODIFIED_BY="[Empty name]" ORDER="574" SE="0.97" STUDY_ID="STD-Challenor-1989" TOTAL_1="22" TOTAL_2="22" WEIGHT="15.58925174312106"/><IV_DATA CI_END="-4.5748403373151385" CI_START="-8.965159662684862" EFFECT_SIZE="-6.77" ESTIMABLE="YES" ESTIMATE="-6.77" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-17 12:48:28 -0500" MODIFIED_BY="[Empty name]" ORDER="1158" SE="1.12" STUDY_ID="STD-Corbin-1986" TOTAL_1="23" TOTAL_2="23" WEIGHT="11.693181572945313"/><IV_DATA CI_END="2.0511470572738797" CI_START="-3.71114705727388" EFFECT_SIZE="-0.83" ESTIMABLE="YES" ESTIMATE="-0.83" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-24 17:53:39 -0500" MODIFIED_BY="[Empty name]" ORDER="884" SE="1.47" STUDY_ID="STD-Ettinger-1984" TOTAL_1="3" TOTAL_2="3" WEIGHT="6.787878645519276"/><IV_DATA CI_END="-10.774066628600899" CI_START="-18.025933371399102" EFFECT_SIZE="-14.4" ESTIMABLE="YES" ESTIMATE="-14.4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-24 17:54:04 -0500" MODIFIED_BY="[Empty name]" ORDER="887" SE="1.85" STUDY_ID="STD-Kahan-1985a" TOTAL_1="5" TOTAL_2="5" WEIGHT="4.285734686662558"/><IV_DATA CI_END="-2.24962665144036" CI_START="-5.15037334855964" EFFECT_SIZE="-3.7" ESTIMABLE="YES" ESTIMATE="-3.7" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-25 19:22:22 -0500" MODIFIED_BY="[Empty name]" ORDER="610" SE="0.74" STUDY_ID="STD-Rodeheffer-1983" TOTAL_1="5" TOTAL_2="5" WEIGHT="26.785841791640987"/><IV_DATA CI_END="11.760202275124898" CI_START="-9.760202275124898" EFFECT_SIZE="1.0" ESTIMABLE="YES" ESTIMATE="1.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-17 12:48:40 -0500" MODIFIED_BY="[Empty name]" ORDER="576" SE="5.49" STUDY_ID="STD-Sarkozi--1986" TOTAL_1="15" TOTAL_2="17" WEIGHT="0.48665820501931323"/></IV_SUBGROUP><IV_SUBGROUP CHI2="39.59246135597011" CI_END="-2.910250894969751" CI_START="-5.470979235708775" DF="5" EFFECT_SIZE="-4.190615065339263" ESTIMABLE="YES" I2="87.37133325699122" ID="CMP-003.01.02" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2016-01-25 20:09:03 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.8043524641075948E-7" P_Z="1.4088175097286144E-10" STUDIES="6" TAU2="0.0" TOTAL_1="60" TOTAL_2="60" WEIGHT="34.37145335509149" Z="6.414936305789881"><NAME>Nifedipine vs placebo for secondary RP</NAME><IV_DATA CI_END="-0.5024561841175155" CI_START="-6.617543815882485" EFFECT_SIZE="-3.56" ESTIMABLE="YES" ESTIMATE="-3.56" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-24 17:54:43 -0500" MODIFIED_BY="[Empty name]" ORDER="885" SE="1.56" STUDY_ID="STD-Ettinger-1984" TOTAL_1="15" TOTAL_2="15" WEIGHT="6.027254670078321"/><IV_DATA CI_END="-6.540036015459946" CI_START="-10.459963984540055" EFFECT_SIZE="-8.5" ESTIMABLE="YES" ESTIMATE="-8.5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-24 17:55:03 -0500" MODIFIED_BY="[Empty name]" ORDER="886" SE="1.0" STUDY_ID="STD-Kahan-1985a" TOTAL_1="10" TOTAL_2="10" WEIGHT="14.667926965102604"/><IV_DATA CI_END="6.294322926915717" CI_START="-2.094322926915716" EFFECT_SIZE="2.1" ESTIMABLE="YES" ESTIMATE="2.1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-17 12:49:22 -0500" MODIFIED_BY="[Empty name]" ORDER="601" SE="2.14" STUDY_ID="STD-Kirch-1987" TOTAL_1="10" TOTAL_2="10" WEIGHT="3.2028838687008916"/><IV_DATA CI_END="3.2902743060447897" CI_START="-10.39027430604479" EFFECT_SIZE="-3.55" ESTIMABLE="YES" ESTIMATE="-3.55" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-17 12:49:36 -0500" MODIFIED_BY="[Empty name]" ORDER="604" SE="3.49" STUDY_ID="STD-Malamet-1984" TOTAL_1="7" TOTAL_2="7" WEIGHT="1.2042534104894542"/><IV_DATA CI_END="2.23152040583352" CI_START="-6.4315204058335205" EFFECT_SIZE="-2.1" ESTIMABLE="YES" ESTIMATE="-2.1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-17 12:49:44 -0500" MODIFIED_BY="[Empty name]" ORDER="608" SE="2.21" STUDY_ID="STD-Meyrick-Thomas-1987" TOTAL_1="9" TOTAL_2="9" WEIGHT="3.0031995587933507"/><IV_DATA CI_END="3.948744896346283" CI_START="-2.0487448963462835" EFFECT_SIZE="0.95" ESTIMABLE="YES" ESTIMATE="0.95" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-25 20:09:03 -0500" MODIFIED_BY="[Empty name]" ORDER="907" SE="1.53" STUDY_ID="STD-Rodeheffer-1983" TOTAL_1="9" TOTAL_2="9" WEIGHT="6.265934881926867"/></IV_SUBGROUP></IV_OUTCOME><IV_OUTCOME CHI2="219.60702649159592" CI_END="-0.5815659247855055" CI_START="-1.0652865798028675" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_SIZE="-0.8234262522941864" ESTIMABLE="YES" I2="98.17856465528298" I2_Q="98.00284515127338" ID="CMP-003.02" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" MODIFIED="2017-11-22 21:08:46 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="1.4831469385967466E-12" P_Z="2.5096686300492327E-11" Q="50.071230112056796" RANDOM="NO" SCALE="7.72" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="54" TOTAL_2="54" WEIGHT="99.99999999999997" Z="6.672800847685412"><NAME>Severity of attacks: nifedipine vs placebo by RP type</NAME><GROUP_LABEL_1>Nifedipine</GROUP_LABEL_1><GROUP_LABEL_2>Placebo</GROUP_LABEL_2><GRAPH_LABEL_1>Favours Nifedipine</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2><EFFECT_MEASURE>Mean Difference</EFFECT_MEASURE><IV_SUBGROUP CHI2="106.28929242329367" CI_END="-1.3875261819623668" CI_START="-2.087890223798434" DF="1" EFFECT_SIZE="-1.7377082028804003" ESTIMABLE="YES" I2="99.05917145819588" ID="CMP-003.02.01" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2016-02-07 17:59:51 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="-2.220446049250313E-16" P_Z="2.33761584597944E-22" STUDIES="2" TAU2="0.0" TOTAL_1="27" TOTAL_2="27" WEIGHT="47.702548723268364" Z="9.725929059283732"><NAME>Primary RP</NAME><IV_DATA CI_END="-0.18840756324658858" CI_START="-1.0115924367534115" EFFECT_SIZE="-0.6" ESTIMABLE="YES" ESTIMATE="-0.6" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-25 20:20:49 -0500" MODIFIED_BY="[Empty name]" ORDER="575" SE="0.21" STUDY_ID="STD-Challenor-1989" TOTAL_1="22" TOTAL_2="22" WEIGHT="34.52983489298575"/><IV_DATA CI_END="-4.053612245256382" CI_START="-5.386387754743618" EFFECT_SIZE="-4.72" ESTIMABLE="YES" ESTIMATE="-4.72" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-25 20:20:49 -0500" MODIFIED_BY="[Empty name]" ORDER="1174" SE="0.34" STUDY_ID="STD-Kahan-1985a" TOTAL_1="5" TOTAL_2="5" WEIGHT="13.172713830282621"/></IV_SUBGROUP><IV_SUBGROUP CHI2="63.24650395624544" CI_END="0.3449707821017544" CI_START="-0.3239187051126143" DF="2" EFFECT_SIZE="0.010526038494570065" ESTIMABLE="YES" I2="96.8377698767609" ID="CMP-003.02.02" LOG_CI_END="-0.46221768669290386" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-1.9777350460659584" MODIFIED="2016-02-07 17:59:46 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.8762769116165146E-14" P_Z="0.9508126560121992" STUDIES="3" TAU2="0.0" TOTAL_1="27" TOTAL_2="27" WEIGHT="52.297451276731614" Z="0.06168629270929993"><NAME>Secondary RP</NAME><IV_DATA CI_END="-2.1672154866477764" CI_START="-3.852784513352223" EFFECT_SIZE="-3.01" ESTIMABLE="YES" ESTIMATE="-3.01" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-25 20:20:49 -0500" MODIFIED_BY="[Empty name]" ORDER="888" SE="0.43" STUDY_ID="STD-Kahan-1985a" TOTAL_1="10" TOTAL_2="10" WEIGHT="8.235617732724021"/><IV_DATA CI_END="1.0323931570626104" CI_START="0.2876068429373897" EFFECT_SIZE="0.66" ESTIMABLE="YES" ESTIMATE="0.66" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-25 20:20:49 -0500" MODIFIED_BY="[Empty name]" ORDER="603" SE="0.19" STUDY_ID="STD-Kirch-1987" TOTAL_1="10" TOTAL_2="10" WEIGHT="42.18187586650059"/><IV_DATA CI_END="0.4339675860860488" CI_START="-3.093967586086049" EFFECT_SIZE="-1.33" ESTIMABLE="YES" ESTIMATE="-1.33" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-25 20:20:49 -0500" MODIFIED_BY="[Empty name]" ORDER="606" SE="0.9" STUDY_ID="STD-Malamet-1984" TOTAL_1="7" TOTAL_2="7" WEIGHT="1.8799576775070015"/></IV_SUBGROUP></IV_OUTCOME></COMPARISON><COMPARISON ID="CMP-004" MODIFIED="2017-11-14 03:13:30 -0500" MODIFIED_BY="[Empty name]" NO="4"><NAME>Subgroup analysis by CCB class</NAME><IV_OUTCOME CHI2="969.1378696563589" CI_END="-5.6118652588238245" CI_START="-6.531557871604294" CI_STUDY="95" CI_TOTAL="95" DF="22" EFFECT_SIZE="-6.071711565214059" ESTIMABLE="YES" I2="97.72994114781616" I2_Q="69.90119930839688" ID="CMP-004.01" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" MODIFIED="2017-11-14 03:12:51 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="-2.220446049250313E-16" P_Q="0.06834241836813049" P_Z="0.0" Q="3.322391514021279" RANDOM="NO" SCALE="25.9" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="23" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="511" TOTAL_2="513" WEIGHT="99.99999999999999" Z="25.878942218220242"><NAME>Frequency of attacks (average/week)</NAME><GROUP_LABEL_1>CCBs</GROUP_LABEL_1><GROUP_LABEL_2>Placebo</GROUP_LABEL_2><GRAPH_LABEL_1>Favours CCBs</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2><EFFECT_MEASURE>Mean Difference</EFFECT_MEASURE><IV_SUBGROUP CHI2="965.8154781423375" CI_END="-5.669560874849694" CI_START="-6.599053134287532" DF="21" EFFECT_SIZE="-6.134307004568613" ESTIMABLE="YES" I2="97.82567162410861" ID="CMP-004.01.01" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2017-11-14 03:12:34 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.1102230246251565E-16" P_Z="0.0" STUDIES="22" TAU2="0.0" TOTAL_1="495" TOTAL_2="497" WEIGHT="97.90251340566748" Z="25.870082675756425"><NAME>Dihydropyridines vs placebo</NAME><IV_DATA CI_END="-2.32127311138369" CI_START="-10.27872688861631" EFFECT_SIZE="-6.3" ESTIMABLE="YES" ESTIMATE="-6.3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-23 10:47:00 -0500" MODIFIED_BY="[Empty name]" ORDER="569" SE="2.03" STUDY_ID="STD-Aldoori-1986" TOTAL_1="9" TOTAL_2="9" WEIGHT="1.3357867985552305"/><IV_DATA CI_END="2.0047593025302612" CI_START="-2.424759302530261" EFFECT_SIZE="-0.21" ESTIMABLE="YES" ESTIMATE="-0.21" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-24 15:39:05 -0500" MODIFIED_BY="[Empty name]" ORDER="572" SE="1.13" STUDY_ID="STD-Challenor-1987" TOTAL_1="36" TOTAL_2="36" WEIGHT="4.3109435493509665"/><IV_DATA CI_END="-0.9988349349961474" CI_START="-4.801165065003852" EFFECT_SIZE="-2.9" ESTIMABLE="YES" ESTIMATE="-2.9" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-23 10:47:00 -0500" MODIFIED_BY="[Empty name]" ORDER="574" SE="0.97" STUDY_ID="STD-Challenor-1989" TOTAL_1="22" TOTAL_2="22" WEIGHT="5.850402612569081"/><IV_DATA CI_END="-4.5748403373151385" CI_START="-8.965159662684862" EFFECT_SIZE="-6.77" ESTIMABLE="YES" ESTIMATE="-6.77" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-23 10:47:00 -0500" MODIFIED_BY="[Empty name]" ORDER="1158" SE="1.12" STUDY_ID="STD-Corbin-1986" TOTAL_1="23" TOTAL_2="23" WEIGHT="4.388268349941204"/><IV_DATA CI_END="0.44273949402729107" CI_START="-6.142739494027291" EFFECT_SIZE="-2.85" ESTIMABLE="YES" ESTIMATE="-2.85" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-23 10:47:00 -0500" MODIFIED_BY="[Empty name]" ORDER="1159" SE="1.68" STUDY_ID="STD-Ettinger-1984" TOTAL_1="19" TOTAL_2="19" WEIGHT="1.950341488862758"/><IV_DATA CI_END="-2.002091839422862" CI_START="-11.997908160577138" EFFECT_SIZE="-7.0" ESTIMABLE="YES" ESTIMATE="-7.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-23 10:47:00 -0500" MODIFIED_BY="[Empty name]" ORDER="1164" SE="2.55" STUDY_ID="STD-Ferri-1992" TOTAL_1="18" TOTAL_2="18" WEIGHT="0.84654268637697"/><IV_DATA CI_END="0.0671164441329255" CI_START="-9.027116444132925" EFFECT_SIZE="-4.48" ESTIMABLE="YES" ESTIMATE="-4.48" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-23 10:47:00 -0500" MODIFIED_BY="[Empty name]" ORDER="1166" SE="2.32" STUDY_ID="STD-Finch-1988" TOTAL_1="15" TOTAL_2="15" WEIGHT="1.0227117676438482"/><IV_DATA CI_END="0.37397658995103533" CI_START="-2.1739765899510353" EFFECT_SIZE="-0.9" ESTIMABLE="YES" ESTIMATE="-0.9" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-23 10:47:00 -0500" MODIFIED_BY="[Empty name]" ORDER="577" SE="0.65" STUDY_ID="STD-French-Co_x002d_op-1991" TOTAL_1="60" TOTAL_2="60" WEIGHT="13.028742764890524"/><IV_DATA CI_END="-0.5852406974697386" CI_START="-5.014759302530261" EFFECT_SIZE="-2.8" ESTIMABLE="YES" ESTIMATE="-2.8" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-23 10:47:00 -0500" MODIFIED_BY="[Empty name]" ORDER="1169" SE="1.13" STUDY_ID="STD-Gjorup-1986a" TOTAL_1="19" TOTAL_2="19" WEIGHT="4.3109435493509665"/><IV_DATA CI_END="-1.0064237702035639" CI_START="-3.5935762297964358" EFFECT_SIZE="-2.3" ESTIMABLE="YES" ESTIMATE="-2.3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-23 10:47:00 -0500" MODIFIED_BY="[Empty name]" ORDER="1171" SE="0.66" STUDY_ID="STD-Hawkins-1985" TOTAL_1="57" TOTAL_2="57" WEIGHT="12.636923365854562"/><IV_DATA CI_END="-8.028443578706534" CI_START="-12.771556421293466" EFFECT_SIZE="-10.4" ESTIMABLE="YES" ESTIMATE="-10.4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-23 10:47:00 -0500" MODIFIED_BY="[Empty name]" ORDER="1173" SE="1.21" STUDY_ID="STD-Kahan-1985a" TOTAL_1="15" TOTAL_2="15" WEIGHT="3.759745794799705"/><IV_DATA CI_END="-20.352820528812167" CI_START="-22.58717947118783" EFFECT_SIZE="-21.47" ESTIMABLE="YES" ESTIMATE="-21.47" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-23 10:47:00 -0500" MODIFIED_BY="[Empty name]" ORDER="600" SE="0.57" STUDY_ID="STD-Kahan-1985c" TOTAL_1="30" TOTAL_2="30" WEIGHT="16.942578695494763"/><IV_DATA CI_END="-0.9656410576243384" CI_START="-5.4343589423756615" EFFECT_SIZE="-3.2" ESTIMABLE="YES" ESTIMATE="-3.2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-23 10:47:00 -0500" MODIFIED_BY="[Empty name]" ORDER="1178" SE="1.14" STUDY_ID="STD-Kahan-1987" TOTAL_1="20" TOTAL_2="20" WEIGHT="4.235644673873691"/><IV_DATA CI_END="6.294322926915717" CI_START="-2.094322926915716" EFFECT_SIZE="2.1" ESTIMABLE="YES" ESTIMATE="2.1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-23 10:47:00 -0500" MODIFIED_BY="[Empty name]" ORDER="601" SE="2.14" STUDY_ID="STD-Kirch-1987" TOTAL_1="10" TOTAL_2="10" WEIGHT="1.2019922740340307"/><IV_DATA CI_END="3.2902743060447897" CI_START="-10.39027430604479" EFFECT_SIZE="-3.55" ESTIMABLE="YES" ESTIMATE="-3.55" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-23 10:47:00 -0500" MODIFIED_BY="[Empty name]" ORDER="604" SE="3.49" STUDY_ID="STD-Malamet-1984" TOTAL_1="7" TOTAL_2="7" WEIGHT="0.45193748968943165"/><IV_DATA CI_END="2.23152040583352" CI_START="-6.4315204058335205" EFFECT_SIZE="-2.1" ESTIMABLE="YES" ESTIMATE="-2.1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-23 10:47:00 -0500" MODIFIED_BY="[Empty name]" ORDER="608" SE="2.21" STUDY_ID="STD-Meyrick-Thomas-1987" TOTAL_1="9" TOTAL_2="9" WEIGHT="1.1270538723953742"/><IV_DATA CI_END="0.16676110330325877" CI_START="-4.066761103303259" EFFECT_SIZE="-1.95" ESTIMABLE="YES" ESTIMATE="-1.95" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-23 10:47:00 -0500" MODIFIED_BY="[Empty name]" ORDER="610" SE="1.08" STUDY_ID="STD-Rodeheffer-1983" TOTAL_1="15" TOTAL_2="15" WEIGHT="4.719344837248154"/><IV_DATA CI_END="-0.5292352951507471" CI_START="-4.370764704849253" EFFECT_SIZE="-2.45" ESTIMABLE="YES" ESTIMATE="-2.45" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-23 10:47:00 -0500" MODIFIED_BY="[Empty name]" ORDER="611" SE="0.98" STUDY_ID="STD-Rupp-1987" TOTAL_1="27" TOTAL_2="27" WEIGHT="5.731615804004839"/><IV_DATA CI_END="11.760202275124898" CI_START="-9.760202275124898" EFFECT_SIZE="1.0" ESTIMABLE="YES" ESTIMATE="1.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-23 10:47:00 -0500" MODIFIED_BY="[Empty name]" ORDER="576" SE="5.49" STUDY_ID="STD-Sarkozi--1986" TOTAL_1="15" TOTAL_2="17" WEIGHT="0.18263522079111372"/><IV_DATA CI_END="-5.087660866127308" CI_START="-11.712339133872693" EFFECT_SIZE="-8.4" ESTIMABLE="YES" ESTIMATE="-8.4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-23 10:47:00 -0500" MODIFIED_BY="[Empty name]" ORDER="614" SE="1.69" STUDY_ID="STD-Smith-1982" TOTAL_1="17" TOTAL_2="17" WEIGHT="1.9273288113743385"/><IV_DATA CI_END="-0.3636392568513407" CI_START="-4.636360743148659" EFFECT_SIZE="-2.5" ESTIMABLE="YES" ESTIMATE="-2.5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-23 10:47:00 -0500" MODIFIED_BY="[Empty name]" ORDER="616" SE="1.09" STUDY_ID="STD-Waller-1986" TOTAL_1="27" TOTAL_2="27" WEIGHT="4.633148571808978"/><IV_DATA CI_END="0.42835354005667003" CI_START="-4.62835354005667" EFFECT_SIZE="-2.1" ESTIMABLE="YES" ESTIMATE="-2.1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-23 10:47:00 -0500" MODIFIED_BY="[Empty name]" ORDER="618" SE="1.29" STUDY_ID="STD-Wigley-1987" TOTAL_1="25" TOTAL_2="25" WEIGHT="3.3078804267569537"/></IV_SUBGROUP><IV_SUBGROUP CHI2="0.0" CI_END="0.025141654954888182" CI_START="-6.325141654954888" DF="0" EFFECT_SIZE="-3.15" ESTIMABLE="YES" I2="0.0" ID="CMP-004.01.02" LOG_CI_END="-1.599606138180702" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2017-11-14 03:12:51 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.051841878717651564" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="16" WEIGHT="2.097486594332513" Z="1.9444444444444442"><NAME>Non-dihydropyridines vs placebo</NAME><IV_DATA CI_END="0.025141654954888182" CI_START="-6.325141654954888" EFFECT_SIZE="-3.15" ESTIMABLE="YES" ESTIMATE="-3.15" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-23 10:49:21 -0500" MODIFIED_BY="[Empty name]" ORDER="1175" SE="1.62" STUDY_ID="STD-Kahan-1985b" TOTAL_1="16" TOTAL_2="16" WEIGHT="2.097486594332513"/></IV_SUBGROUP></IV_OUTCOME><IV_OUTCOME CHI2="944.6350932885405" CI_END="-5.803400698751631" CI_START="-6.733250610502367" CI_STUDY="95" CI_TOTAL="95" DF="21" EFFECT_SIZE="-6.268325654626999" ESTIMABLE="YES" I2="97.77691934703664" I2_Q="98.83744070063817" ID="CMP-004.02" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" MODIFIED="2017-11-14 03:13:00 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="-2.886579864025407E-15" P_Q="1.887379141862766E-15" P_Z="0.0" Q="172.0342352513015" RANDOM="NO" SCALE="25.9" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="21" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="479" TOTAL_2="481" WEIGHT="99.99999999999999" Z="26.42510876471597"><NAME>Frequency of attacks (average/week)</NAME><GROUP_LABEL_1>CCBs</GROUP_LABEL_1><GROUP_LABEL_2>Placebo</GROUP_LABEL_2><GRAPH_LABEL_1>Favours CCBs</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2><EFFECT_MEASURE>Mean Difference</EFFECT_MEASURE><IV_SUBGROUP CHI2="764.5349653101111" CI_END="-8.033887916375761" CI_START="-9.200674219976026" DF="14" EFFECT_SIZE="-8.617281068175894" ESTIMABLE="YES" I2="98.16882148819428" ID="CMP-004.02.01" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2016-01-31 17:31:46 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="-2.220446049250313E-16" P_Z="0.0" STUDIES="15" TAU2="0.0" TOTAL_1="290" TOTAL_2="292" WEIGHT="63.510139023623864" Z="28.950563588497264"><NAME>Nifedipine vs placebo</NAME><IV_DATA CI_END="-2.32127311138369" CI_START="-10.27872688861631" EFFECT_SIZE="-6.3" ESTIMABLE="YES" ESTIMATE="-6.3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-31 17:05:49 -0500" MODIFIED_BY="[Empty name]" ORDER="569" SE="2.03" STUDY_ID="STD-Aldoori-1986" TOTAL_1="9" TOTAL_2="9" WEIGHT="1.3654552109760794"/><IV_DATA CI_END="-0.9988349349961474" CI_START="-4.801165065003852" EFFECT_SIZE="-2.9" ESTIMABLE="YES" ESTIMATE="-2.9" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-31 17:05:49 -0500" MODIFIED_BY="[Empty name]" ORDER="574" SE="0.97" STUDY_ID="STD-Challenor-1989" TOTAL_1="22" TOTAL_2="22" WEIGHT="5.980342628240328"/><IV_DATA CI_END="-4.5748403373151385" CI_START="-8.965159662684862" EFFECT_SIZE="-6.77" ESTIMABLE="YES" ESTIMATE="-6.77" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-31 17:05:49 -0500" MODIFIED_BY="[Empty name]" ORDER="1158" SE="1.12" STUDY_ID="STD-Corbin-1986" TOTAL_1="23" TOTAL_2="23" WEIGHT="4.485733720433133"/><IV_DATA CI_END="0.44273949402729107" CI_START="-6.142739494027291" EFFECT_SIZE="-2.85" ESTIMABLE="YES" ESTIMATE="-2.85" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-31 17:05:49 -0500" MODIFIED_BY="[Empty name]" ORDER="1159" SE="1.68" STUDY_ID="STD-Ettinger-1984" TOTAL_1="19" TOTAL_2="19" WEIGHT="1.9936594313036153"/><IV_DATA CI_END="0.0671164441329255" CI_START="-9.027116444132925" EFFECT_SIZE="-4.48" ESTIMABLE="YES" ESTIMATE="-4.48" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-31 17:05:49 -0500" MODIFIED_BY="[Empty name]" ORDER="1166" SE="2.32" STUDY_ID="STD-Finch-1988" TOTAL_1="15" TOTAL_2="15" WEIGHT="1.0454266459035606"/><IV_DATA CI_END="-1.0064237702035639" CI_START="-3.5935762297964358" EFFECT_SIZE="-2.3" ESTIMABLE="YES" ESTIMATE="-2.3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-31 17:05:49 -0500" MODIFIED_BY="[Empty name]" ORDER="1171" SE="0.66" STUDY_ID="STD-Hawkins-1985" TOTAL_1="57" TOTAL_2="57" WEIGHT="12.917594992909374"/><IV_DATA CI_END="-8.028443578706534" CI_START="-12.771556421293466" EFFECT_SIZE="-10.4" ESTIMABLE="YES" ESTIMATE="-10.4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-31 17:05:49 -0500" MODIFIED_BY="[Empty name]" ORDER="1173" SE="1.21" STUDY_ID="STD-Kahan-1985a" TOTAL_1="15" TOTAL_2="15" WEIGHT="3.84325140284907"/><IV_DATA CI_END="-20.352820528812167" CI_START="-22.58717947118783" EFFECT_SIZE="-21.47" ESTIMABLE="YES" ESTIMATE="-21.47" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-31 17:05:49 -0500" MODIFIED_BY="[Empty name]" ORDER="600" SE="0.57" STUDY_ID="STD-Kahan-1985c" TOTAL_1="30" TOTAL_2="30" WEIGHT="17.318880821518388"/><IV_DATA CI_END="6.294322926915717" CI_START="-2.094322926915716" EFFECT_SIZE="2.1" ESTIMABLE="YES" ESTIMATE="2.1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-31 17:05:49 -0500" MODIFIED_BY="[Empty name]" ORDER="601" SE="2.14" STUDY_ID="STD-Kirch-1987" TOTAL_1="10" TOTAL_2="10" WEIGHT="1.228689051207818"/><IV_DATA CI_END="3.2902743060447897" CI_START="-10.39027430604479" EFFECT_SIZE="-3.55" ESTIMABLE="YES" ESTIMATE="-3.55" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-31 17:05:49 -0500" MODIFIED_BY="[Empty name]" ORDER="604" SE="3.49" STUDY_ID="STD-Malamet-1984" TOTAL_1="7" TOTAL_2="7" WEIGHT="0.4619752201469054"/><IV_DATA CI_END="2.23152040583352" CI_START="-6.4315204058335205" EFFECT_SIZE="-2.1" ESTIMABLE="YES" ESTIMATE="-2.1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-31 17:05:49 -0500" MODIFIED_BY="[Empty name]" ORDER="608" SE="2.21" STUDY_ID="STD-Meyrick-Thomas-1987" TOTAL_1="9" TOTAL_2="9" WEIGHT="1.1520862347026726"/><IV_DATA CI_END="0.16676110330325877" CI_START="-4.066761103303259" EFFECT_SIZE="-1.95" ESTIMABLE="YES" ESTIMATE="-1.95" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-31 17:05:49 -0500" MODIFIED_BY="[Empty name]" ORDER="610" SE="1.08" STUDY_ID="STD-Rodeheffer-1983" TOTAL_1="15" TOTAL_2="15" WEIGHT="4.824163562166772"/><IV_DATA CI_END="11.760202275124898" CI_START="-9.760202275124898" EFFECT_SIZE="1.0" ESTIMABLE="YES" ESTIMATE="1.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-31 17:05:49 -0500" MODIFIED_BY="[Empty name]" ORDER="576" SE="5.49" STUDY_ID="STD-Sarkozi--1986" TOTAL_1="15" TOTAL_2="17" WEIGHT="0.18669162938780307"/><IV_DATA CI_END="-5.087660866127308" CI_START="-11.712339133872693" EFFECT_SIZE="-8.4" ESTIMABLE="YES" ESTIMATE="-8.4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-31 17:05:49 -0500" MODIFIED_BY="[Empty name]" ORDER="614" SE="1.69" STUDY_ID="STD-Smith-1982" TOTAL_1="17" TOTAL_2="17" WEIGHT="1.970135632124689"/><IV_DATA CI_END="-0.3636392568513407" CI_START="-4.636360743148659" EFFECT_SIZE="-2.5" ESTIMABLE="YES" ESTIMATE="-2.5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-31 17:05:49 -0500" MODIFIED_BY="[Empty name]" ORDER="616" SE="1.09" STUDY_ID="STD-Waller-1986" TOTAL_1="27" TOTAL_2="27" WEIGHT="4.736052839753659"/></IV_SUBGROUP><IV_SUBGROUP CHI2="8.003792979407773" CI_END="-1.0399082947398588" CI_START="-2.804947559915218" DF="4" EFFECT_SIZE="-1.9224279273275384" ESTIMABLE="YES" I2="50.023694887021264" ID="CMP-004.02.02" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2016-01-31 17:31:46 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.09143940349470825" P_Z="1.959395880559475E-5" STUDIES="5" TAU2="0.0" TOTAL_1="150" TOTAL_2="150" WEIGHT="27.753449268990636" Z="4.2694681923255855"><NAME>Nicardipine vs placebo</NAME><IV_DATA CI_END="-2.002091839422862" CI_START="-11.997908160577138" EFFECT_SIZE="-7.0" ESTIMABLE="YES" ESTIMATE="-7.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-31 17:05:49 -0500" MODIFIED_BY="[Empty name]" ORDER="1164" SE="2.55" STUDY_ID="STD-Ferri-1992" TOTAL_1="18" TOTAL_2="18" WEIGHT="0.8653447718433409"/><IV_DATA CI_END="0.37397658995103533" CI_START="-2.1739765899510353" EFFECT_SIZE="-0.9" ESTIMABLE="YES" ESTIMATE="-0.9" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-31 17:05:49 -0500" MODIFIED_BY="[Empty name]" ORDER="577" SE="0.65" STUDY_ID="STD-French-Co_x002d_op-1991" TOTAL_1="60" TOTAL_2="60" WEIGHT="13.318116873162893"/><IV_DATA CI_END="-0.9656410576243384" CI_START="-5.4343589423756615" EFFECT_SIZE="-3.2" ESTIMABLE="YES" ESTIMATE="-3.2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-31 17:05:49 -0500" MODIFIED_BY="[Empty name]" ORDER="1178" SE="1.14" STUDY_ID="STD-Kahan-1987" TOTAL_1="20" TOTAL_2="20" WEIGHT="4.329720205379597"/><IV_DATA CI_END="-0.5292352951507471" CI_START="-4.370764704849253" EFFECT_SIZE="-2.45" ESTIMABLE="YES" ESTIMATE="-2.45" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-31 17:05:49 -0500" MODIFIED_BY="[Empty name]" ORDER="611" SE="0.98" STUDY_ID="STD-Rupp-1987" TOTAL_1="27" TOTAL_2="27" WEIGHT="5.858917512402461"/><IV_DATA CI_END="0.42835354005667003" CI_START="-4.62835354005667" EFFECT_SIZE="-2.1" ESTIMABLE="YES" ESTIMATE="-2.1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-31 17:05:49 -0500" MODIFIED_BY="[Empty name]" ORDER="618" SE="1.29" STUDY_ID="STD-Wigley-1987" TOTAL_1="25" TOTAL_2="25" WEIGHT="3.3813499062023453"/></IV_SUBGROUP><IV_SUBGROUP CHI2="0.06209974771977501" CI_END="-1.4252828682771441" CI_START="-4.571192971039757" DF="1" EFFECT_SIZE="-2.9982379196584508" ESTIMABLE="YES" I2="0.0" ID="CMP-004.02.03" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2016-01-31 17:31:46 -0500" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.8032074672540623" P_Z="1.8702818708974024E-4" STUDIES="2" TAU2="0.0" TOTAL_1="39" TOTAL_2="39" WEIGHT="8.73641170738549" Z="3.7359226091377535"><NAME>Nisoldipine vs placebo</NAME><IV_DATA CI_END="-0.5852406974697386" CI_START="-5.014759302530261" EFFECT_SIZE="-2.8" ESTIMABLE="YES" ESTIMATE="-2.8" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-31 17:05:49 -0500" MODIFIED_BY="[Empty name]" ORDER="1169" SE="1.13" STUDY_ID="STD-Gjorup-1986a" TOTAL_1="19" TOTAL_2="19" WEIGHT="4.406691502005893"/><IV_DATA CI_END="-0.9656410576243384" CI_START="-5.4343589423756615" EFFECT_SIZE="-3.2" ESTIMABLE="YES" ESTIMATE="-3.2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-31 17:05:49 -0500" MODIFIED_BY="[Empty name]" ORDER="1178" SE="1.14" STUDY_ID="STD-Kahan-1987" TOTAL_1="20" TOTAL_2="20" WEIGHT="4.329720205379597"/></IV_SUBGROUP></IV_OUTCOME><IV_OUTCOME CHI2="187.0009534924303" CI_END="-0.5093952201934386" CI_START="-0.7231830497121683" CI_STUDY="95" CI_TOTAL="95" DF="15" EFFECT_SIZE="-0.6162891349528035" ESTIMABLE="YES" I2="91.97865052564708" I2_Q="81.97453890868191" ID="CMP-004.03" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" MODIFIED="2017-11-14 03:13:21 -0500" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="-2.220446049250313E-16" P_Q="0.018505006378241817" P_Z="1.3117227249800086E-29" Q="5.547708294028869" RANDOM="NO" SCALE="7.72" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="16" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="374" TOTAL_2="374" WEIGHT="100.00000000000003" Z="11.300030607822947"><NAME>Severity of attacks (average, on a 10-cm VAS)</NAME><GROUP_LABEL_1>CCBs</GROUP_LABEL_1><GROUP_LABEL_2>Placebo</GROUP_LABEL_2><GRAPH_LABEL_1>Favours CCBs</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2><EFFECT_MEASURE>Mean Difference</EFFECT_MEASURE><IV_SUBGROUP CHI2="181.45324519840142" CI_END="-0.49701003488028456" CI_START="-0.7117171552678109" DF="14" EFFECT_SIZE="-0.6043635950740477" ESTIMABLE="YES" I2="92.28451385110674" ID="CMP-004.03.01" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2016-01-31 17:45:06 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="-4.440892098500626E-16" P_Z="2.6217466245839526E-28" STUDIES="15" TAU2="0.0" TOTAL_1="358" TOTAL_2="358" WEIGHT="99.14551241020484" Z="11.033922654957273"><NAME>Dihydropyridines vs placebo</NAME><IV_DATA CI_END="-0.18840756324658858" CI_START="-1.0115924367534115" EFFECT_SIZE="-0.6" ESTIMABLE="YES" ESTIMATE="-0.6" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-23 10:47:00 -0500" MODIFIED_BY="[Empty name]" ORDER="575" SE="0.21" STUDY_ID="STD-Challenor-1989" TOTAL_1="22" TOTAL_2="22" WEIGHT="6.744832879993222"/><IV_DATA CI_END="1.2931578619118635" CI_START="-3.2931578619118635" EFFECT_SIZE="-1.0" ESTIMABLE="YES" ESTIMATE="-1.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-23 10:47:00 -0500" MODIFIED_BY="[Empty name]" ORDER="1161" SE="1.17" STUDY_ID="STD-Ettinger-1984" TOTAL_1="19" TOTAL_2="19" WEIGHT="0.2172891591845285"/><IV_DATA CI_END="-1.490409364019586" CI_START="-2.5095906359804143" EFFECT_SIZE="-2.0" ESTIMABLE="YES" ESTIMATE="-2.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-23 10:47:00 -0500" MODIFIED_BY="[Empty name]" ORDER="1165" SE="0.26" STUDY_ID="STD-Ferri-1992" TOTAL_1="18" TOTAL_2="18" WEIGHT="4.400105473486701"/><IV_DATA CI_END="-0.6052136858747794" CI_START="-2.094786314125221" EFFECT_SIZE="-1.35" ESTIMABLE="YES" ESTIMATE="-1.35" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-23 10:47:00 -0500" MODIFIED_BY="[Empty name]" ORDER="1168" SE="0.38" STUDY_ID="STD-Finch-1988" TOTAL_1="15" TOTAL_2="15" WEIGHT="2.0598831717984836"/><IV_DATA CI_END="-0.029608643710387017" CI_START="-0.9703913562896129" EFFECT_SIZE="-0.5" ESTIMABLE="YES" ESTIMATE="-0.5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-23 10:47:00 -0500" MODIFIED_BY="[Empty name]" ORDER="578" SE="0.24" STUDY_ID="STD-French-Co_x002d_op-1991" TOTAL_1="60" TOTAL_2="60" WEIGHT="5.16401267374481"/><IV_DATA CI_END="-0.2216104444833843" CI_START="-1.3583895555166157" EFFECT_SIZE="-0.79" ESTIMABLE="YES" ESTIMATE="-0.79" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-23 10:47:00 -0500" MODIFIED_BY="[Empty name]" ORDER="1170" SE="0.29" STUDY_ID="STD-Gjorup-1986a" TOTAL_1="19" TOTAL_2="19" WEIGHT="3.536826753956018"/><IV_DATA CI_END="-0.6568061226281907" CI_START="-1.3231938773718093" EFFECT_SIZE="-0.99" ESTIMABLE="YES" ESTIMATE="-0.99" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-23 10:47:00 -0500" MODIFIED_BY="[Empty name]" ORDER="1172" SE="0.17" STUDY_ID="STD-Hawkins-1985" TOTAL_1="57" TOTAL_2="57" WEIGHT="10.292288235560589"/><IV_DATA CI_END="-2.7572154866477767" CI_START="-4.4427845133522235" EFFECT_SIZE="-3.6" ESTIMABLE="YES" ESTIMATE="-3.6" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-23 10:47:00 -0500" MODIFIED_BY="[Empty name]" ORDER="1174" SE="0.43" STUDY_ID="STD-Kahan-1985a" TOTAL_1="15" TOTAL_2="15" WEIGHT="1.6086918875484104"/><IV_DATA CI_END="-0.5100090038649865" CI_START="-1.4899909961350135" EFFECT_SIZE="-1.0" ESTIMABLE="YES" ESTIMATE="-1.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-23 10:47:00 -0500" MODIFIED_BY="[Empty name]" ORDER="1177" SE="0.25" STUDY_ID="STD-Kahan-1987" TOTAL_1="20" TOTAL_2="20" WEIGHT="4.759154080123217"/><IV_DATA CI_END="1.0323931570626104" CI_START="0.2876068429373897" EFFECT_SIZE="0.66" ESTIMABLE="YES" ESTIMATE="0.66" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-23 10:47:00 -0500" MODIFIED_BY="[Empty name]" ORDER="603" SE="0.19" STUDY_ID="STD-Kirch-1987" TOTAL_1="10" TOTAL_2="10" WEIGHT="8.239532687193934"/><IV_DATA CI_END="0.4339675860860488" CI_START="-3.093967586086049" EFFECT_SIZE="-1.33" ESTIMABLE="YES" ESTIMATE="-1.33" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-23 10:47:00 -0500" MODIFIED_BY="[Empty name]" ORDER="606" SE="0.9" STUDY_ID="STD-Malamet-1984" TOTAL_1="7" TOTAL_2="7" WEIGHT="0.3672186790218531"/><IV_DATA CI_END="-0.09556320537593518" CI_START="-0.4444367946240648" EFFECT_SIZE="-0.27" ESTIMABLE="YES" ESTIMATE="-0.27" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-23 10:47:00 -0500" MODIFIED_BY="[Empty name]" ORDER="612" SE="0.089" STUDY_ID="STD-Rupp-1987" TOTAL_1="27" TOTAL_2="27" WEIGHT="37.55171443096845"/><IV_DATA CI_END="-1.6944129655655804" CI_START="-3.1055870344344196" EFFECT_SIZE="-2.4" ESTIMABLE="YES" ESTIMATE="-2.4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-23 10:47:00 -0500" MODIFIED_BY="[Empty name]" ORDER="615" SE="0.36" STUDY_ID="STD-Smith-1982" TOTAL_1="17" TOTAL_2="17" WEIGHT="2.2951167438865823"/><IV_DATA CI_END="-0.5884075632465886" CI_START="-1.4115924367534114" EFFECT_SIZE="-1.0" ESTIMABLE="YES" ESTIMATE="-1.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-23 10:47:00 -0500" MODIFIED_BY="[Empty name]" ORDER="617" SE="0.21" STUDY_ID="STD-Waller-1986" TOTAL_1="27" TOTAL_2="27" WEIGHT="6.744832879993222"/><IV_DATA CI_END="0.37039135628961295" CI_START="-0.570391356289613" EFFECT_SIZE="-0.1" ESTIMABLE="YES" ESTIMATE="-0.1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-23 10:47:00 -0500" MODIFIED_BY="[Empty name]" ORDER="619" SE="0.24" STUDY_ID="STD-Wigley-1987" TOTAL_1="25" TOTAL_2="25" WEIGHT="5.16401267374481"/></IV_SUBGROUP><IV_SUBGROUP CHI2="0.0" CI_END="-0.8436212491213679" CI_START="-3.1563787508786323" DF="0" EFFECT_SIZE="-2.0" ESTIMABLE="YES" I2="0.0" ID="CMP-004.03.02" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2017-11-14 03:13:21 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="6.993584867112831E-4" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="16" WEIGHT="0.8544875897951769" Z="3.3898305084745766"><NAME>Non-dihydropyridines vs placebo</NAME><IV_DATA CI_END="-0.8436212491213679" CI_START="-3.1563787508786323" EFFECT_SIZE="-2.0" ESTIMABLE="YES" ESTIMATE="-2.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-23 10:51:31 -0500" MODIFIED_BY="[Empty name]" ORDER="1176" SE="0.59" STUDY_ID="STD-Kahan-1985b" TOTAL_1="16" TOTAL_2="16" WEIGHT="0.8544875897951769"/></IV_SUBGROUP></IV_OUTCOME><IV_OUTCOME CHI2="181.4532451984014" CI_END="-0.49701003488028456" CI_START="-0.7117171552678108" CI_STUDY="95" CI_TOTAL="95" DF="14" EFFECT_SIZE="-0.6043635950740477" ESTIMABLE="YES" I2="92.28451385110672" I2_Q="75.5397934566101" ID="CMP-004.04" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" MODIFIED="2017-11-14 03:13:30 -0500" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="-1.1102230246251565E-15" P_Q="0.01676824044252534" P_Z="2.6217466245839526E-28" Q="8.176545837633077" RANDOM="NO" SCALE="7.1" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="15" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="358" TOTAL_2="358" WEIGHT="100.0" Z="11.033922654957273"><NAME>Severity of attacks (average, on a 10-cm VAS)</NAME><GROUP_LABEL_1>CCBs</GROUP_LABEL_1><GROUP_LABEL_2>Placebo</GROUP_LABEL_2><GRAPH_LABEL_1>Favours CCBs</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2><EFFECT_MEASURE>Mean Difference</EFFECT_MEASURE><IV_SUBGROUP CHI2="126.71138050695538" CI_END="-0.6142263271672403" CI_START="-0.9584652108163223" DF="8" EFFECT_SIZE="-0.7863457689917813" ESTIMABLE="YES" I2="93.68643923853321" ID="CMP-004.04.01" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2016-02-07 13:25:02 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.9984014443252818E-15" P_Z="3.418931272965684E-19" STUDIES="9" TAU2="0.0" TOTAL_1="189" TOTAL_2="189" WEIGHT="38.90209994034075" Z="8.954301561066286"><NAME>Nifedipine vs placebo</NAME><IV_DATA CI_END="-0.18840756324658858" CI_START="-1.0115924367534115" EFFECT_SIZE="-0.6" ESTIMABLE="YES" ESTIMATE="-0.6" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-31 17:05:57 -0500" MODIFIED_BY="[Empty name]" ORDER="575" SE="0.21" STUDY_ID="STD-Challenor-1989" TOTAL_1="22" TOTAL_2="22" WEIGHT="6.802963357622418"/><IV_DATA CI_END="1.2931578619118635" CI_START="-3.2931578619118635" EFFECT_SIZE="-1.0" ESTIMABLE="YES" ESTIMATE="-1.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-31 17:05:57 -0500" MODIFIED_BY="[Empty name]" ORDER="1161" SE="1.17" STUDY_ID="STD-Ettinger-1984" TOTAL_1="19" TOTAL_2="19" WEIGHT="0.21916187016666566"/><IV_DATA CI_END="-0.6052136858747794" CI_START="-2.094786314125221" EFFECT_SIZE="-1.35" ESTIMABLE="YES" ESTIMATE="-1.35" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-02-07 13:24:58 -0500" MODIFIED_BY="[Empty name]" ORDER="1168" SE="0.38" STUDY_ID="STD-Finch-1988" TOTAL_1="15" TOTAL_2="15" WEIGHT="2.0776363162821925"/><IV_DATA CI_END="-0.6568061226281907" CI_START="-1.3231938773718093" EFFECT_SIZE="-0.99" ESTIMABLE="YES" ESTIMATE="-0.99" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-02-07 13:24:55 -0500" MODIFIED_BY="[Empty name]" ORDER="1172" SE="0.17" STUDY_ID="STD-Hawkins-1985" TOTAL_1="57" TOTAL_2="57" WEIGHT="10.380992528413445"/><IV_DATA CI_END="-2.7572154866477767" CI_START="-4.4427845133522235" EFFECT_SIZE="-3.6" ESTIMABLE="YES" ESTIMATE="-3.6" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-02-07 13:25:02 -0500" MODIFIED_BY="[Empty name]" ORDER="1174" SE="0.43" STUDY_ID="STD-Kahan-1985a" TOTAL_1="15" TOTAL_2="15" WEIGHT="1.6225564308877698"/><IV_DATA CI_END="1.0323931570626104" CI_START="0.2876068429373897" EFFECT_SIZE="0.66" ESTIMABLE="YES" ESTIMATE="0.66" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-31 17:05:57 -0500" MODIFIED_BY="[Empty name]" ORDER="603" SE="0.19" STUDY_ID="STD-Kirch-1987" TOTAL_1="10" TOTAL_2="10" WEIGHT="8.31054526512877"/><IV_DATA CI_END="0.4339675860860488" CI_START="-3.093967586086049" EFFECT_SIZE="-1.33" ESTIMABLE="YES" ESTIMATE="-1.33" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-31 17:05:57 -0500" MODIFIED_BY="[Empty name]" ORDER="606" SE="0.9" STUDY_ID="STD-Malamet-1984" TOTAL_1="7" TOTAL_2="7" WEIGHT="0.37038356058166494"/><IV_DATA CI_END="-1.6944129655655804" CI_START="-3.1055870344344196" EFFECT_SIZE="-2.4" ESTIMABLE="YES" ESTIMATE="-2.4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-31 17:05:57 -0500" MODIFIED_BY="[Empty name]" ORDER="615" SE="0.36" STUDY_ID="STD-Smith-1982" TOTAL_1="17" TOTAL_2="17" WEIGHT="2.314897253635406"/><IV_DATA CI_END="-0.5884075632465886" CI_START="-1.4115924367534114" EFFECT_SIZE="-1.0" ESTIMABLE="YES" ESTIMATE="-1.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-31 17:05:57 -0500" MODIFIED_BY="[Empty name]" ORDER="617" SE="0.21" STUDY_ID="STD-Waller-1986" TOTAL_1="27" TOTAL_2="27" WEIGHT="6.802963357622418"/></IV_SUBGROUP><IV_SUBGROUP CHI2="46.56531885381297" CI_END="-0.32826069503079824" CI_START="-0.6113327705452904" DF="4" EFFECT_SIZE="-0.46979673278804435" ESTIMABLE="YES" I2="91.40991600947136" ID="CMP-004.04.02" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2016-01-31 17:57:35 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.8783179456249854E-9" P_Z="7.735541330882353E-11" STUDIES="5" TAU2="0.0" TOTAL_1="150" TOTAL_2="150" WEIGHT="57.530591093296" Z="6.505655315139087"><NAME>Nicardipine vs placebo</NAME><IV_DATA CI_END="-1.490409364019586" CI_START="-2.5095906359804143" EFFECT_SIZE="-2.0" ESTIMABLE="YES" ESTIMATE="-2.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-31 17:05:57 -0500" MODIFIED_BY="[Empty name]" ORDER="1165" SE="0.26" STUDY_ID="STD-Ferri-1992" TOTAL_1="18" TOTAL_2="18" WEIGHT="4.438027870874979"/><IV_DATA CI_END="-0.029608643710387017" CI_START="-0.9703913562896129" EFFECT_SIZE="-0.5" ESTIMABLE="YES" ESTIMATE="-0.5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-31 17:05:57 -0500" MODIFIED_BY="[Empty name]" ORDER="578" SE="0.24" STUDY_ID="STD-French-Co_x002d_op-1991" TOTAL_1="60" TOTAL_2="60" WEIGHT="5.2085188206796635"/><IV_DATA CI_END="-0.5100090038649865" CI_START="-1.4899909961350135" EFFECT_SIZE="-1.0" ESTIMABLE="YES" ESTIMATE="-1.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-31 17:05:57 -0500" MODIFIED_BY="[Empty name]" ORDER="1177" SE="0.25" STUDY_ID="STD-Kahan-1987" TOTAL_1="20" TOTAL_2="20" WEIGHT="4.800170945138378"/><IV_DATA CI_END="-0.09556320537593518" CI_START="-0.4444367946240648" EFFECT_SIZE="-0.27" ESTIMABLE="YES" ESTIMATE="-0.27" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-31 17:05:57 -0500" MODIFIED_BY="[Empty name]" ORDER="612" SE="0.089" STUDY_ID="STD-Rupp-1987" TOTAL_1="27" TOTAL_2="27" WEIGHT="37.87535463592332"/><IV_DATA CI_END="0.37039135628961295" CI_START="-0.570391356289613" EFFECT_SIZE="-0.1" ESTIMABLE="YES" ESTIMATE="-0.1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-31 17:05:57 -0500" MODIFIED_BY="[Empty name]" ORDER="619" SE="0.24" STUDY_ID="STD-Wigley-1987" TOTAL_1="25" TOTAL_2="25" WEIGHT="5.2085188206796635"/></IV_SUBGROUP><IV_SUBGROUP CHI2="0.0" CI_END="-0.2216104444833843" CI_START="-1.3583895555166157" DF="0" EFFECT_SIZE="-0.79" ESTIMABLE="YES" I2="0.0" ID="CMP-004.04.03" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2016-01-31 18:35:24 -0500" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.006446957566020439" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="19" WEIGHT="3.567308966363242" Z="2.724137931034483"><NAME>Nisoldipine vs placebo</NAME><IV_DATA CI_END="-0.2216104444833843" CI_START="-1.3583895555166157" EFFECT_SIZE="-0.79" ESTIMABLE="YES" ESTIMATE="-0.79" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-31 17:05:57 -0500" MODIFIED_BY="[Empty name]" ORDER="1170" SE="0.29" STUDY_ID="STD-Gjorup-1986a" TOTAL_1="19" TOTAL_2="19" WEIGHT="3.567308966363242"/></IV_SUBGROUP></IV_OUTCOME></COMPARISON><COMPARISON ID="CMP-005" MODIFIED="2017-11-14 03:15:30 -0500" MODIFIED_BY="[Empty name]" NO="5"><NAME>Subgroup analysis by CCB dose</NAME><IV_OUTCOME CHI2="969.137869656359" CI_END="-5.6118652588238245" CI_START="-6.531557871604294" CI_STUDY="95" CI_TOTAL="95" DF="22" EFFECT_SIZE="-6.071711565214059" ESTIMABLE="YES" I2="97.72994114781618" I2_Q="99.47724476169448" ID="CMP-005.01" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" MODIFIED="2017-11-14 03:14:06 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.6653345369377348E-15" P_Q="9.992007221626409E-16" P_Z="0.0" Q="191.2941137120722" RANDOM="NO" SCALE="25.9" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="23" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="511" TOTAL_2="513" WEIGHT="100.0" Z="25.878942218220242"><NAME>Frequency of attacks (average/week)</NAME><GROUP_LABEL_1>CCBs</GROUP_LABEL_1><GROUP_LABEL_2>Placebo</GROUP_LABEL_2><GRAPH_LABEL_1>Favours CCBs</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2><EFFECT_MEASURE>Mean Difference</EFFECT_MEASURE><IV_SUBGROUP CHI2="40.838701075760284" CI_END="-2.365309352998972" CI_START="-3.6319638470265376" DF="13" EFFECT_SIZE="-2.998636600012755" ESTIMABLE="YES" I2="68.16744985134672" ID="CMP-005.01.01" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2017-11-14 03:13:58 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0119970481103913E-4" P_Z="1.696220676712527E-20" STUDIES="14" TAU2="0.0" TOTAL_1="309" TOTAL_2="311" WEIGHT="52.719230140281354" Z="9.279909819860851"><NAME>Low-dose CCBs vs placebo</NAME><IV_DATA CI_END="-2.32127311138369" CI_START="-10.27872688861631" EFFECT_SIZE="-6.3" ESTIMABLE="YES" ESTIMATE="-6.3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-12-25 13:08:24 -0500" MODIFIED_BY="[Empty name]" ORDER="569" SE="2.03" STUDY_ID="STD-Aldoori-1986" TOTAL_1="9" TOTAL_2="9" WEIGHT="1.3357867985552305"/><IV_DATA CI_END="2.0047593025302612" CI_START="-2.424759302530261" EFFECT_SIZE="-0.21" ESTIMABLE="YES" ESTIMATE="-0.21" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-24 15:39:26 -0500" MODIFIED_BY="[Empty name]" ORDER="572" SE="1.13" STUDY_ID="STD-Challenor-1987" TOTAL_1="36" TOTAL_2="36" WEIGHT="4.3109435493509665"/><IV_DATA CI_END="-0.9988349349961474" CI_START="-4.801165065003852" EFFECT_SIZE="-2.9" ESTIMABLE="YES" ESTIMATE="-2.9" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-12-25 13:08:24 -0500" MODIFIED_BY="[Empty name]" ORDER="574" SE="0.97" STUDY_ID="STD-Challenor-1989" TOTAL_1="22" TOTAL_2="22" WEIGHT="5.850402612569081"/><IV_DATA CI_END="-4.5748403373151385" CI_START="-8.965159662684862" EFFECT_SIZE="-6.77" ESTIMABLE="YES" ESTIMATE="-6.77" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-12-25 13:08:24 -0500" MODIFIED_BY="[Empty name]" ORDER="1158" SE="1.12" STUDY_ID="STD-Corbin-1986" TOTAL_1="23" TOTAL_2="23" WEIGHT="4.388268349941204"/><IV_DATA CI_END="-2.002091839422862" CI_START="-11.997908160577138" EFFECT_SIZE="-7.0" ESTIMABLE="YES" ESTIMATE="-7.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-12-25 13:08:24 -0500" MODIFIED_BY="[Empty name]" ORDER="1164" SE="2.55" STUDY_ID="STD-Ferri-1992" TOTAL_1="18" TOTAL_2="18" WEIGHT="0.84654268637697"/><IV_DATA CI_END="-0.5852406974697386" CI_START="-5.014759302530261" EFFECT_SIZE="-2.8" ESTIMABLE="YES" ESTIMATE="-2.8" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-12-25 13:08:24 -0500" MODIFIED_BY="[Empty name]" ORDER="1169" SE="1.13" STUDY_ID="STD-Gjorup-1986a" TOTAL_1="19" TOTAL_2="19" WEIGHT="4.3109435493509665"/><IV_DATA CI_END="-1.0064237702035639" CI_START="-3.5935762297964358" EFFECT_SIZE="-2.3" ESTIMABLE="YES" ESTIMATE="-2.3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-12-25 13:08:24 -0500" MODIFIED_BY="[Empty name]" ORDER="1171" SE="0.66" STUDY_ID="STD-Hawkins-1985" TOTAL_1="57" TOTAL_2="57" WEIGHT="12.636923365854562"/><IV_DATA CI_END="-0.9656410576243384" CI_START="-5.4343589423756615" EFFECT_SIZE="-3.2" ESTIMABLE="YES" ESTIMATE="-3.2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-12-25 13:08:24 -0500" MODIFIED_BY="[Empty name]" ORDER="1178" SE="1.14" STUDY_ID="STD-Kahan-1987" TOTAL_1="20" TOTAL_2="20" WEIGHT="4.235644673873691"/><IV_DATA CI_END="6.294322926915717" CI_START="-2.094322926915716" EFFECT_SIZE="2.1" ESTIMABLE="YES" ESTIMATE="2.1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-12-25 13:08:24 -0500" MODIFIED_BY="[Empty name]" ORDER="601" SE="2.14" STUDY_ID="STD-Kirch-1987" TOTAL_1="10" TOTAL_2="10" WEIGHT="1.2019922740340307"/><IV_DATA CI_END="2.23152040583352" CI_START="-6.4315204058335205" EFFECT_SIZE="-2.1" ESTIMABLE="YES" ESTIMATE="-2.1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-12-25 13:08:24 -0500" MODIFIED_BY="[Empty name]" ORDER="608" SE="2.21" STUDY_ID="STD-Meyrick-Thomas-1987" TOTAL_1="9" TOTAL_2="9" WEIGHT="1.1270538723953742"/><IV_DATA CI_END="-0.5292352951507471" CI_START="-4.370764704849253" EFFECT_SIZE="-2.45" ESTIMABLE="YES" ESTIMATE="-2.45" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-25 20:46:37 -0500" MODIFIED_BY="[Empty name]" ORDER="611" SE="0.98" STUDY_ID="STD-Rupp-1987" TOTAL_1="27" TOTAL_2="27" WEIGHT="5.731615804004839"/><IV_DATA CI_END="11.760202275124898" CI_START="-9.760202275124898" EFFECT_SIZE="1.0" ESTIMABLE="YES" ESTIMATE="1.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-25 20:46:41 -0500" MODIFIED_BY="[Empty name]" ORDER="576" SE="5.49" STUDY_ID="STD-Sarkozi--1986" TOTAL_1="15" TOTAL_2="17" WEIGHT="0.18263522079111372"/><IV_DATA CI_END="-5.087660866127308" CI_START="-11.712339133872693" EFFECT_SIZE="-8.4" ESTIMABLE="YES" ESTIMATE="-8.4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-25 20:46:55 -0500" MODIFIED_BY="[Empty name]" ORDER="614" SE="1.69" STUDY_ID="STD-Smith-1982" TOTAL_1="17" TOTAL_2="17" WEIGHT="1.9273288113743385"/><IV_DATA CI_END="-0.3636392568513407" CI_START="-4.636360743148659" EFFECT_SIZE="-2.5" ESTIMABLE="YES" ESTIMATE="-2.5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-12-25 13:08:24 -0500" MODIFIED_BY="[Empty name]" ORDER="616" SE="1.09" STUDY_ID="STD-Waller-1986" TOTAL_1="27" TOTAL_2="27" WEIGHT="4.633148571808978"/></IV_SUBGROUP><IV_SUBGROUP CHI2="737.0050548685265" CI_END="-8.829506089411893" CI_START="-10.167026531807782" DF="8" EFFECT_SIZE="-9.498266310609838" ESTIMABLE="YES" I2="98.91452576245531" ID="CMP-005.01.02" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2017-11-14 03:14:06 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="2.220446049250313E-15" P_Z="0.0" STUDIES="9" TAU2="0.0" TOTAL_1="202" TOTAL_2="202" WEIGHT="47.280769859718646" Z="27.83697249668693"><NAME>Medium/high-dose CCBs vs placebo</NAME><IV_DATA CI_END="0.44273949402729107" CI_START="-6.142739494027291" EFFECT_SIZE="-2.85" ESTIMABLE="YES" ESTIMATE="-2.85" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-31 18:46:09 -0500" MODIFIED_BY="[Empty name]" ORDER="1159" SE="1.68" STUDY_ID="STD-Ettinger-1984" TOTAL_1="19" TOTAL_2="19" WEIGHT="1.950341488862758"/><IV_DATA CI_END="0.0671164441329255" CI_START="-9.027116444132925" EFFECT_SIZE="-4.48" ESTIMABLE="YES" ESTIMATE="-4.48" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-31 18:46:12 -0500" MODIFIED_BY="[Empty name]" ORDER="1166" SE="2.32" STUDY_ID="STD-Finch-1988" TOTAL_1="15" TOTAL_2="15" WEIGHT="1.0227117676438482"/><IV_DATA CI_END="0.37397658995103533" CI_START="-2.1739765899510353" EFFECT_SIZE="-0.9" ESTIMABLE="YES" ESTIMATE="-0.9" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-02-03 19:32:40 -0500" MODIFIED_BY="[Empty name]" ORDER="577" SE="0.65" STUDY_ID="STD-French-Co_x002d_op-1991" TOTAL_1="60" TOTAL_2="60" WEIGHT="13.028742764890524"/><IV_DATA CI_END="-8.028443578706534" CI_START="-12.771556421293466" EFFECT_SIZE="-10.4" ESTIMABLE="YES" ESTIMATE="-10.4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-02-07 13:32:46 -0500" MODIFIED_BY="[Empty name]" ORDER="1173" SE="1.21" STUDY_ID="STD-Kahan-1985a" TOTAL_1="15" TOTAL_2="15" WEIGHT="3.759745794799705"/><IV_DATA CI_END="0.025141654954888182" CI_START="-6.325141654954888" EFFECT_SIZE="-3.15" ESTIMABLE="YES" ESTIMATE="-3.15" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-02-03 19:33:01 -0500" MODIFIED_BY="[Empty name]" ORDER="1175" SE="1.62" STUDY_ID="STD-Kahan-1985b" TOTAL_1="16" TOTAL_2="16" WEIGHT="2.097486594332513"/><IV_DATA CI_END="-20.352820528812167" CI_START="-22.58717947118783" EFFECT_SIZE="-21.47" ESTIMABLE="YES" ESTIMATE="-21.47" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-02-07 13:32:47 -0500" MODIFIED_BY="[Empty name]" ORDER="600" SE="0.57" STUDY_ID="STD-Kahan-1985c" TOTAL_1="30" TOTAL_2="30" WEIGHT="16.942578695494763"/><IV_DATA CI_END="3.2902743060447897" CI_START="-10.39027430604479" EFFECT_SIZE="-3.55" ESTIMABLE="YES" ESTIMATE="-3.55" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-31 18:46:03 -0500" MODIFIED_BY="[Empty name]" ORDER="604" SE="3.49" STUDY_ID="STD-Malamet-1984" TOTAL_1="7" TOTAL_2="7" WEIGHT="0.45193748968943165"/><IV_DATA CI_END="0.16676110330325877" CI_START="-4.066761103303259" EFFECT_SIZE="-1.95" ESTIMABLE="YES" ESTIMATE="-1.95" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-31 18:46:05 -0500" MODIFIED_BY="[Empty name]" ORDER="610" SE="1.08" STUDY_ID="STD-Rodeheffer-1983" TOTAL_1="15" TOTAL_2="15" WEIGHT="4.719344837248154"/><IV_DATA CI_END="0.42835354005667003" CI_START="-4.62835354005667" EFFECT_SIZE="-2.1" ESTIMABLE="YES" ESTIMATE="-2.1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-31 18:46:07 -0500" MODIFIED_BY="[Empty name]" ORDER="618" SE="1.29" STUDY_ID="STD-Wigley-1987" TOTAL_1="25" TOTAL_2="25" WEIGHT="3.3078804267569537"/></IV_SUBGROUP></IV_OUTCOME><IV_OUTCOME CHI2="43.592613195383" CI_END="-0.036379312186622936" CI_START="-3.294365406355406" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_SIZE="-1.6653723592710146" ESTIMABLE="YES" I2="88.53016684824583" I2_Q="93.98076935145433" ID="CMP-005.02" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" MODIFIED="2017-11-14 03:14:22 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="2.8019394471279213E-8" P_Q="4.582630024929646E-5" P_Z="0.045098490347929704" Q="16.61341886344919" RANDOM="NO" SCALE="7.170538904619482" SHOW_PARTICIPANTS="YES" SORT_BY="WEIGHT" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="69" TOTAL_2="69" WEIGHT="100.0" Z="2.0037346696241545"><NAME>Duration of attacks (minutes)</NAME><GROUP_LABEL_1>CCBs</GROUP_LABEL_1><GROUP_LABEL_2>Placebo</GROUP_LABEL_2><GRAPH_LABEL_1>CCBs</GRAPH_LABEL_1><GRAPH_LABEL_2>Placebo</GRAPH_LABEL_2><EFFECT_MEASURE>Mean Difference</EFFECT_MEASURE><IV_SUBGROUP CHI2="24.650893822438896" CI_END="4.729871573270217" CI_START="-0.24421249351525098" DF="2" EFFECT_SIZE="2.242829539877483" ESTIMABLE="YES" I2="91.88670392884714" ID="CMP-005.02.01" LOG_CI_END="0.6748493488187258" LOG_CI_START="NaN" LOG_EFFECT_SIZE="0.3507962674734082" MODIFIED="2017-11-14 03:14:15 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="4.437406663893029E-6" P_Z="0.07714329596606392" STUDIES="3" TAU2="0.0" TOTAL_1="28" TOTAL_2="28" WEIGHT="42.9014736836336" Z="1.7675073692364283"><NAME>Low-dose CCBs vs placebo</NAME><IV_DATA CI_END="-17.52429172522556" CI_START="-49.27570827477444" EFFECT_SIZE="-33.4" ESTIMABLE="YES" ESTIMATE="-33.4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-23 11:13:02 -0500" MODIFIED_BY="[Empty name]" ORDER="570" SE="8.1" STUDY_ID="STD-Aldoori-1986" TOTAL_1="9" TOTAL_2="9" WEIGHT="1.0528639154954074"/><IV_DATA CI_END="1.8965630182735573" CI_START="-23.896563018273557" EFFECT_SIZE="-11.0" ESTIMABLE="YES" ESTIMATE="-11.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-23 11:13:02 -0500" MODIFIED_BY="[Empty name]" ORDER="609" SE="6.58" STUDY_ID="STD-Meyrick-Thomas-1987" TOTAL_1="9" TOTAL_2="9" WEIGHT="1.595476794737061"/><IV_DATA CI_END="6.267552819747472" CI_START="1.1324471802525289" EFFECT_SIZE="3.7" ESTIMABLE="YES" ESTIMATE="3.7" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-23 11:13:02 -0500" MODIFIED_BY="[Empty name]" ORDER="602" SE="1.31" STUDY_ID="STD-Kirch-1987" TOTAL_1="10" TOTAL_2="10" WEIGHT="40.25313297340113"/></IV_SUBGROUP><IV_SUBGROUP CHI2="2.3283005094949263" CI_END="-2.446042173854197" CI_START="-6.757625428814416" DF="2" EFFECT_SIZE="-4.6018338013343065" ESTIMABLE="YES" I2="14.100435410124266" ID="CMP-005.02.02" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2017-11-14 03:14:22 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.312187875538224" P_Z="2.8666024760966572E-5" STUDIES="3" TAU2="0.0" TOTAL_1="41" TOTAL_2="41" WEIGHT="57.0985263163664" Z="4.183812757449588"><NAME>Medium-dose CCBs vs placebo</NAME><IV_DATA CI_END="-1.0901530657047687" CI_START="-17.74984693429523" EFFECT_SIZE="-9.42" ESTIMABLE="YES" ESTIMATE="-9.42" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-23 11:14:49 -0500" MODIFIED_BY="[Empty name]" ORDER="1167" SE="4.25" STUDY_ID="STD-Finch-1988" TOTAL_1="15" TOTAL_2="15" WEIGHT="3.824409771385671"/><IV_DATA CI_END="-1.3864958011234547" CI_START="-11.813504198876544" EFFECT_SIZE="-6.6" ESTIMABLE="YES" ESTIMATE="-6.6" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-23 11:14:58 -0500" MODIFIED_BY="[Empty name]" ORDER="605" SE="2.66" STUDY_ID="STD-Malamet-1984" TOTAL_1="7" TOTAL_2="7" WEIGHT="9.762903710731765"/><IV_DATA CI_END="-1.2604453794795316" CI_START="-6.199554620520468" EFFECT_SIZE="-3.73" ESTIMABLE="YES" ESTIMATE="-3.73" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-23 11:14:40 -0500" MODIFIED_BY="[Empty name]" ORDER="1160" SE="1.26" STUDY_ID="STD-Ettinger-1984" TOTAL_1="19" TOTAL_2="19" WEIGHT="43.51121283424897"/></IV_SUBGROUP></IV_OUTCOME><IV_OUTCOME CHI2="187.00095349243028" CI_END="-0.5093952201934387" CI_START="-0.7231830497121684" CI_STUDY="95" CI_TOTAL="95" DF="15" EFFECT_SIZE="-0.6162891349528036" ESTIMABLE="YES" I2="91.97865052564707" I2_Q="81.42925486144394" ID="CMP-005.03" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" MODIFIED="2017-11-14 03:14:50 -0500" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="-1.3322676295501878E-15" P_Q="0.020312831034682954" P_Z="1.3117227249799898E-29" Q="5.384813547001019" RANDOM="NO" SCALE="6.06" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="16" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="374" TOTAL_2="374" WEIGHT="100.00000000000001" Z="11.300030607822949"><NAME>Severity of attacks (average, on a 10-cm VAS)</NAME><GROUP_LABEL_1>CCBs</GROUP_LABEL_1><GROUP_LABEL_2>Placebo</GROUP_LABEL_2><GRAPH_LABEL_1>Favours CCBs</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2><EFFECT_MEASURE>Mean Difference</EFFECT_MEASURE><IV_SUBGROUP CHI2="123.19471722623642" CI_END="-0.445977956460711" CI_START="-0.6784598753059538" DF="8" EFFECT_SIZE="-0.5622189158833324" ESTIMABLE="YES" I2="93.50621505522133" ID="CMP-005.03.01" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2017-11-14 03:14:42 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="6.661338147750939E-16" P_Z="2.5502771183728808E-21" STUDIES="9" TAU2="0.0" TOTAL_1="217" TOTAL_2="217" WEIGHT="84.56440416516195" Z="9.479694868588995"><NAME>Low-dose CCBs vs placebo</NAME><IV_DATA CI_END="-0.18840756324658858" CI_START="-1.0115924367534115" EFFECT_SIZE="-0.6" ESTIMABLE="YES" ESTIMATE="-0.6" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-12-25 13:58:20 -0500" MODIFIED_BY="[Empty name]" ORDER="575" SE="0.21" STUDY_ID="STD-Challenor-1989" TOTAL_1="22" TOTAL_2="22" WEIGHT="6.744832879993222"/><IV_DATA CI_END="-1.490409364019586" CI_START="-2.5095906359804143" EFFECT_SIZE="-2.0" ESTIMABLE="YES" ESTIMATE="-2.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-12-25 13:58:20 -0500" MODIFIED_BY="[Empty name]" ORDER="1165" SE="0.26" STUDY_ID="STD-Ferri-1992" TOTAL_1="18" TOTAL_2="18" WEIGHT="4.400105473486701"/><IV_DATA CI_END="-0.2216104444833843" CI_START="-1.3583895555166157" EFFECT_SIZE="-0.79" ESTIMABLE="YES" ESTIMATE="-0.79" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-12-25 13:58:20 -0500" MODIFIED_BY="[Empty name]" ORDER="1170" SE="0.29" STUDY_ID="STD-Gjorup-1986a" TOTAL_1="19" TOTAL_2="19" WEIGHT="3.536826753956018"/><IV_DATA CI_END="-0.6568061226281907" CI_START="-1.3231938773718093" EFFECT_SIZE="-0.99" ESTIMABLE="YES" ESTIMATE="-0.99" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-02-03 19:46:07 -0500" MODIFIED_BY="[Empty name]" ORDER="1172" SE="0.17" STUDY_ID="STD-Hawkins-1985" TOTAL_1="57" TOTAL_2="57" WEIGHT="10.292288235560589"/><IV_DATA CI_END="-0.5100090038649865" CI_START="-1.4899909961350135" EFFECT_SIZE="-1.0" ESTIMABLE="YES" ESTIMATE="-1.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-12-25 13:58:20 -0500" MODIFIED_BY="[Empty name]" ORDER="1177" SE="0.25" STUDY_ID="STD-Kahan-1987" TOTAL_1="20" TOTAL_2="20" WEIGHT="4.759154080123217"/><IV_DATA CI_END="1.0323931570626104" CI_START="0.2876068429373897" EFFECT_SIZE="0.66" ESTIMABLE="YES" ESTIMATE="0.66" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-02-03 19:46:14 -0500" MODIFIED_BY="[Empty name]" ORDER="603" SE="0.19" STUDY_ID="STD-Kirch-1987" TOTAL_1="10" TOTAL_2="10" WEIGHT="8.239532687193934"/><IV_DATA CI_END="-0.09556320537593518" CI_START="-0.4444367946240648" EFFECT_SIZE="-0.27" ESTIMABLE="YES" ESTIMATE="-0.27" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-02-03 19:46:19 -0500" MODIFIED_BY="[Empty name]" ORDER="612" SE="0.089" STUDY_ID="STD-Rupp-1987" TOTAL_1="27" TOTAL_2="27" WEIGHT="37.55171443096845"/><IV_DATA CI_END="-1.6944129655655804" CI_START="-3.1055870344344196" EFFECT_SIZE="-2.4" ESTIMABLE="YES" ESTIMATE="-2.4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-02-03 19:46:22 -0500" MODIFIED_BY="[Empty name]" ORDER="615" SE="0.36" STUDY_ID="STD-Smith-1982" TOTAL_1="17" TOTAL_2="17" WEIGHT="2.2951167438865823"/><IV_DATA CI_END="-0.5884075632465886" CI_START="-1.4115924367534114" EFFECT_SIZE="-1.0" ESTIMABLE="YES" ESTIMATE="-1.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-02-03 19:46:24 -0500" MODIFIED_BY="[Empty name]" ORDER="617" SE="0.21" STUDY_ID="STD-Waller-1986" TOTAL_1="27" TOTAL_2="27" WEIGHT="6.744832879993222"/></IV_SUBGROUP><IV_SUBGROUP CHI2="58.42142271919284" CI_END="-0.6404378976591107" CI_START="-1.1845912121900624" DF="6" EFFECT_SIZE="-0.9125145549245866" ESTIMABLE="YES" I2="89.72979478976492" ID="CMP-005.03.02" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2017-11-14 03:14:50 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="9.412781665218972E-11" P_Z="4.914636899651183E-11" STUDIES="7" TAU2="0.0" TOTAL_1="157" TOTAL_2="157" WEIGHT="15.435595834838072" Z="6.57349910498085"><NAME>Medium/high-dose CCBs vs placebo</NAME><IV_DATA CI_END="1.2931578619118635" CI_START="-3.2931578619118635" EFFECT_SIZE="-1.0" ESTIMABLE="YES" ESTIMATE="-1.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-12-25 14:05:45 -0500" MODIFIED_BY="[Empty name]" ORDER="1161" SE="1.17" STUDY_ID="STD-Ettinger-1984" TOTAL_1="19" TOTAL_2="19" WEIGHT="0.2172891591845285"/><IV_DATA CI_END="-0.6052136858747794" CI_START="-2.094786314125221" EFFECT_SIZE="-1.35" ESTIMABLE="YES" ESTIMATE="-1.35" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-12-25 14:05:52 -0500" MODIFIED_BY="[Empty name]" ORDER="1168" SE="0.38" STUDY_ID="STD-Finch-1988" TOTAL_1="15" TOTAL_2="15" WEIGHT="2.0598831717984836"/><IV_DATA CI_END="-0.029608643710387017" CI_START="-0.9703913562896129" EFFECT_SIZE="-0.5" ESTIMABLE="YES" ESTIMATE="-0.5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-02-03 19:46:48 -0500" MODIFIED_BY="[Empty name]" ORDER="578" SE="0.24" STUDY_ID="STD-French-Co_x002d_op-1991" TOTAL_1="60" TOTAL_2="60" WEIGHT="5.16401267374481"/><IV_DATA CI_END="-2.7572154866477767" CI_START="-4.4427845133522235" EFFECT_SIZE="-3.6" ESTIMABLE="YES" ESTIMATE="-3.6" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-02-03 19:47:09 -0500" MODIFIED_BY="[Empty name]" ORDER="1174" SE="0.43" STUDY_ID="STD-Kahan-1985a" TOTAL_1="15" TOTAL_2="15" WEIGHT="1.6086918875484104"/><IV_DATA CI_END="-0.8436212491213679" CI_START="-3.1563787508786323" EFFECT_SIZE="-2.0" ESTIMABLE="YES" ESTIMATE="-2.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-02-03 19:47:07 -0500" MODIFIED_BY="[Empty name]" ORDER="1176" SE="0.59" STUDY_ID="STD-Kahan-1985b" TOTAL_1="16" TOTAL_2="16" WEIGHT="0.8544875897951769"/><IV_DATA CI_END="0.4339675860860488" CI_START="-3.093967586086049" EFFECT_SIZE="-1.33" ESTIMABLE="YES" ESTIMATE="-1.33" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-12-25 14:06:41 -0500" MODIFIED_BY="[Empty name]" ORDER="606" SE="0.9" STUDY_ID="STD-Malamet-1984" TOTAL_1="7" TOTAL_2="7" WEIGHT="0.3672186790218531"/><IV_DATA CI_END="0.37039135628961295" CI_START="-0.570391356289613" EFFECT_SIZE="-0.1" ESTIMABLE="YES" ESTIMATE="-0.1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-02-03 19:47:13 -0500" MODIFIED_BY="[Empty name]" ORDER="619" SE="0.24" STUDY_ID="STD-Wigley-1987" TOTAL_1="25" TOTAL_2="25" WEIGHT="5.16401267374481"/></IV_SUBGROUP></IV_OUTCOME><IV_OUTCOME CHI2="10.844447438021737" CI_END="-0.7374175154045095" CI_START="-2.206471841470634" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_SIZE="-1.4719446784375718" ESTIMABLE="YES" I2="72.33607321031688" I2_Q="87.98835013434947" ID="CMP-005.04" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" MODIFIED="2017-11-14 03:15:14 -0500" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.012597477319962858" P_Q="0.003909816641398223" P_Z="8.578334593756844E-5" Q="8.325250995366423" RANDOM="NO" SCALE="3.11" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="62" TOTAL_2="62" WEIGHT="100.0" Z="3.927640395299003"><NAME>Pain (10-cm visual analogue scale)</NAME><GROUP_LABEL_1>CCBs</GROUP_LABEL_1><GROUP_LABEL_2>Placebo</GROUP_LABEL_2><GRAPH_LABEL_1>Favours CCBs</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2><EFFECT_MEASURE>Mean Difference</EFFECT_MEASURE><IV_SUBGROUP CHI2="2.421582559791975" CI_END="-1.7477195058608228" CI_START="-4.339452507564026" DF="1" EFFECT_SIZE="-3.0435860067124243" ESTIMABLE="YES" I2="58.70469103122775" ID="CMP-005.04.01" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2017-11-14 03:15:06 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.1196741838562676" P_Z="4.15761148059022E-6" STUDIES="2" TAU2="0.0" TOTAL_1="36" TOTAL_2="36" WEIGHT="32.128851053101876" Z="4.603343749596291"><NAME>Low-dose CCBs vs placebo</NAME><IV_DATA CI_END="-1.188825931131161" CI_START="-4.011174068868839" EFFECT_SIZE="-2.6" ESTIMABLE="YES" ESTIMATE="-2.6" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-23 11:19:39 -0500" MODIFIED_BY="[Empty name]" ORDER="571" SE="0.72" STUDY_ID="STD-Aldoori-1986" TOTAL_1="9" TOTAL_2="9" WEIGHT="27.09284089801222"/><IV_DATA CI_END="-2.156860145818109" CI_START="-8.70313985418189" EFFECT_SIZE="-5.43" ESTIMABLE="YES" ESTIMATE="-5.43" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-23 11:19:39 -0500" MODIFIED_BY="[Empty name]" ORDER="613" SE="1.67" STUDY_ID="STD-Rupp-1987" TOTAL_1="27" TOTAL_2="27" WEIGHT="5.036010155089653"/></IV_SUBGROUP><IV_SUBGROUP CHI2="0.09761388286334052" CI_END="0.16362919206405724" CI_START="-1.6195511009577666" DF="1" EFFECT_SIZE="-0.7279609544468546" ESTIMABLE="YES" I2="0.0" ID="CMP-005.04.02" LOG_CI_END="-0.7861392139814993" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2017-11-14 03:15:14 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.7547121012366784" P_Z="0.10954061685626217" STUDIES="2" TAU2="0.0" TOTAL_1="26" TOTAL_2="26" WEIGHT="67.87114894689813" Z="1.6002613515309596"><NAME>Medium-dose CCBs vs placebo</NAME><IV_DATA CI_END="0.9987719079412423" CI_START="-2.0587719079412423" EFFECT_SIZE="-0.53" ESTIMABLE="YES" ESTIMATE="-0.53" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-23 11:20:35 -0500" MODIFIED_BY="[Empty name]" ORDER="1162" SE="0.78" STUDY_ID="STD-Ettinger-1984" TOTAL_1="19" TOTAL_2="19" WEIGHT="23.085024197122834"/><IV_DATA CI_END="0.2675798313424306" CI_START="-1.9275798313424306" EFFECT_SIZE="-0.83" ESTIMABLE="YES" ESTIMATE="-0.83" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-23 11:20:44 -0500" MODIFIED_BY="[Empty name]" ORDER="607" SE="0.56" STUDY_ID="STD-Malamet-1984" TOTAL_1="7" TOTAL_2="7" WEIGHT="44.7861247497753"/></IV_SUBGROUP></IV_OUTCOME><IV_OUTCOME CHI2="1.93368700265252" CI_END="-0.017995301367367933" CI_START="-0.72863599836738" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_SIZE="-0.373315649867374" ESTIMABLE="YES" I2="48.28532235939643" I2_Q="48.28532235939643" ID="CMP-005.05" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" MODIFIED="2017-11-14 03:15:30 -0500" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.164355900179179" P_Q="0.164355900179179" P_Z="0.0394725050120816" Q="1.93368700265252" RANDOM="NO" SCALE="25.009696411215767" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="96" TOTAL_2="96" WEIGHT="100.0" Z="2.0592269249257633"><NAME>Patient global</NAME><GROUP_LABEL_1>CCBs</GROUP_LABEL_1><GROUP_LABEL_2>Placebo</GROUP_LABEL_2><GRAPH_LABEL_1>Favours CCBs</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2><EFFECT_MEASURE>Mean Difference</EFFECT_MEASURE><IV_SUBGROUP CHI2="0.0" CI_END="0.2311920765988119" CI_START="-0.6311920765988119" DF="0" EFFECT_SIZE="-0.2" ESTIMABLE="YES" I2="0.0" ID="CMP-005.05.01" LOG_CI_END="-0.636027054111282" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2017-11-14 03:15:23 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.3633021512011777" STUDIES="1" TAU2="0.0" TOTAL_1="36" TOTAL_2="36" WEIGHT="67.90450928381964" Z="0.9090909090909092"><NAME>Low-dose CCBs vs placebo</NAME><IV_DATA CI_END="0.2311920765988119" CI_START="-0.6311920765988119" EFFECT_SIZE="-0.2" ESTIMABLE="YES" ESTIMATE="-0.2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-02-02 19:59:24 -0500" MODIFIED_BY="[Empty name]" ORDER="573" SE="0.22" STUDY_ID="STD-Challenor-1987" TOTAL_1="36" TOTAL_2="36" WEIGHT="67.90450928381964"/></IV_SUBGROUP><IV_SUBGROUP CHI2="0.0" CI_END="-0.1128115249471826" CI_START="-1.3671884750528174" DF="0" EFFECT_SIZE="-0.74" ESTIMABLE="YES" I2="0.0" ID="CMP-005.05.02" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2017-11-14 03:15:30 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.02075014531580953" STUDIES="1" TAU2="0.0" TOTAL_1="60" TOTAL_2="60" WEIGHT="32.09549071618037" Z="2.3125"><NAME>High-dose CCBs vs placebo</NAME><IV_DATA CI_END="-0.1128115249471826" CI_START="-1.3671884750528174" EFFECT_SIZE="-0.74" ESTIMABLE="YES" ESTIMATE="-0.74" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-23 11:34:24 -0500" MODIFIED_BY="[Empty name]" ORDER="579" SE="0.32" STUDY_ID="STD-French-Co_x002d_op-1991" TOTAL_1="60" TOTAL_2="60" WEIGHT="32.09549071618037"/></IV_SUBGROUP></IV_OUTCOME></COMPARISON><COMPARISON ID="CMP-006" MODIFIED="2017-11-14 03:16:02 -0500" MODIFIED_BY="[Empty name]" NO="6"><NAME>Minor outcomes</NAME><DICH_OUTCOME CHI2="2.2840055396183367" CI_END="4.203598645113328" CI_START="1.3467846284995753" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="2.3793574846206424" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="9" I2="12.43453812576106" I2_Q="0.0" ID="CMP-006.01" LOG_CI_END="0.6236212433853239" LOG_CI_START="0.12929815093263125" LOG_EFFECT_SIZE="0.37645969715897754" METHOD="MH" MODIFIED="2017-11-14 03:15:55 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.3191795088133025" P_Q="1.0" P_Z="0.0028331500444473178" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="31" TOTAL_2="28" WEIGHT="100.00000000000001" Z="2.985284156568367"><NAME>Number of participants with improvement</NAME><GROUP_LABEL_1>CCBs</GROUP_LABEL_1><GROUP_LABEL_2>Placebo</GROUP_LABEL_2><GRAPH_LABEL_1>Favours CCBs</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2><DICH_DATA CI_END="12.070489775713986" CI_START="1.0473456788868525" EFFECT_SIZE="3.5555555555555554" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="2" LOG_CI_END="1.0817248925144551" LOG_CI_START="0.02009004524670718" LOG_EFFECT_SIZE="0.5509074688805811" MODIFIED="2016-01-30 15:58:35 -0500" MODIFIED_BY="[Empty name]" ORDER="60052" O_E="0.0" SE="0.6236095644623235" STUDY_ID="STD-Constantini-1987" TOTAL_1="9" TOTAL_2="8" VAR="0.38888888888888884" WEIGHT="22.146274777853726"/><DICH_DATA CI_END="8.428375165884077" CI_START="1.0678214748234889" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="3" LOG_CI_END="0.9257438587878607" LOG_CI_START="0.028498650651464348" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2016-01-30 15:58:42 -0500" MODIFIED_BY="[Empty name]" ORDER="60057" O_E="0.0" SE="0.5270462766947299" STUDY_ID="STD-Muller_x002d_Buhl-1983" TOTAL_1="12" TOTAL_2="12" VAR="0.2777777777777778" WEIGHT="31.37388926862611"/><DICH_DATA CI_END="3.1251328157845895" CI_START="0.6271733444736577" EFFECT_SIZE="1.4" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" LOG_CI_END="0.49486847925981775" LOG_CI_START="-0.20261240790334165" LOG_EFFECT_SIZE="0.146128035678238" MODIFIED="2016-01-30 15:58:49 -0500" MODIFIED_BY="[Empty name]" ORDER="179" O_E="0.0" SE="0.40970372570571384" STUDY_ID="STD-Sauza-1984" TOTAL_1="10" TOTAL_2="8" VAR="0.16785714285714282" WEIGHT="46.479835953520166"/></DICH_OUTCOME><DICH_OUTCOME CHI2="3.168254770190264" CI_END="1.4474582603610842" CI_START="0.8700298725506087" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1221995926680244" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="26" I2="36.873763473260915" I2_Q="0.0" ID="CMP-006.02" LOG_CI_END="0.16060604904457282" LOG_CI_START="-0.0604658355869397" LOG_EFFECT_SIZE="0.05007010672881655" METHOD="MH" MODIFIED="2017-11-14 03:16:02 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.20512683329380188" P_Q="1.0" P_Z="0.3746396096071999" Q="0.0" RANDOM="NO" SCALE="36.2" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="40" TOTAL_2="38" WEIGHT="100.0" Z="0.8878162508464763"><NAME>Side effects</NAME><GROUP_LABEL_1>CCBs</GROUP_LABEL_1><GROUP_LABEL_2>Placebo</GROUP_LABEL_2><GRAPH_LABEL_1>Favours CCBs</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2><DICH_DATA CI_END="2.002108717336782" CI_START="0.34685651105310555" EFFECT_SIZE="0.8333333333333334" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" LOG_CI_END="0.3014876565886039" LOG_CI_START="-0.45985014868385343" LOG_EFFECT_SIZE="-0.0791812460476248" MODIFIED="2016-02-08 20:10:09 -0500" MODIFIED_BY="[Empty name]" ORDER="60031" O_E="0.0" SE="0.44721359549995804" STUDY_ID="STD-Constantini-1987" TOTAL_1="12" TOTAL_2="12" VAR="0.20000000000000007" WEIGHT="21.9959266802444"/><DICH_DATA CI_END="1.8431028464224017" CI_START="1.018887771582686" EFFECT_SIZE="1.3703703703703705" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="13" LOG_CI_END="0.2655495698297752" LOG_CI_START="0.00812634998624029" LOG_EFFECT_SIZE="0.1368379599080077" MODIFIED="2016-02-08 20:10:09 -0500" MODIFIED_BY="[Empty name]" ORDER="131" O_E="0.0" SE="0.15121167360158175" STUDY_ID="STD-Sarkozi--1986" TOTAL_1="18" TOTAL_2="18" VAR="0.02286497023339129" WEIGHT="49.490835030549896"/><DICH_DATA CI_END="1.3718208353474188" CI_START="0.6093495198556591" EFFECT_SIZE="0.9142857142857143" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" LOG_CI_END="0.13729739467912072" LOG_CI_START="-0.21513352673986" LOG_EFFECT_SIZE="-0.03891806603036967" MODIFIED="2016-02-08 20:10:09 -0500" MODIFIED_BY="[Empty name]" ORDER="178" O_E="0.0" SE="0.20701966780270623" STUDY_ID="STD-Sauza-1984" TOTAL_1="10" TOTAL_2="8" VAR="0.042857142857142844" WEIGHT="28.513238289205702"/></DICH_OUTCOME></COMPARISON></ANALYSES_AND_DATA><FIGURES MODIFIED="2017-11-29 09:38:41 -0500" MODIFIED_BY="[Empty name]"><FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2017-07-23 17:12:25 -0400" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER"><CAPTION><P>Flow diagram of study.</P></CAPTION><FILE>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</FILE></FIGURE><FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2017-11-29 09:38:41 -0500" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT"><CAPTION><P>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P></CAPTION><FILE>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</FILE></FIGURE><FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2017-11-29 09:38:41 -0500" MODIFIED_BY="[Empty name]" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT"><CAPTION><P>Risk of bias summary: review authors' judgements about each risk of bias item for each included study.</P></CAPTION><FILE>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</FILE></FIGURE><FIGURE FILENAME="Funnel plot.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2017-11-14 03:10:10 -0500" MODIFIED_BY="[Empty name]" NO="4" REF_ID="CMP-001.01" SETTINGS="DISTINGUISH_SUBGROUPS:YES;SHOW_STUDY_NAMES:NO;SHOW_EFFECT_ESTIMATE:YES;SHOW_CI_LINES:YES;SHOW_AUTOGENERATED_NUM_FOR_STUDY_NAMES:NO;" SHORT_VERSION_FIGURE="YES" TYPE="FUNNEL_PLOT"><CAPTION><P>Funnel plot of comparison: 1 CCBs vs placebo (generic inverse variance method), outcome: 1.1 Frequency of attacks (average/week).</P></CAPTION><FILE>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</FILE></FIGURE><FIGURE FILENAME="Funnel plot.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2017-11-14 03:16:33 -0500" MODIFIED_BY="[Empty name]" NO="5" REF_ID="CMP-001.04" SETTINGS="DISTINGUISH_SUBGROUPS:YES;SHOW_STUDY_NAMES:NO;SHOW_EFFECT_ESTIMATE:YES;SHOW_CI_LINES:YES;SHOW_AUTOGENERATED_NUM_FOR_STUDY_NAMES:NO;" SHORT_VERSION_FIGURE="YES" TYPE="FUNNEL_PLOT"><CAPTION><P>Funnel plot of comparison: 11 CCBs vs placebo (generic inverse variance method), outcome: 11.4 Severity of attacks (average, on a 10-cm VAS).</P></CAPTION><FILE>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</FILE></FIGURE></FIGURES><FEEDBACK MODIFIED="2015-03-26 13:49:16 -0400" MODIFIED_BY="[Empty name]"/><APPENDICES MODIFIED="2017-11-23 20:36:55 -0500" MODIFIED_BY="[Empty name]"><APPENDIX ID="APP-01" MODIFIED="2017-11-23 20:36:55 -0500" MODIFIED_BY="[Empty name]" NO="1"><TITLE MODIFIED="2017-11-14 03:17:17 -0500" MODIFIED_BY="[Empty name]">Appendix 1: search methods</TITLE><APPENDIX_BODY MODIFIED="2017-11-23 20:36:55 -0500" MODIFIED_BY="[Empty name]"><P>Appendix 1: search methods</P><TABLE COLS="4" ROWS="8"><TR><TD COLSPAN="4" VALIGN="TOP"><P><B>Raynaud's phenomenon</B></P></TD></TR><TR><TD VALIGN="TOP"><P><B>Database and coverage</B></P></TD><TD VALIGN="TOP"><P><B>Search date</B></P></TD><TD VALIGN="TOP"><P><B>Number of references retrieved</B></P></TD><TD VALIGN="TOP"><P><B>With duplicates removed</B></P></TD></TR><TR><TD VALIGN="TOP"><P>The Cochrane Library<BR/>Cochrane Reviews<BR/>Issue 12 of 12, December 2015<BR/>Other Reviews (DARE)<BR/>Issue 2 of 4, April 2014</P><P>CENTRAL</P><P>Methods studies<BR/>Issue 3 of 4, July 2012</P><P>Technology assessments<BR/>Issue 2 of 4, April 2014</P><P>Economic evaluation</P></TD><TD VALIGN="TOP"><P>December 2, 2015</P></TD><TD VALIGN="TOP"><P>14<BR/>26<BR/></P><P>1011<BR/></P><P>5<BR/></P><P/><P>2<BR/></P><P>3</P></TD><TD VALIGN="TOP"><P>8<BR/>26<BR/></P><P>358<BR/></P><P>2<BR/></P><P/><P>3<BR/></P><P>3</P></TD></TR><TR><TD VALIGN="TOP"><P>Ovid MEDLINE(R) 1946-present</P></TD><TD VALIGN="TOP"><P/></TD><TD VALIGN="TOP"><P>1027</P></TD><TD VALIGN="TOP"><P>1005</P></TD></TR><TR><TD VALIGN="TOP"><P>Ovid Embase Classic + Embase 1947-present</P></TD><TD VALIGN="TOP"><P/></TD><TD VALIGN="TOP"><P>1251</P></TD><TD VALIGN="TOP"><P>884</P></TD></TR><TR><TD VALIGN="TOP"><P>Clinicaltrials.gov</P></TD><TD VALIGN="TOP"><P/></TD><TD VALIGN="TOP"><P>50</P></TD><TD VALIGN="TOP"><P>48</P></TD></TR><TR><TD VALIGN="TOP"><P>WHO portal (who.int/trialsearch, all years)</P></TD><TD VALIGN="TOP"><P/></TD><TD VALIGN="TOP"><P>0</P></TD><TD VALIGN="TOP"><P>0</P></TD></TR><TR><TD VALIGN="TOP"><P/></TD><TD VALIGN="TOP"><P><B>Totals</B></P></TD><TD VALIGN="TOP"><P><B>3389</B></P></TD><TD VALIGN="TOP"><P><B>2337</B></P></TD></TR></TABLE><P/><P><B>Cochrane Library &#8211; Issue 6, 2014<BR/>Search name: Raynaud's<BR/>Last saved: 02/12/2015 13:58:12.787<BR/>Description: </B></P><P><B>ID search: </B></P><P>#1 MeSH descriptor: [Raynaud Disease] explode all trees</P><P>#2 raynaud*:ti,ab,kw</P><P>#3 vasospasm:ti,ab,kw</P><P>#4 #1 or #2 or #3<BR/><BR/></P><P><B>Database: Ovid MEDLINE(R) In-Process &amp; Other Non-Indexed Citations and Ovid MEDLINE(R) &lt;1946 to present&gt;</B></P><P><B>Search strategy:</B></P><P><B>--------------------------------------------------------------------------------</B></P><P>1 Raynaud Disease/ (5811)</P><P>2 Vasospasm.ti,ab. (9022)</P><P>3 raynaud$.tiw. (5879)</P><P>4 or/1-3 (16735)</P><P>5 randomized controlled trial.pt. (376269)</P><P>6 controlled clinical trial.pt. (88551)</P><P>7 randomized.ab. (296657)</P><P>8 placebo.ab. (154994)</P><P>9 clinical trials as topic.sh. (170411)</P><P>10 randomly.ab. (214652)</P><P>11 trial.ti. (127683)</P><P>12 or/5-11 (909747)</P><P>13 exp animals/ not humans.sh. (3951755)</P><P>14 12 not 13 (839533)</P><P>15 4 and 14 (1027)</P><P><B>Database: Embase Classic + Embase &lt;1947 to June 20, 2014&gt;</B></P><P><B>Search strategy:</B></P><P><B>--------------------------------------------------------------------------------</B></P><P>1 Raynaud phenomenon/ (11646)</P><P>2 vasospasm/ (7831)</P><P>3 raynaud$.tiw. (8895)</P><P>4 or/1-3 (20897)</P><P>5 random$.tiw. (900126)</P><P>6 factorial$.tiw. (23754)</P><P>7 crossover$.tiw. (50156)</P><P>8 cross over.tw. (22510)</P><P>9 cross-over.tw. (22510)</P><P>10 placebo$.tiw. (207490)</P><P>11 (doubl$ adj blind$).tiw. (150810)</P><P>12 (singl$ adj blind$).tiw. (14649)</P><P>13 assign$.tiw. (244100)</P><P>14 allocate$.tiw. (85325)</P><P>15 volunteer$.tiw. (186103)</P><P>16 crossover procedure/ (39529)</P><P>17 double blind procedure/ (118455)</P><P>18 randomized controlled trial/ (346367)</P><P>19 single blind procedure/ (18431)</P><P>20 or/5-19 (1457107)</P><P>21 4 and 20 (1251)</P><P><B>Clinicaltrials.gov<BR/></B>Advanced search screen</P><P>Condition=raynaud</P><P><B>Updated search performed on May 19, 2017</B></P><TABLE COLS="4" ROWS="8"><TR><TD COLSPAN="4" VALIGN="TOP"><P><B>Raynaud's phenomenon</B></P></TD></TR><TR><TD VALIGN="TOP"><P><B>Database and coverage</B></P></TD><TD VALIGN="TOP"><P><B>Search date</B></P></TD><TD VALIGN="TOP"><P><B>Number of references retrieved</B></P></TD><TD VALIGN="TOP"><P><B>With duplicates removed</B></P></TD></TR><TR><TD VALIGN="TOP"><P>EBM Reviews - CENTRAL (via OVID)</P></TD><TD VALIGN="TOP"><P>May 19, 2017</P></TD><TD VALIGN="TOP"><P>101</P></TD><TD VALIGN="TOP"><P/></TD></TR><TR><TD VALIGN="TOP"><P>Ovid Medline(R) 1946-present</P></TD><TD VALIGN="TOP"><P>May 19, 2017</P></TD><TD VALIGN="TOP"><P>50</P></TD><TD VALIGN="TOP"><P/></TD></TR><TR><TD VALIGN="TOP"><P>Ovid Embase Classic + Embase 1947-present</P></TD><TD VALIGN="TOP"><P>May 19, 2017</P></TD><TD VALIGN="TOP"><P>104</P></TD><TD VALIGN="TOP"><P/></TD></TR><TR><TD VALIGN="TOP"><P/></TD><TD VALIGN="TOP"><P/></TD><TD VALIGN="TOP"><P/></TD><TD VALIGN="TOP"><P/></TD></TR><TR><TD VALIGN="TOP"><P/></TD><TD VALIGN="TOP"><P/></TD><TD VALIGN="TOP"><P/></TD><TD VALIGN="TOP"><P/></TD></TR><TR><TD VALIGN="TOP"><P/></TD><TD VALIGN="TOP"><P><B>Totals</B></P></TD><TD VALIGN="TOP"><P><B>255</B></P></TD><TD VALIGN="TOP"><P/></TD></TR></TABLE><P/><P><B>CENTRAL<BR/>Search name: Raynaud's<BR/>Last saved: May 19, 2017<BR/>Description: </B></P><P><B>ID search: </B></P><P><B>C1 - Database: EBM Reviews - Cochrane Central Register of Controlled Trials &lt;April 2017&gt;</B></P><P>Search Strategy:</P><P>--------------------------------------------------------------------------------</P><P>1 Raynaud Disease/ (267)</P><P>2 Vasospasm.ti,ab. (570)</P><P>3 raynaud$.tiw. (524)</P><P>4 or/1-3 (1084)</P><P>5 limit 4 to yr="2015 -Current" (101)</P><P><BR/><B>C1 - Database: Ovid MEDLINE(R) In-Process &amp; Other Non-Indexed Citations and Ovid MEDLINE(R) &lt;1946 to present&gt;</B></P><P><B>Search strategy:</B></P><P><B>--------------------------------------------------------------------------------</B></P><P>1 Raynaud Disease/ (6394)</P><P>2 Vasospasm.ti,ab. (10215)</P><P>3 raynaud$.tiw. (6728)</P><P>4 or/1-3 (18859)</P><P>5 randomized controlled trial.pt. (462560)</P><P>6 controlled clinical trial.pt. (94063)</P><P>7 randomized.ab. (395329)</P><P>8 placebo.ab. (186432)</P><P>9 clinical trials as topic.sh. (185904)</P><P>10 randomly.ab. (275397)</P><P>11 trial.ti. (177271)</P><P>12 or/5-11 (1120634)</P><P>13 exp animals/ not humans.sh. (4399234)</P><P>14 12 not 13 (1032602)</P><P>15 4 and 14 (1163)</P><P>16 limit 15 to ed=20151202-20170519 (50)</P><P><B>C1 - Database: Embase &lt;1974 to May 18, 2017&gt;</B></P><P><B>Search strategy:</B></P><P><B>--------------------------------------------------------------------------------</B></P><P>1 Raynaud phenomenon/ (11924)</P><P>2 vasospasm/ (7993)</P><P>3 raynaud$.tiw. (9084)</P><P>4 or/1-3 (21611)</P><P>5 random$.tiw. (1188308)</P><P>6 factorial$.tiw. (30059)</P><P>7 crossover$.tiw. (61652)</P><P>8 cross over.tw. (27084)</P><P>9 cross-over.tw. (27084)</P><P>10 placebo$.tiw. (254043)</P><P>11 (doubl$ adj blind$).tiw. (177952)</P><P>12 (singl$ adj blind$).tiw. (19292)</P><P>13 assign$.tiw. (311284)</P><P>14 allocate$.tiw. (115199)</P><P>15 volunteer$.tiw. (219603)</P><P>16 crossover procedure/ (51208)</P><P>17 double blind procedure/ (138220)</P><P>18 randomized controlled trial/ (449401)</P><P>19 single blind procedure/ (26863)</P><P>20 or/5-19 (1850737)</P><P>21 4 and 20 (1495)</P><P>22 Raynaud phenomenon/ (11924)</P><P>23 vasospasm/ (7993)</P><P>24 raynaud$.tiw. (9084)</P><P>25 or/22-24 (21611)</P><P>26 random$.tiw. (1188308)</P><P>27 factorial$.tiw. (30059)</P><P>28 crossover$.tiw. (61652)</P><P>29 cross over.tw. (27084)</P><P>30 cross-over.tw. (27084)</P><P>31 placebo$.tiw. (254043)</P><P>32 (doubl$ adj blind$).tiw. (177952)</P><P>33 (singl$ adj blind$).tiw. (19292)</P><P>34 assign$.tiw. (311284)</P><P>35 allocate$.tiw. (115199)</P><P>36 volunteer$.tiw. (219603)</P><P>37 crossover procedure/ (51208)</P><P>38 double blind procedure/ (138220)</P><P>39 randomized controlled trial/ (449401)</P><P>40 single blind procedure/ (26863)</P><P>41 or/26-40 (1850737)</P><P>42 25 and 41 (1495)</P><P>43 limit 42 to dd=20151202-20170519 (104)</P></APPENDIX_BODY></APPENDIX><APPENDIX ID="APP-02" MODIFIED="2017-11-23 19:53:09 -0500" MODIFIED_BY="[Empty name]" NO="2"><TITLE MODIFIED="2017-11-22 21:10:10 -0500" MODIFIED_BY="[Empty name]">Appendix 2: dosage guidelines</TITLE><APPENDIX_BODY MODIFIED="2017-11-23 19:53:09 -0500" MODIFIED_BY="[Empty name]"><P>Dosage guidelines*</P><TABLE COLS="4" ROWS="8"><TR><TD VALIGN="TOP"><P>Calcium channel blocker</P></TD><TD VALIGN="TOP"><P>Low dose</P><P>(daily dose)</P></TD><TD VALIGN="TOP"><P>Medium dose</P><P>(daily dose)</P></TD><TD VALIGN="TOP"><P>High dose</P><P>(daily dose)</P></TD></TR><TR><TD VALIGN="TOP"><P>Amlodipine</P></TD><TD VALIGN="TOP"><P>2.5 mg</P><P/></TD><TD VALIGN="TOP"><P>5 mg</P></TD><TD VALIGN="TOP"><P>10 mg</P></TD></TR><TR><TD VALIGN="TOP"><P>Isradipine</P></TD><TD VALIGN="TOP"><P>5 mg</P><P/></TD><TD VALIGN="TOP"><P>10 mg</P></TD><TD VALIGN="TOP"><P>-</P></TD></TR><TR><TD VALIGN="TOP"><P>Nicardipine</P></TD><TD VALIGN="TOP"><P>60 mg</P><P/></TD><TD VALIGN="TOP"><P>90 mg</P></TD><TD VALIGN="TOP"><P>120 mg</P></TD></TR><TR><TD VALIGN="TOP"><P>Nifedipine</P></TD><TD VALIGN="TOP"><P>&lt; or = 30 mg</P><P/></TD><TD VALIGN="TOP"><P>&gt;30 mg</P></TD><TD VALIGN="TOP"><P>90 mg</P></TD></TR><TR><TD VALIGN="TOP"><P>Nisoldipine</P></TD><TD VALIGN="TOP"><P>20 mg</P><P/></TD><TD VALIGN="TOP"><P>30 mg</P></TD><TD VALIGN="TOP"><P>60 mg</P></TD></TR><TR><TD VALIGN="TOP"><P>Diltiazem</P></TD><TD VALIGN="TOP"><P>180 mg</P><P/></TD><TD VALIGN="TOP"><P>240 mg</P></TD><TD VALIGN="TOP"><P>360 mg</P></TD></TR><TR><TD VALIGN="TOP"><P>Verapamil</P></TD><TD VALIGN="TOP"><P>180 mg</P><P/></TD><TD VALIGN="TOP"><P>240 mg</P></TD><TD VALIGN="TOP"><P>360 mg</P></TD></TR></TABLE><P>*Dosage based on Greater Rochester Independent Practice Association (GRIPA) guidelines.</P></APPENDIX_BODY></APPENDIX><APPENDIX ID="APP-03" MODIFIED="2017-11-22 21:10:34 -0500" MODIFIED_BY="[Empty name]" NO="3"><TITLE MODIFIED="2017-11-22 21:10:34 -0500" MODIFIED_BY="[Empty name]">Appendix 3: Dichotomous outcomes from cross-over trials</TITLE><APPENDIX_BODY MODIFIED="2017-11-14 03:24:42 -0500" MODIFIED_BY="[Empty name]"><TABLE COLS="17" ROWS="34"><TR><TD><P>Study</P></TD><TD COLSPAN="4"><P>General improvement</P></TD><TD COLSPAN="4"><P>Treatment preference</P></TD><TD COLSPAN="4"><P>Side effects</P></TD><TD COLSPAN="4"><P>Withdrawals</P></TD></TR><TR><TD><P/></TD><TD COLSPAN="2"><P>Treatment</P></TD><TD COLSPAN="2"><P>Placebo</P></TD><TD COLSPAN="2"><P>Treatment</P></TD><TD COLSPAN="2"><P>Placebo</P></TD><TD COLSPAN="2"><P>Treatment</P></TD><TD COLSPAN="2"><P>Placebo</P></TD><TD COLSPAN="2"><P>Treatment</P></TD><TD COLSPAN="2"><P>Placebo</P></TD></TR><TR><TD><P/></TD><TD><P>Events</P></TD><TD><P>Total</P></TD><TD><P>Events</P></TD><TD><P>Total</P></TD><TD><P>Events</P></TD><TD><P>Total</P></TD><TD><P>Events</P></TD><TD><P>Total</P></TD><TD><P>Events</P></TD><TD><P>Total</P></TD><TD><P>Events</P></TD><TD><P>Total</P></TD><TD><P>Events</P></TD><TD><P>Total</P></TD><TD><P>Events</P></TD><TD><P>Total</P></TD></TR><TR><TD><P>Aldoori 1986</P></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD ALIGN="RIGHT"><P>10</P></TD><TD ALIGN="RIGHT"><P>13</P></TD><TD ALIGN="RIGHT"><P>4</P></TD><TD ALIGN="RIGHT"><P>13</P></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD></TR><TR><TD><P>Bravard 1983</P></TD><TD ALIGN="RIGHT"><P>5</P></TD><TD ALIGN="RIGHT"><P>5</P></TD><TD ALIGN="RIGHT"><P>3</P></TD><TD ALIGN="RIGHT"><P>5</P></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD></TR><TR><TD><P>Challenor 1989</P></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD ALIGN="RIGHT"><P>16</P></TD><TD ALIGN="RIGHT"><P>24</P></TD><TD ALIGN="RIGHT"><P>5</P></TD><TD ALIGN="RIGHT"><P>24</P></TD><TD ALIGN="RIGHT"><P>2</P></TD><TD ALIGN="RIGHT"><P>24</P></TD><TD ALIGN="RIGHT"><P>0</P></TD><TD ALIGN="RIGHT"><P>24</P></TD></TR><TR><TD><P>Corbin 1986</P></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD ALIGN="RIGHT"><P>15</P></TD><TD ALIGN="RIGHT"><P>22</P></TD><TD ALIGN="RIGHT"><P>2</P></TD><TD ALIGN="RIGHT"><P>22</P></TD><TD ALIGN="RIGHT"><P>14</P></TD><TD ALIGN="RIGHT"><P>23</P></TD><TD ALIGN="RIGHT"><P>2</P></TD><TD ALIGN="RIGHT"><P>23</P></TD><TD ALIGN="RIGHT"><P>3</P></TD><TD ALIGN="RIGHT"><P>22</P></TD><TD ALIGN="RIGHT"><P>0</P></TD><TD ALIGN="RIGHT"><P>22</P></TD></TR><TR><TD><P>Ettinger 1984</P></TD><TD ALIGN="RIGHT"><P>15</P></TD><TD ALIGN="RIGHT"><P>19</P></TD><TD ALIGN="RIGHT"><P>12</P></TD><TD ALIGN="RIGHT"><P>19</P></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD ALIGN="RIGHT"><P>12</P></TD><TD ALIGN="RIGHT"><P>22</P></TD><TD ALIGN="RIGHT"><P>1</P></TD><TD ALIGN="RIGHT"><P>22</P></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD></TR><TR><TD><P>Ferri 1992</P></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD ALIGN="RIGHT"><P>2</P></TD><TD ALIGN="RIGHT"><P>21</P></TD><TD ALIGN="RIGHT"><P>0</P></TD><TD ALIGN="RIGHT"><P>21</P></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD></TR><TR><TD><P>French Co-op 1991</P></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD ALIGN="RIGHT"><P>19</P></TD><TD ALIGN="RIGHT"><P>69</P></TD><TD ALIGN="RIGHT"><P>7</P></TD><TD ALIGN="RIGHT"><P>69</P></TD><TD ALIGN="RIGHT"><P>2</P></TD><TD ALIGN="RIGHT"><P>69</P></TD><TD ALIGN="RIGHT"><P>5</P></TD><TD ALIGN="RIGHT"><P>69</P></TD></TR><TR><TD><P>Gjorup 1986a</P></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD ALIGN="RIGHT"><P>12</P></TD><TD ALIGN="RIGHT"><P>19</P></TD><TD ALIGN="RIGHT"><P>4</P></TD><TD ALIGN="RIGHT"><P>19</P></TD><TD ALIGN="RIGHT"><P>5</P></TD><TD ALIGN="RIGHT"><P>19</P></TD><TD ALIGN="RIGHT"><P>0</P></TD><TD ALIGN="RIGHT"><P>19</P></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD></TR><TR><TD><P>Gjorup 1986b</P></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD ALIGN="RIGHT"><P>19</P></TD><TD ALIGN="RIGHT"><P>21</P></TD><TD ALIGN="RIGHT"><P>0</P></TD><TD ALIGN="RIGHT"><P>21</P></TD><TD ALIGN="RIGHT"><P>16</P></TD><TD ALIGN="RIGHT"><P>21</P></TD><TD ALIGN="RIGHT"><P>0</P></TD><TD ALIGN="RIGHT"><P>21</P></TD><TD ALIGN="RIGHT"><P>4</P></TD><TD ALIGN="RIGHT"><P>26</P></TD><TD ALIGN="RIGHT"><P>0</P></TD><TD ALIGN="RIGHT"><P>26</P></TD></TR><TR><TD><P>Hawkins 1985</P></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD ALIGN="RIGHT"><P>19</P></TD><TD ALIGN="RIGHT"><P>57</P></TD><TD ALIGN="RIGHT"><P>6</P></TD><TD ALIGN="RIGHT"><P>57</P></TD><TD ALIGN="RIGHT"><P>7</P></TD><TD ALIGN="RIGHT"><P>57</P></TD><TD ALIGN="RIGHT"><P>1</P></TD><TD ALIGN="RIGHT"><P>57</P></TD></TR><TR><TD><P>Kahan 1985a</P></TD><TD ALIGN="RIGHT"><P>12</P></TD><TD ALIGN="RIGHT"><P>15</P></TD><TD ALIGN="RIGHT"><P>1</P></TD><TD ALIGN="RIGHT"><P>15</P></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD ALIGN="RIGHT"><P>6</P></TD><TD ALIGN="RIGHT"><P>15</P></TD><TD ALIGN="RIGHT"><P>2</P></TD><TD ALIGN="RIGHT"><P>15</P></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD></TR><TR><TD><P>Kahan 1985b</P></TD><TD ALIGN="RIGHT"><P>9</P></TD><TD ALIGN="RIGHT"><P>16</P></TD><TD ALIGN="RIGHT"><P>3</P></TD><TD ALIGN="RIGHT"><P>16</P></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD ALIGN="RIGHT"><P>6</P></TD><TD ALIGN="RIGHT"><P>16</P></TD><TD ALIGN="RIGHT"><P>2</P></TD><TD ALIGN="RIGHT"><P>16</P></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD></TR><TR><TD><P>Kahan 1985c</P></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD ALIGN="RIGHT"><P>9</P></TD><TD ALIGN="RIGHT"><P>30</P></TD><TD ALIGN="RIGHT"><P>3</P></TD><TD ALIGN="RIGHT"><P>30</P></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD></TR><TR><TD><P>Kahan 1987</P></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD ALIGN="RIGHT"><P>7</P></TD><TD ALIGN="RIGHT"><P>20</P></TD><TD ALIGN="RIGHT"><P>2</P></TD><TD ALIGN="RIGHT"><P>20</P></TD><TD ALIGN="RIGHT"><P>7</P></TD><TD ALIGN="RIGHT"><P>20</P></TD><TD ALIGN="RIGHT"><P>2</P></TD><TD ALIGN="RIGHT"><P>20</P></TD></TR><TR><TD><P>Kallenberg 1987</P></TD><TD ALIGN="RIGHT"><P>14</P></TD><TD ALIGN="RIGHT"><P>15</P></TD><TD ALIGN="RIGHT"><P>0</P></TD><TD ALIGN="RIGHT"><P>15</P></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD></TR><TR><TD><P>Kinney 1982</P></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD ALIGN="RIGHT"><P>3</P></TD><TD ALIGN="RIGHT"><P>14</P></TD><TD ALIGN="RIGHT"><P>10</P></TD><TD ALIGN="RIGHT"><P>14</P></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD></TR><TR><TD><P>Kirch 1987</P></TD><TD ALIGN="RIGHT"><P>8</P></TD><TD ALIGN="RIGHT"><P>10</P></TD><TD ALIGN="RIGHT"><P>2</P></TD><TD ALIGN="RIGHT"><P>10</P></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD ALIGN="RIGHT"><P>2</P></TD><TD ALIGN="RIGHT"><P>10</P></TD><TD ALIGN="RIGHT"><P>2</P></TD><TD ALIGN="RIGHT"><P>10</P></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD></TR><TR><TD><P>La Civita 1997</P></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD ALIGN="RIGHT"><P>11</P></TD><TD ALIGN="RIGHT"><P>20</P></TD><TD ALIGN="RIGHT"><P>0</P></TD><TD ALIGN="RIGHT"><P>20</P></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD></TR><TR><TD><P>Leppert 1989</P></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD ALIGN="RIGHT"><P>5</P></TD><TD ALIGN="RIGHT"><P>10</P></TD><TD ALIGN="RIGHT"><P>3</P></TD><TD ALIGN="RIGHT"><P>10</P></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD></TR><TR><TD><P>Meyrick Thomas 1987</P></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD ALIGN="RIGHT"><P>1</P></TD><TD ALIGN="RIGHT"><P>9</P></TD><TD ALIGN="RIGHT"><P>2</P></TD><TD ALIGN="RIGHT"><P>9</P></TD><TD ALIGN="RIGHT"><P>1</P></TD><TD ALIGN="RIGHT"><P>10</P></TD><TD ALIGN="RIGHT"><P>0</P></TD><TD ALIGN="RIGHT"><P>10</P></TD></TR><TR><TD><P>Nilsson 1987</P></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD ALIGN="RIGHT"><P>20</P></TD><TD ALIGN="RIGHT"><P>28</P></TD><TD ALIGN="RIGHT"><P>8</P></TD><TD ALIGN="RIGHT"><P>28</P></TD><TD ALIGN="RIGHT"><P>1</P></TD><TD ALIGN="RIGHT"><P>28</P></TD><TD ALIGN="RIGHT"><P>0</P></TD><TD ALIGN="RIGHT"><P>28</P></TD></TR><TR><TD><P>Rhedda 1985</P></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD ALIGN="RIGHT"><P>2</P></TD><TD ALIGN="RIGHT"><P>19</P></TD><TD ALIGN="RIGHT"><P>1</P></TD><TD ALIGN="RIGHT"><P>19</P></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD></TR><TR><TD><P>Rodeheffer 1983</P></TD><TD ALIGN="RIGHT"><P>9</P></TD><TD ALIGN="RIGHT"><P>15</P></TD><TD ALIGN="RIGHT"><P>2</P></TD><TD ALIGN="RIGHT"><P>15</P></TD><TD ALIGN="RIGHT"><P>15</P></TD><TD ALIGN="RIGHT"><P>27</P></TD><TD ALIGN="RIGHT"><P>11</P></TD><TD ALIGN="RIGHT"><P>27</P></TD><TD ALIGN="RIGHT"><P>12</P></TD><TD ALIGN="RIGHT"><P>15</P></TD><TD ALIGN="RIGHT"><P>3</P></TD><TD ALIGN="RIGHT"><P>15</P></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD></TR><TR><TD><P>Rupp 1987</P></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD ALIGN="RIGHT"><P>15</P></TD><TD ALIGN="RIGHT"><P>27</P></TD><TD ALIGN="RIGHT"><P>9</P></TD><TD ALIGN="RIGHT"><P>27</P></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD></TR><TR><TD><P>Smith 1982</P></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD ALIGN="RIGHT"><P>15</P></TD><TD ALIGN="RIGHT"><P>17</P></TD><TD ALIGN="RIGHT"><P>1</P></TD><TD ALIGN="RIGHT"><P>17</P></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD></TR><TR><TD><P>Taixeira Da Costa 1987</P></TD><TD ALIGN="RIGHT"><P>4</P></TD><TD ALIGN="RIGHT"><P>14</P></TD><TD ALIGN="RIGHT"><P>6</P></TD><TD ALIGN="RIGHT"><P>14</P></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD></TR><TR><TD><P>Waller 1986</P></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD ALIGN="RIGHT"><P>26</P></TD><TD ALIGN="RIGHT"><P>29</P></TD><TD ALIGN="RIGHT"><P>5</P></TD><TD ALIGN="RIGHT"><P>29</P></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD></TR><TR><TD><P>Wigley 1987</P></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD ALIGN="RIGHT"><P>12</P></TD><TD ALIGN="RIGHT"><P>25</P></TD><TD ALIGN="RIGHT"><P>7</P></TD><TD ALIGN="RIGHT"><P>25</P></TD><TD ALIGN="RIGHT"><P>12</P></TD><TD ALIGN="RIGHT"><P>25</P></TD><TD ALIGN="RIGHT"><P>7</P></TD><TD ALIGN="RIGHT"><P>25</P></TD></TR><TR><TD><P>White 1982</P></TD><TD ALIGN="RIGHT"><P>9</P></TD><TD ALIGN="RIGHT"><P>11</P></TD><TD ALIGN="RIGHT"><P>1</P></TD><TD ALIGN="RIGHT"><P>11</P></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD></TR><TR><TD><P>Wollersheim 1991</P></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD ALIGN="RIGHT"><P>2</P></TD><TD ALIGN="RIGHT"><P>25</P></TD><TD ALIGN="RIGHT"><P>1</P></TD><TD ALIGN="RIGHT"><P>25</P></TD></TR><TR><TD><P>Total</P></TD><TD ALIGN="RIGHT"><P>76</P></TD><TD ALIGN="RIGHT"><P>109</P></TD><TD ALIGN="RIGHT"><P>29</P></TD><TD ALIGN="RIGHT"><P>109</P></TD><TD ALIGN="RIGHT"><P>61</P></TD><TD ALIGN="RIGHT"><P>89</P></TD><TD ALIGN="RIGHT"><P>17</P></TD><TD ALIGN="RIGHT"><P>89</P></TD><TD ALIGN="RIGHT"><P>265</P></TD><TD ALIGN="RIGHT"><P>573</P></TD><TD ALIGN="RIGHT"><P>85</P></TD><TD ALIGN="RIGHT"><P>573</P></TD><TD ALIGN="RIGHT"><P>39</P></TD><TD ALIGN="RIGHT"><P>281</P></TD><TD ALIGN="RIGHT"><P>15</P></TD><TD ALIGN="RIGHT"><P>281</P></TD></TR></TABLE></APPENDIX_BODY></APPENDIX></APPENDICES><EXTENSIONS MODIFIED="2015-03-26 13:49:16 -0400" MODIFIED_BY="[Empty name]"><EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART"><ALIAS ALIAS_ID="1"><FLOWCHARTBOX TEXT="&lt;p&gt;38 trials were included in qualitative and quantitative meta-analysis&lt;/p&gt;"><FLOWCHARTBOX TEXT="&lt;p&gt;77 remaining articles screened&lt;/p&gt;&lt;p&gt;&lt;/p&gt;"><FLOWCHARTBOX TEXT="&lt;p&gt;305 remaining articles screened&lt;/p&gt;"><FLOWCHARTBOX TEXT="&lt;p&gt;2337 articles were screened&lt;/p&gt;"><FLOWCHARTBOX TEXT="&lt;p&gt;2337 remained after 1052 duplicate records were removed&lt;/p&gt;&lt;p&gt;&lt;/p&gt;"><FLOWCHARTBOX TEXT="&lt;p&gt;Cochrane library (including CENTRAL): 1061 articles retrieved&lt;/p&gt;"/><FLOWCHARTBOX TEXT="&lt;p&gt;Embase: 1251 articles retrieved&lt;/p&gt;"/><FLOWCHARTBOX TEXT="&lt;p&gt;Medline: 1027 articles retrieved&lt;/p&gt;&lt;p&gt;&lt;/p&gt;"/><FLOWCHARTBOX TEXT="&lt;p&gt;Clinicaltrials.gov: 50 articles retrieved&lt;/p&gt;"/></FLOWCHARTBOX><OUT TEXT="&lt;p&gt;2,032 articles excluded&lt;/p&gt;"/></FLOWCHARTBOX><OUT TEXT="&lt;p&gt;228 articles excluded&lt;/p&gt;"/></FLOWCHARTBOX><OUT TEXT="&lt;p&gt;1-30 trials excluded and reasons noted&lt;/p&gt;&lt;p&gt;2- 7 trial awaiting classification&lt;/p&gt;&lt;p&gt;3-2 trials were on going&lt;/p&gt;"/></FLOWCHARTBOX></FLOWCHARTBOX></ALIAS></EXTENSION></EXTENSIONS></COCHRANE_REVIEW>